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Resumo 
 
 
O trabalho apresentado nesta tese teve como principais objectivos contribuir 
para o conhecimento da composição do líquido amniótico humano (LA), 
colhido no 2º trimestre de gravidez, assim como investigar possíveis alterações 
na sua composição devido à ocorrência de patologias pré-natais, recorrendo à 
metabonómica e procurando, assim, definir novos biomarcadores de doenças 
da grávida e do feto. 
Após uma introdução descrevendo o estado da arte relacionado com este 
trabalho (Capítulo 1) e os princípios das metodologias analíticas usadas 
(Capítulo 2), seguida de uma descrição dos aspectos experimentais 
associados a esta tese (Capítulo 3), apresentam-se os resultados da 
caracterização da composição química do LA (gravidez saudável) por 
espectroscopia de ressonância magnética nuclear (RMN), assim como da 
monitorização da sua estabilidade durante o armazenamento e após ciclos de 
congelamento-descongelamento (Capítulo 4). Amostras de LA armazenadas a 
-20°C registaram alterações significativas, tornando-se estas menos 
pronunciadas (mas ainda mensuráveis) a -70°C, temperatura recomendada 
para o armazenamento de LA. Foram também observadas alterações de 
composição após 1-2 ciclos de congelamento-descongelamento (a ter em 
conta aquando da reutilização de amostras), assim como à temperatura 
ambiente (indicando um período máximo de 4h para a manipulação e análise 
de LA). A aquisição de espectros de RMN de 
1
H de alta resolução e RMN 
acoplado (LC-NMR/MS) permitiu a detecção de 75 compostos no LA do 2º 
trimestre, 6 dos quais detectados pela primeira vez no LA. Experiências de 
difusão (DOSY) permitiram ainda a caracterização das velocidades de difusão 
e massas moleculares médias das proteínas mais abundantes. 
O Capítulo 5 descreve o estudo dos efeitos de malformações fetais (FM) e 
de cromossomopatias (CD) na composição do LA do 2º trimestre de gravidez. 
A extensão deste trabalho ao estudo dos efeitos de patologias no LA que 
ocorrem no 3º trimestre de gravidez é descrita no Capítulo 6, nomeadamente 
no que se refere ao parto pré-termo (PTD), pré-eclampsia (PE), restrição do 
crescimento intra-uterino (IUGR), ruptura prematura de membranas (PROM) e 
diabetes mellitus gestacional (GDM). Como complemento a estes estudos, 
realizou-se uma análise preliminar da urina materna do 2º trimestre para o 
estudo de FM e GDM, descrita no Capítulo 7. Para interpretação dos dados 
analíticos, obtidos por espectroscopia RMN de 
1
H, cromatografia líquida de 
ultra eficiência acoplada a espectrometria de massa (UPLC-MS) e 
espectroscopia do infravermelho médio (MIR), recorreu-se à análise 
discriminante pelos métodos dos mínimos quadrados parciais e o método dos 
mínimos quadrados parciais ortogonal (PLS-DA e OPLS-DA) e à correlação 
espectral. Após análise por validação cruzada de Monte-Carlo (MCCV), os 
modelos PLS-DA de LA permitiram distinguir as FM dos controlos 
(sensibilidades 69-85%, especificidades 80-95%, taxas de classificação 80-
90%), revelando variações metabólicas ao nível do metabolismo energético, 
dos metabolismos dos aminoácidos e glícidos assim como possíveis 
alterações ao nível do funcionamento renal. Observou-se também um grande 
impacto das FM no perfil metabólico da urina materna (medido por UPLC-MS), 
tendo no entanto sido registados modelos PLS-DA com menor sensibilidade 
(40-60%), provavelmente devido ao baixo número de amostras e maior 
variabilidade da composição da urina (relativamente ao LA). Foram sugeridos 
possíveis marcadores relacionados com a ocorrência de FM, incluindo lactato, 
glucose, leucina, valina, glutamina, glutamato, glicoproteínas e conjugados de 
ácido glucurónico e/ou sulfato e compostos endógenos e/ou exógenos (<1 M) 
(os últimos visíveis apenas na urina). No LA foram também observadas 
variações metabólicas devido à ocorrência de vários tipos de 
cromossomopatias (CD), mas de menor magnitude. Os perfis metabólicos de 
LA associado a pré- PTD produziram modelos que, apesar do baixo poder de 
previsão, sugeriram alterações precoces no funcionamento da unidade 
fetoplacentária, hiperglicémia e stress oxidativo. Os modelos obtidos para os 
grupos pré- IUGR 
  
 
  
  
pré- PE, pré- PROM e pré-diagnóstico GDM (LA e urina materna) registaram 
baixo poder de previsão, indicando o pouco impacto destas condições na 
composição do LA e/ou urina do 2º trimestre. 
Os resultados obtidos demonstram as potencialidades da análise dos perfis 
metabólicos do LA (e, embora com base em menos estudos, da urina materna) 
do 2º trimestre para o desenvolvimento de novos e complementares métodos 
de diagnóstico, nomeadamente para FM e PTD. 
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Abstract 
 
The work presented in this thesis aimed to contribute to knowledge of 2
nd
 
trimester human amniotic fluid (AF) composition and to investigate the possible 
metabolic effects of prenatal disorders on AF composition through 
metabonomics, in order to define new potential disorder biomarkers. 
After an introduction describing the state-of-the-art (Chapter 1), the analytical 
methodologies used (Chapter 2) and the description of the experimental details 
of the work performed (Chapter 3), the results from the chemical 
characterization of AF (healthy pregnancy) by nuclear magnetic resonance 
(NMR) spectroscopy are presented, as well as the results of AF stability 
assessment during storage and after freeze-thaw cycles (Chapter 4). AF 
samples stored at -20°C registered significant compositional changes, less 
marked (but still measurable) at -70°C, the latter temperature being then 
recommended for AF storage. In addition, significant compositional changes 
were also observed after 1-2 freeze-thaw cycles (to be considered when 
sample re-usage is necessary), and at room temperature (indicating a 
maximum period of 4h for handling and analysis of AF). High resolution 
1
H 
NMR and hyphenated NMR (LC-NMR/MS) analysis enabled the detection of 75 
different compounds in 2
nd
 trimester AF, 6 of which were detected for the first 
time in AF. Moreover, diffusion-edited spectroscopy (DOSY) experiments 
allowed the characterization of the main AF proteins in terms of diffusivity and, 
hence, average molecular weight.  
Chapter 5 describes the study of the effects of fetal malformations (FM) and 
chromosomal disorders (CD) on the composition of 2
nd
 trimester AF. In Chapter 
6, this approach is extended, to the effects of 3
rd
 trimester disorders, namely 
preterm delivery (PTD), preeclampsia (PE), intrauterine growth restriction 
(IUGR), premature rupture of the membranes (PROM) and gestational diabetes 
mellitus (GDM). These studies were complemented by a preliminary analysis of 
2
nd
 trimester maternal urine to study FM and GDM (Chapter 7). Interpretation of 
the analytical data obtained by 
1
H NMR spectroscopy, ultra performance liquid 
chromatography-mass spectrometry (UPLC-MS) and mid-infrared spectroscopy 
(MIR) was performed through partial least squares and orthogonal partial least 
squares - discriminant analysis (PLS-DA and OPLS-DA) and statistical 
correlation spectroscopy. Monte-Carlo cross-validated (MCCV) PLS-DA models 
of AF revealed separation of FM cases from controls (sensitivities 69-85%, 80-
95% specificities, classification rates: 80-90%), revealing disturbances in 
energy metabolism, amino acids and sugar metabolisms and possibly 
abnormal kidney function. A high impact of FM on maternal urine was also 
observed (by UPLC-MS), however, the models obtained were of lower 
sensitivity (40-60%), probably due to the low sample numbers and higher 
variability of urine composition (in relation to AF). Possible markers of FM were 
suggested including lactate, glucose, leucine, valine, glutamine, glutamate, 
glycoproteins and conjugation products of glucuronic acid and/or sulfate with 
endogenous and/or exogenous metabolites (<1 M). In addition, metabolite 
variations were found in AF related to the occurrence of several types of 
chromosomal disorders (CD), although of smaller magnitude. Second trimester 
AF profiling associated with pre-PTD produced models, which, despite their low 
predictive power, enabled the detection of metabolite variations suggestive of 
early fetal-placental dysfunction, hyperglycaemia and oxidative stress. The 
models obtained for pre-IUGR, pre-PE, pre-PROM and pre-diagnostic GDM 
(both AF and urine) showed low predictive power, reflecting the small impact of 
these disorders in 2
nd
 trimester AF and/or urine composition. 
The results presented demonstrate the potential of metabolic profiling of 2
nd
 
trimester AF (and, although based on less studies, maternal urine) for the 
development of new complementary prenatal diagnosis methods, namely for 
FM and PTD. 
 
  
  
  
List of publications including the work presented in this thesis 
 
Papers in peer-reviewed journals: 
 
Graça, G., Duarte, I. F., Goodfellow, B. J., Barros, A. S., Carreira, I. M., Couceiro, A. B., Spraul, M. and 
Gil, A. M.; Potential of NMR spectroscopy for the study of human amniotic fluid. Analytical Chemistry, 
2007, 79(21): 8367-8375. 
Graça, G., Duarte, I. F., Goodfellow, B. J., Carreira, I. M., Couceiro, A. B., do Rosario Domingues, M., 
Spraul, M., Li-Hong, T. and Gil, A. M.; Metabolite profiling of human amniotic fluid by hyphenated 
nuclear magnetic resonance spectroscopy. Analytical Chemistry, 2008, 80(15): 6085-6092. 
Graça, G., Duarte, I. F., Barros, A. S., Goodfellow, B. J., Diaz, S., Carreira, I. M., Couceiro, A. B., 
Galhano, E. and Gil, A. M.; 1H NMR based metabonomics of human amniotic fluid for the metabolic 
characterization of fetus malformations. Journal of Proteome Research, 2009, 8(8): 4144-4150. 
                                                                                                                
l., Pita, C. and Gil, A. M.; Impact of prenatal disorders on the metabolic profile of second trimester 
amniotic fluid: a nuclear magnetic resonance metabonomic study. Journal of Proteome Research, 
2010, 9(11): 6016-6024. 
Graça, G., Diaz, S. O., Pinto, J., Barros, A. S., Duarte, I. F., Goodfellow, B. J., Galhano, E., Pita, C., 
Almeida, M. d. C., Carreira, I. M., and Gil, A. M. ; Can biofluids metabolic profiling help to improve 
healthcare during pregnancy?, Spectroscopy: An International Journal, 2012, 27(5-6): 515-523. 
Graça, G., Goodfellow, B. J., Barros, A. S., Diaz, S. O., Duarte, I. F., Spagou, K., Veselkov, K., Want, E. J., 
Lindon, J. C., Carreira, I. M., Galhano, E., Pita, C. and Gil, A. M.; UPLC-MS metabolic profiling of 
second trimester amniotic fluid and maternal urine and comparison with NMR spectral profiling for 
the Identification of pregnancy disorder biomarkers, Molecular BioSystems, 2012, 8: 1243-1254. 
Graça, G., Moreira, A. S., Correia, A.J.V., Goodfellow, B. J., Barros, A. S., Duarte, I. F., , Carreira, I. M., 
Galhano, E., Pita, C., and Gil, A. M.; Mid-infrared (MIR) metabolic fingerprinting of amniotic fluid: a 
possible avenue for early diagnosis of prenatal disorders?, Analytica Chimica Acta, 2013, 764: 24–31. 
 
Book chapter: 
Gil, A. M. and Graça, G.; Nuclear Magnetic Resonance Methods for Metabolomic Investigation of 
Amniotic Fluid. Methodologies for Metabolomics: Experimental Strategies and Techniques. N. W. 
Lutz, J. V. Sweedler and R. A. Wevers, UK, Cambridge University Press, 2013. 
 
 
 
 
 
 
 
 
  
  
xix 
 
Contents 
 
Contents ................................................................................................................ xix 
Abbreviations and symbols ................................................................................... xxiii 
1. Introduction ......................................................................................................... 1 
1.1. Pregnancy and fetal development ...................................................................................... 1 
1.2. Pregnancy-related disorders and prenatal diagnosis: present status and challenges ....... 2 
1.2.1. Fetal malformations (FM) ............................................................................................ 3 
1.2.2. Chromosomal disorders (CD) ....................................................................................... 5 
1.2.3. Preterm delivery (PTD) and premature rupture of the membranes (PROM) .............. 9 
1.2.4. Intrauterine growth restriction (IUGR) ...................................................................... 11 
1.2.5. Preeclampsia (PE) ....................................................................................................... 12 
1.2.6. Gestational Diabetes Mellitus (GDM) ........................................................................ 14 
1.3. Prenatal diagnosis research through biofluid composition .............................................. 15 
1.3.1. Chemical composition of human amniotic fluid ........................................................ 15 
1.3.2. Human amniotic fluid as a diagnostic media ............................................................. 19 
1.3.3. Prenatal research using other biofluids ..................................................................... 21 
1.4. Metabonomics: principles and applications ..................................................................... 22 
1.4.1. Principles and general applications ........................................................................... 22 
1.4.2. Metabonomics in prenatal health research............................................................... 24 
1.5. Aims and outline of this work ........................................................................................... 25 
2. Principles of the analytical methods employed ................................................... 27 
2.1. NMR spectroscopy ............................................................................................................ 27 
2.1.1. Principles of NMR spectroscopy ................................................................................ 27 
2.1.2. One-dimensional (1D) and Two-dimensional (2D) NMR methods ............................ 31 
2.1.3. Diffusion Ordered Spectroscopy (DOSY) .................................................................... 35 
2.1.4. Saturation Transfer Difference (STD) experiments .................................................... 37 
2.1.5. Hyphenated NMR methods ....................................................................................... 38 
2.2. Liquid chromatography coupled to mass spectrometry (LC-MS) ..................................... 39 
2.3. Fourier Transform Infrared (FT-IR) Spectroscopy ............................................................. 42 
2.4. Data pre-processing and multivariate analysis (MVA) ..................................................... 45 
2.4.1. Data pre-processing ................................................................................................... 45 
2.4.2. Multivariate Analysis (MVA) methods ....................................................................... 47 
2.4.2.1. Principal Components Analysis (PCA).................................................................. 47 
2.4.2.2. Partial Least Squares and Orthogonal Partial Least Squares - Discriminant 
Analysis (PLS-DA and OPLS-DA) ........................................................................................ 48 
2.4.2.3. Statistical total correlation spectroscopy (STOCSY) and statistical 
heterospectroscopy (SHY) methods ................................................................................. 52 
3.  Experimental procedures ................................................................................... 57 
3.1. Samples and clinical metadata ......................................................................................... 57 
3.1.1. Amniotic fluid and maternal urine collection ............................................................ 58 
3.1.2. Sample classification .................................................................................................. 58 
3.2. Chemicals .......................................................................................................................... 62 
3.3. High resolution NMR spectroscopy .................................................................................. 63 
Contents 
xx 
 
3.3.1. Sample preparation for NMR ..................................................................................... 63 
3.3.1.1. AF sample preparation ........................................................................................ 63 
3.3.1.2. Amniotic fluid stability evaluation for NMR ........................................................ 64 
3.3.1.3. Urine sample preparation for NMR ..................................................................... 66 
3.3.2. NMR experimental details ......................................................................................... 66 
3.3.2.1. NMR equipment .................................................................................................. 66 
3.3.2.2. 1D and 2D 1H NMR experiments ......................................................................... 67 
3.3.2.3. Diffusion Ordered Spectroscopy (DOSY) experiments ........................................ 70 
3.3.2.4. Saturation Transfer Difference (STD) experiments ............................................. 71 
3.3.2.5. Spectral assignments ........................................................................................... 72 
3.3.2.6. Pre-processing and analysis of NMR data ........................................................... 72 
3.4. Liquid Chromatography coupled to NMR and MS (LC-NMR/MS) .................................... 74 
3.4.1. Preparation of amniotic fluid samples for LC-NMR/MS ............................................ 74 
3.4.2. Equipment and experimental setup .......................................................................... 74 
3.4.3. Characterization of less polar metabolites ................................................................ 75 
3.4.4. Characterization of more polar metabolites ............................................................. 76 
3.5. Ultra-Performance Liquid Chromatography - Mass Spectrometry (UPLC-MS) Analysis .. 77 
3.5.1. Sample preparation for UPLC-MS .............................................................................. 77 
3.5.2. Equipment and experimental setup .......................................................................... 78 
3.5.3. Pre-processing and analysis of UPLC-MS data ........................................................... 80 
3.6. Fourier-transform Mid Infrared (MIR) spectroscopy analysis of amniotic fluid ............... 81 
3.6.1. Equipment and experimental setup .......................................................................... 81 
3.6.2. AF sample preparation and MIR spectra acquisition ................................................. 81 
3.6.3. Pre-processing and analysis of MIR data ................................................................... 82 
3.7. Statistical total correlation (STOCSY) and statistical heterospectroscopy (SHY) analysis 83 
4. Study of 2nd trimester human amniotic fluid by 1H NMR spectroscopy: stability 
evaluation and compositional analysis .................................................................... 85 
4.1. Comparison of different protocols for amniotic fluid analysis by 1H NMR: establishment 
of a protocol for metabolic profiling ....................................................................................... 85 
4.2. Study of the human amniotic fluid sample stability ......................................................... 89 
4.2.1. Stability during storage .............................................................................................. 89 
4.2.2. Stability upon freeze-thaw cycles .............................................................................. 92 
4.2.3. Stability at room temperature ................................................................................... 94 
4.3. Compositional analysis of 2nd trimester human amniotic fluid by high resolution NMR 
and hyphenated NMR .............................................................................................................. 96 
4.3.1. Analysis by high resolution 1D and 2D 1H NMR spectroscopy ................................... 96 
4.3.2. Analysis by DOSY and STD spectroscopy ................................................................. 104 
4.3.3. Analysis by LC-NMR/MS ........................................................................................... 110 
4.3.3.1 Characterization of less polar metabolites......................................................... 110 
4.3.3.2 Characterization of more polar metabolites ...................................................... 114 
5. Study of the effects of fetal malformations (FM) and chromosomal disorders (CD) 
on 2nd trimester human amniotic fluid .................................................................. 121 
5.1. Study of the effects of FM on 2nd trimester human amniotic fluid ................................ 121 
5.1.1. 1H NMR profiling to evaluate the effects of maternal age, gestational age and 
malformation type ............................................................................................................. 121 
5.1.2. 1H NMR profiling for comparison of control and FM groups ................................... 124 
  
xxi 
 
5.1.3. UPLC-MS profiling for comparison of control and FM groups ................................. 130 
5.1.4. UPLC-MS/1H NMR SHY analysis for FM cases .......................................................... 137 
5.1.5. MIR profiling for comparison of control and FM groups ......................................... 139 
5.1.6. MIR STOCSY analysis of FM cases ............................................................................ 143 
5.1.7. MIR/1H NMR SHY analysis for FM cases .................................................................. 145 
5.1.8. Proposed interpretation of metabolic alterations occurring in FM cases ............... 147 
5.2. Study of the effects of CD on 2nd trimester human amniotic fluid ................................. 151 
5.2.1. 1H NMR profiling to evaluate the effects of CD type ............................................... 151 
5.2.2. 1H NMR profiling for comparison of control and CD groups ................................... 152 
5.2.3. MIR profiling for comparison of control and CD groups .......................................... 158 
5.2.4. Proposed interpretation of the metabolite variations occurring in CD cases ......... 159 
6. Study of the effects of disorders occurring later in pregnancy (PTD, PROM, PE, 
IUGR and GDM) on 2nd trimester human amniotic fluid ......................................... 161 
6.1. Analysis of 2nd trimester amniotic fluid composition for the prediction of PTD (pre-PTD 
group) .................................................................................................................................... 161 
6.1.1. 1H NMR profiling for comparison of control and pre- PTD groups .......................... 161 
6.1.2. UPLC-MS profiling for comparison of control and pre-PTD groups ......................... 167 
6.1.3. MIR profiling for comparison of control and pre-PTD groups ................................. 169 
6.1.4. STOCSY and SHY analysis of pre-PTD cases .............................................................. 171 
6.1.4.1. UPLC-MS/1H NMR SHY analysis ......................................................................... 171 
6.1.4.2. MIR STOCSY analysis ......................................................................................... 172 
6.1.4.3. MIR/1H NMR SHY analysis ................................................................................. 173 
6.1.5. Proposed interpretation of the metabolite variations in pre- PTD cases ................ 175 
6.2. Analysis of 2nd trimester amniotic fluid composition for the prediction PE, IUGR and 
GDM (pre-PE, pre-IUGR groups, pre-diagnostic GDM) .......................................................... 176 
6.2.1. 1H NMR and MIR profiling for comparison of control and pre- PE groups .............. 177 
6.2.2. 1H NMR and MIR profiling of pre- IUGR cases ......................................................... 181 
6.2.3. Analysis of 2nd trimester amniotic fluid composition for the prediction of GDM (pre-
diagnostic GDM group) ...................................................................................................... 183 
6.3. Analysis of 2nd trimester amniotic fluid composition for the prediction of PROM (pre-
PROM group) ......................................................................................................................... 185 
6.3.1. 1H NMR profiling for comparison of control and pre-PROM groups ....................... 185 
6.3.2. MIR profiling for comparison of control and pre-PROM groups ............................. 186 
6.3.3. Statistical spectroscopy correlation analysis of pre-PROM cases ............................ 188 
6.3.3.1. MIR STOCSY analysis ......................................................................................... 188 
6.3.3.2. MIR and 1H NMR SHY analysis ........................................................................... 190 
6.3.4. Proposed interpretation of the metabolite variations detected in pre-PROM cases
 ........................................................................................................................................... 191 
7. Preliminary study of 2nd trimester maternal urine by ultra-performance liquid 
chromatography mass spectrometry (UPLC-MS) for the study and prediction of 
pregnancy disorders (FM and GDM) ...................................................................... 193 
7.1. Analysis of 2nd trimester maternal urine for the study of FM cases ............................... 193 
7.1.1. UPLC-MS profiling for comparison of control and FM groups ................................. 193 
7.1.2. UPLC-MS/1H NMR SHY analysis of FM cases............................................................ 198 
7.1.3. Proposed interpretation of the urinary metabolite variations occurring in FM cases
 ........................................................................................................................................... 200 
7.2. Analysis of 2nd trimester maternal urine for the study of pre-diagnostic GDM cases .... 201 
Contents 
xxii 
 
8. Conclusions and future perspectives ................................................................. 203 
References ........................................................................................................... 207 
Annexes ............................................................................................................... 231 
Annex I - Informed signed consent and questionnaire. ........................................................ 232 
Annex II - 1H NMR pulse programs. ....................................................................................... 233 
Annex III - UPLC-MS reproducibility evaluation ..................................................................... 236 
Annex IV - MIR reproducibility evaluation ............................................................................. 239 
Annex V – Full list of AF compounds identified by high resolution NMR and LC-NMR/MS .. 241 
Annex VI - Lists of UPLC-MS unassigned features detected in AF ......................................... 242 
Annex VII - Lists of UPLC-MS unassigned features detected in maternal urine .................... 244 
 
 
Abbreviations and Symbols 
xxiii 
 
Abbreviations and symbols 
 
1D  One-dimensional 
2D  Two-dimensional 
ACN  Acetonitrile 
ANN  Artificial neuronal networks 
AF  Amniotic Fluid 
ANOVA  Analysis Of Variance 
ATR  Attenuated Total Reflectance 
-hCG   -human chorionic gonadotropin 
BPPLED  Bipolar pulse longitudinal eddy current delay 
cAMP  Cyclic adenosine monophosphate nucleotide 
CD  Chromosomal Disorders 
CE  Capillary Electrophoresis 
CPMG  Carr-Purcell-Meiboom-Gill 
CV  Cross Validation 
DAD  Diode Array Detector 
dB  Decibel 
DNA   Deoxyribonucleic Acid  
DOSY  Diffusion Ordered Spectroscopy 
DSS  Dimethylsilapentanesulfonic acid 
F1  Frequency domain 1 
F2  Frequency domain 2 
FID  Free Induction Decay 
FISH  Florescence in situ hybridization    
FIR  Far-infrared 
FM  Fetal Malformations 
FT  Fourier Transform 
GC  Gas Chromatography 
GDM  Gestational Diabetes Mellitus 
g.w.  Gestational weeks 
HETCOR Heteronuclear Correlation 
HCA  Hierarchical cluster analysis 
HILIC  Hydrophilic Interaction Chromatography  
HPLC  High-Performance Liquid Chromatography 
HSQC  Heteronuclear Single Quantum Correlation 
HMQC  Heteronuclear Multiple Quantum Correlation 
HSS  High-Strength Silica 
Hz  Hertz 
IEM  Inborn Errors of Metabolism 
INEPT  Insensitive Nuclei Enhancement by Polarization Transfer 
IR  Infrared 
IUGR  Intrauterine Growth Restriction 
IVH  Intraventricular hemorrhage  
J-res  J-resolved spectroscopy 
LB  Line Broadening 
LC  Liquid Chromatography 
LOESS  Locally weighted Scatter plot Smoothing 
MCCV  Monte-Carlo Cross Validation 
MHz  Megahertz 
Abbreviations and Symbols 
xxiv 
 
MIR  Mid-infrared 
MLEV-17 Malcolm Levitt-17 sequence 
MRI  Magnetic Resonance Imaging 
MS  Mass Spectrometry 
MSn  nth fragmentation MS experiment 
MSE   MS experiments at different collision energies 
MVA  Multivariate Analysis 
Mw  Molecular weight 
NIR  Near-infrared 
NLM  Non-linear mapping 
NMR  Nuclear Magnetic Resonance 
NMND  N-methyl-nicotinamide 
NS  Number of scans (or transients)  
OGTT  Oral glucose tolerance test 
OPLS  Orthogonal Partial Least Squares 
OPLS -DA Orthogonal Partial Least Squares - Discriminant Analysis 
PAPP-A  Pregnancy-associated plasma protein A 
PCA  Principal Components Analysis 
PE  Preeclampsia 
PlGF  Placental growth factor 
PLS  Partial Least Squares 
PLS -DA  Partial Least Squares - Discriminant Analysis 
PROM  Premature Rupture Of Membranes 
PTD  Preterm Delivery 
Q2  Goodness of prediction or predictive power of a PLS-DA or OPLS-DA model 
Q-TOF  Quadrupole-Time-Of-Flight 
RD  Relaxation Delay 
RF  Radiofrequency 
RDS  Respiratory Distress Syndrome 
ROC  Receiver Operative Characteristics 
RP  Reverse Phase 
RSPA  Recursive Segment-wise Peak Alignment 
SGA  Small for Gestational Age 
SHY  Statistical Heterospectroscopy 
SI  Size of real spectrum 
SIMCA  Soft Independent Modeling of Class Analogy 
STD  Saturation Transfer Difference 
SOM  Self organizing maps 
STOCSY  Statistical Total Correlation Spectroscopy 
SW  Spectral Width  
TD  Time Domain 
TLC  Thin-layer chromatography 
TOCSY  Total Correlation Spectroscopy 
TOF  Time-Of-Flight 
TMS  Tetramethylsilane 
TSP  3-trimethylsilyl propionate 
UPLC  Ultra-Performance Liquid Chromatography 
UV  Ultraviolet 
UV scaling Unit Variance scaling 
VIP  Variable importance to the projection 
WDW  Window function
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
Chapter 1 
1 
 
1. Introduction 
 
1.1. Pregnancy and fetal development 
 
Human pregnancy normally has the duration of 38 to 40 gestational weeks (g.w.) and in order 
to better describe the events that occur throughout gestation it is usually divided into 3 
trimesters. The 1st trimester of pregnancy comprises the period from fertilization until 12 g.w. It is 
during the 1st trimester that most important steps in the fetal organogenesis occurs, and is the 
most critical period of fetal development. The cardiac and central nervous system, for instance, 
are completely differentiated by the end of the 8th week and, by the 12th week the limbs appear 
completely differentiated (Moore and Persaud, 2008). Also at this stage, important fetal-maternal 
structures become completely differentiated ultimately forming the definitive annexes that 
support fetal growth and maintenance and also playing important regulatory and endocrine 
functions (Jauniaux and Gulbis, 2000; Graça and Barros, 2005). Some of the most important of 
these structures, shown in detail in Figure 1.1, are the chorionic villi and the capillary system, 
which form the placenta and the umbilical cord, respectively; the chorion, later forming the 
amniotic sac and the excoelomic cavity which is actively involved in the early amniotic fluid (AF) 
formation (Jauniaux and Gulbis, 2000). 
 
        
Figure 1.1 – The placenta and fetal annexes: a) diagram of the early gestational sac (8–9 g.w.) 
illustrating the fetal fluid compartments; amniotic fluid fills the amniotic sac (AC), and is surrounded by 
the exocoelomic cavity (ECC); the chorionic villous and intervillous fluid fills the intervillous space (IVS); 
D, Decidua; M, myometrium; YS, yolk sac (adapted from Jauniaux et al., 2005); b) detailed 
representation of the placenta and fetal structures at the 10-12th g.w. (adapted from Brown, 2007). 
 
a) b) 
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The 2nd trimester of pregnancy (from 12 to 26 g.w.) is characterized by organ maturation and 
fetal growth. During the 2nd trimester the fetus starts to move more frequently, the fetal kidneys 
acquire the filtration capacity and start to produce fetal urine. The liver starts to secrete bile and 
the spleen initiates the production of erythrocytes. Towards the end of 2nd trimester fetal skin 
becomes keratinized and lung maturation is initiated with the production of the lung surfactant 
which prepares the fetal lung for its normal function after birth (Toot and Lu, 2004; Graça, 2005a). 
Important physiological changes occur during the 3rd trimester (from 26 g.w. until labour), such 
as the initiation of fetal liver lipid biosynthetic function enabling the fetus to synthesize body fat 
in order to maintain temperature. It is also during the 3rd trimester that the bones of the skull 
become completely formed. A marked increase in fetal weight is registered also during this 
period. By the 37th week, fetal maturation is complete and pregnancy is at term, although labour 
can occur after this period, up to 41 or 42 weeks (Toot and Lu, 2004; Graça, 2005a).  
 
In order to support the newly forming life, the maternal body has to adjust its physiology 
without compromising the maternal well-being. However, in some cases the disruptions that 
occur during gestation can cause severe maternal health problems and ultimately affect fetal 
development. For this reason it is important to ensure adequate pregnancy monitoring and 
eventually perform prenatal diagnosis procedures in case of enhanced risk of prenatal disorders, 
in order to allow proper intervention or, in most severe cases, pregnancy termination. 
 
1.2. Pregnancy-related disorders and prenatal diagnosis: present status and challenges 
 
Some of the most important prenatal disorders affecting the fetus, the mother or both are 
summarized in Table 1.1, together with their respective estimated prevalence, i.e. the portion of 
pregnancies registering such disorders.   
 
Table 1.1 - Estimated prevalence of pregnancy-related disorders worldwide. 
Disorder Prevalence reference 
Intrauterine growth restriction (IUGR) 7-15% of all pregnancies Cetin and Alvino, 2009 
Gestational diabetes mellitus (GDM) 1-14% of all pregnancies ADA, 2004 
Premature rupture of the membranes 
(PROM) 
8-10% of all pregnancies Stuart et al, 2005 
Preterm delivery (PTD) 9.6% of all live births Gracie, et al. 2012 
Preeclampsia (PE) 2-6% of all pregnancies Walker, 2000 
Fetal malformations (FM) 3-4% of all live births Bacino, 2012 
Chromosomal disorders (CD) 0.5% of live births Lu and Hobel, 2004 
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Among the most prevalent prenatal disorders, worldwide, are the intrauterine growth 
restriction (IUGR), gestational diabetes mellitus (GDM), the premature rupture of the membranes 
and the preterm delivery (PTD) (Table 1.1). Nevertheless, most of the prenatal disorders 
mentioned induce significant pathophysiologic changes in the mother, fetus of both and, 
therefore, will be described in detail in the following subsections. 
 
1.2.1. Fetal malformations (FM) 
 
Fetal malformations (FM), often designated by congenital fetal malformations, congenital 
anomalies or birth defects, are anatomic alterations which occur during fetal development and 
may affect several organs, tissues and limbs (Table 1.2).   
 
Table 1.2 - Some of the most common fetal malformations grouped according to the affected organ or 
system (Adapted from Chmait and Moore, 2004). 
Affected organ/system Malformations 
Central nervous system (CNS) 
 Hydrocephaly 
 Anencephaly 
 Spina Bifida 
 Ventriculomegaly 
Face  Cleft lip and/or palate  
Limbs 
 Amelia (absence of limbs) 
 Club foot 
 Polydactylia  
 Achondroplasia 
Soft tissue  Cystic hygroma  
Lungs 
 Cystic adenomatoid 
malformation 
 Lung sequestration  
 Diaphragmatic hernia 
Cardiac 
 Atrial septal defect 
 Ventricular septal defect 
 Tetralogy of Fallot 
 Transposition of the 
great vessels 
 Arrhythmias 
Abdominal 
 Gastroschisis 
 Omphalocele 
 Bowel atresia or 
obstruction 
Urogenital 
 Renal agenesis 
 Polycystic kidney disease 
 Hydronephrosis 
 Posterior urethral valves 
Bones  Skeletal dysplasia  
  
Fetal malformations can be caused by genetic factors such as chromosomal alterations and 
gene mutations, environmental factors such as drugs and viruses, or multifactorial inheritance 
(genetic and environmental factors acting together in a complex manner) (Moore and Persaud, 
2008). An example of the effects of an environmental agent is the infection with rubella virus 
during the critical period of development of the eyes, heart, and ears, which may cause severe 
anatomic anomalies, such as cataracts, cardiac defects, and deafness. Another well-known 
example relates to the effects caused by the drug thalidomide, taken by the mothers during early 
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pregnancy to reduce the effects of morning sickness, which caused severe fetal limb anomalies 
and other developmental disruptions. However, for most FM types the etiology is still unknown 
(Moore and Persaud, 2008). 
The worldwide prevalence of FM is 3-4% of all live births (Table 1.1, page 2), being the brain 
defects the most common, occurring in every 10/1000 births, followed by heart defects, which 
occur in 8/1000 births (Miall et al., 2003). 
In terms of severity, FM types include those of minor severity, such as a club foot which can be 
corrected with surgery after birth, and those of major severity such as the cases of open spina 
bifida, transposition of great vessels or even incompatible with life such as anencephaly (Bacino, 
2012). Some fetuses may also show characteristic patterns of abnormality which may suggest a 
“ y    m ” diagnosis, such as those associated with chromosomal disorders, as for instance, 
Down syndrome (trisomy 21) (which will be discussed in detail in the next section) (Bacino, 2012).  
 
The screening for FM types such as those presented in Table 1.2 is normally achieved by 
transabdominal ultrasound monitoring performed in late 1st trimester (11-14 g.w.) and during the 
2nd trimester (around 16 g.w.). The transabdominal ultrasound is of paramount importance in 
prenatal diagnosis since it allows the correct determination of fetal gestational age, the 
evaluation of the biophysical profile of the fetus, which combines the heart rate, breathing 
activity, inspection of fetal movements and tone, as well as amniotic fluid volume evaluation 
(Chmait and Moore, 2004). The sensitivity for FM detection by ultrasound during the 2nd trimester 
ranges from 17% to 74%, which may be due to patient population variations or due to operator 
experience (Chmait and Moore, 2004). On the other hand, the specificity of ultrasound for the 
identification of a normal fetus is almost 100%, i.e. it has a very low false positive rate for the 
identification normal fetus (Chmait and Moore, 2004). Therefore, ultrasound can be very specific 
for ruling out FM, but it lacks sensitivity in detecting them. 
Other diagnostic methods may be used when ultrasound imaging is equivocal or 
nondiagnostic. The main non-invasive alternative is the use of magnetic resonance imaging (MRI) 
for the diagnosis of complex central nervous system malformations such as ventriculomegaly, 
whereas laboratory determination of elevated -fetoprotein levels in AF may be used to assist in 
the diagnosis of open neural tube and ventral wall defects, such as spina bifida and gastroschisis, 
respectively (Chmait and Moore, 2004).  
   
During embryogenesis, the metabolic microenvironment profoundly influences the entire 
organogenesis processes (Prasad et al., 2009). Indeed, specific metabolite variations were 
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described for different types of malformations such as neural tube defects namely increases in 
lactate, glutamate, acetate (Bock, 1994), myo-inositol and succinate (Groenen et al., 2004). 
Decreases in folate and cobalamin levels were also found in association with neural tube defects, 
cleft lip and/or palate, heart defects or omphalocele (Brouns et al., 2008). Moreover, inborn 
errors of metabolism (IEM) have been associated with the development of FM, particularly those 
of central nervous system (Prasad et al., 2009). These IEM are caused by single gene defects 
resulting in enzymatic impairments within biochemical pathways, which may lead to accumulation 
of potentially toxic intermediate compounds. Several metabolite changes are then expected in 
such cases and may be used to further characterize FM cases and be used in the development of 
complementary diagnostic methods. 
 
1.2.2. Chromosomal disorders (CD) 
 
Chromosomal disorders (CD) reflect the occurrence of an atypical number of chromosomes or 
a structural alteration (chromosomal anomalies) in one or more of the 46 chromosomes (23 
chromosome pairs) that constitute the human karyotype (Figure 1.2).  
 
Figure 1.2 - The karyotype of a human composed of 23 pairs of chromosomes. The 23rd pair (XY) 
c                 x    c   m   m        m    (XX      m    )  R p    c      m “T  k  g        y of 
      c T  m ” (   p://    g   m  g v/       y/)  
 
Chromosomal anomalies occur in 0.5% of live births (Table 1.1, page 2) and can be caused by 
errors in cell division or by extrinsic factor such as radiation, chemical substances or viral 
infections (Lu and Hobel, 2004; Tavares, 2005). Women older than 34 years have increased risk of 
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giving birth to children carrying chromosomal anomalies and related FM types (Lu and Hobel, 
2004), hence CD screening is recommended in pregnant women above this age.  
Chromosome anomalies can be divided into three major types: numerical, structural and 
mosaicisms. Some of the most common are summarized in Table 1.3. Depending on the type, 
chromosome anomalies may range from small phenotypic alterations to more severe 
developmental and intellectual impairment such as malformations and mental retardation (Lu 
and Hobel, 2004). 
 
Table 1.3 - Some of the most common types of chromosomal anomalies (Adapted from Lu and Hobel, 
2004 and Tavares, 2005). 
Anomaly Details 
Numerical Monosomies: 
Turner syndrome (45,X) 
 
Trisomies:   
Down syndrome (T21), Edwards syndrome (T18), Patau syndrome (T13), 
Kleinfelter's syndrome (47,XXY), Triple X syndrome (47,XXX), 47,XYY 
syndrome 
 
Polysomies: 
Examples: 48,XXXX, 48,XXXY, 48,XXYY, 49,XXXXY 
 
Structural 
 
Deletions - chromosomal material is missing                       
Duplications - duplication of chromosome portions 
Translocations - transfer of chromosomal material between chromosomes                    
Inversions - inversion of chromosome portions 
Insertions - addition of chromosome material into other chromosomes 
Ring chromosome - simultaneous deletion and junction of telomeres 
Marker chromosome - extra chromosomal material 
 
Mosaicisms 
 
 
Cell line with two or more karyotypes:  
Example: mos 45,X / 46,XX (mosaic, Turner syndrome) 
 
The most common numerical chromosomal anomalies are named aneuploidies and involve the 
repetition or absence of one or more chromosomes (Table 1.4). Numerical anomalies are 
responsible for the most common chromosomal disorders including the autosomal trisomies such 
as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18) and Patau syndrome (trisomy 
13), as well as the sex chromosomal aneuploidies (such as the Turner syndrome, Kleinfelter 
syndrome or the XYY syndrome) (Lu and Hobel, 2004; Tavares, 2005) (Table 1.4). 
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Table 1.4 - Characteristics of the most common chromosomal disorders (syndromes): prevalence, 
karyotype(s) and phenotype changes (Lu and Hobel, 2004; Tavares, 2005; Chen et al., 2011). 
Disorder Karyotypes Prevalence Phenotypic changes 
Down 
syndrome 
(trissomy 21) 
47,XX+21 
47,XY+21 
1/700 
 delayed cognitive ability and physical growth; 
microgenia (abnormally small chin);  
 oblique eye fissures with epicanthic skin folds on 
the inner corners; 
 cardiopathy, thyroid dysfunction, infertility, 
premature aging.  
Edwards 
syndrome 
(trissomy 18) 
47,XX+18 
47,XY+18 
1/6000 
 hypertonia, microcephaly, prominent back portion 
of the head, micrognathia (abnormally small jaw), 
low-set years, clenched hands, rounded bottom 
feet, unusual shaped chest; 
 low birth weight and low survival rate (10%,      
<1 year); 
 associated with congenital malformations: 
cardiac defects, omphalocele and diaphragmatic 
hernia.  
Patau 
syndrome 
(trissomy 13) 
47,XX+13 
47,XY+13 
1/10000 
 severe intra-uterine and post-natal development; 
 malformations: holoprosencephaly, polydactilia, 
cardiac defects, oral-facial clefts and ocular 
anomalies; 
 very low survival rate (few months); 
 found in association with spontaneous abortions.  
Turner 
syndrome 
45,X 1/5000 
 female phenotype, low height (141-146 cm); 
 sexual immaturity, short and thick neck, 
lymphedema, large thorax and cardiac 
anomalies; 
 99% of 45X are loss before birth. 
Kleinfelter 
syndrome 
 
47,XXY 
48,XXYY 
49,XXXXY 
1/1000 
 male phenotype with high stature, long limbs, 
sexual underdevelopment, infertility and 
gynecomasty. 
XYY 
syndrome 
 1/1000 
 male phenotype with high stature and apparently 
no behaviour alterations. 
 
Structural chromosomal anomalies result from alterations within the portions of genetic 
material, either by rearrangement leading to no phenotypic consequences (balanced alterations), 
or by gain or loss of portions of genetic material with phenotypic changes (unbalanced 
alterations) whose severity depends on the chromosome portions and gene(s) affected (Tavares, 
2005). Structural anomalies can be subdivided into deletions, (originating a monosomy for the 
affected chromosomal regions), duplications (originating trisomies for the affected chromosome 
regions), translocations, inversions, insertions, ring-shaped chromosomes (originating from 
deletions at the telomeres level and subsequent junction, resulting in chromosome inactivation 
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and functional monosomy) and marker chromosomes (small chromosomes of undetermined 
origin, which can be associated with malformations) (Tavares, 2005) (Table 1.3, page 6). 
Chromosomal disorders may also arise from the co-existence of two or more cell lines with 
distinct karyotypes called mosaicisms, as for instance a mosaicism for Turner syndrome (Table 1.3, 
page 6). The clinical consequences of a mosaicism depend upon on the proportion of the 
abnormal cell line(s) in the several tissues and on their corresponding karyotype. Usually the 
presence of normal cell lines attenuates the effect of the abnormal ones (Tavares, 2005). 
 
The screening for fetal chromosomal anomalies, especially trisomies, may be performed at 10-
14 weeks with aid of a 1st trimester combined screening, which includes the ultrasound 
measurement of fetal nuchal translucency thickness in conjunction with the measurement 
maternal serum free -human chorionic gonadotropin (-hCG) and pregnancy-associated plasma 
protein A (PAPP-A) (Spencer, 2002). The 1st trimester screening has been associated with 
sensitivities of 89% for trisomy 21 and 90% for other chromosomal anomalies (trisomies 13 and 
18, Turners syndrome, and triploidy) (Spencer, 2002) and the false positive rates of 3.2%–5.6% for 
13, 18 and 21 trisomies (Chen et al., 2011). Another screening procedure performed during the 
2nd trimester, usually at 16-18 weeks, has also been used (Lu and Hobel, 2004). The 2nd trimester 
screening included the measurement of maternal serum -fetoprotein, free or total -hCG and 
maternal age, which registered lower sensitivities of 65-70% for trisomy 21 (Spencer, 2002). 
Nevertheless, the definitive diagnosis of CD involves chromosomal dosage through the use of 
cytogenetics procedures (Tavares, 2005; Wapner and Toy, 2011). 
The most widely used cytogenetic technique in prenatal diagnosis is karyotype analysis, which 
consists in the observation of the chromosomes from cultivated fetal cell lines during the 
metaphase stage of cell division (Tavares, 2005). These cells are usually collected invasively, 
during the 2nd trimester through amniocentesis (to collect amniotic fluid, from which the fetal 
cells, the amniocytes, are obtained), or at the 1st trimester through chorionic villus sampling (CVS) 
to obtain fetal cells. Since it can be performed at an earlier stage of pregnancy, CVS (which has 
nearly the same risk of miscarriage as amniocentesis performed at the 2nd trimester, 0.5 to 1%) 
represents an advance in the early diagnosis of chromosomal disorders and has been increasingly 
used to replace amniocentesis for cell collection for cytogenetic analysis (Wapner and Toy, 2011). 
However, cell culture requires 3 to 7 days for chorionic villus cells and 7 to 10 days for amniocytes 
(Tavares, 2005), extending the period of analysis up to two weeks. Another important cytogenetic 
procedure is fluorescence in situ hybridization (FISH). This procedure consists of the identification 
of specific gene sequences through the use of fluorescence DNA probes, enabling the rapid 
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targeted assessment of chromosomal anomalies especially in non-cultured cells, at several stages 
of cell division, thus allowing results to be obtained in 24 hours. Nevertheless, the results must be 
complemented by conventional karyotype analysis (Tavares, 2005). FISH analysis also allows the 
detection of genetic syndromes (caused by gene deletions), such as Prader-Willi, Angelman-
DiGeorge and Williams (Lu and Hobel, 2004). 
Chromosomal disorders induce alterations in gene expression and, therefore metabolite 
variations can be expected. In fact, several metabolite variations were described in 2nd trimester 
AF of Down syndrome cases (Sims et al., 1993a; Baggot et al., 2008) including increases in 5-
hydroxycaproate, methylsuccinate, -ketoglutarate, adipate and phenylpyruvate thus suggesting 
impaired riboflavin and neurotransmitter metabolism (Baggot et al., 2008). Another study 
considering 2nd trimester AF samples detected decreases in glutamine, gycine, taurine, valine, 
lysine, isoleucine, leucine and ornithine, as well as an increase in glutamate in Down syndrome 
cases (Amorini et al., 2012). However, early metabolic variations resulting from other CD have not 
been explored, despite the occurrence of phenotypical alterations which may result in metabolic 
impairment, such as the impaired sexual development noted in Turner and Klinefelter syndromes 
(Tavares, 2005), which may have an impact in hormonal biosynthesis and regulation. 
 
1.2.3. Preterm delivery (PTD) and premature rupture of the membranes (PROM) 
 
Preterm delivery (PTD) is defined as the delivery occurring between 20 and 37 weeks of 
gestation (Hobel, 2004; Goldenberg et al., 2005). Because prematurity is one of the leading causes 
of infant mortality and morbidity, ranging from 50-70% in the United States (Hobel, 2004) and 
increasing in the last 30 years worldwide (Gracie et al., 2012), the major goals of obstetric care are 
to reduce the occurrence of such condition as well as to increase the gestational age of infants for 
which preterm delivery is unavoidable (Hobel, 2004). There are three etiological types of PTD: 
spontaneous (idiopathic); PTD due to the premature rupture of the fetal membranes prior to the 
occurrence of uterine contractions; and PTD due to induction of labour for medical indications 
(for instance in cases of intrauterine growth restriction or preeclampsia) (Hobel, 2004). The risk 
factors for PTD include socioeconomic factors such as poor antenatal care or poor nutritional 
status, previous PTD, repeated 1st trimester abortions, previous 2nd trimester abortions, urinary 
tract infections, multiple gestation, polyhydramnios (excess of amniotic fluid), uterine anomalies 
and incompetent cervix (Hobel, 2004). 
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The diagnosis of PTD for patients with ruptured and intact membranes is performed when the 
first symptoms appear and it is based on the documented uterine contractions (4 per 20 minutes 
or 8 per 60 minutes), on the documented cervical change (cervix effacement of 80% or dilatation 
of 2 cm or more) and on AF leakage in the cases of ruptured membranes (Hobel, 2004; Graça, 
2005b). About 20% of patients without ruptured membranes usually cease contractions after rest 
and adequate hydration. However, when such measures fail to cease contractions, tocolytic (anti-
contraction or labour repressant) therapy should be implemented to prevent PTD, provided there 
is no contraindication to it (Hobel, 2004; Graça, 2005b). On the other hand, most patients with 
ruptured membranes begin labour spontaneously within several days (Goldenberg et al., 2008). 
After diagnosis of PTD, it is usual to initiate antibiotic and glucocorticoids therapy. The 
antibiotic therapy is used as a prophylactic measure in order to prevent the progression of silent 
infections and the risk of fetal infections. Glucocorticoids therapy, on the other hand, accelerates 
pulmonary maturation of the preterm fetus, therefore reducing the risk for respiratory syndrome 
distress (RDS) and also reducing the risk of intraventricular hemorrhage (IVH) after birth (Hobel, 
2004; Graça, 2005b). 
Several markers have been associated with PTD including various cytokines in periodontal 
(crevicular) fluid, cytokines and microorganisms such as Chlamydia found in urine samples, 
salivary estriol measurements, and a wide variety of microorganisms, cytokines, and proteins 
(such as ferritin, fibronectin or metalloproteinase-9) in AF, serum, plasma and cervicovaginal 
secretions (Goldenberg et al., 2005). A systematic review of 30 of potential early biomarkers of 
PTD has shown that only 3 of these biomarkers (the proteome profile and prolactin in 
cervicovaginal fluid, and matrix metalloproteinase-8 in AF) had some predictive value for the 
prediction of PTD (Conde-Agudelo et al., 2011). However, these biomarkers were evaluated in 
small studies, and therefore were not considered clinically useful for the prediction of PTD 
(Conde-Agudelo et al., 2011). The presence of the fetal protein fibronectin in the cervix or vagina 
at 22-24 g.w. has been suggested as a powerful predictor of PTD (Goldenberg et al., 2005), 
provided that it is sampled in women with intact membranes (Roman et al., 2005). Despite the 
availability of several potential markers, an early predictive test is still not available for PTD. 
 
Besides the work presented in this thesis, which will be presented and discussed in later 
chapters, metabolite variations have been sought in 2nd trimester AF in order to identify woman 
at risk for PTD from a large group of pregnant women comprising: a) those who delivered at term 
with intact membranes, and those who delivered preterm b) with and c) without intra-amniotic 
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infection (Romero et al., 2010). Several metabolites were suggested as markers of PTD, therefore 
showing that metabolic profiling can be used to assess the risk of PTD (Romero et al., 2010). 
 
Premature rupture of the membranes (PROM) is defined as the spontaneous rupture of fetal 
membranes after 37 weeks of gestation before the occurrence of uterine contractions (Stuart et 
al., 2005). PROM is a quite common condition, occurring in approximately 8-10% of all 
pregnancies (Table 1.1, page 2) and increases the risk of maternal/neonatal sepsis, as well as the 
need for neonatal resuscitation at delivery (Stuart et al., 2005). Similarly to PTD, an early diagnosis 
of PROM is not available, being diagnosed when the first symptoms occur. It is therefore 
important to initiate the antibiotic therapeutic prophylactics as soon as diagnosed, in order to 
reduce the risk of infections and sepsis (Hobel, 2004; Graça, 2005c). However, there seems to be 
an association between PROM and fetal membrane weakening mediated by biochemical 
processes involving degradation and dissociation of amnion membranes collagen with the 
involvement of the proteolytic enzymes, matrix metalloproteinases and apoptosis events (Stuart 
et al., 2005; Moore et al., 2006). A closer investigation of such processes should be useful to 
understand the pathophysiology of PROM and ultimately aid the development of predictive 
diagnostic methods.   
 
1.2.4. Intrauterine growth restriction (IUGR) 
 
Intrauterine growth restriction (IUGR) is an important cause of perinatal mortality and 
morbidity and occurs in 7-15% of all pregnancies worldwide (Table 1.1, page 2). IUGR can be 
defined as giving rise to birth weights below the 10th percentile for a given gestational age    
(Figure 1.3).  
 
 
 
 
 
 
 
 
 
 
Figure 1.3 - Birth weight as a function of gestational weeks. Intrauterine 
growth restricted (IUGR) fetuses have birth weight below the 10th 
percentile (pct) (Adapted from Cetin and Alvino, 2009). 
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This definition is different from small for gestational age (SGA), which refers to small but 
anatomically normal fetus with an appropriate AF volume and growth rate, which means the 
outcome will usually be a normal, constitutionally small newborn (Hobel, 2004). 
Two types of fetal IUGR have been described: symmetric, when growth of both fetal head and 
body is inadequate, which has been more commonly associated with FM and occurring as early as 
during the 2nd trimester; and asymmetric, when growth restriction occurs usually late in 
pregnancy, and head size is proportionally larger than the abdominal size (Hobel, 2004).  
IUGR fetuses are prone to problems such as meconium (fetal feces) aspiration, asphyxia, 
polycythaemia, hypoglycaemia and mental retardation (Hobel, 2004). The risk factors, for the 
development of IUGR, result from the pre-existence of maternal diseases (autoimmune, 
endocrine, cardiovascular, hypertension, renal), pregnancy-induced hypertension (preeclampsia), 
alcohol or drug addition, smoking, acquired infections (cytomegalovirus, rubella, herpes simplex, 
malaria) and abnormal placental position. Moreover, FM can also lead to IUGR (Hobel, 2004; Cetin 
and Alvino, 2009). Also, IUGR is thought to be related to an abnormal placental phenotype and, as 
a consequence, to deficient placental metabolism and transport, thus modifying the normal 
supply of nutrients, which may lead to fetal undernutrition (Cetin and Alvino, 2009). 
The diagnosis of IUGR relies solely on the identification of risk factors, the establishment of the 
correct fetal gestational age, the continuous assessment of fetal growth by fundal height (a 
measure of the size of the uterus, which may be used as first screening method) and by 
ultrasound (Hobel, 2004). In cases where IUGR is suspected, delivery can be performed at 34 
weeks or later, provided that lung maturity is ensured. Also, regardless of the type of labour, the 
mother must be carefully monitored to detect the earliest sign of fetal distress. In order to avoid 
hypoglycaemia and respiratory distress in IUGR newborns, careful monitoring of blood glucose, 
and the respiratory function should be performed after birth (Hobel, 2004). 
 
1.2.5. Preeclampsia (PE) 
 
Preeclampsia (PE) is a multisystem disorder that is unique to pregnancy and is characterized by 
the new onset of hypertension and proteinuria in the latter half of pregnancy (Castro, 2004). It is 
associated with significant morbidity and mortality rates for the mother and the neonate, 
affecting about 2 to 6% of pregnancies (Table 1.1, page 2) (Walker, 2000; Farina et al., 2011). 
Specifically, PE can cause several maternal disorders such as placental abruption, disseminated 
intravascular coagulation, renal failure, hepatic failure, permanent neurologic lesions and also 
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increased risk of essential hypertension after pregnancy. Fetal and neonatal complications include 
IUGR, prematurity and perinatal death (Castro, 2004).  
PE is more prevalent in the first pregnancy (Raijmakers et al., 2004), but it can also occur in 
women with previous pregnancies (multiparas), especially in those women with previous 
preeclampsia, twins, and in those with either pre-existing vascular disease or conditions 
associated with increased cardiovascular risk, including renal disease, hypertension, diabetes, 
thrombophilia, and obesity (Castro, 2004; Raijmakers et al., 2004). 
The diagnosis of PE follows two criteria: the development of hypertension (systolic blood 
p         ≥140 mmHg            c b     p         ≥90 mmHg) after the 20th week of pregnancy in 
women with previously normal blood pressures; and the development of proteinuria, which may 
be defined as protein content >0.3 g in a 24 hour urine collection or an urinary protein/creatinine 
ratio 30 mg/mmol (Castro, 2004; Raijmakers et al., 2004). When patients have liver dysfunction, 
thrombocytopenia, and haemolysis, they are classified as having HELLP syndrome (i.e., 
haemolysis, elevated liver enzymes, low platelets), which is a more severe form of PE (Raijmakers 
et al., 2004). 
Commonly, a distinction between early and late PE has been used since there is evidence that 
more severe disease is associated with early onset (prior to 34 g.w.) supporting the concept that 
the etiology of this disease may be different from that of later onset PE. Early onset disease 
appears to be mediated by the placenta, and is associated with abnormal uterine artery flow, 
IUGR, and adverse maternal and fetal outcomes. Later onset of the disease (after 34 g.w.) has 
b       k      m        “c             ”   c        c     b  y m        x (   )      m y b  
associated with more favourable outcomes (Turner, 2010). Several metabolic factors have also 
been associated with PE, such as the metabolic syndrome (dyslipidaemia, hyperinsulinaemia, 
hyperglycaemia, hypertension and obesity), high maternal amino acid concentrations (Evans et 
al., 2003; Turner et al., 2008), altered maternal lipid and ketone bodies content (Turner et al., 
2007) and oxidative stress (Raijmakers et al., 2004; Turner et al., 2009). 
Although PE appears suddenly in the 3rd trimester, the initial damage that triggers it, very likely 
occurs in the 1st trimester of pregnancy at the time when trophoblast cell differentiation/invasion 
initiates (Farina et al., 2011). The identification of reliable screening markers would thus permit 
major improvements in obstetric care through better targeting and antepartum surveillance. 
Although a great number of possible predictive methods and markers have been investigated 
(Kenny et al., 2010; Farina et al., 2011; von Dadelszen et al., 2011; Oh et al., 2012), the results are 
diverse and some of them are conflicting and population dependent (Farina et al., 2011). Delivery 
Introduction 
14 
 
is the only possible cure for PE, for which it is recommended preferably after 34 g.w. if there is no 
fetal compromise, or in more severe cases after a period of stabilization of the disease, regardless 
of the gestational age of the fetus (Castro, 2004).  
 
1.2.6. Gestational Diabetes Mellitus (GDM) 
 
Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance with onset 
or first recognition during pregnancy (Metzger and Coustan, 1998), usually after 24-28 g.w. (ADA, 
2004). The prevalence of GDM may range from 1 to 14% of all pregnancies (Table 1.1, page 2), 
depending on the population studied and the diagnostic tests employed (ADA, 2004). 
GDM affected pregnancies have been associated to fetal macrossomia, delayed fetal organ 
maturity, FM, increased frequency of maternal hypertensive disorders, caesarean delivery 
(Gambone et al., 2004), increased risk of post-natal maternal diabetes mellitus and, in more 
severe cases, an increased risk of intrauterine fetal death during the last 4–8 weeks of gestation 
(ADA, 2004). Several organ and vascular complications in pregnant women may then occur in 
GDM (Gambone et al., 2004). Mothers with GDM also show evidence of altered ketogenesis and 
higher plasma concentrations of -hydroxybutyrate (Tisi et al., 2011) as well as altered placental 
amino acid exchange (Cetin et al., 2005). Early perturbations of glucose and insulin has also been 
observed in women latter developing GDM (Star et al., 1997; Tisi et al., 2011). 
GDM screening is generally performed between 24 and 28 weeks of gestation (ADA, 2004; 
Gambone et al., 2004). However, women with clinical characteristics consistent with a high risk of 
GDM (marked obesity, personal history of GDM, glycosuria, or a strong family history of diabetes) 
should perform the screening as soon as feasible (ADA, 2004).  
GDM screening can be performed by maternal serum or plasma glucose testing either fasting, 
or 1 hour after the oral intake of 50g of glucose (glucose challenge test or O'Sullivan's test)  
(Gambone et al., 2004). If values indicative of glucose intolerance are obtained, that is glucose 
v      >95 mg/ L      g         ≥140 mg/ L           g      '     v  '           p c  v  y   m   
are advised to undertake the 3 hours oral glucose tolerance test (OGTT). The OGTT consists in the 
measurement plasma glucose fasting and after 1, 2 and 3 hours after 100g oral glucose ingestion.  
The test has diagnostic value for GDM if at least two concentrations values exceed the threshold 
values shown in Table 1.5.    
Strict metabolic control is needed after diagnosis of GDM to decrease the incidence of the 
adverse conditions described above. Therefore, an appropriate diet, insulin and exercise should 
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be offered to pregnant woman in order to achieve and maintain euglycaemia (Gambone et al., 
2004; Hod et al., 2008). 
Table 1.5 - Threshold concentration values for oral glucose tolerance test 
according to the American Diabetes Association (ADA, 2004). 
Concentration mg/dL mmol/L 
Fasting 
1 h 
2 h 
3 h 
95 
180 
155 
140 
5.3 
10.0 
8.6 
7.8 
 
 
1.3. Prenatal diagnosis research through biofluid composition 
 
1.3.1. Chemical composition of human amniotic fluid 
 
Amniotic fluid (AF) fills up the amniotic sac preventing contraction of the uterus, allowing 
space for the growth, movement and development of the fetus. It also has a protective role 
against potentially pathogenic bacteria (Toot and Lu, 2004). The formation of AF initiates in the 1st 
trimester from the free passage of molecules such as amino acids through fetal skin and from the 
coelomic fluid (CF), an ultrafiltrate of maternal plasma that fills the exocoelomic cavity (Figure 1.1, 
section 1.1, page 1) (Jauniaux and Gulbis, 2000). Gradually, AF volume increases mainly due to 
production of urine by the fetus, increasing from 30 mL at 10 g.w. to 350 mL at 20 g.w. and 
eventually reaching 1000 mL at 38 g.w. AF volume slowly declines until term mainly due to fetal 
swallowing (Lind, 1981; Graça and Barros, 2005). 
The chemical composition of AF changes from 1st to 2nd trimester, particularly due to the 
keratinisation of the fetal skin which minimizes the free diffusion of small molecules and due to 
the development of fetal kidney filtration. Lung and tracheal fluid contribute to changes in AF 
composition the 3rd trimester due to an increase of lung surfactant contents such as lecithin 
(phosphatidylcholine) and surfactant proteins (Liu et al., 1998b; Liu et al., 2000). In result, several 
ions, metabolites and other small organic molecules can be found in AF, such as glucose, urea, 
creatine, creatinine, uric acid, amino acids, lactic acid, ketone bodies, lipids (triglycerides, 
phospholipids and cholesterol), fatty acids, long-chain alcohols, bile acids, bilirubin, vitamins, 
hormones and prostaglandins, whose compositions change with advancing gestational age (Lind, 
1981; Sims et al., 1996; Jauniaux et al., 2005; Ottolenghi et al., 2010). Some of the most important 
constituents of AF and their concentrations at the three trimesters of pregnancy are summarized 
in Table 1.6. 
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Table 1.6 - Concentrations of human AF constituents measured at the different gestational age ranges 
indicated inside brackets. a (Lind, 1981); b (Jauniaux et al., 2005); c(Groenen et al., 2004), d (Ottolenghi 
et al., 2010), e (Gao et al., 2009). U, enzymatic units (mol/min). 
 Concentrations (gestational weeks) 
Compound 1
st
 trimester 2
nd
 trimester 3
rd
 trimester 
 
Electrolyte ions (mmol/L)
 a
 
   
Sodium 134  (11-12) 134  (17-20) 131  (33-36) 
Potassium  3.9  (11-12) 4.0  (17-20) 4.2  (33-36) 
Chloride 103  (11-12) 111  (17-20) 108  (33-36) 
Phosphate 0.99  (10-16) - 0.44  (35-40) 
Bicarbonate 16.7  (11-14) 16.5  (17-20) 15.7  (37-40) 
Calcium 1.80  (11-12) 1.90  (17-20) 1.90  (33-36) 
Magnesium 0.70  (11-12) 0.65  (17-20) 0.55  (33-36) 
 
   
Amino Acids (mol/L)
 a
    
Alanine 401  (7-18) 312  (15-20) 143  (33-37) 
-aminobutyric acid 15  (7-18) 16  (15-20) 6  (33-37) 
Arginine 15  (7-18) 43  (15-20) 20  (33-37) 
Aspartic acid 8  (7-18) 17  (15-20) 6  (33-37) 
Citruline 6  (7-18) 23  (15-20) 4  (33-37) 
Cystine 89  (7-18) 63  (15-20) 57  (33-37) 
Ethanolamine - 20  (15-20) 13  (33-37) 
Glutamic acid 149  (7-18) 227  (15-20) 76  (33-37) 
Glutamine 50  (7-18) 186  (15-20) 120  (33-37) 
Glycine 164  (7-18) 124  (15-20) 40  (33-37) 
Histidine 102  (7-18) 76  (15-20) 40  (33-37) 
Hydroxyproline - 42  (15-20) 17  (33-37) 
Isoleucine 47  (7-18) 45  (15-20) 13  (33-37) 
Leucine 106  (7-18) 80  (15-20) 24  (33-37) 
Lysine 319  (7-18) 239 (15-20) 150  (33-37) 
Methionine 25  (7-18) 25  (15-20) 21  (33-37) 
Methylhistidine - 1  (15-20) - 
Ornithine 51  (7-18) 38  (15-20) 20  (33-37) 
Phenylalanine 77  (7-18) 59  (15-20) 29  (33-37) 
Proline 198  (7-18) 332  (15-20) 203  (33-37) 
Serine 235  (7-18) 186  (15-20) 120  (33-37) 
Threonine - 186  (15-20) 120  (33-37) 
Taurine 124  (7-18) 83  (15-20) 101  (33-37) 
Tyrosine 64  (7-18) 51  (15-20) 21  (33-37) 
Valine 200  (7-18) 194  (15-20) 69  (33-37) 
    
Amino acids / nucleotide metabolites
 a
   
Creatinine (mol/L) - 70  (15-22) 115  (33-34) 
Uric acid (mol/L) - 250  (19) 547  (34) 
Urea (mmol/L) 3.90  (10-16) 3.89  (19) 5.56  (35-40) 
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Table 1.6 - (cont.) 
 Concentrations (gestational weeks) 
Compound 1
st
 trimester 2
nd
 trimester 3
rd
 trimester 
Sugars 
a, b, c
    
Glucose (mmol/L) 3.0  (5-12)
b
 2.51  (19)
a
 2.25  (37)
a
 
Myo-inositol (mol/L) 100  (5-12)
b
 396 (15)
c
 137  (39)
c
 
Mannose (mol/L) 70  (5-12)
b
 - - 
    
Organic acids 
a, d
    
Lactic acid (mmol/L)
a
 9.1  (10-16) 9.8  (17-20) 9.8  (33-36) 
Citric acid (mol/L)
a
 - 345  (19-24) 277  (33-36) 
Succinic acid (mol/L)
d
 8.4  (<15) 9.8  (15-18) 65.9  (29-36) 
Pyruvic acid (mol/L)
 a
 - - 19  (37-40) 
Fumaric (mol/L)
d
 6.3  (<15) 6.2  (15-18) 5.4  (29-36) 
Malic acid (mol/L)
d
 16.4  (<15) 16.9  (15-18) 13.3  (29-36) 
-hydroxybutyric acid (mol/L)
d
 48.5  (<15) 40.9  (15-18) 45.8  (29-36) 
-oxoglutaric acid (mol/L)
d
 2.5  (<15) 2.4  (15-18) 4.0  (29-36) 
Pyroglutamic acid (mol/L)
d
 33.9  (<15) 61.2  (15-18) 56.3  (29-36) 
Methylmalonic acid (mol/L)
d
 0.7  (<15) 0.7  (15-18) 0.6  (29-36) 
    
Lipids 
a
    
Total lipids (mg/L) 170  (8-24) 331  (35-39) 
Cholesterol (mg/L) 196  (9-24) 57.4  (32-43) 
Bile acids (mg/L) - - 0.5  (28-42) 
Phosphatidylcholine (mg/L) 2.9  (12-14) 2.0  (16-23) 86.3  (36-39) 
Sphingomyelin (mg/L) 4.2  (12) 5.0 (16-22) 21  (34) 
    
Proteins 
a, e
    
Total protein (g/L) 
a
 3.3  (13-16) 5.4  (17-20) 2.5  (33-40) 
Albumin (g/L) - 4.41  (15)
e
 1.23  (36-40)
a
 
Transferrin (mg/L) - 330 (15)
e
 69  (31-42)
a
 
IgG (mg/L)
 a
 330  (11-15) 410  (16-20) 120  (36-40) 
IgA (mg/L) 
a
 28  (11-15) 32  (16-20) 29  (36-40) 
1-antitrypsin (mg/L)
 a
 - 290  (16-20) 132  (31-42) 
2-microglobin (mg/L)
 a
 - 200  (16-20) 6.3  (36) 
-fetoprotein (mg/L)
 a
 15  (14) 16  (17) 1.3  (31-42) 
    
Enzymes (U/L) 
a
    
Lactate dehydrogenase - 87  (19) 130  (33-42) 
Alkaline phospatase - 18.4  (19) 20.5 (37) 
    
Bilirubin (mol/L) 
a
 - 2.2 (15) 3.9  (32-43) 
    
Hormones 
a
    
Estriol (mol/L) - - 2.34 
Cortisol (total) (nmol/L) - 83  (20) 200  (35-40) 
Chorionic gonadotropin (g/L) 933-1139 (8-12) 589-783 (12-20) 42-57 (32-40) 
Thyroxin (total) (nmol/L) - 5.12  (15-19) 5.66  (35-42) 
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Regarding the ionic composition, initially, AF osmolarity is similar to that of maternal plasma, 
then decreasing to values lower than those of maternal plasma with increasing gestational age 
(Graça and Barros, 2005). Several electrolyte ions such as sodium, phosphate, bicarbonate and 
magnesium tend to decrease slightly with gestational age except, potassium, calcium which 
remain practically unchanged and chloride which increases slightly (Table 1.6). An increase in 
creatinine, uric acid and urea can also be observed during gestation (Table 1.6) reflecting kidney 
maturation and increased amino acid and nucleotide metabolisms (Lind, 1981; Sims et al., 1996).  
In terms of amino acids and sugars, during development, a general decrease in major amino 
acids (alanine, glutamate, glycine, histidine, isoleucine, leucine, lysine, phenylalanine, serine, 
threonine, tyrosine and valine) and glucose is observed, especially by the transition between the 
2nd and 3rd trimester (Table 1.6), mostly due to increasing reabsorption by the kidney and 
increased protein synthesis (Lind, 1981). Another sugar, myo-inositol, tends to increase in 
concentration in AF as a result of enhanced biosynthesis from glucose and in order to participate 
in the biosynthesis of phosphatidylinositol (Groenen et al., 2003). 
With respect to organic acids, most of the major ones present in AF (lactic, citric, pyruvic, 
fumaric, malic, -hydroxybutyric and -oxoglutaric acids)  do not vary significantly during normal 
pregnancy (Table 1.6), with the exception of succinic acid which shows an increase especially 
during the 3rd trimester and pyroglutamic acid which increases from 1st to 2nd trimester 
(Ottolenghi et al., 2010). 
Regarding lipids and proteins, the lipid content of AF generally increases during pregnancy, 
particularly during the 3rd trimester. Phospholipids are among the principle contributors to the 
total lipid content (Table 1.6). Their concentration increases sharply towards the end of gestation 
in parallel with lung maturation, since phospholipids are major constituents of human pulmonary 
surfactant (80%), from which phosphatidylcholine is the most abundant constituent (Liu et al., 
1998a). Protein content tends to increase from 1st to 2nd trimester primarily due to free diffusion 
through fetal skin and also due excretion through fetal urine, as occurs for example with -
fetoprotein and 2-microglobulin (Lind, 1981). Protein content increases progressively until the 
32nd week, decreasing afterwards until labour, mainly due to fetal swallowing (Lind, 1981). 
Following a similar trend is the heme degradation product bilirubin (Table 1.6). The enzymatic 
activities change during the course of pregnancy in a pattern roughly parallel to the protein 
concentration (Table 1.6). An exception is -amylase, which may reach high levels during the 3rd 
trimester. Its most probable origin is from fetal urine and saliva (Lind, 1981).  
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Finally, several hormones, second messengers and prostaglandins can be found in AF (Table 
1.6) most of them increasing in concentration during gestation (Lind, 1981). These include the 
non-steroid hormones thyroxin, chorionic gonadotropin, insulin, epinephrine and norepinephrine, 
the steroid hormones from which cortisols and estriols are the most abundant in AF, as well the 
second messenger cyclic adenosine monophosphate (cAMP) (Lind, 1981).  Prostaglandins, from 
which the most abundant in AF are PGF2 e PGF2
  rise sharply during labour due to their 
involvement in uterine contraction (Lind, 1981). 
 
1.3.2. Human amniotic fluid as a diagnostic media 
 
Amniotic fluid has long been considered the ideal media to assess fetal well-being and 
maturation. Indeed, collection of AF is essential for diagnosis of open tube defects and karyotype 
analysis, as described in previous sections 1.2.1 (page 4) and 1.2.2 (page 8), respectively. 
Moreover, AF analysis may be carried out in the diagnosis of infections (CMV, toxoplasmosis, 
rubella, etc.), to predict the severity of fetal haemolysis in red-cell alloimmunized pregnancies 
(determination of AF bilirubin levels) or in the assessment of fetal lung maturity through the 
measurement of phosphatidylcholine/sphigomyelin ratio at the 3rd trimester (Underwood et al., 
2005).  
Extensive work has been conducted in the last three decades in AF composition, to find new 
markers of prenatal disorders, with great contributions from emerging analytical platforms, 
namely nuclear magnetic resonance (NMR) spectroscopy, infrared spectroscopy (IR), mass 
spectrometry (MS) and capillary electrophoresis (CE). 
Analysis of AF by NMR spectroscopy was introduced in the early 80s, with first applications of 
low-field 1H NMR in-vivo and in-vitro to diagnosis the presence of meconium (fetal faeces) in AF 
(Bene, 1980; Bene et al., 1982; Borcard et al., 1982). The potential of 1H NMR spectroscopy to 
probe low molecular weight (Mw) molecules, especially clinically relevant metabolites, was later 
recognized (Nelson et al., 1987). In this study 18 different metabolites were identified including 
several amino acids, lactate, glucose and creatinine using 60MHz and 360MHz spectrometers 
(Nelson et al., 1987). Two subsequent studies applied 1H NMR spectroscopy (at 300MHz) to 
quantify low Mw metabolites present in the mili- and micro-molar ranges, including creatinine, 
glucose, organic acids (acetate, citrate, and lactate) and several amino acids (alanine, histidine, 
leucine, phenylalanine, tyrosine and valine), using either standard addition procedures (McGowan 
et al., 1993) or through the use of internal standards (Sims et al., 1993b). Two-dimensional 1H 
NMR spectroscopy was used for the first time to study AF (Sims et al., 1993b). This thesis builds 
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on this type of knowledge, as it will be shown in chapter 4, in order to expand the knowledge of 
AF composition by NMR spectroscopy. 
In terms of applications to the study of disorders, an early study using high field 1H NMR 
spectroscopy (600 MHz) focused in PE, spina-bifida, trisomy 21 and GDM (Bock, 1994). Significant 
variations were noted in the levels of choline, succinate, acetate in PE and in the levels of  lactate, 
glutamate, and acetate in spina-bifida cases (Bock, 1994). Other studies have found significant 
metabolite variations in AF due to the occurrence of disorders such as trisomy 21 (Sims et al., 
1993a), in cases of decreased digestive enzyme activities and cystic fibrosis (Le Moyec et al., 
1994), maternal insulin dependent diabetes mellitus (McGowan et al., 1999) and spina-bifida 
(Groenen et al., 2004). 1H NMR spectroscopy was also used for a comparative study of AF 
composition between the 2nd and 3rd trimesters (Sims et al., 1996; Cohn et al., 2009) or to predict 
gestational age based on AF through quantitation of several metabolite signals (Cohn et al., 2010). 
The prediction of lung maturity has also been an important application of AF NMR 
spectroscopy in-vitro, particularly through the use of 31P NMR spectroscopy to quantify 
phosphatidylcholine and sphingomyelin, which provided a reliable and straightforward alternative 
to the less reproducible method thin layer chromatography (TLC) commonly used to determine 
the phosphatidylcholine/sphingomyelin ratio (Pearce et al., 1991; Pearce et al., 1993). Spectral 
measurements of choline and related compounds by 1H NMR were also attempted to study fetal 
lung maturation (Clifton et al., 2006; Joe et al., 2008), which resulted in studies of choline and 
related compounds in vivo using standard clinical magnetic resonance imaging (MRI) instruments 
(Fenton et al., 1998; Clifton et al., 2006; Kim et al., 2008). 
The use of infrared spectroscopy in AF analysis has focused in the use of near-infrared (NIR) 
and mid-infrared (MIR) methods as alternatives for the replacement of TLC for the measurement 
of phosphatidylcholine/sphingomyelin ratio (Kobayashi et al., 1990; Liu et al., 1997; Liu et al., 
1998b), and the fluorescence depolarization assays (Liu et al., 2000) in the prediction of lung 
maturity. Other work has also explored the quantitation of glucose and lactate using MIR spectra 
to study preterm infection and fetal distress (Liu and Mantsch, 1999). More recently a NIR study 
of 2nd trimester AF has been reported, describing the development of preliminary predictive 
models for preterm birth, based on genetic algorithm analysis and showing the promise of NIR 
spectroscopy for early diagnosis (Power et al., 2011). 
The use MS coupled to a separation technique such as liquid (LC-MS) or gas chromatography 
(GC-MS) methods for 2nd trimester AF metabolic profiling has been introduced as an approach to 
identify patients at risk for preterm delivery (Romero et al., 2010). More studies have been 
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carried out on 2nd trimester AF using both LC-MS and GC-MS methods in targeted approaches, for 
the prenatal diagnosis of several inborn errors of metabolism such as tyrosinaemia type I or 
propionic acidaemia (Kumps et al., 2004), Smith-Lemli-Opitz syndrome (Griffiths et al., 2008; 
Amaral et al., 2010) and phenylketonuria (Amorini et al., 2012). 
Changes in the protein content of AF in connection with the occurrence of some disorders 
have also been the focus of several studies. Indeed, MS-based proteomics studies have revealed 
important changes in AF proteins in individuals affected by Turner syndrome (Mavrou et al., 
2008), Kleinfelter syndrome (Anagnostopoulos et al., 2010), trisomies 18 and 21 (Wang et al., 
2009; Kolialexi et al., 2011), congenital heart defects (Nath et al., 2009), IUGR (Cecconi et al., 
2011), PTD (Buhimschi et al., 2008; Bujold et al., 2008; Romero et al., 2008), PROM (Thadikkaran 
et al., 2005; Wang et al., 2011b) and PE (Joong Shin et al., 2008; Oh et al., 2012), which may 
provide important clues for biomarkers of such disorders (Horgan et al., 2009).  
With respect to capillary electrophoresis (CE), this technique has also been used in the 
characterization of  2nd trimester human AF, enabling the simultaneous detection of the major AF 
proteins (albumin, transferrin, and IgG) and also low Mw molecules such as uric acid (Stewart et 
al., 2001; Gao et al., 2008; Gao et al., 2009). In one of such studies, authors have found an 
association with the increase in the 2nd trimester AF concentrations of transferrin and the later 
occurrence of PTD, and that the uric acid concentration is a good predictor of newborn birth 
weight (Gao et al., 2008). CE has also been employed in the simultaneous analysis of AF amino 
acids and amino acid derivatives (Tuma et al., 2006). More recent studies explored the use of CE 
electrophoretic profiles of 2nd trimester AF and chemometric methods for the early prediction of 
GDM and macrosomia (Boisvert et al., 2012a; Boisvert et al., 2012b). 
 
1.3.3. Prenatal research using other biofluids 
 
In spite of the great potential of AF for diagnosis and monitoring of pregnancy, amniocentesis 
still carries some risk of fetal loss and preterm birth. For this reason the search for novel less-
invasive diagnosis methods has been an important field of activity, especially using biological 
materials obtained less invasively such as maternal blood and urine. 
The analysis of circulating nucleic acids and cell free DNA from maternal plasma from the 2nd 
trimester have been tested for the prenatal diagnosis of genetic disorders (Ding et al., 2004), the 
detection of trisomy 21 (Ghanta et al., 2010; Bianchi et al., 2012), trisomies 18 and 13 (Chen et al., 
2011; Bianchi et al., 2012); and monosomy X (Turner syndrome) (Bianchi et al., 2012). Cell free 
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fetal DNA was also found in measurable amounts in 3rd trimester maternal urine, however, its low 
concentration makes it inappropriate for non-invasive prenatal diagnosis (Majer et al., 2007). 
Specific metabolites and proteins from maternal serum and plasma have also been suggested 
as predictive markers of PE, IUGR and GDM. Recently, the maternal serum concentration of 
placental growth factor (PlGF) and the protein PAPP-A in the 1st trimester were evaluated as 
screening markers for early-onset PE and IUGR, thus revealing that only placental growth factor 
was a moderate predictor of PE (Vandenberghe et al., 2011). Maternal blood samples obtained at 
11–14 g.w. were analysed for 40 acylcarnitine species and 32 amino acids by LC-MS, of these only 
hydroxyhexanoylcarnitine, alanine, phenylalanine, and glutamate were able to predict  PE (Odibo 
et al., 2011). With respect to GDM, it has been found that maternal plasma insulin and 
adiponectin concentrations, when measured at 11 g.w. may be predictive of gestational diabetes 
(Georgiou et al., 2008). 
Maternal urine metabolite composition has also been explored. For instance, the amino acid 
composition of urine from preeclamptic women has been evaluated revealing disturbances in 
urinary amino acid excretion (Glew et al., 2004). The increase in maternal urine inositol 
phosphoglycan P-type has recently been identified as a possible marker of PE (Scioscia et al., 
2007a; Paine et al., 2010). The same metabolite was also found to be associated with GDM in 
another study, where an increased urinary excretion of inositol phosphoglycan P-type was 
detected in GDM cases and was positively correlated with blood glucose levels (Scioscia et al., 
2007b). Maternal urine measurements of steroid compounds were also found effective for 
detecting fetal steroid sulfatase deficiency in 2nd trimester pregnancies (Marcos et al., 2009). 
With respect to other fluids, cervicovaginal secretions and saliva analysis have found some use 
in the prediction of PTD. In fact, the high concentration of the fetal protein fibronectin detected at 
22-24 g.w. may be predictive of PTD, whereas the salivary concentration of unconjugated-estriol 
levels seem to have predictive value for late PTD (near 36 g.w.) (Goldenberg et al., 2005). 
 
1.4. Metabonomics: principles and applications 
 
1.4.1. Principles and general applications 
 
Systems biology seeks to interpret of the complex interactions in an biological system using a 
holistic approach (Snoep and Westerhoff, 2005), and several disciplines have emerged from it 
namely, genomics (the study of genes), transcriptomics (the study of gene expression), 
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proteomics (the study of protein expression) and metabolomics (the nonbiased identification and 
quantification of all metabolites in a biologic system) (Fiehn, 2002; Ellis et al., 2007). 
The concept of metabonomics may be viewed as a successor of the term metabolomics, and 
can be defined as the quantitative measurement of the dynamic multi-parametric metabolic 
response of living systems to pathophysiological stimuli or genetic modification (Nicholson et al., 
1999). Both terms are often used interchangeably in the literature in association with terms such 
   “m   b   c p       g”     “m   b   c    g  p      g”. The latter has also been defined as the 
global high-throughput analysis to provide sample classification from different biological status or 
origin, for instance to discriminate between disease/healthy subjects without the need for 
metabolite identification and quantification (Ellis et al., 2007). In the context of systems biology, 
metabonomics has some advantages over genomics, transcriptomics or proteomics in that 
metabolites provide real biological endpoints, therefore providing markers for disease diagnosis 
or evaluation of beneficial or adverse drug effects (Lindon et al., 2004). 
Metabonomics involves the generation of metabolic databases based on tissue or biofluid 
samples (such as urine, blood, etc.), for control animals and humans, diseased patients, animals 
models used in drug safety testing, etc., allowing the simultaneous acquisition of multiple 
biochemical parameters on biological samples (Lindon et al., 2004). This requires the use of 
analytical platforms that provide high-throughput, reproducibility and atom-specific molecular 
structural information. Such platforms are NMR spectroscopy and MS in tandem with liquid (LC-
MS) or gas chromatography (GC-MS) (Lindon and Nicholson, 2008a). Nevertheless, vibrational 
spectroscopy (infrared and Raman spectroscopies) have been also used been used in an 
increasing number of metabonomics (metabolic fingerprinting) studies (Ellis and Goodacre, 2006). 
Vibrational spectroscopy methods presents the clear advantages of reproducibility, rapidity, low 
cost, and portability (Ellis and Goodacre, 2006). The interpretation of the complex metabolite 
information gathered in metabonomics experiments requires the use of multivariate statistical 
methods (Lindon and Nicholson, 2008a), which will be explained in detail in chapter 2. 
Metabonomics has been used in several different contexts ranging from the study of drug 
toxicity (Azmi et al., 2005; Coen et al., 2007; Dong et al., 2012), drug metabolism and 
development (Lindon et al., 2006; Keun et al., 2008), to evaluate the effects of nutritional 
intervention (Rezzi et al., 2007) and in epidemiological studies such as the study of the human 
metabolic phenotype and its association with diet and blood pressure (Holmes et al., 2008). 
Applications of metabonomics to the clinical research span several areas either using animal 
models or human subjects. Some of these applications include the study of diabetes (Griffin and 
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Vidal-Puig, 2008), diagnosis of coronary heart disease (Brindle et al., 2002), ischemic heart failure 
(Kang et al., 2011), several types of cancers including lung (An et al., 2010; Carrola et al., 2011), 
liver (Chen et al., 2009) and kidney (Kind et al., 2007); in the context of liver and kidney 
transplantation assessment (Duarte et al., 2005; Chen et al., 2012), autism (Yap et al., 2010), 
glycogen storage disease (Duarte et al., 2007), neurological diseases (Sinclair et al., 2010), in the 
understanding of parasitic infections (Wang et al., 2004; Garcia-Perez et al., 2010) and also in 
neonatal screening (Atzori et al., 2009; Dessì et al., 2011). 
 
1.4.2. Metabonomics in prenatal health research 
 
Metabonomics studies involving prenatal diagnosis have been carried out using blood plasma, 
with strong emphasis on the study of PE (Kenny et al., 2005; Turner et al., 2007; Kenny et al., 
2008; Turner et al., 2008; Kenny et al., 2010; Heazell et al., 2012). Indeed several metabolites 
were found by 1H NMR to be altered in plasma leading to the observation of low lipid and ketone 
bodies and different aromatic amino acid profiles (Turner et al., 2007; Turner et al., 2008). Several 
metabolites detected by Gas Chromatography-Mass Spectrometry (GC-MS) (Kenny et al., 2005) 
and Ultra-Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) were found to be 
associated with the onset of PE (Kenny et al., 2008). In addition, an UPLC-MS study of maternal 
plasma (15 g.w.) allowed a multivariate predictive model to be built for PE based on 14 relevant 
metabolites (Kenny et al., 2010). Moreover, a recent 1H NMR metabonomics study has found 
metabolite differences in cord and maternal blood of very-low birth weight neonates (Tea et al., 
2012), while a study using UPLC-MS found variations in free fatty acids, glycerolipids, 
progesterone metabolites, sterol lipids, vitamin D metabolites, and sphingolipids associated with 
the occurrence of SGA, PTD and neonatal intensive care admission in 3rd trimester maternal 
plasma (Heazell et al., 2012). 
When compared to maternal blood plasma, metabonomics investigation on maternal urine is 
still underexplored. However, a recent report on 2nd trimester maternal urine and plasma 1H NMR 
on FM, pre-diagnostic GDM, pre-PTD, pre-PROM and CD, revealed important metabolite 
variations, thus laying the ground for potential development of less-invasive diagnostic based on 
metabonomics approaches for such disorders (Diaz et al., 2011).  
Amniotic fluid is an obviously interesting media to study in a metabonomics perspective and 
this is the main theme of this thesis, where metabonomics studies of FM, CD, pre-PTD, pre-
diagnostic GDM and pre-PROM (      et al., 2010; Graça et al., 2012; Graça et al., 2013), as well 
as pre-PE and pre-IUGR, are described. Furthermore, once the changes in AF composition are 
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established, it was of interest to investigate if equivalent and complementary information could 
be obtained in a non-invasive way that is, using maternal urine (Graça et al., 2012). This 
relationship between AF and urine was explored in chapter 7, using UPLC-MS. 
A few metabonomics studies have also been performed using other biofluids and tissues. 
Indeed, metabolic profiling have been performed using cervicovaginal secretions, thus revealing 
several possible metabolite marker candidates of PTD which were still unassigned (Auray-Blais et 
al., 2011). Placental tissues, namely on cultured placental explants, which have been used as 
models of hypoxia mimicking PE and SGA conditions have also been investigated (Dunn et al., 
2009; Horgan et al., 2010; Heazell et al., 2011). 
 
1.5. Aims and outline of this work 
 
The main goal of the work presented in this thesis was to study 2nd trimester AF composition 
from women appointed to amniocentesis using metabonomics approaches, in order to contribute 
further to the knowledge of the biochemistry of prenatal disorders and eventually to the 
development of complementary diagnostic methods for FM and CD, as well as predictive methods 
of disorders occurring later in pregnancy, namely PTD, PE, IUGR, GDM and PROM.  Second 
trimester maternal urine samples from some of the AF donors were also analysed in order to 
establish a relationship between AF compositional changes and those measured non-invasively 
through maternal urine.  This should contribute to the evaluation of fetal/maternal synergism, in 
relation to prenatal disorders. Hence, the work presented comprised the following specific aims: 
 
1  - Characterization of 2nd trimester AF by 1H NMR spectroscopy: a) establishment of  a protocol 
for the metabolic profiling of AF; b) assessment of compositional changes in AF during sample 
storage, handling and analysis; c) establishment of a database of metabolites of AF; 
 
2 - Characterization and prediction of pregnancy disorders by metabonomics of 2nd trimester AF 
using 1NMR, UPLC-MS and MIR: a) for the study of diagnosed FM and CD conditions; b) for the 
study of conditions occurring later in pregnancy, namely PTD, PROM, PE, IUGR and GDM;  
 
3 - Characterization of the effects of FM and pre-diagnostic GDM on 2nd trimester maternal urine 
and their relation to those measured in AF: a preliminary investigation. 
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2. Principles of the analytical methods employed 
 
2.1. NMR spectroscopy 
 
2.1.1. Principles of NMR spectroscopy  
 
Nuclear magnetic resonance (NMR) spectroscopy uses the magnetic properties of atomic 
nuclei to provide information on the structure and dynamics of molecules. Atomic nuclei possess 
an intrinsic angular momentum with both magnitude and direction, the nuclear spin, I,  which 
may be zero, a positive integer or a half integer (I = 0,  1/2, 1, 3/2, 2,...) (Harwood and Claridge, 
1999). However, only the positive integer and half integer nuclei are NMR active, such as 1H, 13C, 
19F, 31P  (I=1/2);  2H, 14N (I=1); or 17O (I =5/2). On the other hand, 12C and 16O have I=0 therefore are 
not NMR active. 
NMR active nuclei possess a net positive charge and motion (spinning), which produces a weak 
magnetic field, and therefore a magnetic moment, μ. When placed in an external magnetic field 
(B0), the nuclei experience a torque which forces them into precession about the axis of the 
external field (Figure 2.1a).  
 
Figure 2.1 - a) The precession of magnetic moment μ in the presence of an external magnetic 
field B0; b) the precession of magnetic moments in  (mI =1/2) and  (mI = - 1/2) spin states; c) 
the build-up of magnetization M due to the small excess of population of nuclei in the  spin 
state (Reproduced from Reynolds, 2000). 
 
This motion is known as Larmor precession and it occurs at a frequency   , the Larmor 
frequency, which is directly proportional to the strength of the applied magnetic field, B0. The 
Larmor frequency (  ) is also dependent on the magnetogyric ratio of the nucleus, γ, and it can 
be given by the expression:  
    
   
  
                                     [Eq. 2.1] 
a) b) c) 
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In the presence of the external magnetic field, the nuclei can assume several possible 
orientations or energy levels, defined by the magnetic quantum number, mI: 
                                                             [Eq. 2.2] 
Hence, with I=1/2,  two orientations are possible with two possible associated energy levels, 
parallel (lower energy, ) and anti-parallel (higher energy, ) to the field (Figure 2.1b). Therefore, 
energy transitions between levels involve a change in spin orientation.  
The frequencies required to promote these transitions correspond to the Larmor frequency of 
the nucleus, which fall in the radiofrequency (RF) region of the spectrum and are expressed by 
Equation 2.1. However, at equilibrium the distribution of the spin states is defined by the 
Boltzman distribution as: 
  
  
             [Eq. 2.3]  
where N is number of nuclei in a spin state, E, the energy of transition, R, the gas constant and T, 
the absolute temperature. According to this distribution, at equilibrium, there will be an excess of 
spins in the  state originating a bulk magnetization, M, parallel to the field B0 (Figure 2.1c). 
In order to observe a signal, that is a resonance, the nuclei are irradiated with an RF pulse, 
usually of s duration. In the case of I=1/2 nuclei, the RF pulse causes a change in the populations 
of the equilibrium spin states. Therefore, the magnetization vector, M (Figure 2.1c), shifts 
direction from the z axis to the rotating plane (x'-y' plane), where the magnetization M starts 
precessing at the Larmor frequency (Figure 2.2a). Due to the change in the orientation of the 
magnetization, the RF pulse is named a 90° pulse (Keller, 1988).  
 
Figure 2.2 - The NMR experiment: a) After an RF pulse, M lies in the x'-y' plane and precesses about 
the z-axis (Adapted from Keller, 1988); b) time domain free induction decay (FID) detected after the 
application of a RF pulse (solid bar) preceded by a preparation step and c) the same signal in the 
frequency domain after Fourier transformation of signal in (a) (Adapted from Rinaldi, 2000). 
 
After the short RF pulse, the magnetization vector gradually returns back into its original 
orientation, a process known as spin relaxation and can be described by equations 2.4 and 2.5.  
x'-y'
a) b) c)
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  ( )       
          [Eq. 2.4] 
   ( )   
          [Eq. 2.5] 
The spin relaxation is characterized by two time rate constants T1 and T2 describing the 
exponential decay of the longitudinal and transverse of magnetization components (Eq. 2.4 and 
2.5), respectively (Claridge, 2009). The T1 relaxation rate constant (Eq. 2.4) is related to the 
recovery of the z component of the magnetization (Mz) which involves the exchange of energy 
with the surroundings, being also known as spin-lattice relaxation (Claridge, 2009). T2, also known 
as spin-spin relaxation is related to the loss of magnetization in the x'-y' plane components of the 
magnetization and differs from nuclei to nuclei due to the local inhomogeneity they experience 
inside a sample. T2 is an important parameter in molecular dynamics since it is inversely related to 
molecular tumbling, and therefore to molecular size. Hence, smaller molecules are associated 
with higher T2 relaxation constants (Claridge, 2009). 
During relaxation, an oscillating current is created in the receiver coil of the NMR probe (Figure 
2.2a) enabling the detection of a signal known as the free induction decay (FID) (Figure 2.2b). The 
signal intensity in the time domain, f(t), is then transformed to the frequency domain, f(ω), 
through Fourier transformation (FT): 
 ( )  ∫  ( )
  
  
             [Eq. 2.6] 
resulting in the NMR spectrum (Figure 2.2c), a one-dimensional (1D), as explained better detail in 
the next section. However, according to the Heisenberg principle, there is an uncertainty in the 
spin energy levels, which means that in an NMR experiment the sample needs to be irradiated 
with a range of frequencies, rather than single frequency, during the 90° pulse (Harwood and 
Claridge, 1999). 
    Each nucleus is surrounded by electrons creating their own local magnetic field (Bloc), whose 
direction opposes that of the external magnetic field (B0), creating a shielding effect in the 
nucleus. The effective field experience by the nucleus (Beff) is then given: 
                                         [Eq. 2.7] 
In this way, each nuclei inside a molecule resonates at a different frequency () depending on the 
chemical environment hence, each nuclei has a different position in the NMR spectrum.  
Since the measured frequencies depend upon the strength of B0, the NMR spectrum scales are 
usually not reported as frequency (). Rather they are reported using a relative scale, the 
chemical shift, , a dimensionless property usually in the order of 10-6, with units of parts per 
million (ppm).  
Principles of the analytical methods employed 
30 
 
b)a)
The chemical shift is defined as: 
        
       
    
    ×  106    [Eq. 2.8] 
where ref is the frequency of a nucleus in the B0, for instance 500MHz for 
1H or 125MHz for 13C in 
a 11.7 Tesla magnet. The zero of the ppm scale is usually calibrated with the frequencies of the 
methyl groups bound to the silicon atom of the chemically inert compounds tetramethylsilane 
(TMS), dimethylsilapentanesulfonic acid (DSS) or trimethylsilyl propionate (TSP), which are used 
as 1H and 13C NMR chemical shift references. These are chosen specifically due to the shielding 
effect exerted by the silicon atom over the methyl groups, which results in lower observed 
frequencies. Figure 2.3 shows a series of 1H and 13C NMR chemical shifts ranges for various 
chemical environments (Atkins and de Paula, 2006).  
 
Figure 2.3 - The range of typical chemical shifts of a) 1H resonances and b) 13C resonances in several 
chemical groups (Adapted from Atkins and De Paula, 2006). 
 
The more shielded 1H or 13C nuclei resonate at lower frequencies, therefore are situated at 
lower ppm values, whereas less shielded nuclei (higher frequencies) are situated at higher ppm 
values (Figure 2.3). It is this shielding effect that enables chemical group identification and 
ultimately molecular structure determination. In addition, NMR is inherently quantitative since 
the intensity of an NMR resonance is proportional to the number of respective nuclei producing 
this resonance, provided that quantitative conditions are employed during spectral acquisition. 
These conditions are achieved if a delay of duration of 5×T1 of a isolated compound (or 5× the 
longest T1 of a compound in a mixture), which is approximately the time needed for a I=1/2 
nucleus to relax back to the equilibrium, is placed after each new RF pulse, thus enabling full 
relaxation of the nuclei under observation (Harwood and Claridge, 1999). A further effect relates 
to the interaction with neighbouring nuclei, known as spin-spin coupling, scalar coupling or J-
coupling. The interaction between two coupling neighbouring spins originates new energy levels, 
hence transitions differing very slightly in energy (Harwood and Claridge, 1999). This energy 
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difference causes splitting of the resonances observed and it can be measured through the 
coupling constant, J, measured in Hz (Hore, 2000). This effect is illustrated in the 1H NMR 
spectrum of ethanol shown in Figure 2.4. 
 
Figure 2.4 - 1H NMR spectrum of liquid ethanol, C2H5OH. Splitting of the resonances at 
chemical shifts 1.2 and 3.6 corresponding to protons of CH3 and CH2 groups arises from 
spin-spin coupling of the two sets of protons. No splitting of OH group is observed due to 
the rapid intermolecular change of the hydroxyl proton (Reproduced from Hore, 2000).  
 
2.1.2. One-dimensional (1D) and Two-dimensional (2D) NMR methods 
 
One-dimensional (1D) NMR experiments, introduced in the previous section, are usually 
composed of a preparation step, where the population of nuclei are allowed to reach equilibrium 
and an acquisition step (t1) immediately following the RF pulse or pulses. The resulting spectrum is 
obtained from the Fourier transformation (FT) of the free induction decay (FID) as shown 
previously in Figure 2.2b. There are 3 types of 1D 1H NMR experiments which are particularly 
useful to study complex mixtures such as biofluids. One of such experiments, mentioned 
throughout this work as "standard" experiment, consist of an RF 90° pulse usually preceded by a 
presaturation pulse to saturate the intense water signal, therefore used to register the 
resonances from all compounds present in a mixture. The other two experiments, edited on the 
basis of molecular diffusion coefficients (diffusion-edited) and on T2 relaxation times (such as the 
Carr-Purcell-Meiboom-Gill, CPMG spin-echo sequence, Meiboom and Gill, 1958) can be used to 
select only the contributions from macromolecules, or alternatively to select only the signals from 
the small molecules, respectively (Lindon and Nicholson, 2008a). 
The resulting 1D NMR spectra can be difficult to interpret due to strong signal overlap, 
especially the spectra of complex mixtures such as biofluids which are composed of several 
hundreds of measurable resonances (Lindon et al., 1999). Two-dimensional (2D) NMR 
spectroscopy methods are powerful tools to overcome spectral overlap, as the information is 
spread along two frequency dimensions, thus allowing a better identification of the individual 
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compounds resonances. In contrast with 1D, the 2D NMR experiments are composed of several 
steps: preparation, evolution (t1), mixing and acquisition (t2) (Rinaldi, 2000) (Figure 2.5).  
 
Figure 2.5 - An example of a 2D NMR experiment with its four basic steps 
represented. (Reproduced from Rinaldi, 2000). 
    
Firstly, after the preparation step which allows the population of nuclei to reach equilibrium, 
one first 90° pulse brings the magnetization into the x'-y' plane as shown previously in Figure 2.2a. 
Then a series of pulses may be used to transfer the magnetization between nuclei of the same 
molecule during the evolution step, which is increased over time during the 2D experiment 
(Figure 2.5). After the evolution time (t1) and depending on the experiment, additional pulses may 
be introduced in a step called mixing, in order to further manipulate magnetization before the 
actual acquisition of the NMR signal (t2) (Figure 2.6a).  
 
 
 
Figure 2.6 - Schematic illustration of the process used to produce a 2D NMR spectrum. 
(Reproduced from Rinaldi, 2000). 
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After acquisition, FT is performed in the t2 acquired domain, originating a frequency domain 
(f2) with different peaks intensities and phases according to t1 (Figure 2.6b).  A second FT is then 
applied with respect to the evolution time (t1) (Figure 2.6c), originating the f1 frequency domain 
(Figure 2.6d). The 2D spectrum is now a 3D plot with f1 and f2 frequency domains (1
st and 2nd 
dimensions, respectively) and intensity represented as 3rd dimension (Figure 2.6d). However, 2D 
NMR spectra are more conveniently presented as 2D plots where intensity is represented through 
contour levels (Rinaldi, 2000).      
The most commonly used 2D NMR experiments in complex mixture analysis in general and in 
metabonomics are the 1H-1H total correlation spectroscopy (TOCSY), 1H-13C heteronuclear single 
quantum correlation (HSQC) spectroscopy and 1H J-resolved spectroscopy (J-resolved) (Beckonert 
et al., 2007), which are described below. 
 
TOCSY is the abbreviation for TOtal Correlation SpectroscopY, also known as HOHAHA 
(HOmonuclear HArtmann HAhn) (Hicks et al., 1994). In the TOCSY pulse sequence, illustrated in 
Figure 2.7, after the evolution period t1, the magnetization is spin-locked during the mixing time 
thus allowing its exchange through scalar coupling, a phenomena designated by isotropic mixing. 
This is achieved through the use of a composite pulse sequence, such as MLEV-17 sequence 
(Malcolm Levitt-17 sequence) which is a sequence of 16 composite 180° pulses, followed by a 
regular 180° pulse (Bax and Davis, 1985). During this spin-lock period, the magnetization behaves 
as a strongly coupled spin system enabling a coherence transfer between all coupled nuclei in a 
spin-system even if they are not directly coupled, thus enabling the assignment of the spin-system 
of a molecule.  
 
Figure 2.7 - 1H-1H TOCSY pulse sequence. Adapted from the Bruker Avance 
1D/2D manual (Bruker, 2003). 
 
 
The Heteronuclear Single Quantum Correlation (HSQC) experiment correlates protons with 
their directly attached heteronuclei (Bodenhausen and Ruben, 1980). The 1H magnetization is 
detected (during t2 - detection time) while the heteronuclei (such as 
13C) magnetization evolves 
during the evolution time - t1 (Keeler, 2002), as shown in the pulse sequence in Figure 2.8.  
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Figure 2.8 - 1H-13C HSQC pulse sequence depicting both 1H and 13C channels. A and C: 
INEPT sequences for 1H-13C magnetization exchange, B: evolution period. Acquisition 
takes place during t2 with 
13C decoupling. JCH is the 
1H-13C single bond coupling constant 
which is about 150Hz. (Adapted from Keeler, 2002). 
 
Magnetization transfer between the directly attached 1H-13C takes place through the use of an 
Insensitive Nuclei Enhancement by Polarization Transfer (INEPT) sequence, which is also used to 
recover the magnetization from 13C to 1H before acquisition (Figure 2.8). The 180° pulse in the mid 
evolution period removes the 1H coupling and chemical shift effects (Figure 2.8). Because of the 
detection is performed on the high frequency nuclei (1H), this sequence is much more sensitive 
than the sequences involving the direct detection of 13C, such as the heteronuclear correlation 
(HETCOR) pulse sequence (Reynolds, 2000). The HSQC is usually applied to confirm the 
assignments obtained in 1D and 2D homonuclear correlation experiments (TOCSY). Another 
commonly used heteronuclear NMR experiment is the Heteronuclear Multiple Quantum 
Correlation (HMQC), which provides the same information as the HSQC. However, the latter 
offers better resolution in the heteronuclei dimension compared to HMQC, in which broadening 
of heteronuclei occurs due to homonuclear proton couplings (Claridge, 2009).  
 
Finally, the 1H J-resolved spectroscopy, also known as J-resolved (or just J-RES), involves the 
separation of the effects of chemical shift and J-coupling into separate dimensions (Ludwig and 
Viant, 2010). An example of a homonuclear 2D J-resolved pulse sequence is shown in Figure 2.9.  
 
 
Figure 2.9 - Scheme for the 2D 1H J-resolved basic pulse sequence. The increment 
time delay t1 used to create the indirect time axis for the second dimension (t2) is 
mediated by a 180° pulse. (Adapted from Ludwig and Viant, 2010). 
 
 
t1
2
t1
2
t2
90º 180º
Chapter 2 
35 
 
After the 90° pulse to create magnetization, the chemical shift evolution created during the 
first t1/2 delay is refocused by a 180° which then allows the observation of only the J-scalar 
couplings in the second dimension (Figure 2.9). This experiment allows the assignment of signals 
based in the measurement of J-scalar coupling. Additionally, the skyline projection of the 2D J-
resolved produces a 1D-like spectrum without multiplicity information, i.e. all resonances are 
singlets. This representation which has been used in metabonomics and metabolite quantification 
studies, enables, in principle, the direct comparison of spectra acquired at different field strengths 
(such as 500 and 600 MHz), because of the absence of multiplicity (splitting) which is dependent 
of field strength (Ludwig and Viant, 2010). 
 
2.1.3. Diffusion Ordered Spectroscopy (DOSY) 
 
Molecular diffusion, the translational motion of the molecules in the liquid state or in solution, 
can be studied also by NMR, therefore providing additional information on the composition of 
complex mixtures such as biofluids (Smith et al., 2007; Balayssac et al., 2009). The measurement 
of diffusion by NMR spectroscopy is possible due to pulse field gradient techniques (Johnson, 
1999). By the use of a gradient pulse applied in the same direction of the external magnetic field, 
B0, the molecules can be encoded according to their position in the sample (Kerssenbaum, 2006). 
Their motion after a certain diffusion time, , can be decoded after a second gradient pulse. In 
this way, the measured NMR signal intensity is attenuated depending on the diffusion time (), 
gradient strength (G) and duration () (Kerssenbaum, 2006). The attenuated signal intensity is 
given by equation 2.9: 
          
         (   
 
 
)     [Eq. 2.9] 
where I  is the observed (attenuated) intensity, I0 the unattenuated signal intensity, D the 
diffusion coefficient,  the magnetogyric ratio of the observed nucleus, G the gradient strength,  
the gradient length and  the diffusion time (Kerssenbaum, 2006).  
Pulsed field gradients are also used in the attenuation of signals from fast diffusing species in 
order to observe only signals from slower diffusion species, which is the basis for 1D NMR 
diffusion-edited experiments mentioned earlier in the previous section (Kerssenbaum, 2006). An 
example of a diffusion-type NMR experiment pulse sequence using two bipolar gradients (Wu et 
al., 1995), i.e. two gradient pulses with opposite orientations, is illustrated in Figure 2.10.   
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Figure 2.10 - An example of a diffusion-edited pulse sequence using bipolar 
gradients. , diffusion time; , gradient length. Adapted from Kerssenbaum, 2006. 
 
In diffusion ordered spectroscopy (DOSY), a series of 1D NMR spectra are obtained with 
increasing gradient strength (G) values. The resulting spectral intensities experience an 
exponential decay, as shown previously in equation 2.9 and exemplified in Figure 2.11a for a 
mixture of standard compounds. By fitting each measured signal intensity to an exponential 
function, it is possible to determine each respective diffusion coefficient and obtain a pseudo-2D 
representation of chemical shift versus diffusion coefficient as shown in Figure 2.11b.  
Figure 2.11 - DOSY of a standard mixture of caffeine, water and 2-ethoxyethanol. a) signals decay as 
function of gradient strength (G); b) pseudo-2D DOSY spectra. (Adapted from Mestrelab Research 
website: http://mestrelab.com/). 
 
The information provided by the DOSY spectra is also very useful in the estimation of the 
molecular weight (Mw) of molecules. By assuming a globular shape for the molecules with fixed 
density, the Mw of a molecule is proportional to the inverse of the cube of the diffusion coefficient 
(Nilsson et al., 2004). This relation enables the estimation of the Mw of an unknown compound 
from the resolved spin-systems in a DOSY spectra with the aid of a suitable Mw calibrant 
compound (Nilsson et al., 2004).  
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2.1.4. Saturation Transfer Difference (STD) experiments 
 
STD NMR experiments are generally used to characterize ligand-receptor complexes (Mayer 
and Meyer, 1999; Viegas et al., 2011) and are useful to characterize specific interactions between 
high and low Mw molecules in complex mixtures. In an STD experiment, the resonances from a 
receptor macromolecule, for instance a protein bound to a small ligand, can be selectively 
saturated with an RF pulse. This saturation is spread over the entire protein by intramolecular 
saturation transfer (spin diffusion). The ligand molecules interacting with the receptor 
macromolecule are saturated by intermolecular saturation transfer. Through chemical exchange 
these saturated ligands are transferred into solution, provided there is a weak binding between 
ligand and receptor (dissociation constants, KD, ranging from 10
-8 to 10-3 mol/L) (Mayer and 
Meyer, 1999). By performing the difference between the 1D spectrum acquired with the selective 
saturation set to a frequency other than those of the ligand or the macromolecule (off-resonance) 
and the spectrum acquired with the selective saturation set only to one of the macromolecule 
resonances (on-resonance), positive signals from the ligand bound to the receptor will show up 
indicating that binding occurred (Figure 2.12). 
 
Figure 2.12 - Scheme of the STD-NMR experiment. The exchange between free and bound ligand 
allows intermolecular transfer of magnetization from the macromolecule to the bound small molecule 
(Reproduced from Viegas et al. 2011). 
 
Because the chemical groups from the ligand in close contact with the macromolecule receive 
more saturation, the difference spectrum contains only the resonances from the ligand chemical 
groups which effectively bind to the macromolecule, thus aiding the mapping of the ligand 
binding sites (Mayer and Meyer, 1999). 
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2.1.5. Hyphenated NMR methods 
 
The introduction of a chromatographic step before NMR analysis as in liquid chromatography-
NMR (LC-NMR) enables further resolution of highly overlapped signals in NMR, such as those from 
higher abundance metabolites over the less abundant ones.   
The LC-NMR setup consists of a computer operated high-performance liquid chromatography 
(HPLC) system connected in parallel with to an NMR system, as shown in Figure 2.13.  
 
Figure 2.13 - Scheme of an experimental LC-NMR setup. BPSU, Bruker peak sampler unit; 
(—) capillary connections; (---) electronic connections (Reproduced from Albert, 2002). 
 
The eluting fractions from the HPLC column pass through an UV detector, and are then 
directed to an NMR flow probe via an LC-NMR interface sample unit (Figure 2.13). The HPLC 
fractions can be either stored prior to NMR analysis (fraction storage or loop storage) or analysed 
on-line either in a continuous HPLC flow (on-flow experiment) or by interrupting the HPLC flow for 
NMR acquisition (stop-flow or time-slice experiment) (Albert, 2002). After NMR analysis, the HPLC 
fractions can be collected for further analysis or discarded (Figure 2.13).  
Hyphenated NMR can be further extended by splitting the outlet of the HPLC column to a mass 
spectrometer (MS, discussed in the next section), in a LC-NMR/MS combination. The addition of a 
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parallel mass spectrometer enables a more complete structural characterization of a complex 
mixture (Lindon et al., 2000b). In fact, hyphenated NMR techniques, namely LC-NMR and LC-
NMR/MS, have been applied to the analysis of several types of biological matrices such as 
beverages and liquid food samples (Duarte et al., 2003; Gil et al., 2003), in phytochemistry 
(Wolfender et al., 2005), natural products research (Jaroszewski, 2005) and in pharmaceutical 
research and drug discovery (Lindon et al., 2000b; Corcoran and Spraul, 2003). The techniques 
have also been used in biofluid analysis, in the characterization of plasma lipoproteins (Daykin et 
al., 2001), of polar metabolites in urine (Dear et al., 2000; Godejohann, 2007) or in the 
identification of bile metabolites (Duarte et al., 2009). 
The introduction of cryo-probe technology and with the continuous increase in magnet field 
strengths, has led to significant sensitivity enhancements in hyphenated NMR, enabling the 
detection of metabolites at sub-micromolar concentration in complex matrices such as urine 
(Spraul et al., 2003).  
 
2.2. Liquid chromatography coupled to mass spectrometry (LC-MS) 
 
In mass spectrometry (MS), the molecules from a sample are ionized and subsequently 
accelerated in an electric field under high vacuum, thus enabling the measurement of their mass-
to-charge ratio (m/z) (Harwood and Claridge, 1999). One of the greatest strengths of MS is its high 
sensitivity compared to other spectroscopic methods used in complex mixtures analysis, such as 
NMR. MS is able to detect compounds down to picomolar and also has a greater dynamic range in 
terms of compounds concentrations to be detected (Lindon et al., 2000b). The analytical 
capability of MS is usually extended by coupling it to a separation technique such LC, GC or CE. 
Biofluids contain hundreds or thousands of molecules in solution which makes the LC-MS the 
most suited hyphenated MS method for their comprehensive characterization. However, GC-MS 
has proven very useful in analysis of the more volatile compounds of complex biofluids such as 
urine (Rocha et al., 2012). 
The LC-MS setup is composed of an HPLC whose effluent is connected directly to the mass 
spectrometer source, usually an electrospray ionization (ESI) source, as shown in Figure 2.14a. 
The ESI ionization enables molecules to be taken directly from solution into the gas phase in an 
ionized state by passing the solution through the exit of a fine charged steel capillary, held at a 
fixed charged potential (Figure 2.14a). Positive or negative potential can be placed on the 
capillary, therefore enabling the production of singly or doubly charged positive and negative 
ions, respectively (Harwood and Claridge, 1999). 
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Figure 2.14 - Details of mass spectrometer components: a) an electrospray ionization (ESI) source; b) 
time-of-flight TOF mass analyser; c) quadrupole mass analyser (Adapted from Harwood and Claridge, 
1999); d) ion trap mass analyser (Adapted from http://www.matrixscience.com/).  
 
The ions produced, are conducted to a mass analyser such as the time-of-flight (TOF) mass 
analyser (Figure 2.14b). In a TOF mass analyser, the charged accelerated ions, subjected to the 
same potential difference are allowed to travel through a field free region between the ion 
accelerator and the detector (Figure 2.14b). The lighter ions will have a shorter time-of-flight 
compared to heavier ones, therefore registering lower m/z values (Harwood and Claridge, 1999). 
Commonly, TOF mass analysers also possess a reflectron mediating the accelerator and the 
detector, which functions as an ion mirror, thus increasing the resolution especially in the low m/z 
values. The TOF mass spectrometers are commonly used in metabolic profiling due to their high 
resolution and fast scanning capabilities (Want et al., 2006). The quadrupole mass analysers 
(Figure 2.14c), another type of analyser, are commonly used in tandem with TOF mass analysers 
in the so called quadrupole-TOF (Q-TOF) instruments (Want et al., 2006). In the quadrupole, the 
ions cross a path parallel to four voltage carrying rods (Figure 2.14c). Under the application of a 
specific RF and voltage current, only ions of a particular m/z will be collected and analysed (Figure 
2.14c). In Q-TOF instruments, the ions travelling from the quadrupole analyser pass through a 
collision chamber. The introduction of a collision inert gas (He or N2) in the collision chamber can 
be used to perform mass fragmentation (MS/MS) experiments which are very important for 
structure determination. The resulting mass fragments are then analysed in the TOF analyser. 
a) b)
c) d)
a) 
c) 
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Another commonly used type of mass analyser is the ion trap (Figure 2.14d), which can be 
used for both MS scanning and MS/MS studies. However, the ion traps have a poorer sensitivity, 
dynamic range, mass accuracy and resolution when compared with triple quadrupole and TOF 
mass analysers (Want et al., 2006). 
 
The analysis of complex mixtures by LC-MS comes at a cost of speed due to the introduction of 
a chromatographic separation step, which in HPLC can take from 20 to 60 min per sample, 
depending on the method and column used. An alternative approach to the traditional HPLC one 
is ultra-performance liquid chromatography (UPLC), which uses columns with much smaller 
particle size packing material (1.4-1.7 m) than HPLC columns, thus allowing for improved 
separation and higher resolution (Wilson et al., 2005a; Wilson et al., 2005b) (Figure 2.15).  
 
 
Figure 2.15 - Comparison between UPLC-MS and HPLC-MS chromatograms 
(Reproduced from Want et al., 2006). 
 
UPLC technology enables pumping and injection of liquids at pressures exceeding 10000 psi. 
Therefore sample analysis times can be reduced to as little as 5 min or less, resulting in much 
higher throughput (Want et al., 2006). UPLC also allows narrower chromatographic peaks to be 
obtained (peak widths at half-height <1 s), resulting in increased peak capacity, lower ion 
suppression and improved signal-to-noise ratio, and thus increased sensitivity (Figure 2.15). In 
terms of sensitivity, UPLC can also detect more compounds than HPLC, with a 20% increase 
reported over the same chromatographic length and also enabling superior retention time 
reproducibility and signal-to-noise ratios over HPLC (Want et al., 2006). Although both methods 
have been extensively used, UPLC-MS is increasingly becoming the method of choice for LC-MS-
based metabolic profiling studies (Wilson et al., 2005a; Want et al., 2010). 
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2.3. Fourier Transform Infrared (FT-IR) Spectroscopy  
 
The principle behind infrared (IR) spectroscopy lies in the ability to excite the molecular 
vibrations of chemical bonds with radiation in the infrared frequency region of the 
electromagnetic spectrum, provided that the electric dipole moment of the molecule changes 
during the vibration (Atkins and de Paula, 2006). The frequency of single bond (C-H, for instance) 
vibrations can be predicted by Hooke's law as:  
  
 
  
√
 
 
                                                     [Eq. 2.10] 
where, is the frequency of vibration, k is the bond resistance to vibration (or force constant) and 
 is the reduced mass of a two atom system, that is for two atoms with masses m1 and m2,  = 
(m1m2)/(m1+m2) (Harwood and Claridge, 1999). However, transitions in IR are quantized, and non-
linear molecules with n constituent atoms possess (3n-6) fundamental vibrational modes, some of 
which may be degenerate (Harwood and Claridge, 1999).  
The IR region of the electromagnetic spectrum is usually expressed as a function of the 
reciprocal of wavelength, the wavenumber (cm-1), and can be divided into far-IR (FIR) 400-10 cm-1, 
mid IR (MIR) between 200 and 4000 cm-1 and near-IR (NIR) between 14000-4000 cm-1. The 
absorption of NIR radiation is commonly associated with the excitation of low-lying electronic 
excited states and overtones or combinations of molecular vibrations (Andrews, 2000). The FIR 
region relates mostly to low-frequency molecular vibrations and inversions, or rotations in small 
molecules (Andrews, 2000). In the MIR region, mostly fundamental molecular vibrations occur 
making this region the richest in chemical information (Spragg, 2000).  
The two main molecular vibration modes active in the MIR range are the stretching () and 
bending () modes, corresponding to higher and lower energy transitions, respectively, and 
whose frequencies of vibration depend on the chemical functional groups and on the chemical 
bonds involved (Harwood and Claridge, 1999). The MIR spectra is most commonly acquired and 
represented as the percentage of transmittance (%T) as a function of wavenumbers, where the 
vibration bands are represented as dips (Harwood and Claridge, 1999). However, for quantitative 
and semi-quantitative applications, spectra are acquired in the absorbance mode, due to the 
linear relation between absorbance and analyte concentration predicted by Beer's law (Harwood 
and Claridge, 1999).  
MIR spectroscopy covers a wide range of applications, from organic chemistry, through food 
science, forensics or quality control in industrial contexts. The MIR region has also been of great 
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interest in metabolic profiling (Ellis and Goodacre, 2006; Khaustova et al., 2009), therefore it will 
be the focus of the remainder of this section.  
Figure 2.16a shows a scheme of the optics system of a modern MIR spectrometer. Its mode of 
operation is based on the Michelson interferometer (Figure 2.16b).  
 
     
Figure 2.16 - Optics of an FT-MIR spectrometer. a) general optical scheme; b) the Michelson 
interferometer (Reproduced from Spragg, 2000a). 
 
The single beam of IR radiation coming from the source falls on a beam splitter that divides it 
into two beams with approximately equal intensities (Figure 2.16a). These two beams strike 
mirrors that return them to the beam splitter where they recombine, creating interference, and 
then proceed to a detector, after passing through the sample (Figure 2.16a). Moving one of the 
mirrors creates a varying optical path difference between the two beams (Figure 2.16b). As the 
path difference changes, the two beams move in and out of phase with each other, so that there 
is alternating constructive and destructive interference (Spragg, 2000). Monochromatic radiation 
produces a sinusoidal signal, the frequency of which is directly proportional to the wavenumber. 
The signal from a broadband source consists of a combination of overlapping sinusoidal signals is 
called an interferogram. The interferogram is then converted into the spectrum of intensities at 
different wavenumbers by FT (Eq. 2.6, page 29) (Spragg, 2000). The samples to be analysed are 
placed in between a radiation path originating from the interferometer. Liquid samples can be 
placed in non-opaque cells, such as special sodium chloride cells, whereas solid samples are 
usually mixed with dispersing agents such as potassium bromide or the commercial mixture 
Nujol® (Harwood and Claridge, 1999). Alternatively, the MIR spectrometers can be equipped with 
an attenuated total reflectance (ATR) apparatus (Figure 2.17). The ATR is composed of a crystal 
(usually a ZnSe crystal), on top of which the liquid or solid sample is placed. The great advantage 
of the ATR is that the sample placed in the radiation path prior to spectra collection without the 
need of dispersing agents or special cells. 
a) b) 
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Figure 2.17 - A scheme of an Attenuated Total Reflectance (ATR) 
apparatus (Reproduced from Spragg, 2000b). 
 
 
The radiation coming from the interferometer is thus reflected along the ATR crystal, passing 
through the sample several times, being then conducted to the detector (Figure 2.17), which 
allows an increase in sensitivity of detection. 
In the MIR spectrum, the region of 4000-1500 cm-1 contains most of the interpretable bond 
stretching absorptions whereas the 1500-600 cm-1 region is usually referred to as the fingerprint 
region, because the rigorous assignments of the vibrations occurring in this region are not easily 
obtained (Harwood and Claridge, 1999). Table 2.1 summarizes some of the most intense MIR 
active vibrations for molecules commonly found in biofluids.  
 
Table 2.1 - Mid-infrared stretching () and bending () vibrations of chemical functional groups from 
biofluid components. (Pretsch et al., 1989; Harwood and Claridge, 1999; Liu and Mantsch, 1999). 
Regions / bands (cm
-1
) Vibrations Molecules / assignments 
4000-1500 cm
-1
 region 
 
 
3600 

 O-H 
 
Free, non H-bonded (sharp band), 
water and proteins 
3600-3000  O-H (broad) H-bonded (broad band), water and 
proteins 
3300  N-H (broad) Amino acids and N-containing 
molecules 
3000-2800  C-H Sugars, proteins, glucose, amino 
acids and lipids 
1750  C=O Carboxylate groups of amino acids, 
organic acids, fatty acid esters (lipids) 
1650 Amide I  ( C=O and  C-NH) Proteins 
1600  as COO
-
, (asymmetric) Amino acids and other organic acids 
1560-1510 Amide II  ( N-H and  C-N) Proteins 
 
1500-600 cm
-1
 (fingerprint) region  
 
1400 

 sy COO
-
 (symmetric) 
 
Amino acids and other organic acids 
1230-1260 Amide III (very weak)   Proteins 
1200-900  C-O and   C-C Sugars, proteins, glucose, amino 
acids and lipids 
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2.4. Data pre-processing and multivariate analysis (MVA) 
 
Metabonomics data sets contain hundreds or thousands of variables thus requiring the 
appropriate statistical methods in order to extract meaningful biological and biochemical 
information. Conventional univariate statistical for instance Student's t-test, Mann-Whitney test 
or Analysis of Variance (ANOVA), which consist of separate analysis of each variable, can be 
unpractical for metabonomics analysis. Multivariate analysis (MVA), on the other hand, has the 
advantages of taking all the variables into account in one single analysis and, more importantly, 
allows the construction of predictive models. Therefore, MVA provides the appropriate tools for 
metabonomics data analysis. 
 
2.4.1. Data pre-processing 
 
The data sets gathered in metabonomics usually translate into two-dimension data tables of  
intensities, each line corresponding to a different observation or object (different sample, time-
point, etc.) whereas each column represents a variable, for instance a chemical shift, 
wavenumber or MS feature (m/z, retention time pair) (Figure 2.18).  
 
 variable 1 variable 2 ... variable k 
sample 1 I11 I12 ... I1k 
sample 2 I21 I22 ... I2k 
... ... ... ... ... 
sample n In1 In2 ... Ink 
Figure 2.18 - Example of a typical two-dimensional data table obtained in metabonomics, 
comprising n samples and k variables. Ink is the intensity of variable k for sample n. 
 
Data pre-processing is required to prepare the metabolic profiling data acquired in each of the 
previously described analytical platforms (NMR, LC-MS and MIR) for MVA. Generally, pre-
processing can be considered into i) peak positional correction, ii) normalization and iii) scaling 
operations, which will be described in better detail for NMR, LC-MS and MIR as follows.  
 
Regarding 1H NMR, pH and ionic strength can originate drifts in peak position, therefore 
requiring the use of "binning" or peak alignment. Spectral "binning" or "bucketing" involves 
spectral integration over fixed spectral intervals whose width commonly ranges between 0.01 and 
0.05 ppm, therefore accommodating the small peak deviations under the same intervals between 
samples. Since this procedure has an obvious drawback of reducing the spectral resolution, peak 
alignment can be used in order to correct the drifts in peak positions over the whole spectral 
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range (Savorani et al., 2010). Several peak alignment algorithms are available such as fuzzy Hough 
transform (Alm et al., 2009), recursive segment-wise peak alignment (RSPA)(Veselkov et al., 
2009), correlation shifting of spectral intervals combined with fast Fourier transform (iCOSHIFT) 
(Savorani et al., 2010) or hierarchical Cluster-based Peak Alignment (CluPA) (Vu et al., 2011). 
Inter-sample dilution variation is a natural source of variation occurring in biofluids such as 
urine. In order to correct this source of variation, the 1H NMR data sets are usually normalized to 
total spectral area or using other normalization methods such as probabilistic quotient 
normalization (also known as median fold-change normalization), quantile normalization, locally 
weighted scatter plot smoothing (LOESS) or group aggregating normalization (GAN)(Dieterle et al., 
2006; Dong et al., 2011; Veselkov et al., 2011). However, the choice of normalization method is 
dependent upon the sample type and problem under analysis (Dieterle et al., 2006; Dong et al., 
2011; Veselkov et al., 2011; Kohl et al., 2012).   
Complex samples such as biofluids are composed of metabolites with a large range of 
concentrations generating signals of varying intensities in 1H NMR spectra. In order to avoid the 
dominance of the high intensity signals over lower ones in MVA it is necessary to apply scaling to 
the data sets (Veselkov et al., 2011). In 1H NMR it is common to apply the unit variance (UV) 
scaling (Ebbels and Cavill, 2009), which consists in the division of each element of the data table 
by the standard deviation of the respective column (variable). Alternatively, other scaling 
methods such as Pareto scaling (each element is divided by the square root of  the standard 
deviation of the respective column) and logarithmic transformations (by application of the 
logarithm to each element of the data table), may be used (Veselkov et al., 2011). 
 
In relation to LC-MS data, small shifts in retention times may occur in data sets due to the 
variable interaction of the analytes with the stationary phase of the chromatographic column. 
Therefore, peak alignment strategies, such as those employed for 1H NMR data are usually also 
performed after peak picking in LC-MS (Katajamaa et al., 2006; Smith et al., 2006). Prior to MVA, it 
is also common to apply normalization using similar methods to those described for 1H NMR data, 
followed by scaling to UV, Pareto scaling and logarithmic transformation (Veselkov et al., 2011).   
     
In relation to MIR data, normalization is usually performed using standard normal variate 
(SNV) transformation, which consist in the division of each element of a line from the data table 
by the standard deviation of the respective line (Barnes et al., 1989). Because the MIR bands are 
relatively broad, shifts due to small inter-sample pH and ionic strength variation are not usually 
observed, therefore, no peak alignment is necessary. Scaling is not usually performed for MIR 
data. 
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2.4.2. Multivariate Analysis (MVA) methods 
 
The MVA methods used in metabonomics can be considered into supervised and 
unsupervised. In the unsupervised methods no a priori knowledge of the class information of the 
observations is considered, for instance which samples belong to the control or a disease group. 
These methods are employed to obtain an overview of the similarities and differences between 
the samples under analysis. The unsupervised methods which have been used in metabonomics 
include the principal components analysis (PCA), hierarchical cluster analysis (HCA), non-linear 
mapping procedures (NLM), self-organizing maps (SOM) and k-means clustering (Ebbels, 2007). 
On the other hand, when class membership of the samples is known, supervised methods may be 
used to explore the differences between classes and remove confounding factors resulting from 
inter-individual differences. Examples of supervised methods used in metabonomics include soft 
independent modeling of class analogy (SIMCA), partial least squares - discriminant analysis (PLS-
DA), orthogonal PLS-DA (OPLS-DA), artificial neuronal networks (ANN) and genetic programming 
(Ebbels, 2007; Trygg and Lundstedt, 2007). 
PCA, PLS-DA and OPLS-DA are the most used MVA methods in metabonomics, since they 
provide straightforward interpretation of the results, as it will be explained in the next sections.  
   
2.4.2.1. Principal Components Analysis (PCA) 
 
The multidimensional data table generated in metabonomics constitutes a matrix X with K 
variables and N objects (i.e. samples or observations) (Figure 2.18) or, in other words N×K 
dimensions, thus forming a scatter plot in the K-hyper-space (Figure 2.19).  
 
Figure 2.19 - Principal components analysis (PCA) geometric interpretation 
(Adapted from Trygg et al. 2007). 
(PC1)
(PC2)
PC1
PC2
PC1
PC2
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In PCA the K-space is reduced into a low-dimensional plane, representative of the objects in X 
(Figure 2.19). The new variables defining the plane are called the principal components (PCs) and 
are mutually linearly orthogonal to each other as shown in Figure 2.19 for a model with two PCs. 
The PCs result from the decomposition of the original data matrix X according to the equation:  
                             [Eq. 2.11] 
where T represents the scores matrix, i.e. the matrix containing the vectors which are used to 
define the low-dimensional planes that closely approximates the objects (samples) in X (Figure 
2.19), meaning that position of each object in the planes (scores) is used to relate samples to each 
other. Hence, samples that are close to each other have a similar multivariate profile. The P 
matrix contains the weight vectors, or loadings, of the individual X-variables from the model. The 
loadings indicate which variables contribute for separation of different groups of objects in the 
scores, since directions in the score plot correspond to directions in the loading plot, and vice 
versa as illustrated in Figure 2.19 (right). The part of X that is not explained by the model, i.e. the 
residuals (E, equation 2.11) represents the distance between each point in K-space and its 
projection on the plane (Trygg et al., 2007). Therefore, PCA provides a summary, or overview of all 
samples from the data table, making it possible to extract and display the systematic variation in 
the data. 
 
2.4.2.2. Partial Least Squares and Orthogonal Partial Least Squares - Discriminant Analysis (PLS-
DA and OPLS-DA) 
 
In partial least squares (PLS), a quantitative relationship between two data tables is sought 
between a matrix X, usually comprising spectral or chromatographic data of a set of samples, and 
another matrix, Y, containing quantitative values, for example, concentrations of endogenous 
metabolites (Wold et al., 2001; Trygg et al., 2007). The X matrix, represented in the K-dimensional 
space (Figure 2.19), can be projected into hyper-planes defined by new variables, the latent 
variables (LVs), which are good predictors of the information contained in Y matrix. The PLS 
models can be described by the following equations: 
                 [Eq. 2.12] 
                  [Eq. 2.13] 
where matrices X and Y are modeled by new variables, latent vectors (LVs) or components. The P 
and C matrices represent the X and Y loadings, respectively, whereas E and F matrices represent 
the residuals resulting from the modeling of X and Y matrices, respectively. The T matrices 
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represent the scores common to both X and Y. Moreover, the T scores are linear combinations of 
the original X variables and the weights W and, therefore, T can be expressed in the following 
equation: 
                          (   )       [Eq. 2.14] 
Combining equations 2.10 and 2.11, a PLS regression equation can be obtained: 
                     [Eq. 2.15] 
where B contains the PLS regression coefficients and B = W(PTW)-1CT. The properties expressed in 
Y can then be predicted using this regression equation (Eq. 2.15). 
While PLS is used to predict quantitative variables expressed in Y, it can also be used as a 
supervised discriminant analysis method, by using a Y matrix that encodes qualitative values 
(usually zeros and ones), called dummy variables, for example, to express class membership, 
gender, disease or treatment (Trygg et al., 2007). This PLS variant is then designated by PLS-
Discriminant Analysis (PLS-DA) (Wold et al., 2001; Trygg et al., 2007) (Figure 2.20, left). 
 
 
Figure 2.20 - A geometrical illustration of PLS and OPLS models. t1, t2 and t1p, t2o are the latent 
variables of PLS and OPLS models, respectively (Reproduced from Trygg et al., 2007). 
 
An important modification of the PLS method is the orthogonal-PLS (OPLS) method, in which 
the systematic variation in X is separated into two parts, one that is linearly related to Y and one 
that is unrelated (orthogonal) to Y. The resulting scores plots condensate the separation 
information into one single LV (Figure 2.20, right) therefore facilitating model interpretation when 
compared with PLS models (Trygg et al., 2007). The OPLS model comprises two modeled 
components, the Y-predictive (TpPp
T) and the Y-orthogonal (ToPo
T) components, from which only 
the Y-predictive component is used for the modeling of Y (TpCp
T) (Trygg and Wold, 2002), as 
described by the equations:        
      
                     [Eq. 2.16] 
           
          [Eq. 2.17] 
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where E and F are the residual matrices of X and Y, respectively. OPLS can, analogously to PLS-DA, 
be used for discriminant analysis (OPLS-DA) (Bylesjö et al., 2006). 
 
The apparent separation present in PLS-DA and OPLS-DA scores alone is insufficient as a means 
to evaluate differences between the sample classes. In fact, for the purpose of classification of 
new samples, the models robustness needs to be assessed, which raises the need for appropriate 
model validation. The ideal validation of a model is such that it can precisely predict the Y-values 
of observations with new X-values, that is a validation data set of new samples (Westerhuis et al., 
2008). However, the samples gathered in metabonomics experiments are usually limited in size 
and almost all of them are used in the construction of the predictive model, i.e. to make a training 
set. In the absence of an external test set, validation can be performed by cross-validation (CV). 
The CV is performed by splitting the data sets in a number G of groups, usually five to nine, and 
then iteratively developing a number of parallel models (G) from reduced data set (training set), 
with one of the groups left out (used as validation set) (Wold et al., 2001). The performance of the 
classification for each model in the CV procedure can be evaluated by means of a measure of the 
prediction error, given by goodness of prediction or predictive power (Q2), which focuses on how 
efficiently the correct class label can be predicted from new data and can be defined as: 
    
     [Eq. 2.18]                                                                       
 
where ŷi refers to the predicted value of class membership for sample i, while ӯ refers to the 
mean value of y for all samples (Westerhuis et al., 2008). The value of Q2 reported is usually the 
mean value of the G-fold CV iterations corresponding to each model produced. The optimal Q2 
value of 1 is difficult to obtain as it would require that the class prediction of each sample should 
be exactly equal to its class label, something that is hard to obtain due to the inherent variation 
between the individuals in the same class. The value of Q2 depends, therefore, on the inter-class 
separation and also on the intra-class variability, which makes it is difficult to give a general Q2 
value that corresponds to a good classification (Westerhuis et al., 2008). For this reason, it is usual 
to perform a permutations analysis, in which class memberships (Y-matrix) is randomly permuted, 
to provide a whole distribution of Q2 values for models of incorrect class membership to relate 
the original Q2 value (Westerhuis et al., 2008). 
Monte Carlo Cross Validation (MCCV) (Shao, 1993), is another validation method which can be 
performed in order to obtain the Q2 distributions for both randomly permuted and original class 
memberships. In MCCV, 500-1000 random permutations are performed either by randomly 
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setting the Y-matrix (permuted classes) or by randomly sorting the original class memberships 
(true classes), i.e. randomly changing the order of samples in X and Y matrices simultaneously. 
The randomly created matrices (of permuted and true classes) are used to produce PLS-DA 
models which are evaluated through CV, the resultant Q2 values being used to derive the Q2 
distributions.  
Confusion matrices (Figure 2.21), which consist of the number of False Positive (FP), False 
Negative (FN), True Positive (TP) and True Negative (TN) classifications obtained by CV 
(Broadhurst and Kell, 2006), can also be used to derive other prediction measures to complement 
Q2 distributions such as the classification rates (CR) and receiver operative characteristics (ROC) 
plots (Westerhuis et al., 2008).  
  Predicted classes 
  D C 
Actual 
classes 
D TP FP 
C FN TN 
Figure 2.21 - Example of a confusion matrix for two classes: D, disease and C, 
control. False Positive (FP), False Negative (FN), True Positive (TP) and True 
Negative (TN). 
 
The classification rate is merely the ratio between the sum true positive (TP) and the true 
negative (TN) classifications and the total number of classifications: 
classification rate(CR)  
     
           
   x 100  [Eq. 2.19]  
 
The receiver operative characteristics (ROC) plots can be used to plot the true positives rate 
(TPR) and false positives rate (FPR) of a classification model (Fawcett, 2006).  The TPR and FPR are 
equivalent measures to the sensitivity and 1-specificity of a model, respectively. The sensitivity (or 
true positive rate, TPR) is defined as the number of true positives found as a percentage of all 
positives (for instance, disease in a confusion matrix, Figure 2.21) as: 
                           sensitivity (TPR)  
  
     
   [Eq. 2.20] 
On the other hand, 1-specificity (the false positive rate, FPR) is the number of false positives (FP) 
as a percentage of all negatives (for instance, controls in the confusion matrix, Figure 2.21):  
              1-specificity (FPR)  
  
     
    [Eq. 2.21] 
Each obtained PLS-DA model can be represented as a point with its associated sensitivity and 1-
specificity value in a ROC space plot (Figure 2.22). 
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Figure 2.22 - ROC space plot of five example models (●). Perfect classification, 
i.e. sensitivity (TPR) of 1 and 1-specificity of 0 is illustrated. Dashed line, indicates 
the random classification. 
 
The sensitivity values fall between 0 and 1 and should ideally be close to 1. Specificity values 
should ideally also be close to 1 and hence 1-specificity should be close to 0.  A sensitivity value of 
1 and 1-specificity of 0 indicates a perfect classification, whereas the values falling in the diagonal 
of the ROC space plot indicate a random classification performance (Figure 2.22).  
 
2.4.2.3. Statistical total correlation spectroscopy (STOCSY) and statistical heterospectroscopy 
(SHY) methods 
 
Statistical Total COrrelation SpectroscopY (STOCSY) enables the identification of linear 
relationships within spectroscopic data sets which may result from the same analytes (aiding 
spectral assignments) or from different analytes indicating dynamic processes, for instance 
metabolic reactions or physiologic processes (Lindon and Nicholson, 2008b).  
Generalized two-dimensional correlation spectroscopy was introduced by Noda in an 
application to infrared spectroscopy  to study time-course processes (Noda, 1989). The method 
was later extended to   mp  −  mp   c            p c    c py     b              m       b    
the species perturbation-dependent dynamics in chemical processes (Š š ć et al., 2000). STOCSY 
was introduced more recently as a different approach to measure correlations in spectroscopic 
data sets. It is based on the principles in which the multicollinearity of the intensity variables in a 
set of spectra (for example 1D NMR) can be used to produce a pseudo-two dimensional spectrum 
showing correlation among the intensities of the various peaks across the whole sample (Cloarec 
et al., 2005; Lindon and Nicholson, 2008b). This method allows the visualization of much more 
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a) b)
information than that usually displayed, for instance, in a 2D NMR spectrum such as a TOCSY. An 
example is shown in Figure 2.23a for 1H NMR spectra of human urine. In fact, in STOCSY two or 
more molecules involved in the same pathway can also present high intermolecular correlations 
or can even be anti-correlated (negatively correlated) due to common metabolic pathway control 
(Cloarec et al., 2005).  
STOCSY is based on the properties of the correlation matrix C, computed from a set of sample 
spectra according to the expression:                    
   
   
              [Eq. 2.22] 
where X1 and X2 denote the autoscaled (UV scaled) experimental matrices of n × v1 and n × v2, 
respectively; n is the number of spectra (one for each sample) and v1 and v2 are the number of 
variables in the spectra for each matrix. C is therefore a correlation matrix of v1 × v2, where each 
value is a correlation coefficient between two variables of the matrices X1 and X2. Correlation 
coefficient (r) can have values between -1 and 1, depending on whether two variables are varying 
on opposite directions or same direction, respectively. In real samples, |r|         y  b  ≥0     
<1 because of spectral noise or peak overlaps from other molecules (Cloarec et al., 2005). In 
practice, the correlation matrix from a set of spectra containing different amounts of the same 
molecule shows very high correlations between the variables corresponding to the signals of the 
same molecule. Plotting the correlation matrix provides a graphic representation of the multi-
sample spectroscopic data set comparable to that of a 2D correlation experiment, such as an 2D 
NMR experiment (Cloarec et al., 2005). The simplest application of STOCSY is the auto-correlation 
analysis where X1 = X2, illustrated in Figure 2.23a.  
Figure 2.23 - STOCSY and SHY analysis of human urine samples. a) 1H-1H NMR STOCSY map (Adapted 
from Keun et al., 2008); b) UPLC-MS / 1H NMR SHY map shows positive correlations (red) between 
signals the of ibuprofen and acetaminophen in both spectroscopic domains (Adapted from Crockford 
et al., 2008). 
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Furthermore, the use of two different matrices has been explored, by correlating 1H NMR and 
31P NMR matrices (Coen et al., 2007), and also notably 1H NMR and UPLC-MS matrices to obtain 
an heterospectral correlation matrix, designated Statistical HeterospectroscopY (SHY) (Crockford 
et al., 2006). In SHY, direct cross-correlation of chemical shifts from NMR and m/z data from MS 
provided improved structural information for a series of molecules in urine (Figure 2.23b). 
Higher level biological information can also be obtained on metabolic pathway activity and 
connectivities by examination of different levels of the NMR to MS correlation and anti-
correlations in rat and human urine (Crockford et al., 2006; Crockford et al., 2008). Besides NMR 
and MS, SHY analysis can be of general applicability to complex mixture analysis, if two or more 
independent spectroscopic data sets are available for any sample cohort (Crockford et al., 2006). 
For instance, the SHY concept has been extended to study the metabolic correlations between 1H 
NMR and MRS of different biofluids and tissues from HIV-1 individuals (Maher et al., 2011). 
Another example is the application of SHY for the 1st time to correlate MIR and 1H NMR of AF 
(Graça et al., 2013), a work which will be presented in chapters 5 and 6 of this thesis. 
It is sometimes convenient to express STOCSY results as a one-dimension spectral 
representation (1D STOCSY, Figure 2.24) instead of the direct representation of the correlation 
matrix (a two-dimensional result).  
 
Figure 2.24 - 1H NMR 1D STOCSY spectral representation. The representation was obtained 
from a series of 1H NMR spectra obtained in a LC-NMR experiment by calculating the correlation 
(r) and covariance between the chemical shift 7.13 ppm and the full spectral range, thus 
highlighting the signals of phenyl glucuronide (Cloarec et al., 2007). 
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In the 1D STOCSY, the covariance between one selected variable of X1 matrix (for instance one 
resonance or MS intensity), and all the other variables of the X2 matrix (for instance a matrix of 
NMR spectra) is plotted with a colour code corresponding to the correlation between the selected 
variable from X1 and all the other variables of X2. In this way, the correlated peaks are highlighted 
by the projection of a colour coding to show degree of correlation (Cloarec et al., 2005; Cloarec et 
al., 2007). If, for instance X2 is an NMR matrix (as in the example of Figure 2.24), the shape of the 
correlated peaks in 1D spectra is respected, therefore facilitating analysis. 
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3.  Experimental procedures 
 
The present chapter describes the sample and metadata collection procedures, as well as the 
experimental and data analysis strategies used to conduct the experimental work presented 
throughout the thesis. 
 
3.1. Samples and clinical metadata  
 
The AF and urine samples used in this work were collected between 2006 and 2011 at the 
Centro de Diagnóstico Pré-Natal, Maternidade Bissaya Barreto, Centro Hospitalar de Coimbra. 
Between January 2008 and June 2011, this work was supported by the Portuguese Foundation of 
Science and Technology (FCT) funding through the PTDC/QUI/66523/2006 project. Samples were 
collected under the approval of the ethical committee of Centro Hospitalar de Coimbra 
(Refs.18/04 and 29/09) and informed consents were obtained from each subject participating in 
the study (Annex I - Informed signed consent and questionnaire). The donors comprised 
Caucasian pregnant women, from the central part of Portugal, mostly in their second trimester of 
pregnancy recommended to undergo amniocentesis due to maternal age or for several medical 
reasons listed in Table 3.1.  
 
Table 3.1 - Reasons for undergoing amniocentesis relating to the participants in the studies. AF and 
urine samples were collected between 2006 and 2011.* median (minimum-maximum) maternal age 
(years). 
Reasons for 
amniocentesis 
Description 
Maternal 
age* 
Numbers 
(%) 
Advanced 
maternal age 
Women over 35 for whom karyotype 
analysis is recommended 
37 (35-46) 583 (64%) 
Positive biochemical 
test 
Positive trisomy 18 or 21 screening tests 31 (18-39) 67 (7%) 
Suspected fetal 
malformation 
Ultrasound detected malformation 30 (13-37) 73 (8%) 
Ultrasound signs of 
alert 
Ultrasound detected signs of alert such as 
nuchal translucence, growth restriction, etc. 
32 (17-41) 30 (3%) 
Previous 
chromosomal disorder 
Previous child with chromosome disorder 33 (18-35) 17 (2%) 
Parent with 
chromosomal disorder 
One of the parents carried chromosomal 
disorder 
30 (27-35) 8 (1%) 
Maternal anxiety Amniocentesis requested by mother with no 
apparent medical indications 
36 (34-37) 6 (1%) 
Others AF collected for Rh immunization, mothers 
diagnosed with infections  such as 
Toxoplasmosis, CMV, Rubella 
31 (25-35) 24 (3%) 
Undefined Cases with incomplete clinical information 34 (18-40) 106 (12%) 
Total   914 
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Every sample was given an arbitrary code number so that confidentiality was ensured after 
collection and during the analysis process. Regardless of the reason for undergoing 
amniocentesis, sample classification and inclusion in the study was performed after labour, when 
all relevant clinical information was available. 
Due to medical restrictions in controlling/limiting the diet of pregnant women up to the time 
of sample collection, samples were obtained under non-fasting conditions during the morning 
period. However, the effects from the occurrence of disease are expected to have a stronger and 
long-term effect on metabolic profile than those resulting from the diet and life style.  
 
3.1.1. Amniotic fluid and maternal urine collection  
 
About 10-20 mL of AF was collected through ultrasound-guided trans-abdominal 
amniocentesis. The AF samples were transported to the cytogenetics laboratory of the Faculdade 
de Medicina da Universidade de Coimbra within a maximum period of 4 hours, during which 
samples were kept at room temperature. For this reason the subject AF stability at room 
temperature was addressed specifically in chapter 4 (section 4.2.3). Samples were then 
centrifuged at 177.41×g at 22°C for 10 minutes in order to collect the cells (pellet) for karyotype 
analysis. The supernatants were immediately frozen and stored at -70°C/-80°C. The AF samples 
containing blood were discarded.         
Maternal urine samples (20-50 mL) were also collected from women who attended the 
prenatal diagnosis appointments to perform amniocentesis. Therefore, most of the urine samples 
were obtained from the same donors of AF. The urine samples were maintained and transported 
at room temperature to the cytogenetics laboratory of the Faculdade de Medicina da 
Universidade de Coimbra, within a maximum period of 4 hours. No significant metabolic changes 
are however expected in human urine in these conditions, based on a previous report (Barton et 
al., 2008). Urine samples were then immediately stored at -80°C. 
Prior to analysis all samples were transported to the Departamento de Química, Universidade 
de Aveiro in dry ice (approximately -70°C) and stored at -70°C/-80°C until analysis. 
 
3.1.2. Sample classification  
 
A total of 914 AF samples were obtained between 2006 and 2011 as shown in Table 3.1, which 
corresponded to the duration of the project presented in this thesis. A smaller number of 588 
maternal urine samples were also obtained between 2006 and 2009, from which a smaller group 
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was used in the UPLC-MS study described in better detail in section 3.4. Information on pregnant 
women life-style (diet, physical exercise), medication, maternal and gestational age, known 
diseases and blood pressure were obtained from the questionnaire which accompanied the 
signed consent (Annex I - Informed signed consent and questionnaire).  
 
Clinically relevant metadata regarding the time course of pregnancy such as pre-existing 
diseases, blood type, maternal height and weight before pregnancy (used to calculate the body 
mass index, BMI), smoking habits, obstetrical history, blood pressure records, clinical chemistry 
and urine analysis results, karyotype results, obstetrical data (including ultrasound monitoring and 
medical the diagnosis results in the cases of obstetrical disorders) were obtained through 
consultation of the medical team, after delivery. Information about the labour and pregnancy 
outcome, including fetal sex, weight and medical physical examination records up to the second 
day of life was obtained by consultation of the neonatology medical team. The gathered metadata 
allowed the classification of the samples into controls and several disorder groups. The samples 
comprising the control group were obtained from healthy non obese women, who were not 
under medication, and who did not register any obstetrical complication and delivered healthy 
term newborns (Table 3.2).  
The fetal malformations (FM) group comprised pregnancies affected by some type of 
congenital malformation, diagnosed by morphological ultrasound examination, usually after 12 
weeks of gestation and eventually confirmed by other imaging methods (such as magnetic 
resonance imaging). Third trimester (28-36 weeks) FM samples were also obtained, but their use 
was not considered given the extent of AF compositional differences occurring between 
trimesters (Lind, 1981; Sims et al., 1996; Cohn et al., 2009). Fetal malformations cases obtained 
are listed in Table 3.3, where they were divided by organic system affected, also with the 
indication of each FM type. One of the cardiac malformation cases also carried a 21 trisomy (Table 
3.3) and another was from a twin pregnancy. Similarly to the FM group, an chromosomal 
disorders (CD) cases were considered as a group comprising cases from diverse types of 
chromosome disorders (numerical, structural and mosaicisms), usually diagnosed up to two 
weeks after amniocentesis (Table 3.3). 
Second trimester samples were also obtained from women who later (during the 3rd trimester) 
developed GDM, PTD, PROM, PE and IUGR. These sample groups were designated pre-diagnostic 
GDM, pre-PTD, pre-PROM, pre-PE and pre-IUGR (Table 3.2) and were considered in order to 
evaluate the 2nd trimester AF composition predictive value for those prenatal disorders.  
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Table 3.2 - AF and maternal urine sample numbers subdivided by group and respective maternal ages 
(years), gestation ages (weeks) and pre-pregnancy body-mass index (BMI, kg/m2) values. a samples 
with known classification at the time of analysis; b median values and corresponding range in brackets; 
c mean BMI value, in brackets: the number of cases with known BMI; d one FM case carrying a 
chromosomal disorder; e one case carrying chromosomal disorders; f one case also with diagnosed 
with PE; g one case of twin gestation, f either due to insufficient sample numbers, cases outside the 
scope of this work, existence of confounding effects or lack of clinical information. 
 
 
Table 3.3 - The different types of fetal malformations (FM) (italic), grouped by affected organic system 
(underlined); and chromosomal disorders (CD) and respective number. a one FM case carried a 21 
trisomy; b one pre-diagnostic GDM case. 
Malformation types and sample numbers  
Urogenital 5 Soft tissues 2 Poly-malformed 3 
Polycystic kidney 2 Cystic hygroma 2 Cleft-lip + tetramelia 1 
Hydronephrosis 1 Abdominal 2 Jaw malformation+  club foot 1 
Multicystic dysplastic kidney 1 Omphalocele 1 Cardiophaty + polydactylia  1 
Bladder agenesis 1 Enlarged stomach 1 Central Nervous System 13 
Cardiac  5 Limbs 5 Corpus callosum agenesis 3 
Complex cardiophaty
 
 2 Polydactylia 1 Complex cranioencephalic 2 
Great vessels malformation 1 Club-feet 4 Holoprosencephaly 1 
Mitral valve agenesis 1 Lungs 1 Hydrocephaly 1 
Septal malformation
 a
 1 Cystic adenomatoid 1 Spina bifida 2 
    Ventriculomegaly 4 
Chromosomal disorder types and sample numbers  
Trisomy 21 7 XYY syndrome 2 Mosaicisms 3 
Trisomy 18 1 XXX syndrome 1 Inversions 2 
Kleinefelter syndrome 
b
 3 Marker chromosome 1 Translocations 4 
 
  samples  Age   
Groups included in this study AF urine
a
 gestational
b
 maternal
b
 BMI
c
 
Controls 90 68 17 (15-22) 36 (25-44) 22 (35) 
Fetal Malformations (FM) 
d,g
 36 13 22 (14-25) 29 (13-37) 23.8 (13) 
Chromosomal Disorders (CD) 22 - 17 (15-23) 38 (22-40) 26.3 (14) 
Prediagnostic Gestational Diabetes 
Mellitus (pre-diagnostic GDM) 
e,g
 
35 20 17 (16-21) 37 (30-44) 27.1 (21) 
Pre-Preterm Delivery (pre-PTD) 
g
 18 6 17 (16-17) 36 (30-39) 25.8 (10) 
Pre-Premature rupture of membranes  
(pre-PROM) 
45 - 17 (15-23) 36 (27-42) 23.4 (29) 
Pre-Preeclampsia (pre-PE) 8 - 17 (16-17) 35 (24-41) 24.9 (7) 
Intrauterine Growth Restriction  
(pre-IUGR) 
g
 
8 - 16 (15-17) 36 (31-39) 21.9 (2) 
AF samples from groups not included in this study 
f
     
Chronic Hypertension 5 Fetal death 
 
2 
Diabetes Mellitus 5 Other disorders/infections/medication 356 
Macrosomia 15 No classification 
 
267 
Post-diagnostic Gestational Diabetes 2       
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A pre-diagnostic GDM group, as opposed to post-diagnostic which refers to cases already 
diagnosed with GDM, was obtained considering only cases from women diagnosed with GDM 
only after amniocentesis (after 24–28 gestational weeks). This group contained one case also 
carrying a chromosomal disorder and one case of twin pregnancy (Table 3.3). 
The pre-PTD group comprised cases from women who delivered before 37 gestational with or 
without membrane rupture (between 34 and 36 weeks). The pre-PROM group, on the other hand, 
was composed of cases from women who later had premature membrane rupture of the fetal 
membranes prior to labour after 37 gestational weeks (between 37 and 40 weeks). The PROM 
condition is clinically very similar to a healthy pregnancy, except for the fact that the membrane 
rupture occurs spontaneously at term before labour initiation. The number of pre-PROM cases 
registered was higher than those registered for other disorders considered here. Therefore only 
the pre-PROM cases with no overlapping conditions were considered to avoid misinterpretations 
of the results.  
The pre-PE group comprised samples from women who later developed PE, diagnosed 
between 31 and 36 gestational weeks, whereas the pre-IUGR group was composed from cases 
where fetuses were diagnosed with IUGR at 34-38 gestational weeks. One case from this group 
was also diagnosed with PE later in pregnancy and another case was a twin pregnancy (Table 3.2). 
It was not possible to obtain the pre-pregnancy BMI for all subjects, therefore, these were only 
considered for the samples indicated in Table 3.2. It is also important to mention that the cases 
registering obesity (BMI>30), multiple gestation and chronic disease were usually included in the 
respective disorder group, except for the pre-PROM group, as mentioned above. This was justified 
by the fact that obesity, multiple gestation and pre-existing chronic diseases are risk factors for 
many of the disorders studied and also due to the low sample numbers obtained.  
Regarding the AF samples not included in this study (Table 3.2, bottom), these comprised AF 
samples obtained from donors which registered other conditions in the absence of the previously 
described prenatal disorders. These conditions included chronic hypertension (0.5%), diabetes 
mellitus (0.5%), macrosomia (1.6%), gestational diabetes (post-diagnostic) (0.2%) and fetal death 
cases (0.2%) (Table 3.2). Cases comprising other chronic diseases, maternal infections and cases of 
reported medication and the pre-PROM cases with overlapping conditions, accounting 38.9% of 
the total AF samples, were included in a separate group (other diseases/infections/medication) 
(Table 3.2). Samples for which no classification was possible (mainly due to incomplete clinical 
records, 29.2% of the total) were also not considered in this study (Table 3.2).  
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The maternal urine samples used in this study were collected between 2006 and 2009, and the 
numbers shown in Table 3.2 refer to the cases for which classification was known at the time of 
the analysis. 
 
3.2. Chemicals 
 
All solid chemicals, deuterated and non-deuterated solvents and solutions used in the 
experimental work performed were from analytical grade or equivalent and are listed in Table 3.4. 
 
Table 3.4 - Chemicals used throughout the work. Manufacturer, purity or concentration (*) in case of 
solutions are indicated. Standard compounds for: aNMR and bMIR are also indicated.     
Deuterated solvents/solutions (for NMR and LC-NMR)  
Name Purity Manufacturer 
Acetonitrile (d3) 97.0% Euriso-top (Saclay, France) 
Deuterium oxide (D2O) 99.9% Euriso-top (Saclay, France) 
Deuterium oxide containing 0.75 % TSP 
(3-(trimethylsilyl)propionic-2,2,3,3-d4 acid) 
sodium salt  
99.9% Aldrich (St Louis, USA) 
Methanol (d4) 99.8% Euriso-top (Saclay, France) 
Non-deuterated solvents/solutions  
Name Purity Manufacturer 
Acetonitrile 99.9% Fluka (Steinheim, Germany) 
Formic acid 98.0% Fluka (Steinheim, Germany) 
Hydrochloric acid * 37.0% Merk (Darmstadt, Germany) 
L-lactic acid 98.0% Sigma (Steinheim, Germany) 
Methanol 99.9% Sigma-Aldrich (St Louis, USA) 
Sulphuric acid * 95.0% Fluka (Steinheim, Germany) 
Water (LC-MS grade) 100.0% Fluka (Steinheim, Germany) 
Solid chemicals   
Name Purity Manufacturer 
Ammonium acetate 98.0% Sigma (St. Louis, USA) 
Alanine 
a,b
 98.0% Sigma (St. Louis, USA) 
Bovine serum albumin (BSA) 
a,b
 96.0% Sigma (St. Louis, USA) 
L-citrulline 
a
 98.0% Fluka (Steinheim, Germany) 
Creatine 
a
 98.0% Aldrich (St Louis, USA) 
Creatinine 
a,b
 98.0% Sigma-Aldrich (St. Louis, USA) 
L-Cystine 
a
 98.0% Sigma (St. Louis, USA) 
Ethanolamine 
a
 98.0% Sigma (St. Louis, USA) 
D-Glucose 
a,b
 99.0% Riedel-de-Haën (Seelze, Germany) 
Glutamic acid 
a,b
 99.0% Sigma (St. Louis, USA) 
Glutamine 
a,b
 99.0% Sigma (St. Louis, USA) 
Glycine 
a,b
 99.0% Sigma (St. Louis, USA) 
-ketoglutarate 
a
 98.0% Riedel-de-Haën (Seelze, Germany) 
L-lysine 
a,b
 98.0% Sigma (St. Louis, USA) 
L-malic acid 
a
 99.0% Aldrich (St Louis, USA) 
Ornithine 
a
 99.0% Aldrich (St Louis, USA) 
Potassium hydroxide 99.0% Merk (Darmstadt, Germany) 
Potassium di-hydrogenophosphate 99.0% Merk (Darmstadt, Germany) 
Shikimic acid 
a
 99.0% Sigma (St. Louis, USA) 
Sodium hydroxide 99.0% Merk (Darmstadt, Germany) 
di-Sodium hydrogenophospate 99.0% Fluka (Buchs, Switzerland) 
Taurine 
a
 99.0% Sigma (St. Louis, USA) 
Urea 
b
 99.0% Panreac (Barcelona, Spain) 
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3.3. High resolution NMR spectroscopy 
 
3.3.1. Sample preparation for NMR 
 
3.3.1.1. AF sample preparation 
 
In this work, AF sample quality was evaluated by 1H NMR to assess the effects of a) freeze-
drying versus direct dilution, b) buffering, c) ultrafiltration and, hence, define the best protocol for 
AF sample preparation. Each AF sample was thawed at room temperature. The AF preparation 
methods are described in detail below. 
 
Direct dilution: to 500L of each AF sample 50L of 0.24% TSP sodium salt solution in 100% 
D2O were added, which resulted in pH values in the interval 8.75±0.25; 
 
Freeze-drying:  1mL of each AF sample were frozen in liquid N2 prior to freeze-drying during 8-
12h (T=25°C, P=13Pa) and were then reconstituted into 720L of D2O and 80L of 0.24% TSP in 
100% D2O solution, which resulted in an 1.3-fold concentration factor. The resulting pH values of 
the samples were within the interval 9.23±0.12; 
 
Buffering: to each 500L of sample 100L of buffer A (0.5 M sodium phosphate buffer pH 7.20 
±0.10 in 100% D2O) were added, which resulted in pH values in the interval 7.32±0.07; 
 
Ultrafiltration: AF samples were also subjected to size-selective ultrafiltration using Amicon 
centricon 3kDa and 10kDa cut-off membrane centrifuge filters (Millipore Corporation, Billerica, 
MA, USA), as shown in Figure 3.1.  
 
 
Figure 3.1 - Sequential amniotic fluid fractionation by ultrafiltration through centrifuge membrane 
filters: a) through 10kDa cut-off filter, fractions with Mw≥10k       Mw<10kDa were obtained; b) the 
Mw<10kDa fraction was further filtered through 3kDa cut-off filte           g           c         3≤Mw 
<10 kDa and another with Mw<3 kDa. 
AF (1mL)
10K 3K
Mw ≥ 10kDa 
Mw < 3kDa 
3kDa≤ Mw<10kDa 
10K
Centrifugation
10000xg, 4ºC,
30 to 60 min
Mw < 10kDa 
3K
a) b)
Centrifugation
10000xg, 4ºC,
30 to 60 min
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 Briefly, 1mL of each of six control samples was subjected to two sequential filtrations, the first 
employing 10kDa cut-off filters where fractions with Mw≥10k       Mw<10kDa were obtained 
(Figure 3.1a); secondly each fraction of Mw<10kDa was further filtered through 3kDa cut-off filters 
      b      g 3≤ Mw <10 kDa and Mw<3 kDa fractions (Figure 3.1b); the higher molecular weight 
fraction (Mw≥10k  )     v       y         v     times with buffer A (0.5 M sodium phosphate 
buffer pH 7.20±0.10 in 100% D2O) and was finally diluted back to the initial volume (1mL). 
All AF samples and fractions were centrifuged (13400xg, 25°C, 5 min) and transferred into 
5mm NMR tubes, prior to spectral acquisition. A scheme of the preparation procedures for AF 
samples is shown in Figure 3.2.  
 
Figure 3.2 - Scheme of AF preparation procedures for 1H NMR analysis. Buffer A 
(sodium phosphate buffer 0.5M at pH 7.2 in 100% D2O); * detailed description in 
Figure 3.1. 
 
 
 3.3.1.2. Amniotic fluid stability evaluation for NMR 
 
 AF sample stability was assessed during storage, after freeze-thaw cycles and at room 
temperature by 1D 1H NMR (using "standard" experiments, details in section 3.3.2) using healthy 
control AF samples. The stability tests are represented in the scheme of Figure 3.3 and explained 
in detail below. 
 
Evaluation of stability with storage time: 3 AF samples were subdivided into aliquots, 6 
aliquots per sample were stored at -20°C and other 6 were stored -70°C (Figure 3.3a). After each 
month one aliquot of each sample was thawed from -20°C and from -70°C, prepared with 
buffering as described in the previous subsection (page 63) and analysed by 1H NMR (Figure 3.3a);  
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Figure 3.3 - Schematic representation of the tests to evaluate sample stability: a) during storage at -
20°C and -70°C; b) with freeze-thaw cycles at -20°C and -70°C; c) at room temperature (22-25°C). 
Buffering: addition of 100L of sodium phosphate buffer 0.5M at pH 7.2 in 100% D2O to 500L of AF 
sample. 
 
Evaluation of the effect of freeze-thaw cycles: 3 other AF samples were subdivided into 2 
aliquots each and prepared with buffering and transferred to NMR tubes (Figure 3.3b). After 
analysis by 1H NMR, 3 tubes were frozen at -20°C and other 3 tubes at -70°C. The tubes were 
thawed and analysed by 1H NMR. After 1H NMR analysis, the procedure was repeated once more 
(Figure 3.3b). The procedure was repeated once more for one of the samples. 
 
Evaluation of stability at room temperature (22-25°C): 6 samples were prepared with buffering 
and then repeatedly analysed by 1H NMR in regular intervals (when possible) of 1 hour up to 8 
hours or at 0, 10, 13 or 28 hour periods (Figure 3.3c). 
 
All AF samples and fractions were centrifuged and (13400xg, 25°C, 5 min) and transferred into 
5mm NMR tubes, prior to spectral acquisition. 
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3.3.1.3. Urine sample preparation for NMR 
 
Maternal urine was prepared by dilution with a phosphate buffer, according to a previously 
published preparation method (Bernini et al., 2011), summarized in Figure 3.4. 
 
Figure 3.4 - Scheme of maternal urine sample preparation procedure for 1H NMR analysis. Buffer B 
(potassium phosphate 1.5M, at pH 7.0 with 0,1% TSP and 2mM NaN3 in 100% D2O). 
 
Each urine sample was thawed at room temperature and, after gentle mixing, 1mL of each 
sample was centrifuged (13400×g, 25°C, 5 min) to remove any particulate matter. To 540 L of 
each urine supernatant, 60L of potassium phosphate buffer 1.5M with 0,1% TSP with 2mM NaN3 
(used to prevent bacterial growth) in 100% D2O at pH 7.00±0.10 (buffer B) were added to in order 
to minimize inter-sample pH differences (Figure 3.4). The pH of each buffered sample was 
measured once more and, if necessary, adjusted to pH 7.00±0.10 with volumes of 0.5 - 2L of 4M 
HCl or 4M KOH solution prepared in 100% D2O. The buffered samples were centrifuged (13400×g, 
25 °C, 5 min) and 550L of each prepared sample was transferred into 5 mm NMR tubes after for 
NMR spectral acquisition (Figure 3.4). 
 
3.3.2. NMR experimental details 
 
3.3.2.1. NMR equipment 
 
The NMR spectrometers used and respective facilities where the experiments were performed 
are summarized in Table 3.5. The samples were kept at 22°C inside the sample changers prior to 
acquisition for periods no longer than 12 hours in order to prevent sample degradation. Access to 
600MHz and 800MHz spectrometers was provided through courtesy of Faculdade de Ciências e 
Tecnologia, Universidade Nova de Lisboa (FCT-UNL) - Laboratório associado REQUIMTE, 
Portuguese NMR Network (Portugal); and NMR Application, Bruker BioSpin, NMR division 
(Reinstetten, Germany), respectively. 
 
 
 
Maternal 
urine
(1mL)
Centrifugation 
13400xg, 
25ºC, 5 min 
supernatant
(540L)
+
buffer B
(60L)
Centrifugation 
13400xg, 
25ºC, 5 min 
supernatant
1H NMR 
spectral 
acquisition
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Table 3.5 - Equipment used to perform the NMR experiments and respective facility. 
NMR facility Spectrometer and equipment Experiments 
Departmento de Química, 
Universidade de Aveiro, Portugal 
 Bruker Avance DRX 500MHz 
 5mm BBI probe 
 operating at 300K  
 gradient unit (53.5 G/cm, max. output)  
 NMR-Case sample changer  
 xwin-nmr 3.1 software 
1D, 2D NMR 
and DOSY 
FCT-UNL - Laboratório associado 
REQUIMTE, Portuguese NMR 
Network, Portugal 
 Bruker Avance III 600 MHz  
 TCI cryo-probe 
 operating at 300K temperature 
 TopSpin 2.1 software 
Saturation 
transfer 
difference 
(STD) 
NMR Applications, Bruker BioSpin 
NMR division, Germany 
 Bruker Avance 800MHz 
 5 mm TXI probe  
 operating at 298K  
 gradient unit (53.5 G/cm, max. output)  
 NMR-Case sample changer  
 TopSpin 1.3 software 
1D and 2D 
NMR 
 
 
3.3.2.2. 1D and 2D 1H NMR experiments 
 
1D 1H NMR experiments for AF analysis were acquired with water suppression using 
presaturation pulses with 58dB or 53.8dB power at 500MHz and 800MHz, respectively, set at the 
water frequency. Two "standard" 1D experiments which enabled the registration of signals from 
high and low Mw molecules were acquired, namely a zgpr (RD-90°-acquire) and noesypr1d (RD-
90°-t1-90°-tm-90°-acquire) experiments from Bruker library. In the zgpr experiment water 
presaturation is performed during relaxation delay and was used for freeze-dried samples diluted 
in D2O, whereas in noesypr1d water presaturation is performed during relaxation delay and 
mixing time thus enabling more efficient water suppression. The noesypr1d experiment was then 
performed for samples containing more water, namely buffered AF and urine. Moreover, T2 
relaxation edited 1H spectra were acquired using the Carr-Purcell-Meiboom-Gill (CPMG) pulse 
sequence (RD-90°-(-180°-)n-acquire) (Meiboom and Gill, 1958) (cpmgpr1d, from Bruker library) 
in order to filter signals from high Mw molecules. Diffusion-edited spectra were also recorded 
using the bipolar pulse longitudinal eddy current delay (BPPLED) pulse sequence with 2 sine 
gradient pulses (Wu et al., 1995) (ledbpgp2s1dpr, from Bruker library) in order to filter low Mw 
molecule signals. The 1D pulse programs (from Bruker pulse program library, details shown in 
Annex II - 1H NMR pulse programs) as well as the acquisition and processing parameters used are 
summarized in Table 3.6.  
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Table 3.6 - Acquisition and processing parameters used for 1D 1H NMR 500MHz and 800MHz spectra 
of AF. NS, number of transients; RD, relaxation delay; t1, fixed delay; tm, mixing time;, echo time; n, 
number of (-180°-) loops; 2n, total spin-spin relaxation time;, gradient duration; , diffusion time; 
g, strength gradient pulses as % of maximum gradient output (53.5 G/cm); SW, spectral width; TD, size 
of FID; SI, size of real spectrum; WDW, window function; LB, line broadening. 
 
1D 
1
H NMR Acquisition parameters - 800MHz 
(Bruker library pulse program name) 
 
Standard 
(zgpr) 
Standard 
(noesypr1d) 
CPMG 
(cpmgpr1d) 
Diffusion-edited 
(ledbpgp2s1dpr) 
NS: 256 
RD: 5s 
SW: 9615.39 Hz 
TD: 32k points 
NS: 512 
RD: 5s 
t1: 4s 
tm: 100 ms 
SW: 9615.39 
Hz 
TD: 32k points 
NS: 256 or 512 
RD: 5s 
: 1ms 
n: 80 
2n: 160ms 
SW: 9615.39 Hz 
TD: 32k points 
 
NS: 512 
RD: 5s 
: 2ms 
: 200ms 
g: 70% 
SW: 9615.39 Hz 
TD: 32k points 
1D 
1
H NMR Acquisition parameters - 500MHz 
(Bruker library pulse program name) 
Standard 
(noesypr1d) 
CPMG 
(cpmgpr1d) 
Diffusion-edited 
(ledbpgp2s1dpr) 
 
NS: 256 
RD: 3s 
t1: 3s 
tm: 100 ms 
SW: 8012.82 Hz 
TD: 32k points 
 
NS: 256 
RD: 3s 
: 350 s 
n: 300 
2n: 210 ms 
SW:8012.82 Hz 
TD: 32k points 
 
 
NS: 256 
RD: 3s 
: 2ms 
: 200ms 
g: 95% 
SW: 8012.82 Hz 
TD: 32k points 
Processing Parameters (500 and 800MHz) 
Standard 
(zgpr) 
Standard 
(noesypr1d) 
CPMG 
(cpmgpr1d) 
Diffusion-edited 
(ledbpgp2s1dpr) 
SI: 64k points 
WDW:exponential 
LB: 0.3Hz 
SI: 64k points 
WDW: exponential 
LB: 0.3Hz 
SI: 64k points 
WDW: exponential 
LB: 0.3Hz 
SI: 64k points 
WDW: exponential 
LB: 1Hz 
 
The 800MHz experiments, aimed for AF characterization, were based on plasma and serum 
analysis acquisition parameters obtained from literature (Foxall et al., 1993; Daykin et al., 2002). 
The acquisition parameters of the experiments performed at 500MHz, used for AF routine 
analysis, were re-optimized from those of 800MHz, to allow a rapid acquisition (15 min per 
experiment) with an adequate signal-to-noise. 
Spectra processing was performed using Bruker TopSpin 2.1 (Bruker BioSpin, Reinstetten, 
Germany). Prior to FT, the FIDs were zero-filled to 64k points (SI, Table 3.6) and multiplied by an 
exponential line-broadening window functions (WDW) according to the parameters shown in 
Table 3.6. The 1D spectra were manually phased, baseline corrected, and the chemical shifts 
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referenced internally to the -glucose H1 resonance at 5.23 ppm. Although some samples 
contained TSP, the resonance of this compound was not used as reference for chemical shifts due 
to the line-broadening resulting from binding to AF proteins.  
 
Maternal urine 1H NMR spectra were acquired at 500MHz using a standard 1D experiment 
(noesypr1d) with acquisition conditions adapted from previous reports (Beckonert et al., 2007; 
Bernini et al., 2011) with water suppression using a water presaturation pulse with 60dB power. A 
list of acquisition and processing parameters of 1H NMR spectra of maternal urine is shown in 
Table 3.7.  
 
Table 3.7 - Acquisition and processing parameters used for 1D 1H NMR 500MHz spectra of maternal 
urine. NS, number of transients; RD, relaxation delay; t1, fixed delay; tm, mixing time SW, spectral 
width; TD, size of FID; SI, size of real spectrum; WDW, window function; LB, line broadening. 
Acquisition parameters  
(noesypr1d) 
Processing parameters 
NS: 128 
RD: 4s 
t1: 3s 
tm: 100 ms  
SW: 10080.65 Hz 
TD: 64k points 
    SI: 64k points 
    WDW: exponential 
    LB: 0.3Hz 
    Chemical shift reference: 0.00 ppm (TSP) 
 
Maternal urine FIDs were zero-filled to 64k points (Table 3.7) and multiplied by an exponential 
line-broadening window functions (WDW) prior to FT. The 1D spectra were manually phased, 
baseline corrected, and the chemical shifts were referenced internally to TSP resonance at 0.00 
ppm. 
 
The 2D NMR experiments TOCSY, HSQC and J-resolved were performed for AF characterization 
both at 500MHz and 800MHz. The acquisition parameters used were based on previous studies 
(Foxall et al., 1993; Daykin et al., 2002) (Table 3.8). The TOCSY spectra were recorded in phase-
sensitive mode using States-TPPI (time proportional phase incrementation) detection in t1 with a 
MLEV-17 spin lock pulse sequence (Bax and Davis, 1985), with water presaturation using pulses of 
58dB or 53.8dB power, for 500 and 800MHz respectively. The HSQC 1H-13C spectra were acquired 
with inverse detection and 13C decoupling during acquisition.  
The acquired FIDs were zero-filled according the data points defined in SI parameters shown in 
Table 3.8 and multiplied by a sine-bell-squared function (qsine) prior to FT. All spectra were 
manually phased, automatically baseline corrected and manually chemical shifts calibrated 
internally using -glucose H1 resonance at 5.23 ppm using software TopSpin 2.0 (Bruker BioSpin, 
Reinstetten, Germany).  
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Table 3.8 - 2D NMR 500/800MHz spectra experimental acquisition and processing parameters: NS, 
number of transients; RD, relaxation delay; SW, spectral width; TD, time domain; F1, frequency 
domain 1; F2, frequency domain 2; pl10, power for TOCSY spin-lock; SI, size of real spectrum; 
WDW, window function; LB, line broadening. 
 
2D 
1
H NMR Experiment 
(Bruker library pulse program names: 500/800MHz) 
 
1
H-
1
H TOCSY 
(clmlevprtp / mlevphpr) 
1
H-
13
C HSQC 
(invietgpsi / hsqcetgpsp) 
J-Resolved 
(jresqfpr) 
 
Acquisition Parameters 
 
NS: 16 / 24 
RD: 2s 
tm: 600 ms 
TD[F1]: 300 / 256 points 
TD[F2]: 2k / 8k points  
SW[F1]: 8012.82 / 9615.39 Hz 
SW[F2]: 8012.82 / 9615.39 Hz 
pl10: 15.00 / 5.70 dB 
 
NS: 64 
RD: 2s 
TD[F1]: 300 / 256 points 
TD[F2]: 2k points 
SW[F1]: 25153.81 / 32258.06 Hz 
SW[F2]: 8012.82 / 9615.39 Hz 
 
 
NS: 8 
RD: 2s 
SW: 9615.39 Hz 
TD[F1]: 128 points 
TD[F2]: 2k points 
SW[F1]: 50 Hz 
SW[F2]: 9615.39 Hz 
 
Processing Parameters 
 
SI[F1]: 1k points 
SI[F2]: 4k points 
WDW: qsine 
 
 
SI[F1]: 1k points 
SI[F2]: 4k points 
WDW: qsine 
 
SI[F1]: 1k points 
SI[F2]: 4k points 
WDW: qsine 
 
 
3.3.2.3. Diffusion Ordered Spectroscopy (DOSY) experiments 
 
DOSY experiments were performed on AF samples (prepared with buffer A as shown in Figure 
3.2, page 64) and on AF fraction with Mw<3kDa and Mw≥10k   (  g    3 1, page 63). Spectra were 
acquired at 500 MHz, at 300K using the pulse sequence for diffusion measurement ledbpgs2spr 
from Bruker library, which uses a stimulated echo, BPPLED pulses for diffusion, and two spoil 
gradients (Wu et al., 1995). The DOSY acquisition and processing parameters are summarized in 
Table 3.9.  
Each FID was zero-filled and multiplied by exponential line broadening functions prior to FT 
according to the processing parameters shown in Table 3.9. Spectra were baseline corrected and 
chemical shifts referenced internally to the -glucose signal H1 resonance at 5.23 ppm or the 
lactate methyl resonance at 1.32 ppm (for Mw≥10 k         c    ), prior to exponential fitting for 
diffusion coefficient calculation. Shikimic acid, an organic acid which is not found in human AF, 
was used as a molecular weight reference for Mw estimation, and added to Mw≥10 k      c     
prior to spectra collection. Mw values were estimated as the inverse of the cube of the diffusion 
coefficient of the resolved spin-systems in DOSY spectra, assuming a globular molecular shape 
(Nilsson et al., 2004).  
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Table 3.9 - Acquisition and processing parameters form DOSY 500MHz spectra of AF and AF fractions 
of Mw<3kDa and Mw≥10k  : RD, relaxation delay; NS, number of transients per gradient level; , 
gradient duration;, diffusion time; TD[F1], number of gradient levels; TD[F2], size of each FID; SW, 
spectral width; SI, size of each real spectrum; WDW, window function; LB, line broadening.      
 
DOSY 
1
H NMR Experiments (500 MHz) 
 
Amniotic Fluid (AF) 
 
AF Mw<3kDa AF Mw≥10kDa 
Acquisition Parameters 
NS: 128 
RD: 0.5s 
: 1.1 ms 
: 150 ms 
TD[F1]: 16 levels 
TD[F2]: 32k points  
SW: 6009.62 Hz 
NS: 64 
RD: 0.5s 
: 1.1 ms 
: 150 ms 
TD[F1]: 32 levels 
TD[F2]: 8k points 
SW: 6009.62 Hz 
NS: 160 
RD: 3s 
: 1.5 ms 
: 250 ms 
TD[F1]: 32 levels 
TD[F2]: 32k points 
SW: 6009.62 Hz 
 
Processing Parameters 
 
SI: 32k points 
WDW: exponential 
LB: 2 Hz 
 
SI: 16k points 
WDW: exponential 
LB: 2 Hz 
 
SI: 32k points 
WDW: exponential 
LB: 2 Hz 
 
 
 
3.3.2.4. Saturation Transfer Difference (STD) experiments 
 
STD experiments (Mayer and Meyer, 1999) were performed in order to determine the extent 
of lactate binding to AF proteins in both whole AF samples and the Mw≥10k         c       T   
STD spectra were acquired using the Bruker library pseudo-2D saturation transfer difference pulse 
sequence, stddiffesgp.3 (Annex II - 1H NMR pulse sequences) with water suppression using 
excitation sculpting at 600MHz with cryo-probe (courtesy of FCT-UNL - Laboratório Associado 
REQUIMTE and Portuguese NMR Network, Portugal). Each FID consisted in 64 transients acquired 
with 3s relaxation delay, to 32k data points and using a spectral window of 12019.22 Hz. Four 
spectra were gathered per experiment: 2 spectra without signal saturation (off-resonance) and 2 
spectra with saturation of protein signals (on-resonance). The on- and off-resonance frequencies 
were 4242 Hz (in the region of NH groups of the proteins) and 8000 Hz (baseline region), 
respectively. The spectra were processed using TopSpin 2.1 software (Bruker BioSpin, 
Rheinstetten, Germany) with zero-filing to 64k data-points, multiplied by an 0.3Hz line broadening 
function prior to FT, manually baseline corrected and chemical shifts referenced internally to the 
-glucose signal H1 resonance at 5.23 ppm. The difference spectrum was then calculated as the 
difference between the two summed off-resonance spectra and the two summed on-resonance 
spectra. 
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3.3.2.5. Spectral assignments 
 
Databases of NMR spectra of known standards, such as the Metabolic Profiling Database, 
Biorefcode 2.0.0 (courtesy of NMR Applications, NMR division, Bruker BioSpin, Rheinsteten, 
Germany), the Human Metabolome Database (HMDB) (Wishart et al., 2009) and the 
BioMagResBank (BMRB) (Ulrich et al., 2008), were used to aid spectral assignments. Spectra of 
solutions of selected pure compounds (Table 3.4, page 62) were also acquired at 500 MHz using 
the standard noesypr1d and the same acquisition and processing parameters used for AF spectra 
(Table 3.6) to confirm spectral assignments. 
 
3.3.2.6. Pre-processing and analysis of NMR data 
 
After acquisition and processing (described in section 3.3.2.2. page 67), 1D 1H NMR of AF 
acquired at 500MHz were organized into rectangular matrices (X matrix, Figure 3.5).  
 
  
Figure 3.5 - Schematic representation of pre-processing and analysis of AF 1H NMR data. RSPA: 
recursive segment-wise peak alignment; PQN: probability quotient normalization; UV, unit variance; 
CV, cross-validation; MCCV, Monte Carlo cross-validation.  
 
The interfering water region (4.60–4.90 ppm) and the region containing the urea resonance 
(5.60-6.00 ppm, which is also affected by water suppression) were removed. The spectra were 
aligned using the segment-wise peak alignment (RSPA) algorithm (Veselkov et al., 2009) and 
normalized using the probability quotient normalization (PQN) method in MATLAB version 7.9.0 
(The Mathworks Inc., Natick, MA, USA). Prior to data analysis the X matrices were UV-scaled (each 
element of column was divided by the standard deviation of the column) (Figure 3.5).  
1H NMR spectra
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and class separation 
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Alignment
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Normalization
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Multivariate analysis was performed using SIMCA-P 11.5 software (Umetrics, Umeå, Sweden). 
PCA was performed followed by the PLS-DA and OPLS-DA where the sample classification and 
metadata were used to create sample groups. In the PLS-DA and OPLS-DA models, each disease 
was compared with a group of healthy control samples, and model predictive power was 
evaluated by Q2 (goodness of prediction), a parameter obtained from 7-fold cross-validation 
(Figure 3.4). After model validation through MCCV using in-house software, the relevant 
metabolite signals were identified from the weight loadings plots of the PLS-DA or OPLS-DA 
models. The weight loadings plots consist of back-transformed weight loadings (i.e., each value 
from the loadings vector was multiplied by the standard deviation of each variable from the X 
matrix) and coloured by the variable importance in the projection (VIP) parameter. The VIP value 
is a measure of the magnitude of the contribution of each variable to the separation observed in 
the PLS-DA scores (Chong and Jun, 2005). VIP values were automatically calculated in SIMCA-P for 
the respective PLS-DA and OPLS-DA models. The signals identified from the weight loadings plots 
were assigned using 2D NMR, data base searching and eventually through STOCSY analysis 
(described in detail in section 3.6) (Figure 3.4). The metabolite signals were also analysed by 
univatiate Welch (t-test) or Mann-Whitney tests (Mann and Whitney, 1947) using the peak 
integrated areas of the 1H NMR spectra. The distributions of peak integrals were also accessed 
with aid of box-and-whisker plots (box-plots) for group comparison (Figure 3.6). 
 
 
Figure 3.6 - An example of box-and-whisker representation of peak area 
distributions of two sample groups A and B (simulated data sets). Q1, 
quartile 25%; Q3, quartile 75%; IQR, inter-quartile range. 
 
 
 
outlier 
Q3
Q1
Median
IQR
Q3 + 1.5xIQR
Q1 - 1.5xIQR
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3.4. Liquid Chromatography coupled to NMR and MS (LC-NMR/MS) 
 
3.4.1. Preparation of amniotic fluid samples for LC-NMR/MS 
 
AF samples were directly ultrafiltered through 3kDa cut-off filters (see section 3.3.1, page 63), 
to remove protein content and prevent blockage of HPLC columns. About 1 mL of each AF 
Mw<3kDa fraction was freeze-dried and reconstituted in 100 L of either D2O or H2O (without 
buffering) for LC-NMR/MS and LC-MS analysis respectively, in order to obtain 10-fold 
concentrated fractions. 
 
3.4.2. Equipment and experimental setup 
 
Hyphenated NMR experiments were performed for AF samples in two different NMR facilities 
and using three different LC-NMR/MS systems, whose setups are summarized in Table 3.10. 
 
Table 3.10 - Description of the three LC-NMR/MS systems where the hyphenated NMR experiments 
were performed for AF samples.  
 System 1 System 2 System 3 
NMR facility 
Departamento Química 
Universidade de Aveiro 
NMR Applications, NMR division, 
Bruker BioSpin, Rheinsteten, Germany 
HPLC    
System Agilent 1100 Agilent 1200 Agilent 1100 
Column oven - yes yes 
Sample injection manual automatic Automatic 
UV-Vis detector Bruker Agilent Agilent 
NMR    
Spectrometer Bruker Avance DRX500 Bruker Avance 600 Bruker Avance 500 
Probes LCSEI  
(120L active volume) 
Cryo-probe with  
30 or 120L cryo-fits 
LCSEI  
(60L active volume) 
Interface BPSU-36-2 BPSU-36-2 BPSU-36-2 
MS    
Spectrometer - - Bruker Esquire 3000 
Interface - - Bruker BNMI 
SPE - Bruker Prospekt Bruker Prospekt 
 
The use of LC-NMR/MS systems 2 and 3 were a courtesy of NMR Applications, NMR division, 
Bruker BioSpin, (Rheinsteten, Germany). All LC-NMR/MS systems were composed of an HPLC 
systems equipped with quaternary pump and solvent degasser (Agilent Technologies, Inc. 
Waldbronn, Germany). LC-NMR/MS systems 2 and 3 were also equipped with an auto sampler 
and UV-Visible diode array detector (DAD) from Agilent, whereas system 1 was equipped with a 
Bruker UV-Visible DAD detector and manual sample injector (Rheodyne, CA, USA) (Table 3.10). 
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The HPLC systems were connected to NMR spectrometers of 500MHz (systems 1 and 3) and 
600MHz (system 2) field strengths through BPSU-36-2 interface units (Bruker BioSpin, 
Rheinstetten, Germany). The BPSUP-36-2 units controlled the delivery of the HPLC flow to the 
NMR probe head and were also capable of storing up to 36 LC fractions into sample loops for 
post-chromatography NMR analysis (loop-storage). The NMR spectrometers of systems 1 and 2 
were equipped with LC selective inverse (LCSEI) probe-heads with active volumes of 120 and 60 
L, respectively (Table 3.10). System 2 was equipped with a cryo-probe capable of 
accommodating cryofit flowcells of 30 and 120 L active volume (Table 3.10). All probes were 
operated at 300K during spectral acquisition. Both systems 2 and 3 were connected to a solid 
phase extraction (SPE) interface, which enabled the trapping of LC separated compounds into 
hydrophobic cartridges. Finally, in system 3 the flow from the HPLC system was split into an NMR 
(BPSU-36-2) interface as described above and into an BNMI interface (Bruker BioSpin, 
Rheinstetten, Germany) which established the connection to an Esquire 3000 ion trap mass 
spectrometer (Bruker Daltonics, Bremen, Germany). The MS acquisition parameters used are 
summarized in Table 3.11. The MS spectrometer allowed also the acquisition of full MS and MSn 
fragmentation spectra up to MS4, which was set to automatic search for higher intensity peaks.  
 
Table 3.11 - Ion trap MS acquisition parameters used in LC-NMR/MS experiments. 
Condition Values 
Ionization mode Alternating ESI
+
/ESI
-
 
Mass range 50-1000m/z 
Spray voltage 3.5kV 
Desolvation temperature 350ºC 
Sheath gas N2 at 60psi and 11L/min 
 
 
3.4.3. Characterization of less polar metabolites 
 
In order to characterize the less polar fraction of AF metabolites, chromatographic separation 
was performed in a reverse-phase (RP C18) column (Phenomenex, USA) at 35°C, using as a mobile 
phase (at pH 2.0) solution A (D2O+ 0.1% formic acid deuterated to 90%) and solution B 
(acetonitrile + 0.1% formic acid deuterated to 90%), with a flow rate of 0.4mL/min. The following 
gradient program was used: 10-30% B from 0 to 40 min and then from 30 to 90% B from 40 to 
45min. The UV detection was set at 210 nm and at ranges 200-210 and 254-280 nm. The injected 
  mp   v   m        20μL     100μL      n-line solid phase extraction (SPE) and fraction 
collection (loop-storage) respectively.  
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Parallel NMR and MS analysis were performed using system 3 (Table 3.10), for the selected 
chromatography separated fractions, using the loop-storage collection method. 1H NMR spectra 
were recorded for each stored fraction using the lc1pncwps pulse sequence (a noesypr1d pulse 
sequence optimized for LC-NMR, shown in Annex II - 1H NMR pulse programs) with double solvent 
presaturation employed to suppress both acetonitrile (ACN) and water peaks from the mobile 
phase. The number of transients acquired were 512, 1024, or 2048 (depending on the 
chromatographic peak intensity), with 16k data points, a spectral width of 10000Hz, and 0.8s 
acquisition time. Each FID was zero-filled to 32k, multiplied by an exponential function (1Hz line 
broadening), manually phased, and baseline corrected. For selected fractions, 1H-1H TOCSY 
spectra were also recorded. MS and MSn spectra were acquired during the chromatographic run 
in positive mode and during fraction transfer in both positive and negative modes, using the mass 
range 50-1000 m/z.  
Selected chromatographic fractions were trapped into SPE cartridges during chromatography, 
and were later extracted with either methanol-d4 or acetonitrile-d3 before transfer through a 
Prospekt interface into the cryo-probe head (using a cryofit flowcell with 30μL  c  v  v   m )  1H 
NMR spectra were recorded at 600.13 MHz using the same parameters used for loop-stored 
fractions in system 2 (Table 3.10). 
 
3.4.4. Characterization of more polar metabolites 
 
In order analyse the more polar compounds, the AF samples were injected onto a ION300 
300×7.8mm cation-exchange column, with a particle size of 5.0μm (      c         m   g  p y 
Inc., San Francisco, CA, USA), a column specific for organic acids, alcohols and sugars, at a 
temperature of 22°C, under isocratic conditions, using a flow of 0.3mL/min with a total run time 
of 70 min. For LC-N R  100μL      c    mp          j c          m b    p     c mp        
2.5mM H2SO4 in 100% D2O (pH 2.4) was used. UV DAD detection was recorded at 210 nm.  
The LC-NMR experiment was recorded at 600MHz (system 2, Table 3.10) using the time-slice 
stop-flow method, i.e., at every 30s of the chromatography run time, the flow was stopped and 
one 1D spectrum was acquired. The spectra were acquired with the lc1pnf2 sequence from Bruker 
pulse program library (a noesypr1d pulse sequence optimized for LC-NMR, shown in Annex II - 1H 
NMR pulse programs) with water presaturation at 2817.22Hz, with a total of 64 transients 
collected to 32k data points, using a spectral width of 12019Hz, and 1.36 s acquisition time. Each 
FID was multiplied by an exponential function (1Hz line broadening), manually phased, and 
baseline corrected. The processed 1D spectra were then reconstructed as pseudo-onflow 2D 
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spectrum. To confirm some of the results, repetition of 1D and 2D NMR on selected LC fractions 
were performed at 500MHz (system 1, Table 3.10) using the loop-storage method. 
Due to experimental setup constraints, the MS detection for the ion exchange 
chromatography was collected separately as an LC-MS experiment using the same 
chromatographic conditions described above, but replacing the D2O by ultrapure water in the 
mobile phase composition. The injected sample volume was also reduced to 20μL        p c    
were collected in both positive and negative modes, in the mass range of 90-1000 m/z, with 
automatic fragmentation of the most abundant ions (up to MS4). 
 
3.5. Ultra-Performance Liquid Chromatography - Mass Spectrometry (UPLC-MS) Analysis 
 
3.5.1. Sample preparation for UPLC-MS 
 
Amniotic fluid and maternal urine samples used in UPLC-MS profiling analysis were thawed at 
room temperature (25°C) and gently mixed. After thawing, the samples were prepared according 
to the schemes shown in Figure 3.7.  
 
 
Figure 3.7 - Sample preparation procedures used prior to UPLC-MS analysis: a) Amniotic fluid and        
b) maternal urine samples. 
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+
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discarded
Supernatant
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Centrifugation
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discarded
Supernatant (~200L)
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+
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96 sample well plates
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In order to remove proteins which would otherwise damage the UPLC columns, AF samples 
were precipitated with ice-cold methanol (Figure 3.7a). After centrifugation, the supernatants of 
AF extracts were concentrated in a speed-vac sample concentrator (Eppendorf, Hamburg, 
Germany) at 30°C for 3 hours (Figure 3.7a). The dried samples were then reconstituted in HPLC 
grade water, sonicated in an ultrasound bath at room temperature (5 min), centrifuged (9400g, 
10 min) and transferred into 96 well plates. 
Maternal urine samples were centrifuged (9400g, 10 min), then diluted 1:1 with HPLC grade 
water and mixed after being transferred into 96 well plates (Figure 3.7b). Maternal urine and AF 
samples were kept inside the auto-sampler of the UPLC system during the analysis, which was 
maintained at a constant temperature of 4°C. 
 
3.5.2. Equipment and experimental setup 
 
UPLC-MS analysis was performed courtesy of Biomolecular Medicine Department, Division of 
Surgery and Cancer of the Faculty of Medicine, Imperial College of London. Profiling experiments 
were performed in Acquity UPLC systems (Waters Ltd. Elstree, UK) connected to an LCT Premier 
mass spectrometer (Waters MS Technologies, Ltd., Manchester, UK) or connected to a Q-TOF 
Premier mass spectrometer (Waters MS Technologies, Ltd., Manchester, UK). Fragmentation MS 
experiments (MS/MS on selected m/z and MSE) were performed using an Acquity UPLC system 
(Waters Ltd. Elstree, UK) coupled to a Q-TOF Premier mass spectrometer (Waters MS 
Technologies, Ltd., Manchester, UK). Mass spectrometry was performed in both positive and 
negative ion electrospray (ESI+ and ESI-) modes separately, meaning that each sample batch was 
run in UPLC twice, one for each ESI mode. The MS parameters used are summarized in Table 3.12. 
 
Table 3.12 - Acquisition parameters of the time-of-flight mass spectrometers (TOF-MS) used 
in UPLC-MS experiments.  
Condition Values 
Capillary voltage 3.2kV (ESI
+
) / 2.4kV (ESI
-
) 
Source temperature 120ºC 
Desolvation temperature 350ºC 
Desolvation gas flow 900L/h 
Operation mode V optics 
Mass range 50-1000m/z 
Acquisition mode centroid 
Acquisition rate 0.1s (0.01s interscan delay) 
  
A solution of the peptide leucine enkephalin (monoisotopic mass = 555.2693 Da) with 
c  c          200pg/μL (   50:50   N:H2O) was infused into     m     p c   m         3μL/m   
via an auxiliary sprayer to provide a lock mass signal, which was registered every 15s and 
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averaged over 3 scans to perform mass correction. For fragmentation analysis (MS/MS and MSE) 
collision energy ramps of 10-50 Volts were used. 
Two different chromatographic columns were used due to their complementary performances 
in achieving a more complete characterization of a biofluid metabolic profile: High-Strength Silica 
(H  ) ( cq   y   H H   1 8 μm  2 1 × 100 mm  W         p                 U     )     c        
improved retention for polar compounds over regular reversed phase (RP) columns (Masson et 
al., 2011)        Hy   p    c       c         m   g  p y (H L  ) ( cq   y   H H L    1 7 μm  2 1 
× 100 mm, Waters Corporation, Milford, U.S.A.), which retains polar compounds, particularly 
those of basic nature (Gika et al., 2008).  
Gradient elution was used for both HSS and HILIC columns.  For the HSS column a flow rate of 
0.5mL/min was used with a gradient of the following mobile phases: water with 0.1% formic acid 
(AHSS) and acetonitrile (ACN) with 0.1% formic acid (BHSS) (Figure 3.8a). For the HILIC column a flow 
rate of 0.4mL/min was used and the mobile phases consisted in two solutions: 95% Ammonium 
acetate 10mM / 5% ACN with 0.1% formic acid (AHILIC) and 50% Ammonium acetate 10mM / 50% 
ACN with 0.1% formic acid (BHILIC), eluted according to the gradient shown in Figure 3.8b. All 
solvents and reagents were of HPLC grade or equivalent and both columns were constantly 
maintained at 40°C during the analysis. 
 
Figure 3.8 - Time profiles of the UPLC elution gradients: a) HSS column; b) HILIC column. AHSS: 
H2O+0.1% formic acid; BHSS: ACN + 0.1% formic acid; AHILIC: 95% Ammonium acetate 10mM/5% 
ACN+0.1% formic acid; BHILIC: 50% Ammonium acetate 10mM / 50% ACN + 0.1% formic acid.    
 
A sample volume of 5L was injected twice per sample for each column (for positive and 
negative acquisition modes) in a randomised order. At the beginning of each run, a batch of 10 
injections (5L each) of a quality control (QC) sample was used to condition the column. The QC 
samples (of both AF and urine) consisted of mixtures of the control samples prepared in the same 
way as the study samples. The QC samples were repeatedly injected, after every 10 samples, in 
order to assess analytical reproducibility. 
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3.5.3. Pre-processing and analysis of UPLC-MS data 
 
The pre-processing and analysis workflow used for the UPLC-MS data sets is summarized in 
Figure 3.9. The raw UPLC-MS chromatograms were converted to netCDF format using Waters 
MassLynx 4.1 Databridge software (Waters Corporation, Milford, USA), and then processed using 
the freely available software package XCMS (Smith et al., 2006) in R 2.11.1 software (R 
Development Core Team, Vienna, Austria, 2011) using the centWave peak picking algorithm 
(Tautenhahn et al., 2008) (Figure 3.9). 
 
 
Figure 3.9 - Processing and analysis workflow of the AF and maternal urine UPLC-MS data sets. LOESS, 
locally weighted scatter plot smoothing; UV, unit variance; Log T, logarithmic transformation; CV, 
cross-validation; MCCV, Monte Carlo cross-validation; SHY, statistical heterospectroscopy. 
 
Correction of the inter-sample peak retention time (RT) deviations was also performed using 
XCMS (Figure 3.9). Sample data sets and QC samples injected between runs were normalized 
using locally weighted scatter plot smoothing (LOESS) (Veselkov et al., 2011) using R 2.11.1 
software.  
The normalized UPLC-MS data sets were arranged into a rectangular matrix (X matrix), where 
each element corresponded to the intensity of a retention time - m/z pair (column) for a given 
sample (row). The UPLC-MS data sets were subjected to scaling prior to mean centring using UV 
scaling, Pareto scaling, logarithmic transformation (Log transformed) and analysed by MVA 
(Figure 3.9) using SIMCA-P 11.5 software (Umetrics, Umeå, Sweden). Only the RT range of 1-8 min 
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was considered when the data sets were analysed, which corresponded to the range where 
sample metabolites eluted.  
Contrary to NMR, which is a highly reproducible platform for large scale untargeted metabolite 
profiling studies (>100 samples), the reproducibility of MS platforms has to be evaluated and 
ensured throughout the analysis (Dunn et al., 2012). The reproducibility of both AF and urine data 
sets was assessed through the analysis of QC sample distribution with the aid of PCA. The results 
of the reproducibility evaluation are presented in Annex III - UPLC-MS reproducibility evaluation. 
For the PLS-DA and OPLS-DA models only controls versus disorders were considered. After 
validation by MCCV, the loadings from OPLS-DA were evaluated from S-plots of the latent variable 
most relevant for class separation. The S-plot combines covariance and correlation between the 
UPLC-MS variables (RT_m/z pairs) of the X data matrix and PLS-DA scores. A correlation threshold 
of |r|>0.5 were considered in the S-plot analysis. The relevant features were selected based on 
the ratio of absolute mean covariance loading (|p|) and its respective jack-knifed validated 
standard error (pcvSE) (Wiklund et al., 2007). 
 
3.6. Fourier-transform Mid Infrared (MIR) spectroscopy analysis of amniotic fluid 
 
3.6.1. Equipment and experimental setup 
 
The MIR spectrometer used was a PerkinElmer BX FT-IR spectrometer (PerkinElmer Inc., USA), 
equipped with a Golden-Gate single reflection ATR, with a ZnSe crystal (Specac Ltd, Slough, UK). 
Spectra were acquired at 26±1°C and 38±2% relative humidity, in the range of 4000-600 cm-1 
with 64 scans and 4 cm-1 resolution.  
 
3.6.2. AF sample preparation and MIR spectra acquisition 
 
The AF samples were thawed at room temperature and one drop of each AF sample (5L) was 
applied on the ATR crystal. Spectra were consecutively collected during sample drying (at room 
temperature of 26±1°C) in which the AF sample forms a homogeneous film on top of the ATR 
crystal (Figure 3.10). The drying step is intended to remove excess of water which produces a 
strong absorption background and hampers the reproducible spectroscopy in the MIR region 
(Martin et al., 2004; Petrich et al., 2009).  
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Figure 3.10 - Schematic procedure of acquisition of MIR spectra of AF samples. 
 
Samples were considered dry after no visual differences between consecutive spectra were 
noted, usually after 25 to 30 min after sample application. A typical sequence of MIR spectra of AF 
recorded as a function of sample drying time is shown in in Annex IV - MIR reproducibility 
evaluation. After this, a set of 3 spectra were acquired (replicates) for each sample (Figure 3.10). 
In order to evaluate analytical reproducibility, a control sample was divided into 20 aliquots of 
20L and their MIR spectra were acquired between study samples (QC, quality control sample).   
 
3.6.3. Pre-processing and analysis of MIR data 
 
A rectangular matrix (X) was built using the 3 replicate spectra recorded for each dry sample, 
excluding the CO2 absorbance region (2400-2200cm
-1) (Figure 3.11). The matrices used for 
correlation analysis contained only one spectrum replicate per sample. 
 
Figure 3.11 - Schematic procedure of acquisition and pre-processing and analysis of AF by MIR. CV, 
cross-validation; MCCV, Monte Carlo cross-validation; SHY, statistical heterospectroscopy. 
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The MIR matrices were split into smaller matrices (sub-matrices) corresponding to spectral 
regions: 3000-2800 cm-1, 1800-1200 cm-1 and 1200-900 cm-1 (Figure 3.11) Each matrix was mean 
centred and normalization using standard normal variate (SNV) transformation (each intensity of 
a row, i.e. one spectra, was divided by the standard deviation of the intensities of the row) using R 
2.11.1 software (R Development Core Team, Vienna, Austria, 2011) and baseline corrected using 
the software Cats (Barros, 1999). Second derivatives were obtained for the spectral regions 
considering 5 points windows using SIMCA-P 11.5 (Umetrics, Umeå, Sweden) (Figure 3.11).  
All matrices were mean centred prior to MVA. The reproducibility of MIR data sets was 
assessed through the analysis of QC sample distribution with the aid of PCA, the results being 
presented in Annex IV - MIR reproducibility evaluation. PLS-DA models were obtained for controls 
versus disorder, being also subsequently evaluated through MCCV (Figure 3.11).  
To aid spectral assignment (Figure 3.11), literature on MIR AF spectra was consulted (Liu et al., 
1998a; Liu et al., 1998b; Liu and Mantsch, 1999; Liu et al., 2000; Liu et al., 2002), as well as tables 
on MIR spectra assignments of organic compounds (Pretsch et al., 1989). Spectra of aqueous 
solutions of selected standards of 0.1M and pH 8.30±0.30 were also acquired, after drying, using 
the same acquisition conditions as AF samples. Some standards were acquired in their solid state 
using the Golden-Gate apparatus already described. The standards whose MIR spectra were 
acquired are indicated in Table 3.4 (page 62). 
  
3.7. Statistical total correlation (STOCSY) and statistical heterospectroscopy (SHY) 
analysis  
 
 STOCSY analysis of 1H NMR was performed using the 1D version of STOCSY, which consists in 
representing the covariance between the vector of intensities from a peak of interest (driver 
peak) and the full spectrum matrix, with the corresponding Pearson correlation coefficients (r) 
being projected as colour on top of the covariance (Cloarec et al., 2005). The 1D STOCSY plots 
were obtained using all correlation coefficients calculated, i.e. no threshold was applied, to 
facilitate visualization of the correlated peaks. 
STOCSY was also applied to obtain the MIR intra-correlation maps, using the full spectrum 
matrices. Pearson correlations coefficients, r, were calculated, and only those with |r|>0.8 with 
p<0.001 significance level were considered. 
Inter-correlation maps of MIR/NMR were obtained using statistical heterospectroscopy (SHY) 
(Crockford et al., 2006). The matrices of MIR spectral regions were correlated to the full 1H NMR 
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standard spectra matrices. Only the Pearson correlation coefficients with |r|>0.7 and p<0.001 
significance level were considered in the SHY maps. The same criterion was used for MS/NMR SHY 
analysis. However, the results were expressed as 1D STOCSY graphical representations of the 
covariance and correlation coefficients calculated between the matrices containing intensities of 
UPLC-MS features and the matrix containing full 1H NMR CPMG spectra. The CPMG spectra (which 
filter high Mw compound signals) were used instead of the standard spectra (containing signals 
from both high and low Mw compounds) because UPLC-MS conditions were chosen to reflect 
mostly low Mw metabolites (section 3.5.1, pages 77-78).  
Special mention has to be made for 1H NMR maternal urine data, which was only considered 
for SHY analysis with the corresponding UPLC-MS data. The analysis of the 1H NMR maternal urine 
data was performed as part of another PhD thesis and the data used here had been reported 
before (Diaz et al., 2011). The maternal urine 1H NMR spectra were aligned and normalized using 
the same procedure as that used for AF 1H NMR spectra (section 3.3.2.6, page 72). The 
correlations were evaluated through scatter-plots, and those containing strong deviations from 
linearity or affected by the presence of outliers were not considered. All calculations and plots 
were performed using MATLAB version 7.9.0 (The MathWorks Inc., Natick, MA, USA). 
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4. Study of 2nd trimester human amniotic fluid by 1H NMR spectroscopy: 
stability evaluation and compositional analysis 
 
The first section of the present chapter is devoted to the qualitative evaluation of different 
protocols for AF preparation for 1H NMR spectroscopy in order to establish a protocol for 1H NMR 
metabolic profiling and AF characterization. In metabolic profiling, it is important to maintain 
sample integrity throughout the whole study by assuring that adequate sample storage and 
handling conditions are employed. While the effects of stability over storage and sample handling 
have been studied in some detail for biofluids such as serum, plasma and urine (Teahan et al., 
2006; Saude and Sykes, 2007; Barton et al., 2008), similar systematic studies were, to the best of 
our knowledge, lacking for AF samples. Therefore, in section 4.2 the effects of storage under -20° 
and -70°C temperatures, freeze-thawing and storage at room temperature on human AF 
composition were evaluated by 1D 1H NMR (Graça et al., 2007). Once suitable sample preparation 
protocol was defined, comprehensive characterization of human AF was performed (sections 4.3 
and 4.4) by high-resolution 1D 1H NMR and 2D NMR spectroscopy (Graça et al., 2007), and LC-
NMR/MS methods (Graça et al., 2008), thus extending previous knowledge of AF composition as 
viewed by 1H NMR (Sims et al., 1993b; Bock, 1994; McGowan et al., 1999; Groenen et al., 2004). 
The work described in this chapter establishes the ground for 1H NMR based metabolic profiling 
studies of human AF studies described in the next chapters 5 and 6.  
 
4.1. Comparison of different protocols for amniotic fluid analysis by 1H NMR: 
establishment of a protocol for metabolic profiling 
 
Effect of freeze-drying  
 
Qualitative differences were noted between the spectra of an AF sample prepared by direct 
dilution (i.e., 500L of AF diluted with 50L D2O/TSP) (Figure 4.1a) and the spectra of the same 
sample after freeze-drying and reconstitution in D2O (1.3-fold concentrated) (Figure 4.1b). Indeed, 
freeze-drying the sample seemed to cause loss of acetone and/or acetoacetate, ethanol and urea 
signals (Figure 4.1a). Moreover, other changes seemed to have occurred due to freeze-drying 
such as the apparent reduction of pyruvate and formate signal intensities, the broadening of 
citrate peaks intensities and increases in intensities of broader signals from proteins, when 
compared with the diluted sample (Figure 4.1).  
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Figure 4.1 - Standard 1D 1H NMR 800 MHz spectra of a human AF: a) diluted with D2O and b) freeze-
dried reconstituted in D2O and 1.3-fold concentrated. The signals affected by freeze-drying the sample 
are indicated in with arrows; HOD, residual water peak.  
 
 
The total or partial loss of the more volatile compounds acetone, acetoacetate, formate, 
pyruvate and ethanol was expected in upon freeze-drying the sample. In fact similar compound 
losses have been observed after freeze-drying in human urine samples (Lauridsen et al., 2007). 
The disappearance of the urea signal in the freeze-dried sample resulted from the slow exchange 
the NH protons with the deuterium from the solvent since the sample was reconstituted in 100% 
D2O solution. Upon reconstitution, the freeze-dried samples were 1.3 fold concentrated, which 
justifies the higher intensities noted for protein signals (Figure 4.1b). The broadening and intensity 
reduction of the citrate resonances (Figure 4.1a) may have resulted from binding to proteins, as 
observed previously in plasma samples (Daykin et al., 2002). Because of the observed compound 
loss without a significant increase in concentration, freeze-drying process is not recommended for 
routine analysis of AF. Instead direct sample analysis of AF after dilution with D2O to provide NMR 
field lock reference seems the more adequate choice. 
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The effect of sample pH 
 
Another important experimental issue to take into consideration is the pH at which the AF 
sample spectra are collected. In fact the chemical shifts are dependent on pH of the sample (Fan, 
1996). Since the human AF samples analysed in this work registered natural pH variability, with 
values ranging from 6.30 to 8.75 with an average value of 8.15±0.34 (mean±standard deviation), 
the effect of pH on AF spectra was investigated. Figure 4.2 shows 3 spectral expansions of spectra 
acquired for one AF sample after adjusting its pH values to 7.00, 8.00 and 9.00.  
 
 
Figure 4.2 - Spectral expansions of standard 1D 1H NMR 500 MHz spectra obtained for the same AF 
sample with pH adjusted to: a) pH 7.00, b) pH 8.00 and c) pH 9.00; vertical dashed lines indicate the  
changes noted in chemical shifts of the indicated resonances; amino acids indicated with 3 letter code. 
 
The chemical shifts of resonances from histidine, tyrosine, lysine, glutamine, glutamate, 
alanine, threonine, valine and citrate varied with pH (Figure 4.2), which is expected since these 
compounds contain protons near acidic groups and/or basic groups prone to differential 
protonation (Fan, 1996). In addition, the signals of citrate also experienced broadening from pH 
9.00 to pH 7.00, which may be due to an increased binding of citrate to AF proteins (such as 
albumin) and metal ions (such as Fe3+) as a result from pH lowering, as previously suggested for 
human plasma where similar effects occurred (Daykin et al., 2002). 
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It is common to perform buffering at around pH 7.0 in biofluids such as urine in order to 
minimize chemical shift variations, since at this pH values relatively few metabolites are expected 
to have major chemical shift variations (Lindon et al., 2000a). Therefore, a buffering  procedure 
was adapted from a previous study on urine (Solanky et al., 2003) and tested for AF samples. As 
described in chapter 3 (section 3.3.1, page 63), the procedure consisted in the addition of 100L 
of sodium phosphate 0.5M buffer solution at pH 7.20 to each sample. After buffering, the samples 
tested registered pH values in the interval 7.32±0.07. Hence, buffering at pH 7.2 was selected for 
routine sample preparation in 1H NMR profiling analysis described in this work. 
 
Effect of ultrafiltration 
 
Subfractionation of AF by ultrafiltration was also used to obtain fractions differing in Mw 
(Figure 3.1, chapter 3, page 63). The resulting 1D 1H NMR spectra of whole AF sample and the 
respective Mw<3 kDa and high Mw≥3 k      c ions are presented in Figure 4.3a, b and c, 
respectively.  
 
Figure 4.3 - Standard 1D 1H NMR 500 MHz spectra of: a) AF diluted sample and the corresponding 
fractions with b) Mw<3kDa and c) Mw≥3k          g       g pH 7 40   
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The broad signals originating from proteins, which were overlapped with sharp signals from 
low Mw compounds seen in the intact sample spectrum (Figure 4.3a), were lost after filtration as 
expected, which resulted in spectra composed only of sharp peaks from small molecules for Mw<3 
kDa fraction (Figure 4.3b). The spectra of the latter, as it will be shown in later in this chapter 
(section 4.3.1), is very similar to the T2-edited spectrum (CPMG) of the intact AF sample. However, 
some low Mw compounds signals, namely acetate, lactate, citrate, alanine, valine, glucose, 
histidine and formate, were still present in the Mw≥3 k      c          c    g   c mp                
and/or possibly strong binding to proteins. As a consequence, quantitative measurements using 
solely the low Mw fraction, as those reported by Groenen et al (2004), may not be representative 
of the exact concentration of a portion of metabolites inspected. The procedure of ultrafiltration 
is therefore very useful for qualitative analysis, but may be unsuited for quantitative purposes. 
 
4.2. Study of the human amniotic fluid sample stability 
 
4.2.1. Stability during storage 
 
In order to identify any possible changes occurring during storage, the composition of 3 control 
AF samples (A, B and C) stored at  -20°C and -70°C was monitored by 1H NMR monthly, during a 6 
months period (as illustrated previously in Figure 3.3a, page 65). The sample pH was also followed 
during the storage period, and the increases of ∆pH = 1 15 ± 0 34     ∆pH = 0 58 ± 0 28   g        
for -20°C and -70°C storage temperatures, respectively. PCA scores scatter plot of the spectra 
from the stored samples at -20°C and -70°C are presented in Figure 4.4. 
 
 
Figure 4.4 - PCA scores scatter plots obtained for control AF samples stored during 6 months 
(represented by numbers 0-6) at: a) -20°C and at b) -70°C; symbols represent the 3 different from the 3 
different sample       : ∆ ( )  □ ( )     ♦ (C). 
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As shown in both PCA scores scatter plots, the 3 different sample groups were clearly 
distinguished, reflecting the different inter-individual sample composition (Figure 4.4). There was 
however separation in within each sample group, characterized by dispersion of the data points in 
the PC2 axis in both storage temperatures (Figure 4.4). It is worth mentioning that samples from 
both -20 and -70°C groups corresponding to 1 month (sample B and C) as well as 5 and 6 months 
of storage (sample A) were removed from the analysis, as they were strong outliers in the PCA 
scores (not shown), most probably due to instrumental bias (field inhomogeneity) during spectral 
acquisition. Moreover, the -70°C sample corresponding to 4 months of storage could not be 
acquired. Nevertheless, a close inspection of the scores plots reveals that the dispersion along 
PC2 was however slightly more evident for -20°C samples (Figure 4.4a). The dispersion within 
each group indicated underlying compositional changes occurred over the storage period, which 
became apparent after visual inspection, as shown in Figure 4.5 for storage at -20°C.  
 
 
Figure 4.5 - Spectral expansions (1.5 - 2.8 ppm) of standard 1D 1H NMR 500 MHz spectra obtained 
for AF sample C stored at -20°C acquired at: a) 0 months; b) 2 months; c) 4 months; d) 6 months.  
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These variations included the increases in signals of acetate and glutamate and decreases in 
the signals of glutamine, pyruvate as well as subtle decreases in the signals of citrate (Figure 4.5). 
The ratios between the integrals of the peaks of acetate, pyruvate, glutamine, glutamate and 
citrate at each time point (month) and the integrals at 0 month (before storage) were obtained 
and plotted as function of storage time (Figure 4.6). It may be seen that most of the variations 
observed at -20°C seem to occur during the first two months of storage, then stabilizing 
throughout the remaining analysed period of time. The only exception was noted for the variation 
of acetate which seems to increase slowly up to 6 storage months (Figure 4.6a). Comparatively, 
only small changes occurred at -70°C for the same metabolites, with only apparent small increase 
in acetate and decrease of pyruvate integral ratios being noted in the after one month of storage, 
then returning to initial values (Figure 4.6b).  
Figure 4.6 - Variations in the signals of acetate (*, 1.91 ppm), citrate (, 2.52 ppm), glutamate (▲, 2.34 
ppm), glutamine (×, 2.46 ppm) and pyruvate (♦, 2.37 ppm), occurring during sample storage at the 
temperatures a) -20°C and b) -70°C. Normalized plots of the ratio A/A0 (A0 is the integral of the peak at 
t = 0 months). 
 
Increases in acetate have been noted for other biofluids namely in urine during long-term 
storage (up to 6.5 months) at 4°C, but not seen at -25°C (Lauridsen et al., 2007). Acetate increase 
has been interpreted as signs of microbial activity (Lauridsen et al., 2007). However, the bacterial 
activity in carbohydrate rich media (such as AF), would lead to an increase in acetate and 
concomitant decrease in carbohydrates (such as glucose) (Saude and Sykes, 2007). This was not 
observed in AF, meaning that changes in increases in acetate contents had a different origin. 
Similarly, in rat plasma slight increases in acetate and decreases in pyruvate were observed after  
1 week at 4°C, which were not prevented with the addition of an anti-bacterial agent sodium 
azide being therefore not attributed to bacterial activity (Deprez et al., 2002). Glutamate and 
glutamine changed in opposite directions at -20°C, which may indicate to the possible 
degradation of the later by loss of an NH2 group to form glutamate and NH3. The conversion of 
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NH3 to NH4
+ in solution may have led to the increase in pH noted during storage. Similar decreases 
in amino acids arginine and glutamine were observed in rat and human plasma stored at -20°C 
during 6 months, but were not observed after plasma deproteinization prior to storage, which 
indicated the presence of enzymatic activity at -20°C (Van Eijk et al., 1994). These variations were 
not observed when samples were stored -70°C which led to the conclusions that freezing at 
temperatures lower than -20°C was necessary in order to inhibit enzymatic activities (Van Eijk et 
al., 1994). Similarly, the metabolite variations registered in AF samples possibly have resulted 
from enzymatic activity that may have occurred at -20°C but were significantly reduced at -70°C.  
Therefore, the use of lower storage temperatures such as -70°C or lower is strongly 
recommended in order to minimize sample compositional alterations. This is not always possible, 
especially at the place of sample collection, where -70°C freezers may not be readily available, 
and -20°C are much more common. As most of the changes in human AF occurred in the first two 
months of storage at -20°C, in cases where lower temperature storage is not possible, it is 
strongly recommend that analysis should be performed within a few days after collection.     
 
4.2.2. Stability upon freeze-thaw cycles 
 
Sample re-freezing after analysis may be required for sample re-analysis, especially when 
limited volumes of sample are available. Therefore the effects of freeze-thawing in AF 
composition needed to be investigated. For this purpose, spectra were acquired for 3 different AF 
control samples (C, D and E) before and after freeze-thaw cycles (Figure 3.3b, page 65). PCA 
scores plots, resulting from the analysis of the spectra, are shown in Figure 4.7. 
Figure 4.7 - PCA scores scatter plots for control AF samples analysed after consecutive freeze-thaw 
cycles at: a) -20°C and b) -70°    ymb      p         mp      m 3                 : ∆ ( )   (D) and  
(E). Numbers 1-3 indicate the freeze-thaw cycle number and 0 indicates the spectrum acquired the 
prior to freezing the sample.     
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Both PCA scores scatter plots show 3 distinct groups of data points, each corresponding to one 
of the 3 samples used in the study. Trends from the first spectra prior to freezing and up to the 
spectra of 2 or 3 freeze-thaw cycles were observed in the PC2 dimension for each sample. This 
dispersion resulted from small differences observed between spectra after each consecutive 
freeze-thaw cycle both at -20°C and -70°C. After spectra visual inspection, differences were found 
between consecutive freeze-thaw cycles, namely subtle diminution of the intensity of the broad 
signals across the whole spectral range, noted both at -20°C and -70°C. In fact, protein 
precipitation was confirmed visually after the first freeze-thaw cycle by the appearance of pellet 
in the NMR tube. Also at -20°C a decrease in carnitine signal at 3.42 ppm was noted. Most of the 
variations between consecutive freeze-thaw cycles identified were, however, highly dependent 
upon the sample as shown in Table 4.1.  
 
Table 4.1 - Sample-specific metabolite variations noted in 1H NMR spectra of control AF samples (C, 
D and E from Figure 4.7) with freeze-thawing cycles. Arrows indicate increase (↑) or decrease (↓) in 
signal intensity. 
Temperature Sample C Sample D Sample E 
-20ºC 
acetate (1.91 ppm, ↑) 
creatinine (3.04 ppm, ↑) 
betaine (3.26 ppm, ↓) 
 
acetate (1.91 ppm, ↑) 
pyruvate (2.37 ppm,↓) 
betaine (3.26 ppm, ↓) 
glutamine (3.77, ppm ↓) 
formate (8.45 ppm, ↑) 
creatinine (3.04 ppm, ↓) 
betaine (3.26 ppm, ↓) 
glutamine (3.77, ppm ↓) 
 
-70ºC 
acetate (1.91 ppm, ↑) 
glutamate (3.75, ppm ↓) 
creatinine (3.04 ppm, ↓) 
betaine (3.26 ppm, ↓) 
carnitine (3.42 ppm, ↓) 
glutamine (3.77, ppm ↓) 
dimethylglycine (2.92 ppm, ↑) 
creatinine (3.04 ppm, ↓) 
betaine (3.26 ppm, ↓) 
carnitine (3.42 ppm, ↓) 
glutamine (3.77, ppm ↓) 
 
These results contrast with those reported in a previous study, in which the AF spectra 
recorded at 300MHz was unaffected by prior freezing-thawing of AF samples  (Sims et al., 1993b). 
Therefore, the work presented resulted in a significant increase in sensitivity and resolution in 
detection of AF chemical changes occurring after freezing-thawing the samples. Indeed, 
compositional differences were also observed in human plasma, for which mostly the high Mw 
species (lipoproteins) were affected by freeze-thawing (Teahan et al., 2006). Similar changes were 
observed for rat plasma samples, also accompanied by increases in sharp resonances, possibly 
due to protein precipitation originated by freeze-thawing cycles (Deprez et al., 2002). It is 
possible, therefore that the same type of phenomena is responsible for the intensity reduction 
observed in AF after the freeze-thaw cycles. Moreover, several metabolite changes were 
observed in human urine samples freeze-thawed during a period of one month, some of which 
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were also observed in some of the AF samples, namely an increase in acetate and decrease in 
creatinine (Saude and Sykes, 2007).  
In conclusion, small variations were registered in 1H NMR spectra of AF after consecutive 
freeze-thaw cycles at either temperature tested, most of which were sample-dependent. 
Therefore, freeze-thawing of human AF samples should be minimized to one or two cycles, and 
only when necessary.   
 
4.2.3. Stability at room temperature 
 
Amniotic fluid samples may stay for several hours at room temperature in several stages of 
sample analysis and preparation. These may include the period mediating the sample collection 
and their transport to the cytogenetics laboratory in order to collect the amniocytes (as 
mentioned earlier in chapter 3 (section 3.1.1, page 58); during sample handling and preparation 
for analysis; and also during high-throughput analysis, where samples may stay for several hours 
at room temperature in the automatic sample changer while the acquisition of other samples take 
place. Since sample cooling to lower temperatures (4°C for example) is not always available in 
those situations, it is necessary to evaluate any possible composition variations occurring at room 
temperature.  
In order to evaluate human AF stability at room temperature (22°C) over periods of from 1 up 
to 13 hours (typical duration of an overnight run), spectra were acquired for 4 samples in regular 
intervals 1 hour up to 8 hours (samples F, G, H and I) or acquired before and after periods of 10 
hours (for 2 samples: J and K), 13 and 28 hours (for sample K only) (as illustrated in Figure 3.3c, 
page 65). The spectra obtained were analysed by PCA (Figure 4.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 - PCA scores scatter plots of spectra from control AF samples 
analysed at several times (hours) at room temperature (22°C). Symbols 
represent sample from 6 different donors: ○( )  ∆( )  ♦(H) +(I), (J) and (K). 
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The PCA scores scatter plot (Figure 4.8) shows that time points for the spectra collected 
between 0-8h are well clustered together (samples F,G, H and I) as well as those corresponding to 
0h and 10h (sample J) and 0h and 13h of sample K (Figure 4.8). This means that the differences 
between spectra of the different samples were far greater than the differences between spectra 
acquired for the same sample. The only exception is noted for time-point at 28h for sample K, 
which clearly deviates from the time-points at 0h and 13h, therefore indicating that strong 
compositional variation occurred after 28h at room temperature. Visual inspection of the spectra 
of sample K for 0h and 28h time-points revealed intensity decreases of the broad profile as well as 
sharp intensities resonances with an increase of ethanol intensity. The ethanol present in the 
sample originated from the disinfectant used in sample collection and manipulation. Similarly to 
other metabolites such as lactate and citrate, ethanol may be bound to some extent to protein 
(Avdulov et al., 1996). In fact, increases in peak intensities of tyrosine and phenylalanine have also 
been reported in 1H NMR spectra of plasma after 15 and 24 h at room temperature (Deprez et al., 
2002), which were also attributed to the release of these aromatic amino acids from precipitating 
macromolecules. Therefore, the increase in ethanol signal in AF may be linked to protein 
precipitation (visible in the NMR tube).  
Visual inspection of the spectra of samples F, G, H and I revealed consistent variations between 
0-8h.  These variations comprised decreases in glutamine and increases in acetate and glutamate, 
which were integrated and plotted as the ratio between the integral at each time-point and the 
integral at the initial spectrum (t=0 h), and illustrated in Figure 4.9. 
 
Figure 4.9 - Variations of acetate (▲, 1.91 ppm), glutamate (, 2.34 ppm) and 
glutamine (♦, 2.46 ppm) occurring at room temperature (22°C). Normalized plots 
of the ratio A/A0 (A0 is the integral of the peak at t = 0 hours).  
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Sample-specific variations were also found, namely decreases in citrate (sample H) and 
decreases in creatinine (sample I), decreases in pyruvate (F, H, I) and increases in citrate (sample 
F). Decreases in glutamine and increases in acetate and glutamate were also seen between 0h and 
10h (sample J), as well as between 0h and 13h (sample K), the latter also registering decreases in 
creatinine, histidine and citrate. Interestingly, some of the variations noted at room temperature 
in AF, namely those of acetate, glutamine and glutamate were observed during storage at -20°C, 
although with smaller magnitude at room temperature (Figure 4.9). Once more, the enzyme 
activity of the samples could be responsible for the changes observed, rather than any bacterial 
activity since, for instance, no concomitant decreases in glucose were observed with the increases 
in acetate. However, since no sample preserving agent was used nor any enzyme activity assays 
were performed, none of the hypothesis can be ruled out. 
Comparatively to AF, changes in metabolites have also been reported for blood plasma after 
15 and 24h at room temperature as mentioned above (Deprez et al., 2002), as well as in urine 
after 1 week at 22°C (Saude and Sykes, 2007) with changes occurring in the levels of lactate, 
benzoate, hippurate, glycine and creatinine which were attributed to bacterial activity. Hence, AF 
seems to be more susceptible to metabolite changes at room temperature than plasma and urine.   
In conclusion, no large AF profile differences seem to occur after 13h at room temperature, as 
seen by PCA (Figure 4.8). However, close inspection of the spectra reveals that small but 
measurable variations are expected after 1h, which remain nearly constant after 4h (Figure 4.9). It 
is then recommended that acquisition of AF spectra should be performed within 4h. If larger time 
windows up to 8h are to be considered, then variations in the levels of acetate, glutamine and 
glutamate should be taken into account. Although it was not possible to evaluate the AF 
composition during the period between collection and storage (a period not greater than 4 hours 
as mentioned in chapter 3, section 3.1.1, page 58), the observations described identify what 
metabolite changes may have occurred during this period.  
 
4.3. Compositional analysis of 2nd trimester human amniotic fluid by high resolution 
NMR and hyphenated NMR 
 
4.3.1. Analysis by high resolution 1D and 2D 1H NMR spectroscopy 
 
In order to characterize human amniotic fluid composition, AF samples were analysed at the 
field strengths of 500MHz and 800MHz and prepared as described in chapter 3 (section 3.3.1, 
page 63) for direct dilution, with buffer addition or freeze-dried and reconstituted in D2O to 
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obtain more concentrated samples (1.3-fold concentrated). Figure 4.10 shows an example of a 1H 
NMR spectra acquired at 500MHz for an AF sample prepared with buffering.  
 
Figure 4.10 - 1D 1H NMR 500 MHz spectra of a control AF sample prepared with buffering (pH 7.22): a) 
standard, b) T2-edited (CPMG) and c) diffusion-edited; N-acetyl, glycoprotein N-acetylated groups; 
amino acids presented in tree-letter code. 
 
The standard 1D spectrum (Figure 4.10a) shows sharp well resolved signals resulting from low 
Mw molecules, overlapping with a broad envelop of signals arising from macromolecules, mostly 
proteins, which illustrates the complexity of AF. Since the small molecules and macromolecules 
differ in both T2 relaxation times (longer in low Mw molecules) and diffusion rate in solution 
(higher for low Mw molecules), it was possible to selectively filter their respective resonances 
using 1D spectral edited experiments namely T2-edited (CPMG) and diffusion-edited experiments. 
In the CPMG experiment, a spectrum composed only of sharp resonances and a flat baseline was 
obtained (Figure 4.10b). The CPMG spectrum is similar to the spectrum of the Mw<3kDa fraction 
of AF (Figure 4.3, page 88). The diffusion-edited spectrum obtained (Figure 4.10c) was 
predominantly composed of broad signals originating from the AF proteins such as the methyl 
proton (CH3) resonances of from amino acid residues at 0.5-1.0 ppm and resonances from NH 
protons (from amide and side-chains of amino acid residues) at 6.5-8.5ppm (Figure 4.10c). A 
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group of signals observed around 3.0 ppm could be assigned to lysine side-chain protons of 
albumin, which is the most abundant protein in AF (with concentrations around 4mg/mL during 
2nd trimester, according to Gao et al., 2009 and Lind, 1981) and with basis on reported 1D 1H NMR 
spectra of blood plasma (Foxall et al., 1993). A sharp resonance at 2.03 ppm was assigned to the 
N-acetylated groups of amino sugar moieties in highly mobile regions of glycoproteins, from 
which transferrin, an iron transport protein, is one the most abundant in 2nd trimester AF found at 
concentrations of 0.3mg/mL (Gao et al., 2009). 
 
The standard and CPMG spectra acquired for one control AF sample (prepared by direct 
dilution) at 500MHz showed comparable results to those acquired for another control sample at 
800MHz, as it is shown in Figure 4.11a and b, respectively. However, as expected, the spectra 
collected at the higher field strength registered better resolution, as illustrated in the expansions 
of Figure 4.11b and also from half height width values (for alanine doublet at  1 47 ppm: Δν/2 = 
1 47H     800 H      Δν/2 = 1 52H     500MHz). Higher sensitivity was also obtained at 800MHz 
with signal-to-noise ratio (s/n) of 221.7 at 800MHz, compared to 63.4 registered at 500MHz.  
 
 
Figure 4.11 - Sub-region of 0 - 4.5 ppm of 1D 1H NMR spectra of a control AF sample 
acquired at 800MHz (left) and another control sample acquired at 500MHz (right): a) 
standard, b) CPMG (with 1.6-2.2 ppm expansion) and c) diffusion-edited. All spectra 
consisted in 256 transients except the diffusion-edited obtained at 800MHz acquired to 
512 transients. 
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Figure 4.11c (left) shows a diffusion-edited spectrum registered at 800MHz. The acquisition 
conditions required the use of a gradient pulse of 2ms (using 70% of maximum gradient strength) 
and diffusion time of 200ms, which enabled the complete elimination of sharp resonances (from 
low Mw molecules) but required the double number of transients (NS=512) in order to clearly 
visualise the resonances (which doubled the acquisition time of this experiment when compared 
to the standard or CPMG). The acquisition parameters used for 800MHz diffusion experiment 
were also tested at 500MHz. Because a poorer spectrum was obtained, a re-adjustment of the 
gradient pulse, gradient strength and diffusion time was needed in order to obtain a spectrum 
with better s/n at 500MHz. The best compromise between acquisition time and s/n was obtained 
by changing the values of gradient pulse to 1 ms using 95% of maximum gradient strength and 
diffusion time to 100ms. The resulting spectrum registered the higher signal-to-noise ratio of 94.4 
when compared with the signal-to-noise ratio of 71.7 obtained for the 800MHz spectrum. 
However, a complete attenuation of some signals of the most abundant low Mw species was not 
achieved (Figure 4.11c, right). Nevertheless, the spectrum obtained at 500MHz was considered 
satisfactory as the best compromise between acquisition speed, low Mw signal attenuation and 
s/n of the resulting spectrum and these conditions were used for the subsequent metabolic 
profiling studies.  
 
Figure 4.12 shows the expansions of the 800MHz TOCSY and HSQC spectra of a human AF 
freeze-dried reconstituted sample, where several peaks are indicated, corresponding to assigned 
and unassigned spin-systems. The assigned spin-systems are listed in Table 4.2.  
The analysis of 2D spectra enabled the assignments of previously identified metabolites (Bock, 
1994; Le Moyec et al., 1994; McGowan et al., 1999; Groenen et al., 2004), thus confirming their 
identification, as well as the identification of about 20 new metabolite assignments marked with a 
in Table 4.2. The newly assigned metabolites comprised several families of metabolites including 
amino acids: -aminobutyrate (ABA), arginine, aspartate, citruline, cystine, hydroxyproline, 
ornithine and taurine; organic acids: acetoacetate, -hydroxyisobutyrate, -hydroxyisovalerate, 
fumarate, -ketoglutarate and oxaloacetate; and others such as acetone, ethanolamine, urea, 
trimethylamine-N-oxide (TMAO), N-acetyl group (from glycoproteins) and ethanol. The latter, as 
mentioned in the previous section, may originate from the disinfectant used in the amniocentesis 
procedure rather that from endogenous metabolism. 
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Figure 4.12 - Expansions of 800MHz: a) TOCSY spectrum and a b) 1H/13C HSQC correlation spectrum 
of a control human AF sample (pH 9.25). Assignments: 1, isoleucine, 2, -hydroxybutyrate; 3, leucine; 
4, -aminobutyrate; 5, U6; 6, valine; 7, U8; 8, U9; 9, -hydroxybutyrate; 10, lactate; 11, threonine; 
12, U12; 13, alanine; 14, lysine; 15, arginine; 16, proline; 17, glutamate+glutamine; 18, 
hydroxyproline; 19, carnitine; 20, citrate; 21, methionine; 22, U13; 23, U22; 24, tyrosine; 25, 
histidine; 26, ethanolamine; 27, U27; 28, -glucose; 29, -glucose; 30, myoinositol; 31, taurine; 32, 
U24; 33, U4; 34, -oxoisovalerate; 35, -hydroxyisobutyrate; 36, U17; 37, U16; 38, N-acetyl groups 
(glycoproteins); 39, pyruvate; 40, -ketoglutarate; 41, succinate; 42, oxaloacetate; 43, U19; 44, 
creatinine; 45, creatine; 46, choline; 47, betaine; 48, glycine; 49, U28; 50, U15. 
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Table 4.2 - 1H NMR assignments for control human AF samples. 1H, 13C and J-coupling constants 
observed at 800 MHz and pH≈9 0      q     b  ck   : 1H observed at pH≈7 3 (500MHz). a, identified 
for the 1st time by NMR in this work; b, tentative assignment; s, singlet; d, doublet; dd, doublet of 
doublets; t, triplet; q, quadruplet; m, multiplet. 
compound 
1
H in ppm (multiplicity, J in Hz, assignment) /  
13
C in ppm
acetate 1.91(s,CH3)/24.02 
acetone/acetoacetate 
a
 2.22(s, CH3) 
N-acetyl groups 
(glycoproteins) 
a
 
2.03(s, CH3)/23.06 
alanine 1.46(d, 7.4,CH3)/17.2, [1.47]; 3.76(q, CH)/51.4, [3.78] 
-aminobutyrate (ABA) 
a,b
 0.97(t, CH3)/9.30; 1.87(m, CH2)/25.25 
arginine 
a
 1.67(m, CH2)/25.06, [1.66]; 1.85(m, CH2)/29.32, [1.90]; 3.23(t, CH2)/41.47 
aspartate 
a
 
2.68(m, CH2)/37.74, [2.86]; 2.82(m, 'CH2)/37.74, [2.95];  
3.81(m, CH)/52.89 
betaine 3.26(s, N(CH3)3)/54.24; 3.90(s, CH2)/67.20 
carnitine 2.44(dd, CH2)/44.09; 3.23(s, N(CH3)3)/41.46; 3.43(m, CH2)/71.51 
citrate 2.52(d, 15.7, ,CH)/45.99; 2.67(d, 15.3, ',',CH)/45.99, [2.66] 
citrulline 
a,b
 1.54(m, CH2)/26.77; 1.84(m, CH); 3.12(m, CH2) 
choline 3.20(s, N(CH3)3)/54.94, [3.19] 
creatine 3.03(s, NCH3)/37.74; 3.93(s, NCH2)/54.69 
creatinine 3.04(s, NCH3)/31.07; 4.05(s, NCH2)/57.24 
cystine 
a,b
 3.04(dd,CH2); 3.22(dd, 'CH2); 3.82(m, CH), [3.85] 
N,N-dimethylglycine 2.92(s, (CH3)2); 3.79(s, CH) 
ethanol 
a
 1.19(t, CH3)/19.83, [1.18] ; 3.89(q, CH2)/63.43, [3.66] 
ethanolamine 
a
 3.11(m, NCH2)/41.91, [3.15]; 3.80(m, OCH2)/58.93, [3.82] 
formate 8.45(s, CH) 
fumarate 
a
 6.50(s, CH) 
-glucose 3.41(t, C4H)/70.42; 3.53(dd, C2H)/70.20; 3.71(t, C3H)/73.52;  
 
3.76(dd, 5.8, C6H)/61.42; 3.83(m, C5H)/72.73; 3.83(, C6H')/61.42); 
 
 5.23(d, 3.9, C1H) 
-glucose 3.23(dd, C2H)/74.97; 3.40(t, C4H)/70.40; 3.47(dd, C5H)/61.51;  
  3.49(t, C3H)/76.66; 3.71(dd, C6H')/61.54; 3.89(m, C6H)/61.54;  
 4.64(d, 8.1, C1H)/96.69 
glutamate 2.01(m, CH2)/28.22, [2.05]; 2.03(m, 'CH2)/28.22, [2.13];  
 
2.33(m, 'CH2)/34.32, [2.35]; 2.49(m, CH2), [2.35]; 3.69(t, CH)/55.49, [3.75] 
glutamine 2.09(m, CH2)/28.25, [2.06]; 2.11(m, 'CH2)/28.25, [2.13];  
 
2.33(m, CH2)/31.87, [2.45]; 3.69(t, CH)/55.42, [3.77] 
glycine 3.52(s, CH)/42.50, [3.56] 
histidine 3.03(dd, CH2)/29.77; 3.15(dd, 'CH2)/29.83; 3.85(dd, CH)/57.22 
 
7.01(s, C4H, ring)/117.70, [7.08]; 7.72(s, C2H, ring)/137.20, [7.85] 
-hydroxybutyrate 0.89(t, 7.5, CH3)/9.41; 1.65(m, CH2); 1.73(m, CH2); 4.00(m, CH)/74.16 
hydroxybutyrate 1.19(d, 6.5, CH3)/22.54; 2.29(m, CH2)/47.32, [2.31];  

2.39(m, CH2)/47.41, [2.40]; 4.13(m, CH)/66.57, [4.12] 
-hydroxyisobutyrate
a
 1.26(s, CH3)/28.76 
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Table 4.2  (cont.) 
compound 
1
H in ppm (multiplicity, J in Hz, assignment) /  
13
C in ppm,
-hydroxyisovalerate 
a,b
 0.83(d, CH3)/23.45; 0.85(d, CH3)/21.50; 1.99(m, CH2) 
hydroxyproline 
a,b
 2.13(m, CH2)/38.00; 2.38(m,'CH2); 4.29(m, CH2) 
isoleucine 0.93(t,7.2, CH3)/11.90; 1.00(d, 7.0, CH3)/15.60; 1.25(m, CH2)/25.23, [1.27]; 
 
1.45(m, 'CH2)/25.39, [1.46]; 1.94(m, CH)/36.96, [1.98];  
 
3.62(m, CH)/60.52, [3.68] 
indoxyl sulfate 
b
 7.01(m); 7.17(m); 7.30(s, NCH); 7.53(d), [7.54]; 7.72(d), [7.73] 
-ketoglutarate 
a
 2.44(t, CH2)/31.60, [2.43]; 2.99(t, CH2) 
lactate 1.32(d, 7.0, CH3)/20.83; 4.11(q, 6.9, CH)/69.30, [4.14] 
leucine 0.95(d, 6.1, CH)/21.72; 0.96(d, 6.1, CH)/22.73; 1.69(m, CH)/25.00;  
 
1.71(m, CH2)/40.90; 3.69(t, CH)/54.30, [3.74] 
lysine 1.45(m, CH2)/22.38, [1.47]; 1.71(m, CH2)/27.31, [1.72];  
 
1.86(m, bCH2)/31.37, [1.90]; 3.01(t, CH2)/39.97, [3.03];  
 
3.67(t, CH)/55.50, [3.75]  
methionine 2.13(m, CH2)/27.18; 2.14(s, SCH3)/14.85, [2.19]; 
 
 2.62(t, 6.2, CH2)/29.78, [2.63]; 3.73(t, CH)/55.34, [3.86] 
myo-inositol 3.23(t, C5H)/75.21; 3.58(dd, C1H, C3H)/70.27; 3.62(dd, C4H, C6H)/73.42 
 
4.05(t, C2H)/73.03 
ornithine 
a,b
 3.02(t, CH2); 3.67(t, CH) 
oxaloacetate 
a
 2.36(s, CH2)/50.30 
-oxoisovalerate 1.12(d, 7.2, CH3)/17.31; 3.02(m, CH) 
phenylalanine 3.03(dd, 'CH2)/38.12; 3.19(dd, CH2)/38.17; 3.83(dd, CH)/55.00;  
 
7.32(m, C2H, C6H, ring)/130.10; 7.40(m, C4H, ring)/128.60, [7.35];  
 
7.41(m, C3H, C5H, ring)/129.80, [7.42] 
proline 2.01(m, CH)/24.59; 2.06(m, CH)/29.80; 2.35(m, 'CH)/29.80;  
 
3.33(m, CH)/46.91, [3.34]; 3.41(m, 'CH)/46.91; 4.12(m, CH)/62.03, [4.13] 
pyruvate 2.37(s, CH2)/31.87 
succinate 2.39(s, CH2)/34.67, [2.40] 
taurine 
a
 3.19(t, SCH2)/50.11, [3.12]; 3.27(t, NCH2)/36.60, [3.24] 
threonine 1.28(d, CH3)/20.22, [1.32]; 3.44(d, CH)/61.64, [3.58];  
 
4.14(m, CH2)/67.91, [4.25] 
trimethylamine-N-oxide 
(TMAO) 
a
 
3.26(s, N(CH3)3)/60.43 
tyrosine 2.99(dd, 'CH)/37.00; 3.14(dd, CH)/37.15; 3.84(d, CH)/57.12 
 
6.86(d, C3H, ring)/116.85, [6.89]; 7.17(d, C2H, ring)/131.58, [7.19] 
urea 
a
 5.77 (broad s, NH2) 
valine 0.97(d, 7.0, CH3)/17.42, [0.98]; 1.03(d, 7.0, 'CH3)/18.83;  
 
2.24(m, CH)/30.10, [2.27]; 3.57(d, CH)/61.33, [3.61] 
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The 2D J-resolved spectrum (Figure 4.13) enabled the resolution of highly overlapped 
multiplets, for instance the multiplets of glutamine and glutamate at 2.35 ppm (region 6, Figure 
4.13), as well as the measurement of J-coupling constants, as for instance of the triplet of 
isoleucine which was 7.2 Hz (region 1 in Figure 4.13), thus enabling further confirmation of their 
assignments. 
Figure 4.13 - Expansion of 800MHz J-Resolved spectrum of a human AF sample (pH 9.25). Numbered 
regions contain signals corresponding to: 1, isoleucine; 2, leucine, valine, U8 and -oxoisovalerate; 3, 
alanine, lysine; 4, proline, glutamine, glutamate, N-acetyl (glycoproteins); 5, proline, glutamine, 
glutamate; 6, glutamine, glutamate; 7, citrate; 8, lysine, histidine; 9, -glucose; 10, -glucose. 
 
A list of 52 spin-systems, for which no assignment was possible by NMR alone, is presented in 
Table 4.3. This shows on one hand, the potential of 2D analysis to detect many more metabolites 
thus extending the knowledge gathered by 1D NMR experiments in previous reports (Bock, 1994; 
Le Moyec et al., 1994; McGowan et al., 1999; Groenen et al., 2004) and, on the other hand, the 
need for complementary methods such as hyphenated NMR to improve spectral assignment. The 
differences in sensitivity between 800MHz and 500MHz is also noted here by highest number of 
unassigned signals detected in 800MHz, most of them were not detected at 500MHz (Table 4.3).  
The overall detection limit achieved in the 1D and 2D 1H NMR was of the order of a few micro-
molar (M) since the weakest signals observed in the spectra correspond to compounds expected 
to occur in this order of concentration in human AF at the 2nd trimester, for instance -
aminobutyrate (ABA) which registered an average concentration of 7M in human AF at 17-19 
weeks of gestation (Tuma et al., 2006). 
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Table 4.3 - List of still unassigned spin systems. 1H, 13   b   v      800  H      pH≈9      q     
brackets: 1H  b   v      pH≈7 3 (500MHz). 
 
1
H in ppm (observed multiplicity) /  
13
C in ppm
U1 0.66/21.70 U27 3.35/81.08; 3.67/69.10;  
U2 0.77/20.23; 0.85/20.23 
 
3.87/55.86; 4.46 
U3 0.86/14.90 U28 3.41/76.62 
U4 0.86/10.88 U29 3.52/68.42; 3.80/68.42; 3.97/68.42 
U5 0.91/20.84 U30 3.56/63.19; 3.65/63.43 
U6 0.93(broad signal)/19.17, [0.92]; 2.07, [2.08]; U31 3.59/70.21 
 
 2.60; 3.44; 3.97, [3.86]; 4.16 U32 3.74/58.78 
U7 1.04/20.84 U33 3.74/63.19 
U8 1.06(d, CH3)/14.79; 2.48/35.12 U34 3.83/63.32; 3.88/63.43 
U9 1.06; 2.48/45.75;  3.54; 3.71, [3.70] U35 3.93; 5.18(d) 
U10 1.34/69.29 U36 3.99/69.45 
U11 1.36; 4.09 U37 4.35/72.80, [4.34] 
U12 1.40(m)/17.27; 4.31 U38 5.40(m) 
U13 1.54; 1.72; 2.67/40.95; 3.83/63.52  U39 5.66(s), [5.68] 
U14 1.62; 3.94 U40 6.91(s) 
U15 1.65; 3.28/69.61; 3.44/78.25; 3.97/43.27 U41 7.57(s) 
U16 1.65/40.89; 1.83/27.74; 2.98/20.08 U42 7.59(m) 
U17 1.74/20.79 U43 7.63 
U18 1.80/40.24 U44 7.68(s) 
U19 2.51; 2.63/59.51; 3.61/46.31; 3.85; 5.60(m) U45 7.70 
U20 2.53; 2.73; 4.90(d) U46 7.75(m) 
U21 2.75; 5.28(m) U47 7.80(m) 
U22 2.83(m)/52.96, [2.94]; 3.12(m)/48.26, [3.15]; U48 7.85(m) 
 
 3.82/69.39 U49 8.57 
U23 3.04/41.36 U50 8.89(s) 
U24 3.06/51.98; 3.41/37.81 or 76.62 U51 9.28(m) 
U25 3.09; 5.36 U52 1.17; 4.02 
U26 3.15; 3.85/68.97     
 
 
4.3.2. Analysis by DOSY and STD spectroscopy 
 
Figure 4.14 shows the aliphatic and aromatic regions from the DOSY spectrum of a healthy 
human AF sample recorded at 500MHz (pH 7.34). The resonances observed in the DOSY spectrum 
correspond mainly to the most abundant low Mw species characterized by high diffusivity values 
in the order of 10-9 m2/s (Figure 4.14). However, in the aliphatic region the signal at 2.03 ppm 
showed a relatively lower diffusivity value of 1.95×10-9 m2/s (peak 4, Figure 4.14a). The stretched 
shape of the N-acetyl signal along the diffusion dimension resulted from the overlap with other 
resonances occurring in the same region, namely the multiplet of proline (Figure 4.14a). 
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Figure 4.14 - Expansions of the aliphatic and aromatic regions of the 1H NMR 500 MHz DOSY 
spectrum of a healthy human AF sample at pH 7.34. External projection: standard 1D 1H NMR 
spectrum of the same sample; assignments: 1, ethanol; 2, lactate; 3, alanine; 4, N-acetyl groups 
(glycoproteins); 5, pyruvate; 6, citrate; 7, choline; 8, -glucose; 9, betaine; 10, -glucose; 11, 
glycine; 12, threonine; 13, processing artifact; 14, tyrosine; 15, histidine; 16, phenylalanine; 17, 
formate. 
 
The estimates of Mw for N-acetyl groups of glycoproteins using the pyruvate signal (at 2.37 
ppm, assignment 5 in Figure 4.14a) calibration reference gave values of about 3kDa (diffusion was 
measured at the centre of the peak). The signal at 2.03 ppm is related to N-acetylated sugar 
moieties of glycoproteins, therefore estimated Mw values in the range of 52-150kDa should be 
expected, corresponding to some of the most abundant glycoproteins in human AF 1-Anti-
trypsin and Immunoglobulin G (Lind, 1981), respectively. Other macromolecules signals, such as 
the broad resonances observed previously in diffusion-edited spectra (shown in Figure 4.10c, 
page 97) were not observed in DOSY spectrum of AF, possibly due to their lower relative 
intensities and broader line widths. 
 
In order to decrease the overlapping effects and allow better resolution and more accurate 
estimates of the macromolecules Mw, subfractionation by ultrafiltration of AF was performed 
prior to DOSY analysis (Figure 3.1, page 63). Three AF fractions were obtained differing in average 
Mw of their constituents and their respective 1D 
1H NMR spectra are shown in Figure 4.15.  
a) 
b) 
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Figure 4.15 - Standard 1D 1H NMR 500 MHz spectra of subfractions of human AF of different Mw 
(pH≈7 3):  ) Mw<3k    b) 3≤Mw<10kDa and c) Mw ≥10k    H                  peak. 
  
As seen in Figure 4.15, most of the low Mw molecules were registered in the spectrum of Mw 
<3kDa fraction (Figure 4.15a), whereas the spectrum of 3≤Mw<10kDa fraction (Figure 4.15b) 
registered only signals from glycerol from the filter membrane (multiplets at 3.52 - 3.81 ppm), 
lactate (1.32 ppm), ethanol (1.16 ppm) and small amounts of citrate (2.52 and 2.66 ppm). The 
spectrum of Mw≥10k      c     showed mostly broad signals from proteins as well as signals from 
organic acids, namely lactate (1.32 ppm), acetate (1.91 ppm), citrate (2.52 and 2.66 ppm), 
formate (8.45 ppm) and also from glycerol (from the membrane filter) and ethanol used for 
membrane filter washing and storage (Figure 4.15c). Considering that the fraction Mw≥10k      
washed with phosphate buffer and filtered several times prior to spectral acquisition, it is 
suggested that these organic acids were tightly bound to proteins. A similar binding effect was 
observed between citrate and human serum albumin in solution (Daykin et al., 2002).  
 
In order to further investigate the binding of lactate and other organic acids to AF proteins, a 
saturation transfer difference (STD) 1H NMR experiment was performed using an intact AF sample 
(Figure 4.16). In this experiment, two spectra were collected, with saturation of one frequency in 
the noise region (off-resonance, Figure 4.16a) and with saturation of one frequency of NH groups 
of the protein (on-resonance, Figure 4.16b). 
a)  Mw<3kDa 
b)  3≤Mw<10kDa 
c)  Mw ≥10k   
formate 
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Figure 4.16 - Saturation transfer difference (STD) experiment performed in a control human AF 
sample: saturated off- (a) and on-resonance (b) 1H NMR 600 MHz spectra and respective difference 
spectrum between off and on resonance spectra (c). 
 
The difference between the off-resonance and the on-resonance spectrum (Figure 4.16c) showed 
a small increase in lactate signals thus indicating the saturation transfer from protein signals to 
bound lactate. However, no signals from citrate or acetate were observed, probably because 
these molecules are bound to AF proteins to a lesser extent.  
 
DOSY spectrum was then acquired for Mw<3kDa fraction using the same gradient parameters 
used for the intact AF sample (Table 3.9, chapter 3, page 71). The same signals from low Mw 
compound observed previously in the DOSY of the intact AF sample (Figure 4.14) are present in 
the DOSY of the Mw<3kDa fraction as shown in Figure 4.17. In addition the signals from the amino 
acids leucine, valine, alanine and lysine, which registered some overlap with broad profile 
resonances in the intact sample 1D spectra, were also detected in the DOSY spectrum of Mw<3kDa 
fraction (Figure 4.17). Most of the signals registered diffusivity values around 10-7 m2/s whereas in 
the DOSY spectrum of intact AF sample their diffusivity values were of the order of 10-9 m2/s, 
which could be justified by the higher viscosity of the latter, which has direct effect on the 
measured diffusion. 
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Figure 4.17 - Expansion of 500 MHz 1H NMR DOSY spectrum of an Mw<3kDa fraction of a control 
human AF sample (pH 7.40). Assignments: 1, leucine; 2, valine; 3, ethanol; 4, lactate; 5, alanine; 6, 
lysine; 7, acetate; 8, pyruvate; 9, citrate; 10, choline; 11, -glucose; 12, betaine; 13, -glucose; 14, 
glycine; 15, threonine.  
 
The DOSY spectrum of Mw<3kDa fraction improved detection of low Mw compounds. However, 
no new assignment information was obtained. 
DOSY spectra were also acquired for the fraction of Mw≥10k    b   m    y  g     g        
conditions to gradient pulse of 1500s and diffusion time of 250 ms in order to accommodate the 
entire signal decay of the slow diffusing species (those of higher Mw). A DOSY spectrum obtained 
for an AF Mw≥10k   is shown in Figure 4.18.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 - Expansion of 1H NMR DOSY spectrum of an Mw≥10k      c             p k          k m c 
acid, at 500 MHz and pH 7.40 and respective standard 1D 1H NMR spectrum (external projection). 
Assignments: 1 – protein, 0.86 ppm, 2 – protein, 0.92 ppm, 3 – lactate, 1.32 and 4.11 ppm, 4 – protein, 
1.70 ppm, 5 - glycoprotein (N-acetyl group), 2.03 ppm, 6 - glycoprotein (N-acetyl group), 2.06 ppm, 7 – 
shikimic acid, 2.19(dq, C7H), 2.75(dd, C7H), 3.71(dd, C6H), 3.98(m, C6H), 4.40(t, C4H) and 6.43(c, C3H) 
ppm, 8 - protein, 3.00 ppm, 9 - glycerol, 3.56 and 3.65 ppm.  
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The aliphatic region of the DOSY spectrum showed many resolved low diffusivity signals (insert 
of Figure 4.18) and, based on diffusivity values three families of macromolecules (most probably 
proteins) could be identified: A, resonances 1 (0.86 ppm) and 5 (2.03 ppm) with diffusivity of 
7.16x10-11 m2/s; B, resonances 2 (0.92 ppm) and 4 (1.7 ppm) with diffusivity of 8.20×10-11 m2/s; 
and C, resonances 6 (2.06 ppm) and 8 (3.00 ppm) with diffusivity 8.99×10-11 m2/s (Figure 4.18). 
In order to estimate the average Mw of these families of proteins based on their diffusivity 
values an appropriate calibrant had to be chosen. Usually in DOSY, signals from compounds of 
known Mw can be chosen as internal references for Mw estimation. Examples include HOD signal 
in model D2O aqueous solutions (Crutchfield and Harris, 2007), the signal of formic acid in wine 
(Nilsson et al., 2004), or compounds added for chemical shift referencing such as TMS in virgin 
olive oil (Crutchfield and Harris, 2007).  In the case of the Mw≥10k      c     of AF, the only 
compounds of known Mw such as lactate, acetate, ethanol or formate registered signal overlap 
with the broad signals of higher Mw species. There was also the possibility that most of these 
compounds were bound to proteins, therefore, both factors interfere with the apparent 
diffusivity values measured. The HOD signal was also not a good choice since the signal presented 
a stretched shape, spanning several diffusivity values. The alternative was to use an external 
calibrant, shikimic acid (C6H6(OH)3COOH, Mw = 174.15 g/mol), which had at least one non-
overlapped signal when added to AF Mw≥10k      c     (  g       6.43 ppm) as it can be seen in 
the external projection of Figure 4.18. The Mw estimated values for the 3 protein spin-systems 
using shikimic acid signal at 6.43 ppm (diffusivity of 5.46×10-10 m2/s) as calibration reference are 
presented in Table 4.4.  
 
Table 4.4 - Estimated Mw values obtained for low diffusivity protein spin-sytems identified in the 
DOSY spectrum of Mw≥10k         c      
Spin-system Signals (ppm) Diffusivity (×10
-11
 m
2
/s) Estimated Mw (kDa) 
A 0.86, 2.03 7.16 77 
B 0.92, 1.70 8.20 50 
C 2.06, 3.00 8.99 40 
 
It is difficult to dwell on the identity the protein families identified solely based in these NMR 
measurements. Nevertheless, at least for protein system A, which includes the N-acetyl group 
resonance, the estimated Mw roughly matches the Mw of transferrin (80 kDa), one of the most 
abundant glycoproteins in AF (Gao et al., 2008).  The Mw of protein system B (50kDa) is close to 
the Mw of albumin, which is about 67kDa, although the difference in average Mw is considerable. 
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However, the resonance at 3.00 ppm, usually attributed to albumin, was found associated with 
protein system C, which must be related to another protein since it registered a lower Mw (40kDa) 
compared to the Mw of albumin (67kDa). The results show that a deeper characterization analysis 
is needed and, possibly correlation with gel electrophoresis analysis, in order to fully assign the 
spin-systems. However, DOSY of Mw≥10k      c           m      m y    p        c  q        v  
changes in the protein profile of the biofluid, which may be an important indicator of the onset 
and course of disorders. 
 
4.3.3. Analysis by LC-NMR/MS 
 
Human AF metabolite composition was further explored by LC-NMR/MS. Since human AF is 
mainly composed of polar metabolites, two main chromatographic separation approaches were 
followed prior to NMR and/or MS analysis: a reverse phase-type chromatography, which focused 
on less polar metabolites, and an ion exchange type chromatography, which focused mainly on 
sugars and organic acids.  
 
4.3.3.1 Characterization of less polar metabolites 
 
Reverse-phase chromatography (RP-C18) using gradient elution was performed for the analysis 
of 10 times concentrated Mw<3kDa AF fractions. Figure 4.19 shows the UV and MS (ESI
+) 
chromatograms obtained.  
 
Figure 4.19 - RP-C18 chromatograms of a human AF 10x concentrated Mw<3kDa fraction: a) UV 
trace, b) MS ESI+ trace; numbers: the peaks corresponding to the fractions collected (loops). 
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The eluted fractions corresponding to the resolved peaks of the chromatogram were collected 
into sample loops (fractions numbered in the UV trace, Figure 4.19a) being subsequently analysed 
in parallel by NMR and MS.  
The most intense peak in the UV chromatographic trace occurred around 6.5 min (Figure 
4.19a). The corresponding 1H NMR spectrum, loop 1 collected at 6.51 min. (Figure 4.20b), 
contains a good portion of the most intense signals observed in the spectrum of the whole 
Mw<3kDa fraction (Figure 4.20a).  
 
 
Figure 4.20 - 1D 500MHz 1H NMR spectra of a) 10× concentrated AF Mw<3kDa fraction, and several 
fractions resulting from its analysis by RP-C18 LC-NMR/MS: b) loop 1, several co-eluting at 6.5 min; c) 
loop 8, containing tryptophan; d) loop 9, containing 4-aminohippurate; e) loop 11, containing caffeine; 
loop 14, containing 3-methyl-2-oxovalerate. Loop numbers correspond to the fractions indicated in 
figure 4.19. Un., unassigned peak; RG, receiver gain; NS, number of scans; HOD, residual water peak; 
MeOH, residual methanol peak (from the LC system). 
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Highly polar metabolites, eluting first in RP-C18 columns such as glucose, myo-inositol, citrate 
and the amino acids, alanine glutamine, glutamate, lysine and threonine where identified in the 
spectrum of loop 1 (Table 4.5). In the spectrum of loop 2 collected at 7.12 min, several 
compounds also co-eluted including choline, betaine, creatine, lactate, glycine, histidine, proline 
and valine, together with mannose which was newly identified by NMR (Table 4.5). Co-elution of 
polar metabolites was also confirmed in the spectrum of subsequent loops 4 (9.50 min) and 5 
(10.01 min), where creatinine and methionine; leucine, isoleucine and tyrosine, were assigned 
respectively (Table 4.5). The first well resolved metabolite identified was the amino acid 
phenylalanine which eluted at 12.11 min (loop 6, Table 4.5). Up to this point mostly the more 
polar metabolites were eluted and their assignments confirmed both by 1H NMR and MS and 
MS/MS measurements in ESI+ mode. Apart from mannose, all these metabolites had already been 
observed by NMR alone (Table 4.5).  
The 1H NMR and MS spectra collected for the loops 7 (14.27 min), 8 (17.26 min), 11 (24.19 
min) and 13 (24.19 min) allowed the assignment of further metabolites which had not been 
previously observed in human AF by NMR: paraxanthine, tryptophan (Figure 4.20c), caffeine 
(Figure 4.20e) and hippurate, respectively. These metabolites had been detected in human AF 
previously by targeted analytical methods such as GC-MS and capillary electrophoresis (Sommer 
et al., 1975; Ng et al., 1982; Stewart et al., 2001; Tuma et al., 2006). Therefore, LC-NMR/MS 
presents a clear advantage over these targeted methods by enabling the detection of several 
different metabolites in one single experiment. Tryptophan is a known component of AF, 
although its detection by 1H NMR had not been reported before, probably due to its lower 
concentration when compared to other amino acids such as phenylalanine, which has signals in 
the same spectral regions as tryptophan, being however 5 times more concentrated (Table 4.5). 
Caffeine possibly resulted from free passage from maternal circulation to the fetus, after 
consumption of caffeine containing beverages, then being excreted by the fetus into AF (Sommer 
et al., 1975). Consultation of clinical records of the sample donors revealed that most women 
reported the consumption of coffee, which confirms the finding. Paraxanthine is of the three most 
abundant metabolites of caffeine found in blood circulation after coffee consumption. It 
structurally resembles the structure of caffeine but lacks the methyl group (the b methyl group in 
structure of caffeine shown in Figure 4.20e). Paraxanthine possibly enters the AF by the same 
mechanism as caffeine (Sommer et al., 1975). Hippurate is a metabolite of phenolic compounds of 
mainly dietary origin (Holmes et al., 2008), which may also cross the placenta being excreted by 
the fetal kidney then passing to into AF (Ng et al., 1982). 
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Table 4.5 – Assignments of LC-NMR/MS on human AF using a RP- 18 c   m     pH≈2 0  L  p   mb    
according to Figure 4.19. a new assignment by NMR; b tentative assignment, no MS information 
available. MS and MS/MS m/z values correspond to [M+D]+ adducts except: c[M+Na]+, d[M+H]+. 
Expected concentration values (2nd trimester of pregnancy) are shown in the last column, according to 
references: e, (Tuma et al., 2006); f, (Lind, 1981); g, (Groenen et al., 2004). 
 
 
Loop/ 
RT 
(min) 
MS (m/z) 

1
H, ppm  
(multiplicity,  J in Hz, assignment) 
Assignment 
 
expected 
concentration 
in M (ref)
 MS MS/MS 
1/6.51 
- - 1.49(d, 7.3, CH3) alanine  323 
e
 
193.8
c
 - 2.77(d, 15.3, CH2), 2.86(d, 15.0, CH2) citrate   345 
f
  
202.8
c
 - 
3.41(t, H4), 3.52(dd, H2), 3.70(t, H3), 
3.76(dd, H6), 3.83(m, H5), 5.23(d, H1) 
-D-glucose   
2510 
g
 
 
202.8
c
 - 
3.24(dd, H2), 3.40(t, H4), 3.49(t, H3), 
3.47(dd, H5), 3.73(dd, H’6), 3.90(dd, H6), 
4.64(t, H1) 
-D-glucose  
153.1 - 
1.49(m, CH2), 1.73(m, CH2),  
1.91(m, CH2), 3.03(t, 7.5, CH2) 
lysine   202 
e
 
153.0 - 2.13(m, CH2), 2.50(m, CH2)  
glutamine, 
glutamate   
186,227 
f
 
202.8
c
 - 3.28(t, H5), 3.62(t, H4/H6), 4.06(t, 2.9, H2) myo-inositol 396 
g
 
- - 1.33(d, 6.6, CH3), 4.27(m, CH2) threonine   156
e
 
2/7.12 
- - 3.27(s, CH3) betaine 66 
g
 
- - 3.05(s, CH3) creatine 99.8
g
 
- - 3.20(s, CH3), 4.06(m, CH2) choline   11 
e
 
90.0
c
 - 1.38(d, CH3), 4.26(q, CH) lactate   9800 
f
 
160.9 - 7.41(s, ring H4), 8.48(s, ring H2) histidine   97 
e
 
- - 
2.00(m, CH), 2.35(m, CH’),  
4.13(m, CH) 
proline  181 
e
 
- - 3.56(s, CH3) glycine   167 
e
 
- - 4.89(d, H’6), 5.18(d, H6) D-mannose
a
  
- - 
1.00(d, 7.0, CH3), 1.05(d, 7.0, CH3),  
2.29(m, CH) 
valine   153 
e
 
4/9.50 
- - 3.14 (s, CH3) creatinine 44 
e
 
153.9 133.9 
2.14 (s,SCH3), 2.24 (m, CH2), 
2.67 (t, CH2), 4.01(dd, CH) 
methionine 14 
e
 
5/10.01 
135.9 88.3 
0.98(t, 6.2, CH3), 1.74(m, CH),  
1.81(m, CH2), 3.91(m, CH) 
leucine  68 
e
 
135.9 
88.3 
 
0.96(t, 7.4, CH3), 1.04(d, 7.0, CH3), 
1.32(m, CH), 1.51(m, CH),  
3.86(d, 3.7, CH) 
isoleucine   29 
e
 
6/12.11 
169.8 
166.8
d
 
122.0 
3.16(m, CH), 3.32(m, CH’),  
4.12(dd, CH), 7.34(m, ring H6),  
7.39(m, ring H4), 7.44(m, ring H3/H5) 
phenylalanine   53 
e
 
7/14.27 183.0 - 3.50(s, CH3), 3.95(s, CH3), 7.93(s, CH) paraxanthine
a
 - 
8/17.26 
209.9 
202.8
c
 
190.8 
3.38(m, CH), 3.52(m, CH’),  
4.21(m, CH), 7.21(t, ring H5/H6),  
7.29(t, ring H5/H6), 7.33(s, ring H2),  
7.55(d, ring H7), 7.72(d, ring H4) 
tryptophan
a
   10 
f
 
9/17.79 - - 
3.91(s, CH2), 6.98(d, ring H3/H5),  
7.98(d, ring H2/H6) 
4-amino-hippurate
a,b
 - 
11/24.19 
196.0 
194.9
d
 
138.8 
3.37(s, CH3), 3.56(s, CH3), 3.98(s, CH3), 
7.92(s, ring H2) 
caffeine
a
 - 
13/29.54 - - 
4.19(s, CH2), 7.58(t, H3/H5),  
7.86(d, H2/H6) 
hippurate
a
 - 
14/35.50 - - 
0.91(t, 7.4, CH3), 1.11(d, 7.0, CH3),  
1.45(m, CH), 1.72(m, CH’), 3.00(m, CH) 
3-methyl-2-oxovalerate
a
 - 
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The 1H NMR spectrum from loop 9 (17.79 min) was tentatively assigned to 4-amino-hippurate 
(Figure 4.20d). This compound had been mainly used as ultrasound imaging contrast medium 
used to measure amniotic fluid volume (Kirshon et al., 1990). However this procedure was 
apparently not used in any of the donors of AF samples used, therefore the compound may be of 
endogenous origin. The signals from 1H NMR spectrum of loop 14 collected at 35.5min (Figure 
4.20f) were assigned to metabolite 3-methyl-2-oxovalerate which was identified for the first time 
in AF. Six spin-systems were found for which no assignment was possible at this stage and also the 
spin-systems appearing at several retention times (system contaminants) (Table 4.6). 
 
Table 4.6 - Unassigned spin systems and signals from contaminants detected in the LC-NMR/MS 
experiments of human AF using a RP-C18 column. Loop numbers according to Figure 4.19. 
 
The pre-concentration of the peaks eluted between 15 and 40 min (less polar metabolites) into 
hydrophobic SPE cartridges for LC-SPE-NMR analysis was attempted. However, retention of 
compounds in these cartridges was unsuccessful since no 1H NMR signals were obtained after 
elution of the cartridges.      
 
4.3.3.2 Characterization of more polar metabolites 
 
The more polar fraction of AF metabolites co-eluted in the very early peaks of reverse-phase 
chromatography, as shown in the previous section, thus hampering their resolution and detection 
of those compounds present in lower concentrations. Therefore, in order to characterize the 
more polar compounds of human AF, cation exchange chromatography was performed prior to 
NMR and MS analysis. Several peaks can be observed across the time range of the chromatogram 
UV trace obtained (Figure 4.21a) showing that good retention was achieved for the separated 
metabolites. The MS trace (Figure 4.21b) shows that the MS signal was quite low when compared 
with the obtained reverse-phase MS signal (Figure 4.19b, page 110) with signals occurring only at 
10-20 min. This is justifiable by the lack of organic solvents in the composition of the mobile 
phase, which facilitate the electrospray ionization process (Kebarle and Verkerk, 2009). However, 
their use was not possible due to the incompatibility with this particular column. 
Loop/ 
RT(min) 
Unassigned spin systems Signals from contaminants 

1
H, ppm (multiplicity) 
1
H, ppm (multiplicity) 
2/7.12 
3.30(s); 3.23(s); 3.60(s); 4.48(s);  
7.37(s), 7.43(s) 3.56(dd), 3.65(dd), 3.77(m) 
glycerol  
(membrane filter) 
3/7.93 1.15(d); 1.25(d); 1.10(m) 
4/9.50 1.14(d), 3.45(m), 3.53(dd); 3.88(d) 3.35(s) methanol (system) 
5/10.01 1.14(d); 1.18(t); 3.14(s); 3.65(s) 0.93(t); 0.95(s); 1.14(s);  unidentified (system) 
9/17.79 3.33(s); 3.91(s); 3.97(s) 1.18(d); 1.43(d); 1.26(t) unidentified (system) 
12/29.09 3.19(s); 3.66(s); 4.19(s); 7.37(t), 7.58(m)   
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Figure 4.21 - Cation-exchange chromatograms of a 10× concentrated Mw<3kDa human AF 
fraction: a) UV trace, b) MS ESI+ mode trace. 1, column void elution volume; 2, 
oligosaccharides; 3, pentose; 4, monosaccharides (glucose, myo-inositol, mannose and 
fructose); 5, lactate; 6, succinate and formate; 7, acetate; 8, pyroglutamate.   
 
 
Figure 4.22a shows the pseudo-2D LC-NMR time-slice chromatogram obtained for a 10× 
concentrated Mw<3kDa AF fraction using cation-exchange chromatography. Each line 
corresponded to an 1D 1H NMR spectrum obtained at every 30s of the chromatography as 
exemplified in Figure 4.22b for 4 spectra obtained at 4 different retention times of pseudo-2D LC-
NMR chromatogram. 
Table 4.7 lists the 32 compounds assigned in this experiment, 16 of which having been already 
assigned with 1H NMR alone. The spin-systems of metabolites such as myo-inositol, -
hydroxybutyrate, -hydroxyisobutyrate, -hydroxybutyrate, -hydroxyisobutyrate, -
ketoglutarate and taurine were partially overlapped with spin-systems of other compounds in 1D 
and 2D 1H NMR spectra being completely resolved in this LC-NMR experiment, thus allowing their 
confirmation. Two other metabolites, which were observed in the reverse-phase experiment, 
namely mannose and 3-methyl-2-oxovalerate (Figure 4.22b), were also identified in the cation 
exchange experiment, thus confirming their assignments.  
Newly identified metabolites included malate (Figure 4.22b), hydroxypropionate (Figure 
4.22b), D-fructose, sorbitol, acetylcholine and pyroglutamate (a cyclic derivative of glutamate) 
which were previously found in human AF in other studies (Kumps et al., 2004; Jauniaux et al., 
2005; Tuma et al., 2006). These compounds were completely resolved by cation exchange LC 
which enabled their identification for the first time using 1H NMR. 
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Figure 4.22 - a) Pseudo-2D LC-NMR chromatogram of a 10-fold concentrated AF fraction with 
Mw<3kDa recorded with an cation-exchange LC-NMR experiment at 600MHz with cryo-probe (the 
 pp                            RT’             mp y v   m      c  )     b)     c            k      m  ), 
for retention times of 20 min (containing 3-methyl-2-oxovalerate), 23 min (containing malate), 25.7 
min (containing xylitol) and 32 min (containing hydroxypropionate). RG: 724 and NS: 64 for all lines. 
Un: unassigned peak. 
 
 
 
 
3-methyl-2-oxovalerate 
malate 
xylitol 
hydroxy-
propionate 
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Table 4.7 – Results of LC-NMR on human AF using an cation-exchange column. a, newly found by NMR; 
b, tentative assignment. MS and MS/MS m/z values correspond to [M+Na]+ adducts except c, [M+H]+. 
Expected concentration values (2nd trimester pregnancy) are shown in the last column and respective 
references: d, (Lind, 1981); e, (Groenen et al., 2004); f, (Kumps et al., 2004). 
RT 
(min) 
MS (m/z) 

1
H, ppm 
(multiplicity, J in Hz, assignment) 
Compound 
expected 
concentration 
in M (ref) MS MS/MS 
14.0   3.2 (s), 3.3 (s), 3.6-4.0 (broad profile) 
methoxylated 
oligosaccharide (U2)
a  
16.0 407.0 214.5 3.6-3.9, 4.35, 4.99 (d), 7.40 (s) pentose
a,b
  
19.0   0.94(d, 7.0, CH3) isovalerate
a,b
  
19.5   2.85(d, CH2, 15.8), 3.03(d, 15.8, CH2) citrate   345 
d
 
  2.38(s, CH3) pyruvate  
  
1.58(s, CH3) pyruvate 
(hydrate form) 
 
20.0   0.89(t, 7.5, CH3), 1.09(d, 6.8,’CH3), 
1.46(m, CH), 1.68(m, ’CH), 2.92(m, 
CH) 
3-methyl-2-oxovalerate
a
 
 
20.5 202.8  3.41(t, H4), 3.52(dd, H2), 3.70(t, H3), 
3.76(dd, H6), 3.83(m, H5), 5.23(d, H1) 
-D-glucose 2510 
d
 
202.8  3.24(dd, H2), 3.40(t, H4), 3.49(t, H3), 
3.47(dd, H5), 3.73(dd, H’6), 3.90(dd, 
H6), 4.64(t, H1) 
-D-glucose 
324.9 162.8
c
 3.12(dd), 3.29(m), 3.36(m), 3.59(m), 
3.66(m), 3.96(dd), 4.01(dd), 4.12(m), 
4.25(d), 4.32(t), 4.50(d), 5.50(d) 
hexose disaccharide
a
 
 
21.0   0.94(d, 6.8, CH3), 2.09(m, CH), 
2.64(d, CH) 
2-oxoleucine
a
  
21.5 202.8  3.26(t, H5), 3.61(dd, H4/H6), 4.05(t, H2) myo-inositol 396 
e
 
22.0 202.8  3.56(t, H3), 3.64(m, H3/H4), 3.93(m, 
H2), 
4.90(d, H’6), 5.18(d, H6) 
mannose
a
  
22.5 202.8  3.57(m, H1), 3.80(d, H6), 3.99(m, H4), 
4.03(dd, H5), 4.11(d, H3) 
fructose
a
  
23.5   2.85(m, CH), 2.92(m, CH’), 
4.57(dd, CH) 
malate
a
  
24.5 182.8
c
 164.8
c
 
65.9
c
 
3.63(m, H1/H4/H6), 3.73(d, H6),  
3.76(m, H3), 3.82(d, H1), 3.84(m, 
H2/H5) 
sorbitol
a
  
25.7   3.65(m, H3), 3.72(dd, H1/H5),  
3.80(m, H2/H4) 
xylitol
a
  
30.5   1.42(d, 7.1, CH3), 4.38(q, 7.0, CH) lactate 9800 
d
 
30.8   3.26(t, 6.6, CH2), 3.43(t, 6.6, CH2) taurine 83 
d
 
31.5   2.62(t, 6.0, CH2), 3.86(t, 5.9, CH2) hydroxypropionate
a
 9.5-27 
f
 
32.0   2.68(s, CH2) succinate  
  8.45(s, CH) formate  
32.5   1.25(d, 6.4, CH3), 2.51(m, CH), 
2.59(m, CH’), 4.24(m, CH) 
-hydroxybutyrate 120 
d
 
33.5   1.34(s, CH2), 2.57(s, CH2) -hydroxyisobutyrate  
33.7   0.96(t, 7.5, CH3), 1.74(m, CH), 
1.84(m, CH’), 4.25(m, CH) 
-hydroxybutyrate 50 
d
 
35.0   2.32(s, CH3) acetoacetic  
35.5   2.09(s, CH3) acetate  
37.2   6.81(s, CH) fumarate  
38.5   0.90(d, 6.9, CH3), 1.00(d, 6.9, ’CH3), 
2.06(m, CH), 4.12(d, 4.3, CH) 
-hydroxyisovalerate  
44.0   2.06(s, NCH3), 3.96(s, CH2) N-acetylglycine
a
  
45.0   2.17(m,CH), 2.43(m, CH2),  
2.56(m, CH’), 4.37(dd, CH) 
pyroglutamate
a,b
 [19-50] 
f
 
46.0   3.23(s, CH3) acetylcholine
a,b
  
46.5   1.41(d, 7.3, CH3), 2.03(s, NCH3) N-acetylalanine
a
  
53.5   2.69(t, 7.0, CH2), 3.45(t, 7.1, CH2) -ketoglutarate
b
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Further compounds were identified for the first time in human AF namely D-xylitol (Figure 
4.22b), 2-oxoleucine, the amino acids derivatives N-acetylalanine, N-acetylglycine, as well as the 
tentatively assigned isovalerate (Table 4.7). 
Again, 31 spin-systems were also found for which no assignment could be advanced (Table 
4.8). The corresponding MS data did not contribute much to the assignment of these spin-systems 
due to the poor ionization mentioned previously. Apparently, there is no link between the 
systems listed in Table 4.8 and the unassigned spin-systems found by 1H NMR (Table 4.3), which 
seems to suggest that the unassigned spin-systems detected in the LC-NMR cation-exchange 
originate from less concentrated compounds, therefore undetected by 1H NMR alone. 
 
Table 4.8 – Unassigned spin-systems obtained from the LC-NMR experiment of human AF using a 
cation-exchange column. 
RT 
(min) 

1
H, ppm (multiplicity) 
RT 
(min) 

1
H, ppm (multiplicity) 
RT 
(min) 

1
H, ppm 
(multiplicity) 
12.5 1.0 (m), 1.6 (d), 3.9 (s)  (U1) 25.5 3.62(m), 3.68(m), 3.78(dd) 35.8 3.44(dd), 3.54(dd) 
15.0 3.91(s)  3.56(dd), 4.35(d) 40.5 0.93(d), 3.74(t) 
16.0 3.20(s), 3.33(s) 25.8 1.26(d), 1.32(d) 40.8 2.46(s) 
 3.77(m), 3.97(d), 4.99(m), 26.5 1.27(d), 1.43(s) 42.5 1.18(t) 
 7.46(s)  (U3) 28.8 3.86(t), 4.54(s), 4.58(s) 43.0 3.15(s) 
16.5 2.50(d), 2.75(m) 29.5 3.60(s) 43.5 1.10(t) 
18.0 0.95(d) 30.0 4.21(s) 48.0 1.22(s) 
 1.13(d) 35.5 1.14(d, 7.1), 2.72(m),  49.0 1.15(d) 
20.3 2.73(dd), 2.88(dd)  3.72(d, 6.2) 50.5 2.80(s) 
23.5 3.65(m)  3.67(s) 63.0 1.20(d) 
24.5 1.19(d) 36.0 2.20(s) 64.0 0.96(d) 
 
Regarding sugar and sugar-like compounds, the newly found D-xylitol and sorbitol, like caffeine 
and paraxanthine, may also possibly originate from dietary sources, such as from the 
consumption of sweeteners or some fruits (plums, berries, etc.). There is also the possibility of an 
endogenous origin of these metabolites, due to biosynthesis by the embryo during the first 
trimester of pregnancy, as it has been suggested in a previous study (Jauniaux et al., 2005). An 
hexose disaccharide that co-eluted with glucose, was also identified at 20.5 min retention time 
and confirmed by MS (Table 4.7) but for which no further assignment was possible at this stage. In 
addition, an interesting group of weaker signals resonating in the sugar region may be seen at 
retention times between 12 and 18min (Figure 4.22a). These signals reflect the overlap of at least 
3 different spin-systems (U1, U2 and U3) shown in detail in Figure 4.23, and confirmed by 1H-1H 
TOSCY in the corresponding fraction collected by loop-storage at about 16 min (not shown). The 
further characterization of these spin-systems was attempted by DOSY, but this was hindered by 
the relatively low signal-to-noise characterizing the 12-18 min retention time region. 
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Figure 4.23 - 1H NMR spectra taken from the LC-NMR chromatogram shown in figure 4.22 
for retention times between 12 and 18 min. The spectra were re-processed with 2Hz line 
broadening and recalibrated to the ACN peak. 
 
Although the identification of U1 was not possible at this stage, the profiles of U2 and U3 
resemble sugar-like profiles. The relatively broader profile of U2 and the singlets at 3.2 and 3.3 
ppm (Figure 4.23) may indicate a possibly methoxylated oligosaccharide (Table 4.7). The U3 
system shows clearly resonances at the anomeric region, together with an unassigned resonance 
at 7.4 ppm, while the MS spectra at this retention time have revealed that this compound shows 
ions compatible with a pentose sugar (Table 4.7). Therefore U3 was tentatively assigned to a 
pentose sugar (Table 4.7).   
It is interesting to note that none of the amino acids observed previously in the reverse-phase 
experiment (Table 4.5) was observed in the LC-NMR cation-exchange experiment. This may have 
            m     p                    m     m     c           pH        m b    p     (pH≈2 4)  
especially the protonation of the NH2 groups, which then confers high positive charge densities. 
This may have led to a higher affinity of these compounds to the stationary phase of the column 
and, as a result the amino acids are not eluted. In spite of this, taurine (Figure 4.24a) and the 
U1 U1
U2
U3
U3
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newly detected amino acid derivatives N-acetylglycine, N-acetylalanine and pyroglutamate were 
observed in the chromatograms (Figure 4.24b-c).  
 
Figure 4.24 - 1H NMR spectra taken from the LC-NMR chromatogram shown in Figure 4.22, showing 
the elution of some amino acids derivatives: a) taurine, b) N-acetylglycine, c) pyroglutamate and d) N-
acetylalanine. 
 
     In these compounds, the NH2 group is replaced by a NHR group, where R can be an acetyl or a 
methylene group (Figure 4.24b-c). Furthermore, in the case of taurine, which has free NH2 group 
(Figure 4.24a), the charge density is compensated by the negatively charged sulfonic group. These 
effects have resulted in a decrease in the overall positive charge of these compounds at the 
pH≈2 4, which then could have resulted in the high retention times observed for these 
compounds. 
 
Overall, the results from reverse-phase and cation-exchange LC-NMR/MS experiments enabled 
the detection and assignment of 21 new metabolites, which adding to those identified by 1D and 
2D NMR enabled the establishment of a database of 75 compounds detected in healthy human 
AF. The complete list of compounds can be found in Annex V – Full list of compounds identified in 
AF by high resolution NMR and LC-NMR/MS. 
 
a
bc
a
a
b
c
a
a
b
c c
c
b
b
MeOH
b
Un
acetylcholine
ACN
succinate
lactate
lactate
Un
Un
b
a
a
b
glycerol
taurine
N-acetylglycine
pyroglutamate
N-acetylalanine
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5. Study of the effects of fetal malformations (FM) and chromosomal 
disorders (CD) on 2nd trimester human amniotic fluid 
 
The work presented in the first part of this chapter aims to further explore the metabolic 
effects of fetal malformations on 2nd trimester human amniotic fluid using a metabonomic 
approach comprising three complementary analytical techniques: 1H NMR, UPLC-MS and MIR. 
The second part of this chapter explores the human AF metabolite variations resulting from 
chromosomal disorders using 1H NMR and MIR metabonomics. The 1H NMR, UPLC-MS and MIR 
analytical techniques were chosen since they have different dynamic ranges in terms of 
metabolites detected, therefore, providing complementary information on the complex AF 
metabolite composition. 
 
5.1. Study of the effects of FM on 2nd trimester human amniotic fluid 
 
5.1.1. 1H NMR profiling to evaluate the effects of maternal age, gestational age and 
malformation type 
 
The fetal malformations group of samples considered in this study comprised different types of 
malformations grouped according to the affected organic system, as summarized in Table 5.1. 
Due the time-scale of sample collection, the number of samples (control and FM) varied between 
the three analytical studies as indicated in the same table.   
 
Table 5.1 - Sample numbers and corresponding median age values of gestational and maternal ages of 
control and fetal malformation (FM) groups. Numbers in brackets: age range. 
 
Age Sample numbers per study 
  Gestational Maternal 
1
H NMR UPLC-MS MIR 
Control: 17 (15-22) 36 (25-44) 90 26 41 
Fetal Malformation(FM) type: 
     Urogenital 20 (14-24) 30 (25-33) 5 5 5 
Cardiac 22 (15-23) 22 (13-32) 5 3 4 
Soft tissues 14, 21 21, 22 2 1 2 
Abdominal 16, 23 27, 37 2 2 2 
Limbs 22 (16-23) 29 (19-31) 5 1 5 
Lungs 17 35 1 1 1 
Poly-malformed 19 (15-25) 27 (17-36) 3 2 3 
Central Nervous System 22 (16-24) 32 (24-35) 13 7 13 
Total FM sample numbers: 
  
36 22 35 
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Considering the median age values, differences of 3 to 5 weeks in gestational age and of 4 to 15 
years in maternal age were noted between control and FM samples (Table 5.1). This was justified 
by fact that amniocentesis performed for controls was       y c                m        ≥ 36 
years of age, at around 16 weeks of gestation. On the other hand, for FM cases (which can be 
detected at any maternal age) amniocentesis was usually performed after diagnosis of FM, and 
can thus span a wider range of gestational ages of 2nd and 3rd trimester (14-36 weeks). In order to 
evaluate the possible influence of gestational and maternal ages in the AF composition, 1H NMR 
standard spectra of control samples (15-22 g.w.) were analysed by PCA, without including any 
disorder spectra in this analysis. The PCA scores scatter plot obtained illustrates that the gestation 
age range of the analysed samples spread across the scatter plot (Figure 5.1a), thus, showing that 
no measurable trends were observed with respect to gestational age.  
 
Figure 5.1 - PCA scores scatter plots of standard 1H NMR spectra of control samples (n=90) with: a) 
gestational and b) maternal ages sub-ranges represented. 
 
Similar results were obtained when the PCA scores scatter plot data points were coloured 
according to the maternal age ranges (Figure 5.1b). The results shown indicate that any AF 
compositional variations due to gestational or maternal ages, in the considered ranges, are not 
significant and should be much smaller that the inter-individual changes, thus showing the non-
confounding influence of these variables in the data sets considered. The results are not 
surprising since the major compositional changes in AF occur mainly between trimesters (>10 
g.w.), especially between the 2nd and the 3rd trimester as a response to fetal organ maturation and 
involving changes in the contents of amino acids, proteins, choline and related compounds and 
creatinine (Lind, 1981; Sims et al., 1996; Cohn et al., 2009). 
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The FM group was composed of malformations affecting several organic systems (Table 5.1). In 
order to inspect the differences between the FM types, their spectra were analysed by PCA using 
the different 1H NMR spectra collected: standard, CPMG and diffusion-edited (Figure 5.2). 
Figure 5.2 - PCA scores scatter plots of 1H NMR spectra of AF samples from different fetal 
malformations grouped according to the organic system affected: a) standard, b) CPMG, c) diffusion-
edited spectra. 
 
From the inspection of the PCA scatter plots (Figure 5.2) it is clearly seen that different types of 
FM overlap, showing that the corresponding 1H NMR spectra were indistinguishable. This may 
result partially from the low sample numbers corresponding to different FM organic types. 
Moreover, each organic type of FM considered was composed of different types of FM (as shown 
in chapter 3, Table 3.3, page 60), which may also justify the spread observed in the PCA scores for 
the samples of the same organic type (Figure 5.2). PLS-DA models were also obtained to evaluate 
the differences between central nervous system samples (largest group, n=13) and other FM 
(n=23) types (not shown), since the former group could not be differentiated from the other FM 
in PCA. However, the models could not be validated by MCCV, hence reflecting the absence of 
significant differences between both groups. 
Study of the effects of fetal malformations (FM) and chromosomal disorders (CD) on 2nd trimester 
human amniotic fluid 
124 
 
Due to the low sample number available for each malformation type, the FM group was 
considered as a whole when compared with the control group in the analysis described below, 
therefore attempting to identify general metabolic effects related to FM. 
 
5.1.2. 1H NMR profiling for comparison of control and FM groups 
 
When analysed by PCA, the spectra of control and FM samples showed separation tendencies 
in the first two components (PC1 and PC2) for standard and CPMG spectra (Figure 5.3a and b, left) 
indicating that compositional differences between control and FM were registered in this two 
experiments.  
 
Figure 5.3 - Scores scatter plots from PCA (left), PLS-DA (centre) and OPLS-DA (right) models of control 
(■, n=90) vs FM (, n=36) samples: a) standard; b) CPMG; c) diffusion-edited 1H NMR spectra. 
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A small separation tendency was also obtained in the PCA scores scatter plot of diffusion-
edited spectra, but only when PC3 and PC4 components were considered (Figure 5.3c, left) which 
indicate less compositional differences between control and FM regarding larger compounds 
(proteins mainly). PLS-DA enabled a better separation of control and FM samples (Figure 5.3, 
centre) although with some overlap of FM with control samples seen for standard and diffusion-
edited spectra (Figure 5.3a and c, centre) and an almost complete separation obtained for CPMG 
spectra in the LV1 axis (Figure 5.3b, centre). Similar separation trends were obtained in the OPLS-
DA scores scatter plots in the first component (LV1) (Figure 5.3, right). The PLS-DA models 
obtained registered moderate predictive power (Q2) values between 0.335 and 0.500, and the full 
validation of these models was pursued by Monte-Carlo cross-validation (MCCV) (Figure 5.4).  
 
Figure 5.4 - MCCV results for PLS-DA models of control vs FM: a) standard, b) CPMG, c) diffusion-
edited 1H NMR spectra. Q2 distributions (left) and ROC plots (right) of true classes and permuted 
classes models are shown. The true classes average sensitivity, specificity and classification rate (CR) 
are indicated in the ROC plots. 
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Separation of Q2 distributions of models of true and permuted classes were obtained for all 
models (Figure 5.4, left), with less overlap observed for the CPMG data set (Figure 5.4b, left). The 
ROC plots show also complete separation of true and permuted classes models (Figure 5.4, right) 
and high specificity values >80% for all data sets. In terms of sensitivity, the CPMG models 
registered average values of 74% for true class models (Figure 5.4b, right), the standard spectra 
registered sensitivity values between 40%-80% (Figure 5.4a, right) and diffusion-edited registered 
sensitivity values between 40%-75% (Figure 5.4c, right). The dispersion in sensitivity observed for 
these models indicates a poorer predictive ability when compared with CPMG models. The 
classification rates obtained were however similar for the 3 data sets: 90% for standard spectra 
models and 89% for CPMG and diffusion-edited spectra. The overall MCCV results demonstrate 
the robustness of human AF 1H NMR PLS-DA models in the discrimination of control and FM 
samples, with the CPMG spectra providing the most robust models, which means that low Mw 
metabolites seem to contribute more importantly for that discrimination. Interestingly, the 
sensitivity values obtained for the 1H NMR models for FM detection (62-74%) were within the 
range of sensitivities for FM detection associated with ultrasound methods (14-74%,  Chmait and 
Moore, 2004) with a slight improvement towards intermediate values. However, the specificity of 
ultrasound methods is higher for FM detection is higher (100%, Chmait and Moore, 2004) 
compared to the specificity of 1H NMR models (93-95%). 
    
The 1H NMR signals responsible for the separation observed in the PLS-DA scores scatter plots 
shown in Figure 5.3 (centre) were identified from the corresponding loadings weights plots. In the 
loadings weights plots (Figure 5.5) the signals pointing in the positive direction of the separating 
latent variables (LV1 for standard and for CPMG; and LV2 for diffusion-edited data sets) are 
associated with higher content of the corresponding metabolites in the control group, which were 
characterized by positive values of the latent variable in the corresponding scores scatter plots 
(Figure 5.3, centre); hence these signals are associated with lower contents of the corresponding 
metabolites in the samples of the FM group. The negative signals, on the other hand, are 
associated with higher contents of the corresponding metabolites in the samples of the FM group. 
Moreover the signals in orange-red colour, registering higher variable importance to the 
projection (VIP) values, indicate the signals which had a higher contribution to the class 
separation observed (Figure 5.5). In this way, several metabolite signals decreased in FM group 
were identified from the loadings of standard spectra (Figure 5.5a) namely the amino acids 
isoleucine, leucine, valine, alanine, lysine, proline, glutamine, histidine, phenylalanine and 
tyrosine, together with decreases in glucose, mannose, myo-inositol, lactate, choline, creatine, 
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citrate, pyruvate, formate, fumarate, -oxoisovalerate and two unassigned spin-systems, Un1 
(2.84 ppm, multiplet) and Un2 (2.93, 3.15 ppm, multiplets). Broad signals were found increased in 
the spectra from FM group samples, namely at 0.60 and 7.00 ppm (Figure 5.5a).  
 
 
Figure 5.5 - Loadings from PLS-DA models of control vs FM: a) standard, b) CPMG and c) diffusion-
edited 1H NMR spectra colour-coded with VIP values, corresponding to the scores in Figures 5.3a,b,c 
(centre), respectively. Ui, unassigned signals; br, broad profile; amino acids in three-letter code.  
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The CPMG spectra loadings (Figure 5.5b) further confirmed the decreases of isoleucine, 
leucine, valine, -oxoisovalerate, glucose, phenylalanine and tyrosine in the samples of the FM 
group, as previously noted in the loadings of standard spectra. Furthermore, increases in the 
signals of N-acetyl groups (from glycoproteins), glutamine, succinate, creatinine, glycine, serine, 
ascorbate and threonine as well as in 2 unassigned signals, Un3 (1.06 ppm) and Un4 (7.67 ppm), 
were noted in the FM group. The diffusion-edited spectra loadings (Figure 5.5c) confirmed the 
decrease in lactate as well as the decreases in glucose, alanine and valine as well the increase in 
N-acetyl groups of glycoproteins in the FM group (Figure 5.5c). 
Interestingly, lactate and citrate signals showed an inverse variation in CPMG loadings when 
compared to standard spectra and diffusion-edited spectra loadings (Figure 5.5) indicating an 
increase of these metabolites in FM. As discussed in chapter 4 (pages 106-107), a small portion of 
citrate and lactate may be found bound to the protein. It seems then possible that the two forms 
of lactate and citrate may co-exist in AF samples: one free in solution and other tightly bound to 
proteins. The variations seen in the CPMG loadings should be mainly due to the "free" forms of 
citrate and lactate, whereas those of lactate in diffusion-edited spectra loadings should be mainly 
due to the "bound" form (both forms contributing to the standard spectra).  
 
All the metabolite variations were further evaluated through univariate analysis after 
integration of the respective 1H NMR signals. The list of significant metabolite variations obtained 
is shown in Table 5.2, with indication of the respective direction of variation and magnitude of 
change (mean fold change, i.e. the ratio between the average of integrals (A): Acontrol/AFM or 
AFM/Acontrol, if AFM>Acontrol). The univatiate tests confirmed the variations previously identified in the 
PLS-DA loadings. The integrals from selected metabolites identified as changing more significantly 
in the AF of FM samples (including glucose, valine, glutamine, glutamate, serine, succinate, N-
acetyl group from glycoproteins) were expressed in box-plots (Figure 5.6). The box-plots 
corresponding to the variation of both forms of lactate ("free" and "bound") are also shown to 
better illustrate their change in controls and FM group (Figure 5.6).  
Most of the metabolite variations identified had also been found in the early stages of the 
work presented in this thesis where similar analysis was performed using several FM types but 
with reduced numbers of both FM (n=27) and control (n=82) groups (Graça et al., 2009;       et 
al., 2010), therefore confirming the obtained findings. However, the variations of "free" and 
"bound" citrate, choline, creatine, fumarate, mannose, proline, unassigned signals U1, U2 and U3 
signals, were found here for the first time in AF of FM samples, which may be solely due to the 
use of larger FM (n=36) and control (n=90) groups in the present work.  
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Table 5.2 - List of significant metabolite variations (p<0.05) noted in 2nd trimester human AF of FM 
affected pregnancies. a, signal within the metabolite spin-system chosen for integration; b, signal 
integral measured in CPMG spectra. s, singlet; d, doublet; t, triplet; m, multiplet; br, broad signal; Ui, 
unassigned signals. ( ), very small changes corresponding to magnitude (mean fold change) values >1.0 
and <1.05. 
metabolite 
1
H 
a
 
direction and magnitude 
of change 
p-value 
alanine 1.47(d)  1.3 7.43×10
-9
 
-oxoisovalerate 1.11(d)  1.1 6.53×10
-9
 
ascorbate 
b
 4.01(m)  1.3 2.95×10
-3
 
broad signal (proteins) 0.60(br) () 1.0 5.71×10-7 
choline 3.19(s)  1.2 1.36×10
-5
 
citrate 2.67(d)  1.1 9.77×10
-3
 
citrate ("free" form) 
b
 2.67(d)  1.2 6.75×10
-4
 
creatine 3.92(s)  1.1 4.56×10
-4
 
creatinine 
b
 4.05(s)  1.1 1.04×10
-4
 
formate 8.45(s)  1.3 3.11×10
-7
 
fumarate 6.51(s)  1.1 4.52×10
-4
 
glucose 5.23(d)  1.7 1.70×10-10 
glutamate 2.35(m)  1.2 3.48×10
-7
 
glutamine 
b
 2.45(m)  1.6 2.04×10
-6
 
glycine 
b
 3.55(s)  1.2 4.60×10
-6
 
histidine 7.07(s)  1.1 1.86×10
-8
 
isoleucine 0.94(t)  1.1 1.32×10
-8
 
lactate  1.32(d)  1.3 1.76×10
-4
 
lactate ("free" form) 
b
 1.32(d)  1.1 2.63×10
-2
 
leucine 0.95(t)  1.3 3.77×10
-11
 
lysine 1.72(m)  1.1 1.24×10
-8
 
mannose 5.19(d)  1.2 3.54×10
-4
 
myo-inositol 4.06(t)  1.2 1.97×10
-4
 
N-acetyl (glycoproteins) 
b
 2.03(s)  1.3 7.66×10
-12
 
phenylalanine 7.38(m)  1.2 1.28×10
-10
 
proline 2.00(m)  1.1 1.58×10
-5
 
pyruvate 2.37(s)  1.2 4.37×10
-6
 
serine 
b
 3.95(m)  1.1 6.93×10
-6
 
succinate
 b
 2.40(s)  1.4 4.72×10
-9
 
threonine 
b
 4.26(m)  1.2 4.72×10
-6
 
tyrosine 6.89(d)  1.2 4.30×10
-10
 
valine 1.03(d)  1.4 1.62×10
-11
 
Unassigned resonances 
1
H 
a
 
direction and magnitude 
of change 
p-value 
Un1 2.84(m)  1.1 5.79×10
-7
 
Un2 2.93(m)  1.1 6.93×10
-6
 
Un3 3.10(m)  1.2 3.77×10
-11
 
Un4 
b
 1.06(d)  1.1 2.34×10
-3
 
Un5 
b
 7.67(s)  1.7 4.09×10
-4
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Figure 5.6 - Box-plots for selected metabolites identified as changing significantly in the loadings of AF 
FM 1H NMR PLS-DA models. The respective p-values are also shown. 
 
 
5.1.3. UPLC-MS profiling for comparison of control and FM groups 
 
Further characterization of FM cases was performed through human AF profiling using UPLC-
MS, a technique which offered more sensitivity and greater dynamic range when compared with 
1H NMR. Figure 5.7, illustrates the UPLC-MS chromatograms obtained for a control human AF 
using two complementary chromatographic columns, HSS and HILIC, in both ESI+ and ESI- modes. 
Some assignments based on standards retention time are indicated. 
The UPLC-MS data sets registering good reproducibility (as shown in Annex III - UPLC-MS 
reproducibility evaluation), i.e. Log transformed HSS and HILIC ESI+ and ESI- data sets, as well as 
well as the HSS/ESI+ (Pareto scaled) and HILIC/ESI+ (UV scaled),  were analysed by MVA. 
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Figure 5.8 - Base peak ion (BPI) UPLC-MS chromatograms of control human AF sample obtained using 
two different columns and acquired in both ionization modes: a) HSS/ESI+; b) HILIC/ESI+; c) HSS/ESI-;   
d) HILIC/ESI-. Maximum peak intensities are indicated in each chromatogram. Assignments: 1, glucose; 
2, uric acid; 3, tyrosine; 4, phenylalanine; 5, tryptophan; 6, caffeine; 7, creatinine; 8, choline; 9, 
betaine; 10, creatine; 11, carnitine; 12, citrate; 13, indoxyl sulfate; 14, glutamine/glutamate.  
 
 
Similarly to the results obtained with 1H NMR data (page 123), no distinction was observed for 
different malformation types, with basis on PCA the UPLC-MS profiles of AF (not shown). PCA 
models were then obtained for control vs FM (all FM types as one single group).  
Although very weak tendencies were visible in PCA scores (Figure 5.8, left), separation was 
only obtained through PLS-DA, with most of the separations being observed in the LV1 
component (Figure 5.8, centre). OPLS-DA was also performed in the data sets, resulting in 
increased separation in the LV1 component (Figure 5.8, right). The HSS/ESI+ Pareto scaled and the 
HILIC/ESI+ UV scaled data sets originated similar PLS-DA and OPLS-DA results to those presented 
in Figure 5.8a and c, respectively (not shown). The PLS-DA and OPLS-DA model parameters 
obtained for all data set/scaling combinations used are summarized in Table 5.3. The prediction 
power, which was expressed as Q2 values, was between 0.4-0.6, therefore indicated robustness of 
the models obtained (Table 5.3). The PLS-DA models were subjected to MCCV, which resulted in 
some overlap of Q2 distributions of true and permuted classes with, however a clear separation 
tendency (Figure 5.9a-d).  
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Figure 5.7 - Scores scatter plots from PCA (left), PLS-DA (center) and OPLS-DA (right) models of control 
(■, n=26) vs FM (, n=22) of Log transformed UPLC-MS data sets: a) HSS/ESI+, b) HSS/ESI-, c) HILIC/ESI+, 
d) HILIC/ESI-. 
 
Table 5.3 - Parameters of UPLC-MS PLS-DA and OPLS-DA models of control vs FM. 
UPLC 
column 
detection 
mode 
Scaling 
PLS-DA model parameters OPLS-DA model parameters 
R²X R²Y Q² LV R²X R²Y Q² LV 
HSS ESI+ Pareto 0.187 0.815 0.471 2 0.187 0.815 0.558 1+1 
HSS ESI+ Log 0.179 0.844 0.490 2 0.179 0.844 0.558 1+1 
HSS ESI- Log 0.201 0.859 0.589 2 0.201 0.859 0.591 1+1 
HILIC ESI+ UV 0.243 0.819 0.623 2 0.243 0.819 0.535 1+1 
HILIC ESI+ Log 0.271 0.770 0.538 2 0.271 0.770 0.571 1+1 
HILIC ESI- Log 0.286 0.690 0.438 2 0.286 0.690 0.470 1+1 
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Figure 5.9 - MCCV results for control vs FM PLS-DA models of log transformed UPLC-MS data sets:       
a) HSS/ESI+, b) HSS/ESI-, c) HILIC/ESI+, d) HILIC/ESI-. Q2 distributions (left) of true classes,  permuted 
classes and ROC plots (right) of true (●) and permuted (○) classes models are shown. Average 
sensitivity, specificity and classification rate (CR) values for true classes are shown in the ROC plots. 
 
True class models of HSS data sets registered high specificity and sensitivity of about 80%-98% 
and 70%-75% respectively in ROC plots (Figure 5.9a,b). The HILIC/ESI- data set models registered 
specificity and sensitivity of about 90% and 60%-80%, respectively, for true classes in ROC plot 
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(Figure 5.9d), whereas the HILIC/ESI+ registered more dispersion in the true class models, with 
some models registering specificity of 80% and sensitivity of 60% with the remaining registering 
sensitivity close to 80% and specificity values above 80% (Figure 5.9c). Similar MCCV results were 
obtained for HSS/ESI+ Pareto and HILIC/ESI+ UV data sets (not shown). This means these models 
have good predictive performances. It is clear, however, that the most robust models were 
obtained with HSS data sets.  
Comparing the MCCV of UPLC-MS with those obtained previously by 1H NMR (Figure 5.4, page 
125), it is interesting to note an improvement in sensitivity of the models based on the HSS UPLC-
MS, possibly due to the detection of higher number of more stable signals. On the other hand, the 
balanced number of controls (n=26) and FM (n=22) samples used in UPLC-MS PLS-DA models 
possibly resulted in more stable MCCV parameters obtained through the validation process, 
therefore contributing to the higher overall stability in terms of sensitivity. 
 
The OPLS-DA models were considered for the purpose of identification of MS signals or 
features (consisting of retention time - m/z pairs) with impact in separation between control and 
FM samples. This was justified because OPLS-DA models obtained registered Q2 values equivalent 
to those obtained for the corresponding PLS-DA models (Table 5.3), and have the advantage of 
providing a more straightforward loadings interpretation since separation is condensed in LV1 
(Figure 5.8, right). The loadings from the OPLS-DA models were interpreted with the aid of S-plots 
(Figure 5.10a), as explained previously in chapter 3 (section 3.5.3, page 81).  
In the S-plot, the features with correlation values |p(corr)[1]|>0.5 and covariance values p[1] 
falling outside the diagonal (|p[1]|>0.05) were selected and further evaluated through covariance 
ratio plots jack-knife plot (Figure 5.10b). The latter enables the selection of only the most stable 
features, i.e. those registering lower standard error of covariance across the cross-validation 
rounds (p[1]cvSE). The threshold for feature selection (dashed line in Figure 5.10b) was placed 
above the ratio value 4, which is the ratio where p[1]cvSE is 25% the value of the covariance 
value. 
The selected features were then further evaluated by univariate analysis. Considering all the 
data sets analysed, a total of 83 features were found as varying significantly (p<0.05) between 
control and FM groups, 21 of which were assigned and listed in Table 5.4.  
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Figure 5.10 - Selection of the MS features with higher impact in the OPLS-DA model obtained for 
control vs FM AF HSS/ESI- log transformation. a) S-plot and b) covariance ratio plot of the separating 
latent variable. Dashed boxes in a) represent the groups of selected features (for |p(corr)[1]|>0.5 and 
|p[1]|>0.05) and the dashed line in b) indicates the threshold (>4) of the covariance ratio above which 
the features where selected. 
 
 
Table 5.4 - List of assigned significant UPLC-MS features obtained for 2nd trimester AF of the FM 
compared to the control group. Feature intensities are indicated as: very high (>105), high (>104, <105), 
low (>103, <104) and very low (<103). a metabolite fragment; b metabolite adduct; c isotope of the 
m   c     p  k        c   *      y            m   b      v         ; †         v  y     g       
features. 
metabolite 
UPLC 
column 
detection 
mode 
m/z 
RT 
(min.) 
feature 
intensity 
PLS-DA 
Model 
direction/ 
magnitude 
of variation 
p-value 
leucine/isoleucine HSS ESI
+
 132.09 1.8 high Pareto  1.4 1.8010
-05
 
   86.08
a
 1.8 low Pareto    
carnitine* † HSS ESI
+
 162.00 0.4 low Log  2.5 1.8010-05 
polyol* † HSS ESI
+
 205.07
b
 0.5 high Pareto  1.4 8.7810-04 
pyroglutamate* HSS ESI
+
 130.04 1.4 high Pareto  1.6 2.2410
-06
 
valine HSS ESI
+
 118.07 0.9 high Pareto  1.4 7.4910
-07
 
estriol-3-
glucuronide/ 
estriol-16-
glucuronide*† 
HSS ESI
-
 463.20 4.9 high Log  3.8 3.9010-05 
estriol-3-sulfate-16-
glucuronide* † 
HSS ESI
-
 543.16 4.3 high Log  3.1 1.4710-04 
leucine/isoleucine HSS ESI
-
 491.19
b
 1.9 low Log  2.2 2.2410-06 
 HSS ESI
-
 462.24
b
 1.9 low Log    
 HSS ESI
-
 576.27
b
 1.9 low Log    
 HSS ESI
-
 547.32
b
 1.9 low Log    
glutamine HILIC ESI
+
 130.05
a
 5.7 low UV  2.7 2.8110-04 
 HILIC ESI
+
 84.04 5.7 low Log    
 HILIC ESI
+
 527.14
b
 5.7 very low Log    
isoleucine HILIC ESI
+
 312.04
b
 4.9 low UV  1.7 4.0610
-06
 
lysine HILIC ESI
+
 84.08
a
 7.2 low UV  1.4 1.7410-03 
valine HILIC ESI
+
 72.08
a
 5.2 low UV  1.5 3.5810
-07
 
  HILIC ESI
+
 298.03
b
 5.2 very low UV    
 HILIC ESI
+
 369.10
b
 5.2 very low UV    
glutamate HILIC ESI
-
 146.04 6.1 low Log  1.5 7.0110-03 
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The features corresponding to glutamate, leucine/isoleucine, lysine and valine were found 
decreasing in FM group together with an increase in glutamine, which is in agreement with the 
variations previously observed by 1H NMR. New metabolite variations were also observed by 
UPLC-MS (Table 5.4). Indeed, the feature 205.07 m/z found in HSS/ESI+ data sets was found 
decreasing in FM group. This feature co-eluted with glucose at about 0.5min and was tentatively 
assigned to a sodium adduct of a polyol, possibly sorbitol (Figure 5.11a).  
Figure 5.11 - Mass spectra of newly and tentatively assigned features which had significant variations 
in FM samples: a) polyol, possibly sorbitol, b) pyroglutamate, c) estriol-3-glucuronide, d) estriol-3-
sulfate-16-glucuronide. Peaks corresponding to each feature and to respective fragments are 
indicated, together with the compound structure and possible fragments.  
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Additionally, pyroglutamate (Figure 5.11b), carnitine and the tentatively assigned to 
glucuronidated estriol (estriol-3-glucuronate, Figure 5.11c or estriol-16-glucuronate) and estriol-3-
sulfate-16-glucuronate (Figure 5.11d) were found increased in FM group. Although 
pyroglutamate, carnitine and polyols had been previously detected in human AF by high field 
NMR and LC-NMR (chapter 4, Table 4.2 - page 101 and Table 4.5 - page 113, respectively), their 
variation had not been detected in 1H NMR. This was possibly due to strong overlap of their 
resonances with those of the more abundant one glutamine and glutamate (2.0-2.6 ppm) and 
glucose (3.2-3.5 ppm). Estriol conjugates, on the other hand are expected only in nM levels in 
human AF (Lind, 1981), therefore, it is not surprising not to detect estriol signal variations by 1H 
NMR. A list of 62 features found varying significantly (p<0.05) between control and FM group and 
for which no assignment was obtained at this stage is also presented in annex (see Annex VI - Lists 
of UPLC-MS unassigned features detected in AF). However, it is important to mention that further 
assignment work could reveal other important metabolite variations and should be considered in 
future analysis. 
 
5.1.4. UPLC-MS/1H NMR SHY analysis for FM cases 
 
In order to confirm the obtained MS assignments and find further metabolic relationships, the 
intensities of each significant MS feature of the FM group were correlated with their 
corresponding 1H NMR CPMG spectra using statistical heterospectroscopy (SHY) analysis (chapter 
3, section 3.7, page 83). The results were analysed in the form of 1D STOCSY (Figure 5.12). 
 
Figure 5.12 - Example of UPLC-MS and 1H NMR SHY analysis for leucine/isoleucine HSS/ESI+ MS feature 
(132.09 m/z, 1.8min.). The assigned resonances correspond only to those registering correlation values 
|r|0.70 and (p<0.001). 
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In the 1D STOCSY plot shown in Figure 5.12, the 1H NMR signals with positive covariance and 
correlation show variation in the same direction as the MS feature whereas those with negative 
covariance and correlation show opposite variation with that of the MS feature. Only the positive 
and negative correlations values with |r|0.70 and p<0.001 significance were considered based 
on previous reports (Crockford et al., 2006; Maher et al., 2011). The results of the SHY analysis of 
1H NMR data and the relevant MS features are presented in Table 5.5. 
 
Table 5.5 - List of UPLC-MS/1H NMR correlations obtained from SHY analysis of significant AF MS 
features (shown in Table 5.4) and AF 1H NMR CPMG spectra of FM. Only maximum or minimum 
correlations values |r|0.70 and (p<0.001) were considered. Assigned spin systems are indicated in 
bold. a metabolite fragment; b metabolite adduct; c isotope of the molecular peak or adduct; s, singlet; 
d, doublet; t, triplet; m, multiplet; dd, doublet of doublets; * variation relative to control group; Un, 
still unassigned resonances.  
metabolite m/z 
direction RT 
(min) 
1
H NMR resonances  
correlated positively  
to MS feature / ppm 
1
H NMR resonances 
correlated negatively  
to MS feature / ppm 
of 
variation* 
leucine/ 
isoleucine 
132.09  1.8 leucine: 0.95(t);  
valine: 0.98(d), 1.03(d), 2.25(m) 
citrate: 2.51;  
Un: 1.06(d) 
     isoleucine: 0.93(t), 1.00(d), 
1.70(m)  
leucine/ 
isoleucine 
b
 
491.19  1.9 isoleucine: 0.93(t), 1.01(d); 
leucine: 0.95(t), 1.70(m) 
Un: 1.06(d) 
    valine: 0.98(d), 1.03(d), 2.25(m), 
3.60(d) 
 
    glucose: 3.23(dd), 3.40(m), 
3.53(dd), 3.72(m), 
 
    3.82(m), 3.89(dd)  
isoleucine 
b
 312.04  4.9 isoleucine: 0.93(t), 1.01(d); 
leucine: 0.95(t), 1.70(m) 
- 
    valine: 0.98(d), 1.03(d), 2.25(m), 
3.60(d) 
 
    tyrosine: 6.89(d), 7.19(d)  
glutamine 
a
 130.05  5.7 glutamine: 2.13(m), 2.45(m) glutamate: 2.35(m) 
glutamate 146.04  6.1 glutamate: 2.06(m), 2.35(m) - 
valine 118.07  0.9 leucine: 0.95(t);  
tyrosine: 6.89(d), 7.19(d) 
Un: 6.92(s), 7.67(s),  
4.01, 1.06(d) 
    valine: 0.98(d), 1.03(d), 2.25(m), 
3.60(d)  
     isoleucine: 0.93(t), 1.00(d), 
1.70(m)  
    glucose: 3.23(dd), 3.40(m), 
3.45(m), 3.48(m), 3.53(dd), 
3.72(m), 3.82(m), 3.88(dd), 
5.23(d)  
valine 
a
 72.08  5.2 isoleucine: 0.93(t), 1.01(d); 
leucine: 0.95(t), 1.70(m) 
 
    valine: 0.98(d), 1.03(d), 2.25(m), 
3.60(d) 
- 
pyroglutamate 130.04  1.4 threonine: 3.58(d);  
Un: 0.88(t) 
phenylalanine: 7.32(m), 
7.40(m); 
     tyrosine: 6.89(d), 7.19(d); 
    tyrosine: 6.89(d), 7.19(d)  
lysine 
a
 84.08  7.2 phenylalanine: 7.32(m) - 
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Positive autocorrelations were found for leucine/isoleucine, valine, glutamine and glutamate, 
which simply confirm the MS assignments of these metabolites. In addition, positive correlations 
were found, in several instances, between leucine/isoleucine, valine, tyrosine and glucose, 
indicating the concomitant decreases of these metabolites (Table 5.5). The leucine/isoleucine MS 
feature (decreased in FM) also correlated negatively with citrate, which indicates that citrate 
accumulates at a similar rate to that of glucose and the above amino acid consumption. Other 
UPLC-MS/1H NMR correlations found for the FM group comprise the correlation of the 
pyroglutamate MS feature (increased in FM) with resonances arising from threonine (positive 
correlation), phenylalanine and tyrosine (negative correlations). Furthermore, the lysine MS 
feature (decreased in FM) correlated positively with resonances of phenylalanine, and the 
glutamine MS feature (increased in FM) correlated negatively with glutamate resonances. It is 
also noted that several unassigned NMR resonances were seen to correlate to several of the MS 
features (Table 5.5), which should be considered in future assignment work. 
 
5.1.5. MIR profiling for comparison of control and FM groups 
 
Figure 5.13 shows a typical ATR-MIR spectrum of a dry human AF sample. Most of the signals 
occur in the fingerprint region (1800-600 cm-1) for which proteins, lipids, organic acids (mainly 
lactate), amino acids, and glucose contribute importantly. Also some signals related to stretching 
vibrations () of simple C-H bonds appear in the region of 3000-2800 cm-1, together with O-H and 
N-H stretching vibrations (), more visible around 3600-3100 cm-1 (Figure 5.13). 
 
 
 
Figure 5.13 - ATR - MIR spectra of a dry control AF sample. Main assignments are shown. a.a., amino 
acids. Spectral assignments based on literature data (Liu et al., 1998a; Liu et al., 1998b; Liu and 
Mantsch, 1999; Liu et al., 2000; Liu et al., 2002). 
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The MIR spectra obtained for control and FM AF samples were used to produce PLS-DA 
models. Three spectral replicates were considered for each sample. PLS-DA models were obtained 
for spectral regions for which spectral reproducibility was obtained (Annex IV - MIR reproducibility 
evaluation): 3000-2800 cm-1, 1800-1200 cm-1, 1200-900 cm-1, and for 2nd derivative transformed 
data of the 1200-900 cm-1 region. The corresponding scores scatter plots are shown in Figure 5.14.  
 
 
Figure 5.14 - PLS-DA scores scatter plots of obtained for MIR spectra of AF of control (■, 
n=40) vs. FM cases (, n=34) with 3 spectral replicates were used per sample for the 
spectral regions: a) 3000-2800 cm-1, b) 1800-1200 cm-1, c) 1200-900 cm-1, d) 2nd 
derivative transformed data for the 1200-900 cm-1 region.  
 
The results show a significant overlap of control and FM spectra in the models obtained for the 
region 3000-2800 cm-1 and 1800-1200 cm-1 (Figure 5.14a and b, respectively). However, a 
tendency for separation of control and FM spectra was noted when the spectral region of 1200-
900 cm-1 was used (Figure 5.14c). This tendency is improved when the 2nd derivative of the same 
data is considered (Figure 5.14d), probably resulting from resolution increase which unveils small 
spectral differences between control and FM spectra. One outlier was noted in the scores scatter 
plot from the latter model which corresponds to one of three poly-malformed fetuses cases (the 
other 2 are overlapped with the remaining FM samples, Figure 5.14d). No other clinical info was 
found to justify the separation of this sample from the remaining samples of the FM group. 
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The validation of the PLS-DA models of 1200-900 cm-1 region and 2nd derivative transformed 
data for the 1200-900 cm-1 region was assessed with MCCV (Figure 5.15). The PLS-DA model 
obtained using 1200-900 cm-1 region, revealed mostly separated true and permuted Q2 
distributions, 80% classification rate, 73% of sensitivity and 85% sensitivity (Figure 5.15a), 
whereas the PLS-DA model corresponding to the 2nd derivative transformed data of the 1200-900 
cm-1 region resulted in mostly separated of true and permuted Q2 distributions, a classification 
rate of 80%, 69% sensitivity and 87% specificity (Figure 5.15b). The apparent outlier noted in data 
points of permuted classes of Figure 5.15b (right) results from the random permutation of classes, 
a process that naturally has some probability of originating models similar to the true class 
models, and hence similar values of sensitivity and specificity. However, such an artefact does not 
affect the interpretation of the MCCV results that provide evidence of the validity of the PLS-DA 
models of the 1200-900 cm-1 region and 2nd derivative transformed data of the 1200-900 cm-1 
region. 
 
 
Figure 5.15 - MCCV results for the PLS-DA models obtained for: a) 1200-900 cm-1 region and b) 2nd 
derivative of the 1200-900 cm-1 region of the MIR spectra of control vs FM groups. Left: Plots of the Q2 
values distribution for true and permuted classes; Right: ROC curves for true (●) and permuted (○) 
classes. Average sensitivity, specificity and classification rate (CR) values for true classes are shown in 
the ROC plots. 
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The separation observed between control and FM samples in the PLS-DA scores of the 1200-
900 cm-1 region and 2nd derivative of the 1200-900 cm-1 region (Figures 5.14c,d) occurred mainly 
in LV1. The respective LV1 loadings for both models are shown in Figure 5.16).  
Figure 5.16 - PLS-DA LV1 loadings from MIR models of control vs FM: a) 1200-900 cm-1 spectral region; 
b) 2nd derivative of 1200-900 cm-1 region. VIP values for LV1 are represented as colour. 
 
Inspection of LV1 loadings from the PLS-DA 1200-900 cm-1 region model (Figure 5.16a) 
revealed decreases in bands at 1070, 1020 and 990 cm-1, and a decrease in the band 1168 cm-1 in 
of the FM group. However, the VIP values indicate that the band 1020 cm-1 has the highest impact 
in the separation between control and FM groups.  
The LV1 loadings of the 2nd derivative 1200-900 cm-1 region PLS-DA model suggested the 
involvement of the band 1170 cm-1 (Figure 5.16b). To aid interpretation, a comparison of the LV1 
loadings (5.17a) with a typical record of 2nd derivative of the 1200-900 cm-1 spectral region (Figure 
5.17b) and also with the respective untransformed spectral region (Figure 5.17c) was performed. 
It is important to notice that the 2nd derivative transformation originates signal inversion when 
the transformed (Figure 5.17b) and untransformed (Figure 5.17c) spectral regions are compared. 
Therefore, the variations observed in the loadings should be interpreted as pointing in the 
opposite direction to that observed in the scores scatter plots of (Figure 5.14d). In this way, the 
band 1170 cm-1 is found increased in FM group. Moreover, comparison of 2nd derivative of 1200-
900 cm-1 spectral region (Figure 5.17b) and the untransformed 1200-900 cm-1 region (Figure 
5.17c) clearly shows a very weak 1170 cm-1 band in the 1200-900 cm-1 region (Figure 5.17c), which 
becomes more visible after 2nd derivative transformation (Figure 5.17b), thus demonstrating the 
usefulness of such procedure.  
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Figure 5.17 - PLS-DA loadings analysis of the 2nd derivative of 1200-900 cm-1 region: a) LV1 loadings; b) 
2nd derivative of the 1200-900 cm-1 spectral region from a representative control sample; c) 1200-900 
cm-1 spectral region from the same control sample. Dashed lines indicate the position of the 1170 cm-1. 
 
5.1.6. MIR STOCSY analysis of FM cases 
 
The identification of intra-correlations between MIR bands may help in the assignment of the 
relevant bands identified in PLS-DA loadings and also reveal biochemical relationships. An MIR 
intra-correlation map was obtained for the 1750-900 cm-1 region of the spectra from FM samples, 
using STOCSY (Figure 5.18). 
The high degree of correlation in MIR data leads to intra-correlation maps with large 
correlation areas spanning several correlation values. Therefore, a threshold of |r|>0.8 and a 
significance level of p<0.001 were chosen with basis on previous reports using STOCSY (Crockford 
et al., 2006; Maher et al., 2011) in order to eliminate spurious correlations. The bands from the 
loadings of the FM PLS-DA models were searched along the vertical dimension of the STOCSY map 
and the off-diagonal correlation maxima were identified (Figure 5.18). At the correlation and 
significance thresholds used, all the correlations obtained were positive as shown in Figure 5.18 
and Table 5.6. 
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Figure 5.18 - MIR (1750-900 cm-1) intra-correlation map for the FM group (n=34), with correlation 
threshold |r|>0.8 (p<0.001). Dashed vertical lines indicate the bands of interest identified through 
loadings analysis and their correlations across the 1750-900 cm-1 spectral region. 
 
Table 5.6 - MIR bands from the PLS-DA loadings and respective correlations from the intra-correlation 
map shown in Figure 5.16. *observed in 2nd derivative models; s, symmetric stretching; as, 
asymmetric stretching; s, symmetric bending; in brackets: putative assignments (Pretsch et al., 1989). 
MIR bands (cm⁻¹) change MIR/MIR correlations (cm
-1
) 
1170 (C-C/C-O) *  1485, 1462, 1440 (sNH2) 
1070 (C-C/C-O)  1474, 1459 (sNH2); 1418 (sCOO
-
); 1261 (OC-OH); 
  1200 (C-C/C-O) 
1020 (C-C/C-O)  1473 (sNH2) 
990 (C-C/C-O)  1473 (sNH2) 
 
From the bands decreasing in FM, the one at 1070 cm-1 was found to correlate positively with 
vibrations of functional groups from carboxylate and amine groups (sCOO
-, OC-OH, sNH2) and 
with C-C and/or C-O; 1020 and 990 cm-1 were found correlated with amine group vibrations 
(sNH2) (Table 5.6). These vibrations may be related with amino acid content (decreasing in FM), 
which is consistent with previously observed changes found by 1H NMR and UPLC-MS (Table 5.2, 
page 129 and Table 5.4, page 135, respectively). 
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The 1170 cm-1 band (C-C and/or C-O) was correlated to bands at 1485, 1462 and 1440 cm-1 
all possibly corresponding to sNH2 vibrations (Table 5.6). This suggests a possible relationship to 
amine group containing molecules, such as amino acids, urea or amines. Moreover, the 1170 cm-1 
band may also be related to protein content. Indeed, a small band is seen in the albumin 
spectrum at 1170 cm-1 (Figure 5.19a), also registering a relatively weak 2nd derivative signal 
compared to the region of highest intensity (Figure 5.19b). Other correlations expected with basis 
on this suggestion, for instance in relation to Amide I and Amide II bands may remain 
undetectable due to spectral overlap. However, protein signals in the 1H NMR spectra were found 
to be increased in FM cases, as shown in section 5.1.2 (Table 5.2, page 129) and also in previously 
reported work (Graça et al., 2009;       et al., 2010).  
Figure 5.19 - ATR-MIR spectra of dried standard aqueous solution of bovine serum albumin (7 mg/mL, 
pH 8.60), serving as a model for human AF albumin: a) MIR spectra and b) respective 2nd derivative 
function.  
 
5.1.7. MIR/1H NMR SHY analysis for FM cases 
 
SHY analysis of MIR and 1H NMR of AF samples from FM group was used to search for further 
assignments and metabolite relationship information. SHY was performed by correlating the 
1200-900 cm-1 spectral region of the FM spectra with the corresponding full standard 1H NMR 
spectra. The SHY map obtained is shown in Figure 5.20. The bands from the LV1 loadings of MIR 
PLS-DA models were searched along the horizontal dimension of the SHY map, enabling the 
identification of several positive and negative significant correlations (Table 5.7). Some of the 
correlations corresponded to metabolites already identified to vary with the occurrence of FM 
(Table 5.7). 
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Figure 5.20 - Statistical heterospectroscopy (SHY) maps of MIR (1200-900 cm-1) / 1H-NMR (0-10 ppm) 
with correlation threshold of |r|>0.7 (p<0.001) for the FM group (n=34). Dashed horizontal lines 
indicate the bands of interest identified through loadings analysis and their correlations across the 
NMR 0-10 ppm region. Unassigned signals are indicated with their chemical shift values. 
 
Table 5.7 - List of SHY heterocorrelations found between MIR bands and standard spectra 1H-NMR 
signals. Assignments are given in brackets; amino acids are represented in 3 letter code; Un: 
unassigned signals from 1H-NMR. In bold: metabolites whose variation in FM group was previously 
reported (Table 5.2, page 129 and Table 5.4, page 135 and (Graça et al., 2009;       et al., 2010)).  
MIR bands (cm⁻¹) change 
Positively correlated  
1
H-NMR signals 
Negatively correlated  
1
H-NMR signals 
1170 (C-C/C-O)*  NH groups (6.95 ppm) 
citrate, glucose, formate, 
lactate, Ala, Lys, Pro, Thr, 
2 Un (2.23, 3.27 ppm) 
1020 (C-C/C-O) 
glucose, Ile, Leu, 
1 Un (3.20 ppm) 
- 
990 (C-C/C-O)  glucose, Glu, 1 Un (3.20 ppm) - 
 
The bands at 1020 and 990 cm-1 (decreasing in FM) were positively correlated to specific amino 
acids and glucose (Table 5.7). The presence of an intense band at around 1025 cm-1 in the MIR 
spectrum of a dried glucose solution (Figure 5.21) seems to indicate the relationship of the band 
at 1020 cm-1 with glucose. The concomitant decrease of glucose and several amino acids 
(including leucine and isoleucine, correlating positively with glucose) has been observed 
previously in FM group by 1H NMR and UPLC-MS (sections 5.1.2 and 5.1.4, respectively) seems to 
confirm the consumption of these metabolites in FM. 
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Figure 5.21 - ATR-MIR spectrum of dried standard aqueous solution of glucose (0.1M, pH 8.36). 
 
The 1170 cm-1 band noted to increase in the FM group correlated positively and weakly to a 
signal at 6.95 ppm (NH/aromatic region) and negatively to glucose and some organic and amino 
acids. The correlation to NH/aromatic region may also be related to protein content, as suggested 
in the previous section by the MIR intra-correlations. Further NH resonances in NMR may, 
however, remain undetectable due to spectral and signal broadening in the NMR spectra. The 
negative correlation of the 1170 cm-1 band with alanine, lysine, and proline may possibly indicate 
a concomitant decrease of the amino acids as response to an increasing demand for protein 
synthesis in FM cases. The negative correlation with glucose, lactate and citrate, although with no 
apparently direct metabolic relation, is in agreement with the previously observed increases in 
proteins and decreases of glucose, citrate and lactate in FM cases (Table 5.2, page 129 and Table 
5.4, pages 135).   
 
5.1.8. Proposed interpretation of metabolic alterations occurring in FM cases 
 
The metabolite variations found indicate the possibility of several biochemical alterations 
common to the majority of FM cases. Indeed, as observed by 1H NMR, higher levels of "free" 
lactate were observed in FM group when compared with the control group, accompanied by a 
concomitant decrease in the levels of glucose, mannose, pyruvate, and also a decrease in amino 
acids (supported by UPLC-MS, UPLC-MS/1H NMR and MIR/1H NMR SHY analysis) including alanine, 
lysine, isoleucine, leucine, glutamate, histidine, phenylalanine, tyrosine and valine. These 
variations may suggest derangement in the energy metabolism, which may involve a higher 
utilization of the glycolytic pathway under anaerobic (hypoxic) conditions (Figure 5.22), where 
glucose and possibly mannose are being used for as substrates for energy production. In addition, 
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there seems to be a higher utilization gluconeogenesis and ketogenesis pathways, where the 
amino acids may be used as substrates for glucose and ketone bodies synthesis, respectively 
(Figure 5.22) (Murray et al., 2003). 
 
Figure 5.22 - Schematic representation of the glycolytic and gluconeogenic/ketogenic pathways 
possibly affected in FM cases. The shaded region indicates the glycolytic pathway under hypoxic 
conditions. Metabolites in blue were increased and those in red decreased in the FM group. Dashed 
arrows indicate transformations occurring through several reactions. 
 
Under aerobic conditions, metabolic energy production occurs inside the mitochondria 
through respiratory chain and oxidative phosphorylation, and although the necessary enzymatic 
machinery is completely formed in the fetal tissues at 9-17 weeks gestation, it is not completely 
active until birth, when oxygen partial pressure and energetic demands rise (Minai et al., 2008). 
However, several FM including, hydronephrosis, vertebral abnormalities, anal atresia, cardiac 
abnormalities, tracheoesophageal fistula/atresia, renal agenesis and dysplasia, limb defects and 
gastrointestinal malformations, have been associated with deficiencies in the function and 
regulation of the mitochondrial respiratory chain and oxidative phosphorylation during fetal 
development, and are also thought to be involved in the mechanisms triggering malformations 
(von Kleist-Retzow et al., 2003). Succinate and fumarate, which are the substrate and product 
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respectively of the enzyme complex II of the respiratory chain (Succinate dehydrogenase 
complex) (Murray et al., 2003), were here found altered (succinate increased and fumarate 
decreased) in FM cases by 1H NMR spectroscopy. This observation can be interpreted as a 
possible indicator of the deficient use of the respiratory chain for energy production, therefore 
shifting the energy production to glycolysis.  
Still in connection with the energy metabolism, the decreases in polyol content in FM fetuses 
(detected by UPLC-MS) suggest perturbations in polyol metabolism. Polyol metabolic pathways 
are very active in the fetal-placental unit during first trimester in order to maintain ATP 
concentrations and cellular redox potential at physiological levels, where fetal environment 
conditions are very poor in oxygen (Jauniaux et al., 2005). In this pathway, glucose has two 
possible fates apart from glycolysis: one is to generate sorbitol and NADP+; and a second one is to 
generate NADPH and pentose-phosphates (nucleotide precursors), as well as other polyols, such 
as ribitol or erythritol, and NAD+ (Jauniaux et al., 2005). It seems possible that the decreases in 
glucose contents may have occurred early in pregnancy leading to the decreases in polyols 
observed. On the other hand, a polyol such as sorbitol could possibly be indirectly channelled into 
energy production by  conversion to fructose which is a substrate in the glycolytic pathway 
(Jauniaux et al., 2005).  
 
To replenish glucose levels, the amino acid catabolism could be increased in FM in order to 
feed gluconeogenic pathway, which is already active in the developing liver around 16 weeks 
(Jauniaux et al., 1999). Indeed, the amino acids alanine, glutamate, valine, proline, histidine, 
phenylalanine, tyrosine and isoleucine, were found decreased in FM in connection with the 
decrease in glucose (as observed in MS/NMR and MIR/NMR SHY analysis). Leucine and lysine, 
both ketogenic amino acids, were also found in decreased in FM cases which indicate that the 
ketogenesis pathway may also be active in order to generate acetyl-CoA to feed the tricarboxylic 
acid (TCA) cycle (Figure 5.22). Phenylalanine and tyrosine were also found decreased in FM cases 
(by 1H NMR and MS/NMR SHY analysis) and, being both gluco- and ketogenic amino acids, may 
also be used in the ketogenesis pathway. Another argument supporting the increasing need of 
amino acid by FM fetuses refers to the increase in pyroglutamate in FM fetuses detected by UPLC-
MS. Pyroglutamate may be functioning as an extracellular signal to activate the uptake of amino 
acids at the placenta, as noted before in a mammalian model (Vina et al., 1989). In fact, the 
pyroglutamate correlated negatively (in MS/NMR SHY analysis) with phenylalanine and tyrosine 
and positively with threonine suggesting a possible relationship to the uptake of these amino 
acids. 
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Interestingly, other glucogenic and ketogenic amino acids glycine, glutamine, serine, and 
threonine were found increased in FM cases, which suggests their possible involvement in other 
pathways. For instance, a higher glutamine level (and concomitant lower levels glutamate) is in 
agreement with the hypothesis advanced in a previous study for spina-bifida cases which 
proposed that glutamine to glutamate conversion is hindered in fetal kidneys reflecting 
underdevelopment of these organs (Groenen et al., 2004). Consistently this could also be the 
reason for the accumulation of proteins and glycoproteins (increases in N-acetyl signals in 1H NMR 
and in protein signal in MIR) and creatinine.  
Glycine and serine increases detected by 1H NMR suggest a disturbance in connection to folic 
acid pool regulation, with possible reflections in amino acid biosynthesis and choline metabolism. 
This suggestion is further supported by the observed decreases in choline and formate in FM 
cases, both of which are also connected the folic acid pool. Other indicators of disturbance of 
amino acid biosynthesis relate to the marked decreases in leucine and -oxoisovalerate, 
metabolites which share a common pathway arising from valine, also decreased in the FM cases. 
This may indicate a higher demand for protein synthesis in malformed fetuses. The increase in 
ascorbate may also reflect amino acid and protein synthesis alterations since this compound is 
involved in collagen, carnitine, and tyrosine synthesis (Murray et al., 2003).  
Other metabolic variations did suggest the disturbance of other pathways in FM cases, namely 
lipid metabolism. For instance, the reduction in the contents of choline and myo-inositol in FM 
cases (noted by 1H NMR), may affect biomembrane and lung surfactants phosphatidylcholine and 
phosphatidylinositol biosynthesis, which have been previously associated with the neural tube 
defects (Groenen et al., 2003). The accumulation of citrate in FM cases may indicate, for instance, 
a possible decrease in lipid biosynthesis pathway, which is a metabolic branching point from TCA 
cycle through citrate (Murray et al., 2003).  
An increase in carnitine was detected in FM cases by UPLC-MS. This may be linked to an 
increase in fatty acid transport to the mitochondria for-oxidation, another important source of 
subtracts for ketone bodies (Murray et al., 2003). Therefore, carnitine increase may be 
interpreted as a response to higher energy demand in FM fetuses. 
Finally, two metabolites detected by UPLC-MS and tentatively assigned to estriol-3-sulfate-16-
glucuronide and estriol-3-glucuronide/estriol-16-glucuronide were found increased in FM cases. 
Estriol conjugates are formed in the fetal-placental unit from fetal precursor 
dehydroxyepiandrosterone which are then conjugated with glucuronic acid and/or sulfate in 
maternal liver to be finally excreted in urine (Yang et al., 2003). Reduced unconjugated maternal 
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    m             b       c  b          ’   y    m          c p   y c     (Haddow et al., 
1992; Yaron et al., 1998). However, the increase of conjugated estriol in human AF of FM affected 
pregnancies has not been reported before and no further hypothesis can be put forward with the 
available data. 
 
5.2. Study of the effects of CD on 2nd trimester human amniotic fluid 
 
The effects of chromosomal disorders (CD) on 2nd trimester AF were investigated using the 1H 
NMR and MIR profiling, since only a small number of CD samples (about 5) was available at the 
time of analysis by UPLC-MS.  
 
5.2.1. 1H NMR profiling to evaluate the effects of CD type 
 
The CD samples considered for 1H NMR and MIR analysis are shown in Table 5.8, together with 
the corresponding number of AF samples. Several types of CD were considered (Table 5.8), 
therefore, PCA analysis was performed initially to evaluate any differences between the AF 
profiles of different CD types (Figure 5.23). No separation or tendency of any CD type was 
observed in the scores scatter plots (Figure 5.23), meaning that no differences between the 1H 
NMR spectra of CD types seem to occur. The sample number of each type of CD was quite low, 
which may justify in part the result obtained.  
 
Table 5.8 - Sample numbers corresponding to the chromosomal disorders considered in 1H NMR 
and MIR profiling studies.  
Chromosomal disorders 
Sample numbers 
1
H NMR MIR 
Trisomy 21 7 7 
Trisomy 18 1 1 
Marker chromosome 1 1 
Kleinefelter syndrome 3 2 
XYY syndrome 2 2 
XXX syndrome 1 1 
Mosaicisms 3 3 
Inversions 2 2 
Translocations 4 4 
Total 24 23 
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Figure 5.23 - PCA scores scatter plots of 1H NMR spectra from AF samples affected by different 
types of CD: a) standard, b) CPMG and c) diffusion-edited spectra. 
 
The larger group of CD, Trisomy 21 (n=7), was compared to the remaining CD types (n=17) 
using PLS-DA (not shown) and the models obtained could not be validated through MCCV, which 
means that no significant differences were found between Trisomy 21 and the other CD types. In 
this way, all samples CD were considered as one group to be compared with control samples. 
Therefore, the profiling studies presented consisted of exploratory studies to search for metabolic 
variations common to the majority chromosomal disorders. 
 
 
5.2.2. 1H NMR profiling for comparison of control and CD groups 
 
Figure 5.24 shows the scores plots from the PLS-DA analysis of standard, CPMG and diffusion- 
edited 1H NMR spectra of control vs CD samples. The PLS-DA scores plots revealed separation 
tendencies for all three spectra (Figure 5.24a,b,c), which were however not visible in PCA (not 
shown). Also no spectral differences were apparent by visual inspection of the spectra. The 
separation tendencies were maintained in OPLS-DA scores plots (Figure 5.24d,e,f).  
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Figure 5.24 - Scores scatter plots from PLS-DA and OPLS-DA models of control (■, n=90) vs CD (○, n= 
24). PLS-DA models: a) standard; b) CPMG; c) diffusion-edited 1H NMR spectra; OPLS-DA models: d) 
standard; e) CPMG; f) diffusion-edited. 
 
 
The Q2 values obtained for the PLS-DA models (between 0.20-0.39) motivated their further 
validation through MCCV (Figure 5.25). MCCV revealed only modest results when compared with 
the results obtained for control vs FM models (Figure 5.4, page 125), with only some separation 
tendency noted between true and permuted distributions of Q2 values and the overlapping of 
distributions nearly exceeding 50% (Figure 5.25a,b,c, left). Although high specificity values were 
obtained for true class models in the ROC plots (>90%), low sensitivities were obtained: ranging 
from 10-50% for standard spectra models (Figure 5.25a, right), 20-60% for CPMG models (Figure 
5.25b, right) and 20-50% for diffusion-edited spectra (Figure 5.25c, right). Therefore, CPMG model 
registered the best predictive ability, also expressed by a classification rate of 86% (against 
classification rates of 82%, and 79% for standard and diffusion-edited models, respectively). 
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Figure 5.25 - MCCV results for PLS-DA models of control (n=90) vs chromosomal disorders (n=24) 
shown in Figure 5.21: a) standard, b) CPMG, c) diffusion-edited 1H NMR spectra. Left: Q2 distributions; 
right: ROC plots. Average sensitivity, specificity and classification rate (CR) values for true classes are 
shown in the ROC plots. 
 
In spite of the low predictive ability of the models, the loadings were analysed in order to 
identify possible small metabolite variations accompanying the occurrence of CD. The loadings 
analysis was pursued using the LV1 loadings from OPLS-DA models from Figure 5.24d,e,f, to ease 
model interpretation. The LV1 loadings from standard spectra model (Figure 5.26a) revealed 
increases in -oxoisovalerate, alanine, citrate, pyruvate, methionine, myo-inositol, threonine and 
glucose in CD, together with decreases in -hydroxybutyrate, 3 unassigned spin-systems and 
some broad signals in the broad region of protein NH groups (6.94, 7.15 and 8.00 ppm). 
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Figure 5.26 - Loadings from OPLS-DA models of control vs CD: a) standard, b) CPMG and c) diffusion-
edited 1H NMR spectra colour-coded with VIP values. Ui, unassigned signals; amino acids in three-
letter code. 
 
The increases in -oxoisovalerate, alanine, citrate, myo-inositol, threonine and glucose as well 
as the decreases in -hydroxybutyrate, and 2 unassigned spin systems were confirmed in the LV1 
loadings of CPMG model (Figure 5.26b). Two further variations were observed in the CPMG 
loadings, namely the decrease in glycine and increase in histidine (Figure 5.26b). The diffusion-
edited spectra loadings showed that several signals from the protein profile were decreased in CD 
cases including two broad signals already observed in standard spectra (centered at 7.15 and 8.00 
ppm), and increases in three other signals in the broad profile (Figure 5.26c).  
a) 
b) 
c) 
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The significance of the identified variations was tested after signal integration using univariate 
analysis, with the significant variations being presented in Table 5.9. The p-values obtained for the 
metabolite variations noted in CD  were in the range of 10-2-10-5,  which in comparison to those 
detected previously for FM (in the range of 10-3-10-11) seem to indicate that smaller changes 
occurred in CD. Significant small increases confirmed in CD cases included -oxoisovalerate, 
citrate, methionine, threonine, myo-inositol, glucose and two broad profile signals 0.45 and 9.64 
ppm (Table 5.9). On the other hand, glycine, the 3 unidentified spin-systems (U1, U2 and U4) and 
the broad signals (1.55, 1.82, 2.15, 2.40, 2.95, 3.10, 6.84, 7.15 and 8.00 ppm, which may be 
related to proteins) were all found significantly decreased in CD cases. The results obtained 
present an advance compared to those obtained in a previous stage of this work with less control 
(n=82 vs n=90 here) and CD cases (n=10 vs n=24 here) (      et al., 2010). In that study no 
significant metabolite variations were reported for the same significance level (p<0.05). The 
integrals obtained were also used to produce box-plots for better visualization of the variation of 
metabolites in controls and CD groups (Figure 5.27). 
 
Table 5.9 - List of significant metabolite variations (p<0.05) noted in 2nd trimester human AF of 
CD affected fetuses. a, signal within the metabolite spin-system chosen for integration; b, signal 
integral measured in CPMG spectra; c, signal integral measured in diffusion-edited spectra. s, 
singlet; d, doublet; t, triplet; m, multiplet; br, broad signal. ( ), very small changes corresponding 
to magnitude (mean fold change) values >1.0 and <1.05. 
metabolite 
1
H 
a
 
direction and magnitude 
of change 
p-value 
 
-oxoisovalerate 
b
 1.11(d) 1.2 2.47×10-3   
citrate 
b
 2.67(d) 1.1 9.98×10-4   
glucose 5.23(d) 1.2 4.00×10-2   
glycine 
b
 3.55(s) 1.1 3.26×10-2   
methionine 
b
 2.64(t) 1.1 2.59×10-2   
myo-inositol 
b
 4.06(t) 1.1 3.14×10-4   
threonine 4.26(m) 1.1 2.71×10-2   
Un1  2.84(m) 1.2 1.10×10-4   
Un2 
b
 2.93(m) 1.8 2.15×10-4   
Un4 
b
 1.54(m) 1.2 1.20×10-5   
Broad profile signals 
signal 
direction/magnitude 
of change
p-value signal 
direction/magnitude 
of change
p-value 
0.45(br) 
c
  1.1 2.22×10-3 3.10(br) c  1.1 6.72×10-5 
1.55(br) 
c
 () 1.0 3.70×10-3 5.47(br) c  1.3 2.90×10-2 
1.82(br) 
c
 () 1.0 1.19×10-3 6.84(br) () 1.0 3.24×10-3 
2.15(br) 
c
 () 1.0 8.18×10-5 7.15(br) c () 1.1 1.44×10-3 
2.40(br) 
c
 () 1.0 4.51×10-4 8.00(br) c  () 1.0 6.41×10-3 
2.95(br) 
c  1.1 2.38×10-4 9.64(br) c  1.2 2.92×10-2 
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Figure 5.27 - Box-plots for selected metabolite signals identified from the loadings of AF CD OPLS-DA 
models. The respective p-values are also shown. br, broad signals (possibly from proteins). 
 
From the close inspection of box-plots of -oxoisovalerate, threonine, methionine, glycine and 
glucose, it is clear that despite the differences in their median values, all box-plots show overlap 
of the CD and control distributions (Figure 5.27). Moreover, the dispersion of integral values of 
the above mentioned metabolites is greater in CD than in controls, which may reflect the 
variability due to different types of CD cases under study. The integrals of citrate, myo-inositol, 
glucose, one unassigned metabolite (spin-system Un4, 1.54 ppm) and broad signals at 0.45 and 
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9.64 ppm showed increases in CD group, together with decreases in two unassigned metabolites 
(spin-systems Un1, 2.84 ppm and Un2, 2.93 ppm) and broad signals in the region of 1.55-8.00 
ppm (possibly protein signals) (Table 5.9). No assignment was possible for the unassigned spin-
systems with basis on previous knowledge from LC-NMR or 2D NMR experiments. The described 
variations form a metabolic response common to all or to the majority of the analysed CD cases. 
Regarding the trisomy 21 cases, which comprise 7 out of 24 cases in the CD group used in the 
present study (Table 5.8), new PLS-DA models were performed in order to compare the trisomy 
21 cases to control (n=90). The scores plots showed initially some separation, particularly for 
diffusion-edited spectra (not shown). However, MCCV analysis of the models (from standard, 
CPMG and diffusion-edited) registered very low sensitivity, with average values below 19% (not 
shown), therefore, the models were not considered for further analysis. The low sensitivity may 
due to the reduced number of trisomy 21 cases considered, but on the other hand it may also be 
a result of very small metabolite changes resulting of trisomy 21. 
 
5.2.3. MIR profiling for comparison of control and CD groups 
 
 The MIR analysis of a group of CD (n=23) in comparison with a control group (n=40) was 
attempted. The results scores scatter plots obtained in PLS-DA analysis are shown in Figure 5.28).  
 
Figure 5.28 - PLS-DA scores scatter plots of MIR spectra models of controls (, n=40) vs CD (○, n=23) 
for the spectral regions: a) 3000-2800 cm-1, b) 1800-1200 cm-1, c) 1200-900 cm-1.  
 
There was no separation noted in the PLS-DA scores scatter plots of the spectral regions 3000-
2800 cm-1, 1800-1200 cm-1 and 1200-900 cm-1, with a complete overlap of between controls and 
CD samples being observed (Figure 5.28). The results obtained for 2nd derivative transformed 
spectral regions were quite similar (not shown).  
PLS-DA analysis considering trisomy 21 samples (n=7) and control samples (n=40) was also 
performed considering the same MIR spectral regions as well as their respective 2nd derivative 
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transformations. The resulting PLS-DA models showed mainly no separation in the scores plots 
(not shown), being also accompanied by low Q2<0.2 values. The lack of separation in PLS-DA MIR 
is not surprising, given the small number of metabolite variations detected by 1H NMR. On the 
other hand, the strong overlap of the MIR bands of more abundant metabolites (such as glucose, 
lactate, albumin), may hinder detection of less abundant metabolites.  
 
5.2.4. Proposed interpretation of the metabolite variations occurring in CD cases 
 
Based on the variations observed, slight alterations in pathways of sugar metabolism (with the 
involvement of myo-inositol and glucose) and lipid and biomembranes biosynthesis (due to the 
increase of myo-inositol and citrate, which are involved in the biosynthesis of phospholipids and 
fatty acids, respectively) (Murray et al., 2003), can be suggested as possible metabolite 
derangements in CD cases. Amino acids metabolism may also be affected, as it is suggested by the 
average changes observed, particularly the increases of -oxoisovalerate, threonine and 
methionine, together with a decrease in glycine (Murray et al., 2003). However, the high inter-
individual variability in the levels of these amino acids was also observed inside the CD group, as 
shown in the respective box-plots (Figure 5.27, page 157) hinders the correct interpretation of the 
amino acid changes. Variations in amino acid concentrations in 2nd trimester AF, namely decreases 
in isoleucine, leucine, glycine, lysine, taurine, valine, ornithine and glutamate and increases in 
glutamine have been found of trisomy 21 cases (n=24) (Amorini et al., 2012). This shows the need 
for an improved characterization work using larger numbers of samples of this type of CD.  
Alterations in the 1H NMR protein profile of CD cases (decrease of broad signals) suggest 
decreased fetal protein expression/excretion into AF (Table 5.9). In fact, the differential protein 
expression in human AF have been described for several chromosomal disorders including 21 
trisomy (Cho et al., 2010), Kleinefelter syndrome (Anagnostopoulos et al., 2010) and Turner 
syndrome (Mavrou et al., 2008). However, the protein variations observed by 1H NMR may be 
limited to the most abundant AF proteins as seen in chapter 4 (section 4.3.2, pages 108-110). It is 
particularly difficult to assign the broad signals varying in CD to specific proteins, however, the 
involvement of the major AF glycoproteins can be ruled out due to the absence of variation of the 
N-acetyl group characteristic resonances in the loadings plots. One possibility is the decrease in 
albumin in CD which should have resonances in the 1.55-8.00 and a characteristic group of 
resonances around 3.00 ppm. However, no evidence was found in literature to support this 
hypothesis.  
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The variation of the unassigned spin-systems, Un1, Un2 and Un4 was also observed in CD 
cases. The occurrence of variations of these signals reinforces the need for further assignment 
work. Interestingly, two of these spin-systems, Un1 and Un2  were both found decreased in FM 
(p-v     ≈10-5) and CD (p-v     ≈10-4), thus indicating the possibility of a common metabolite 
alteration, possibly a common stress effect, which is however less pronounced in CD group due to 
the lower significance of the variation. 
The results obtained seem to suggest that small metabolite changes occur in CD cases, 
therefore encouraging the further characterization of larger sample populations of each type of 
chromosomal disorder by 1H NMR and by MIR. 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
161 
 
6. Study of the effects of disorders occurring later in pregnancy (PTD, 
PROM, PE, IUGR and GDM) on 2nd trimester human amniotic fluid 
 
The work presented in this chapter aims at exploring the metabolite composition of 2nd 
trimester human AF as a means to devise predictive multivariate methods for disorders affecting 
both mother and fetus later in pregnancy (during the 3rd trimester). The disorders include preterm 
delivery (PTD), preeclampsia (PE), intrauterine growth restriction (IUGR), gestational diabetes 
mellitus (GDM) and premature rupture of the membranes (PROM). The diagnosis of such 
disorders may be performed 7 - 20 weeks after amniocentesis (average values), depending on the 
disorder. Since AF was collected prior to the occurrence of the disorders, the groups were 
designated throughout the chapter pre-PTD, pre-PE, pre-IUGR, pre-diagnostic GDM and pre-
PROM.  
It is important to mention that due to the sampling time-scales, the numbers of samples (both 
controls and disorders) used in 1H NMR, UPLC-MS and MIR profiling studies was not the same. 
 
6.1. Analysis of 2nd trimester amniotic fluid composition for the prediction of PTD (pre-
PTD group) 
     
6.1.1. 1H NMR profiling for comparison of control and pre- PTD groups 
     
The 1H NMR spectra obtained for 2nd trimester AF samples from women which delivered 
preterm between 34 and 36 weeks, pre-PTD group (n=18) were compared with a control (n=90) 
group. There is an obvious imbalance between the numbers of controls and pre-PTD, however, 
the downsizing of control group was avoided to prevent the biased selection of controls.    
PCA of the 1H NMR spectral data of controls vs pre-PTD did not reveal any separation trend 
between the both classes (not shown). Separation tendencies were only observed between 
control and pre-PTD in PLS-DA and OPLS-DA models of standard and CPMG 1H NMR spectra 
(Figure 6.1a and b, respectively). A tendency for separation was also observed in diffusion-edited 
spectra models (not shown) which registered low Q2 values (Q2<0.2) indicating lower predictive 
ability. This result indicates that the contribution of high Mw compounds to the differentiation 
between classes is not significant. All models were subjected to further validation testing through 
MCCV.  
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Figure 6.1 - Scores scatter plots from PLS-DA and OPLS-DA models of 1H NMR spectra 
2nd trimester AF of control (■, n=90) and pre-PTD (∆, n=18) groups and respective 
parameters: a) standard spectra, b) CPMG spectra. 
 
 
Figure 6.2 - MCCV results for PLS-DA model of CPMG 1H NMR human AF spectra of control 
(n=90) and pre-PTD (n=18). Q2 distributions (left) and ROC plots (right) of true classes and 
permuted classes models are shown. The true classes average sensitivity, specificity and 
classification rate (CR) are indicated in the ROC plot. 
 
Despite the apparently lower Q2 value obtained in 7-fold CV for the CPMG model when 
compared with the standard spectra model (Q2=0.317 vs Q2=0.538, respectively), the former 
registered better results in MCCV (Figure 6.2). As shown in Figure 6.2(left), the Q2 distributions of 
true and permuted class models of CPMG spectra data show a tendency for separation, despite 
the large overlap noted. The sensitivity of the models noted in ROC plot (average 22%) indicated a 
low true positive rate for true classes (Figure 6.2, right). Despite the high specificity noted 
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(average 98%) and classification rate of 86%, the MCCV results denote a low predictive ability of 
PLS-DA model of CPMG spectra. The PLS-DA models of standard and diffusion-edited spectra 
registered a poorer predictive ability, characterized by an almost complete overlap of Q2 
distributions of true and permuted class models (not shown), sensitivities ranging from 0-20% in 
ROC plots (not shown) and classification rates of 84%. A low predictive ability was also obtained in 
an early stage of this work (not shown), where slightly smaller sample groups were considered 
(pre-PTD n=12, controls n=82) (      et al., 2010). In another study, Romero et al. (2010) 
reported accuracies of about 88% for the correct prediction of occurrence of PTD from women 
delivering without membrane rupture (n=40), with membrane rupture (n=33), and with 
membrane rupture with intra-amniotic infection (n=40), based on analysis of 2nd and 3rd trimester 
AF using GC-MS and LC-MS and multivariate analysis. However, the study was performed closer to 
the occurrence of PTD, at the time women experienced the first symptoms of PTD (Romero et al., 
2010), which may have some impact on the results obtained. Nevertheless, the study of Romero 
et al. (2010) also shows that the use of high number of samples may help improve the predictive 
ability of the method. 
 
Despite the low predictive ability of the standard and CPMG spectra models, loadings analysis 
was performed to further explore possible small metabolites variations occurring in pre-PTD. The 
LV1 loadings from OPLS-DA model of standard spectra (which showed improved separation in LV1 
component compared to the corresponding PLS-DA model) and also the LV1 loadings from PLS-DA 
model of CPMG (Figure 6.3a and b, respectively) were inspected. The loadings from the standard 
spectra model, indicated decreases in the contents of several amino acids in pre-PTD group, 
including alanine, isoleucine, leucine, lysine, glutamine, histidine, methionine, phenylalanine, 
tyrosine and valine; together with decreases in the contents of myo-inositol, citrate and formate 
(Figure 6.3a). On the other hand, several signals were found increasing in pre-PTD group, such 
that of allantoin and the unassigned signals at 1.10, 1.22, 2.98 and 7.06 ppm (Figure 6.13a). The 
loadings from CPMG PLS-DA model indicated decreases in pre-PTD group of methionine and the 
unassigned signals 1.80 and 3.11, as well as increases in the signals of acetoacetate, -
hydroxybutyrate, pyruvate, choline, serine, glucose, allantoin, creatinine, threonine and the 
unassigned signal at 7.87 ppm in pre-PTD (Figure 6.3b). Increases in pre-PTD signals 0.85, 0.92 
(both broad signals) and 2.03 (N-acetyl groups) were also noted, raising the possibility of relation 
to glycoprotein content.  
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Figure 6.3 - LV1 Loadings from control vs pre-PTD 1H NMR models colour-coded with VIP values: 
a) OPLS-DA LV1 loadings of standard spectra and b) PLS-DA LV1 loadings of CPMG spectra. Amino 
acids in three-letter code; unassigned signals are indicated with their respective values. 
 
Interestingly, only allantoin (increasing in pre-PTD), methionine and myo-inositol (decreasing in 
pre-PTD) appear to vary consistently in the standard (Figure 6.3a) and CPMG (Figure 6.3b) 
experiments. This may be attributed to overlap of broad and sharp resonances occurring in the 
standard spectra, which interferes in the detection of small differences in sharp signals. 
The integrals of all 1H NMR signals were obtained and evaluated using univariate analysis and 
the statistically significant variations (p<0.05) were summarized in Table 6.1. The variations 
validated through univariate analysis included the increases in pre-PTD for allantoin, 
acetoacetate, glucose, choline, serine, threonine, N-acetyl group (possibly associated glycoprotein 
resonances), -hydroxybutyrate and a broad signal at 0.92 ppm (the latter two registering the 
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most significant increases), as well as 3 unassigned signals (Table 6.1). On the other hand, 
significantly decreases in pre-PTD were registered for the amino acids isoleucine, leucine, alanine, 
lysine, glutamine, histidine, methionine, phenylalanine, tyrosine, formate and 2 unassigned 
signals (registering the most significant decreases) (Table 6.1). 
 
Table 6.1 - Significant metabolite variations (p<0.05) noted in 2nd trimester human AF samples of 
pre-PTD relative to healthy controls. a, signal within the metabolite spin-system chosen for 
integration; all variations measured in CPMG spectra except *, measured in standard spectra. s, 
singlet; d, doublet; t, triplet; m, multiplet; br, broad signal. ( ), very small changes corresponding to 
magnitude (mean fold change) values >1.0 and <1.05. 
metabolite 
1
H 
a
 
direction and magnitude 
of change 
p-value 
acetoacetate 2.27 (s)  1.1 2.58×10
-2
 
alanine * 1.47 (d)  1.1 2.08×10
-2
 
allantoin * 5.39 (s)  1.4 2.19×10
-3
 
-hydroxybutyrate 2.38 (m)  1.1 8.29×10
-4
 
choline 3.19 (s)  1.1 6.77×10
-3
 
formate * 8.45 (s)  1.1 2.17×10
-2
 
glucose 5.23 (d)  1.2 1.44×10
-3
 
glutamine * 1.45 (m)  1.1 4.93×10
-2
 
histidine * 7.83 (s)  1.1 2.17×10
-2
 
Isoleucine * 1.00 (d) () 1.0 1.56×10-2 
leucine * 0.95 (t)  1.1 3.48×10
-2
 
lysine * 1.72 (m) () 1.0 4.43×10-2 
methionine 2.64 (t)  1.1 5.61×10
-3
 
phenylalanine * 7.42 (m) () 1.0 2.52×10-3 
serine 3.95 (m)  1.1 2.42×10
-2
 
threonine 4.26 (m)  1.1 2.86×10
-2
 
tyrosine * 6.91 (d)  1.1 8.24×10
-3
 
valine * 1.03 (d) () 1.0 1.29×10-2 
Possibly glycoprotein related: 
   N-acetyl 2.03 (s)  1.1 6.44×10
-3
 
0.85 ppm 0.85 (br)  1.2 5.26×10
-3
 
0.92 ppm 0.92 (br)  1.1 3.63×10
-4
 
Unassigned:   

  
 1.10 ppm * 1.10 (d) () 1.0 3.08×10-3 
1.22 ppm * 1.22 (m)  1.1 1.39×10
-2
 
1.80 ppm 1.80 (br)  1.1 3.20×10
-4
 
3.11 ppm 3.11  1.2 1.92×10
-5
 
7.87 ppm 7.87  1.9 2.58×10
-2
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Comparing the results obtained in the present work with those from an early stage involving 
less sample numbers (not shown) (      et al., 2010), the only common metabolites variations 
detected were the increase in allantoin and decrease in alanine. Moreover, the significant 
decreases in citrate and myo-inositol observed previously were not found in the present study, 
possibly due to the use of an increased number of samples. Some of the significant metabolite 
variations (p<0.05) obtained in the present study were also expressed in the box-plots shown in 
Figure 6.4.  
 
 
Figure 6.4 - Box-plots of selected 1H NMR signals from metabolites registering significant variations 
in pre-PTD (n=18) relative to control group (n=90). 
 
The distribution of integrals for controls and pre-PTD of alanine, leucine and valine show some 
overlap (Figure 6.4), with a similar trend observed for histidine, isoleucine and lysine indicating 
only slight differences in the levels of these metabolites between groups. Clear decreases in 
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methionine and phenylalanine in the pre-PTD cases were observed when compared with controls 
(Figure 6.4). The pre-PTD cases showed an average increase in the content of allantoin when 
compared with control group. However, 4 out of 90 control samples also registered high allantoin 
levels being noted as outliers in the corresponding box-plot (Figure 6.4). Allantoin is a product of 
oxidation of uric acid and can be regarded as a marker of oxidative stress (Tolun et al., 2010). 
Therefore, extrinsic effects linked to diet or life style may have resulted in higher values of 
allantoin in the control samples. 
 
6.1.2. UPLC-MS profiling for comparison of control and pre-PTD groups 
 
The AF samples from control and pre-PTD were analysed by UPLC-MS using the conditions 
previously described in chapter 3 (section 3.5, pages 77-79).  
No separation was observed in PCA scores scatter plots (not shown) which motivated the 
application of PLS-DA to the data sets. Class separation was then obtained for the data sets 
HSS/ESI+ (Pareto scaled) (Figure 6.5a), HILIC/ESI+ (Log transformed) (Figure 6.5a) and HSS/ESI- (Log 
transformed) (not shown). A list of parameters from the PLS-DA and OPLS-DA UPLC-MS models, 
where separation between control and pre-PTD was observed is shown in Table 6.2. 
 
 
Figure 6.5 - Scores scatter plots for PLS-DA and OPLS-DA UPLC-MS models of control (, n=26) 
vs pre-PTD (Δ  n=11): a) HSS/ESI+ (Pareto scaled), b) HILIC/ESI+ (Log transformed). 
 
 
Table 6.2 - Parameters from control vs pre-PTD PLS-DA and OPLS-DA models from UPLC-MS data. 
UPLC detection scaling or PLS-DA model parameters OPLS-DA model parameters 
column mode transformation R²X R²Y Q² LV R²X R²Y Q² LV 
HSS ESI
+
 Pareto 0.162 0.856 0.387 2 0.162 0.856 0.460 2 
HSS ESI
-
 Log 0.122 0.929 0.296 2 0.122 0.929 0.282 2 
HILIC ESI
+
 Log 0.351 0.899 0.353 3 0.275 0.795 0.031 2 
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MCCV was performed for all separating models as illustrated in Figure 6.6 for the PLS-DA 
model of HSS/ESI+ (Pareto scaled) data set. Mostly overlapped Q2 distributions of true and 
permuted classes models were obtained for the PLS-DA model of HSS/ESI+ (Pareto scaled) data 
set, with a small tendency of separation being observed (Figure 6.6). The ROC plot revealed 
separation between true and permuted class models and average specificity values of 84%, with 
an associated low average sensitivity of only 38% (Figure 6.16). The models from HSS/ESI- and 
HILIC/ESI+ data sets registered similar MCCV results (not shown). The sensitivity values were 
superior to those registered for 1H NMR models (around 20%), but still indicating a very low 
predictive power of the UPLC-MS models.  
 
 
Figure 6.6 - MCCV results for UPLC-MS PLS-DA model of control vs pre-PTD of HSS/ESI+ (Pareto scaled). 
The average sensitivity, specificity and classification rate (CR) for the true class models are shown in 
the ROC plot. 
 
The classification rates registered in UPLC-MS models were much lower (71–75%) then those 
registered by 1H NMR models (84-86%), raising the need for tentative further improvement, for 
instance using larger sample numbers. Bearing in mind that any eventual metabolite changes 
found through loadings analysis are merely indicative and do not bear any predictive power in the 
current study, loadings interpretation was performed using the procedure described previously in 
chapter 5 (section 5.1.3, pages 134-135), and several features were identified from which 38 
registered significant variations (p<0.05) in pre-PTD cases. From these features, 10 features could 
be assigned (Table 6.3). Small decreases were noted in histidine, isoleucine/leucine, methionine, 
phenylalanine and valine, together with an increase in the sodium adduct of an hexose MS 
feature 203.05 m/z (probably arising from glucose, since this is the most abundant 
monosaccharide in human AF), (Table 6.3). These variations were also observed by 1H NMR, as 
shown in the previous section (Table 6.1, page 165).  
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Table 6.3 - List of assigned significant UPLC-MS features obtained for 2nd trimester AF of pre-PTD group 
compared to the control group. Feature intensities are indicated as: very high (>105), high (>104, <105), 
low (>103, <104) and very low (<103). a fragment; b adduct; c isotope of the molecular peak or adduct. 
Metabolite 
UPLC 
column 
detection 
mode 
m/z 
RT 
(min.) 
feature 
intensity 
PLS-DA  
model 
Direction and 
fold change 
p-value 
hexose HSS ESI
+
 203.05
b
 0.5 very high Pareto  1.4 2.0410-03 
 HSS ESI
+
 383.12 0.5 Low Pareto    
isoleucine/leucine HSS ESI
+
 133.09
c
 1.9 Low Pareto  1.3 5.4510-03 
methionine HSS ESI
+
 150.05 1.0 high Pareto  1.3 4.2610-04 
 HSS ESI
+
 133.02
a
 1.0 high Pareto    
 HSS ESI
+
 104.04
a
 1.0 Low Pareto    
phenylalanine HSS ESI
+
 167.08
c
 2.9 high Pareto  1.1 1.3710-03 
valine HSS ESI
+
 118.07 0.9 high Pareto  1.2 4.8510-03 
histidine HSS ESI
-
 309.98
b
 0.8 Low Log  1.7 6.7210-04 
phenylalanine HILIC ESI
+
 210.05
b
 4.8 Low Log  1.6 1.1810-02 
 
Other 1H NMR detected variations such as those of alanine, allantoin, choline, -
hydroxybutyrate, acetoacetate, formate and serine were not detected by UPLC-MS probably due 
to their poor chromatographic retention under the conditions used. Tyrosine and threonine were 
also not detected by UPLC-MS as varying significantly, possibly due to the difference in the sample 
numbers used, rather that due to chromatographic retention issues, since these amino acids are 
well retained under the HSS chromatography conditions used. A list of 28 features with significant 
variation in pre-PTD subjects (p<0.05) for which no assignments were possible at this stage was 
also obtained (see Annex VI - Lists of UPLC-MS unassigned features detected in AF). The 
occurrence of such variations may indicate the presence of more significantly affected 
metabolites, which should be investigated in future studies. In fact a large family of compounds 
has been shown to be associated with the occurrence of PTD, including several amino acids, 
sugars and organic acids, detected by a combination of LC-MS and GC-MS approaches, which 
were not detected in the present study (Romero et al., 2010). However, the low predictive power 
of UPLC-MS models should be improved as well, for instance by increasing the number of cases, 
which should lead to the identification more significant metabolite variations. 
 
6.1.3. MIR profiling for comparison of control and pre-PTD groups 
 
MIR spectra were acquired for pre-PTD AF samples (n=14) and control samples (n=40). PLS-DA 
models were then obtained considering the spectral regions previously introduced in chapter 5 
(3000-2800 cm-1, 1800-1200 cm-1 and 1200-900 cm-1 before and after 2nd derivative 
transformation). Separation was only obtained when the spectral region of 1200-900 cm-1 was 
considered after 2nd derivative transformation (Figure 6.7a).  
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Figure 6.7 - PLS-DA scores scatter plot of pre-PTD (, n=14) vs control (○  n=40) of 2nd derivative of 
1200-900 cm-1 spectral region using 3 technical sample replicates: a) scores scatter plot; b) LV1 
loadings plot coloured by VIP. 
 
The MCCV of the 2nd derivative 1200-900 cm-1 PLS-DA model revealed some tendency in 
separation of Q2 distributions of true and permuted class models (Figure 6.8).  In fact, 70% of true 
class models registered Q2>0.2, while permuted classes models Q2 values spanned from -1 to 0.6 
with the most frequent value being Q2=0, i.e. permuted classes were largely non predictive, as 
expected (Figure 6.8, left). The ROC plot shows that true class models registered sensitivity values 
in the range 30% to 70% (average 41%) and specificity values >80% (average 87%) (Figure 6.8, 
right). Despite the spread in sensitivity values, the PLS-DA model of the MIR of the 2nd derivative 
of 1200-900 cm-1 region has, apparently, an improved predictive ability when compared with 
UPLC-MS and 1H NMR PLS-DA models of controls vs pre-PTD. However, the true class models of 
MIR data were characterized by a classification rate of 75%. Once more, a low value that may be 
increased perhaps using larger sample numbers. 
 
 
Figure 6.8 - MCCV results for the MIR PLS-DA model of control (n=40) vs pre-PTD (n=14) 2nd 
derivative 1200-900 cm-1 region: Q2 distributions (left) and ROC plot (right) of true and permuted 
class models. The average sensitivity, specificity and classification rate (CR) for the true class 
models are shown in the ROC plot. 
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The loadings of the LV1 of 2nd derivative 1200-900 cm-1 PLS-DA model presented in Figure 6.7b 
indicate the variation the bands 1039 and 1122 cm-1. Considering the 2nd transformation of the 
data set, the negative LV1 direction indicates a decrease of these two bands in pre-PTD relative 
control. Both 1122 cm-1 and 1039 cm-1 bands, which were not found in previous MIR studies 
involving biofluids, occur in the region of C-C and C-O stretching vibrations (Pretsch et al., 1989). 
This region of 1200-900 cm-1 has been used for the quantification of lactate and glucose in AF in a 
previous MIR study of preterm infection, fetal distress, and fetal lung maturity (Liu and Mantsch, 
1999). However, several compounds such as organic and amino acids, sugars and proteins exhibit 
vibrations absorbing in the same region. 
 
6.1.4. STOCSY and SHY analysis of pre-PTD cases 
 
6.1.4.1. UPLC-MS/1H NMR SHY analysis 
     
SHY correlation analysis was performed by correlating the MS relevant features obtained from 
the UPLC-MS PLS-DA control vs pre-PTD models and the full CPMG 1H NMR of the pre-PTD AF 
samples as described in chapter 3 (section 3.7, page 83). The significant correlations obtained are 
summarized in Table 6.4. 
 
Table 6.4 - List of UPLC-MS/1H NMR SHY correlations between the AF MS features (shown in Table 6.3) 
and AF 1H NMR spectra of pre-PTD. Only maximum or minimum correlations values |r|0.70 and 
(p<0.001) were considered. Assigned spin-systems are indicated in bold. *variation relative to control 
group. 
metabolite m/z 
direction of 
variation* 
RT 
(min) 
1
H NMR resonances 
correlated positively to  
MS feature / ppm 
1
H NMR resonances 
correlated negatively to  
MS feature / ppm 
histidine 309.98  0.8 unknown: 6.67 unknown: 2.19 
methionine 150.05  1.0 - glucose: 3.23(dd), 5.23(d) 
     
histidine: 7.82(s) 
phenylalanine 167.08  2.9 - unknown: 3.18, 5.67 
 
No UPLC-MS/1H NMR positive correlations were found between the MS detected metabolites 
and their respective 1H NMR resonances (auto-correlations) as it should be expected. This may 
possibly justified, at least partially, by the low number of samples used (n=11) which is a known 
issue in the quality of the correlation calculation (Camacho et al., 2005). However, negative 
correlations were registered between methionine MS feature (decreased in pre-PTD) and the 
glucose spin-system, indicating their concomitant opposite variations, which seems to be in 
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agreement with their variation identified in 1H NMR. An inverse variation was also observed 
between methionine MS feature and a signal from histidine. It is interesting to note that despite 
the decrease in histidine and methionine in pre-PTD relative to control group, apparently these 
two metabolites vary in opposite directions within the pre-PTD group (Table 6.4), which could be 
interpreted as specific metabolic/physiologic relationship in connection with PTD. Some 
unassigned NMR resonances were also found to correlate with MS features (Table 6.4). 
 
6.1.4.2. MIR STOCSY analysis 
 
MIR intra-correlation analysis was performed using the pre-PTD spectra, in order to further 
explore the origin of the relevant LV1 loadings bands from the 2nd derivative 1200-900 cm-1 region 
PLS-DA model (1039 and 1122 cm-1). The 1750-900 cm-1 expansion of the intra-correlation STOCSY 
map obtained for pre-PTD MIR spectra is shown in Figure 6.9, where the vertical lines mark the 
positions of the bands at 1039 and 1122 cm-1. 
 
Figure 6.9 - MIR spectra (1750-900 cm-1) intra-correlation STOCSY map for the pre-PTD group (n=14), 
with correlation threshold |r|>0.8 and p<0.001. Dashed vertical lines indicate the bands of interest 
identified through loadings analysis and their correlations across the 1750-900 cm-1 spectral region. 
 
The correlation map shows firstly that both bands 1122 cm-1 and 1039 cm-1 are not correlated, 
meaning they should correspond to distinct metabolites. The significant correlations found along 
the vertical lines (Figure 6.9) are listed in Table 6.5, together with their possible assignment.  
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Table 6.5 - List of MIR intra-correlations and from STOCSY analysis of pre-PTD spectra. 
MIR bands (cm⁻¹) 
change vs 
controls 
        MIR/MIR correlations (cm
-1
) 
positive correlations negative correlations 
1122 (C-C/C-O) 
1589 (asCOO
-
); 
1424, 1416 (sCOO
-
); 
1647, 1660 (Amide I) 
1039 (C-C/C-O)  1408 (sCOO
-
); 1134 (C-C/C-O) - 
 
In this way the band at 1122 cm-1 was found positively correlated to the asymmetric           
(1589 cm-1) and symmetric (1424, 1416 cm-1) stretching bands of carboxylate groups suggesting a 
possible connection to carboxylate containing metabolites such as organic and amino acids 
(Pretsch et al., 1989; Liu and Mantsch, 1999) (decreasing in pre-PTD) (Table 6.4). Interestingly the 
same 1122 cm-1 band was found anti-correlated to the bands at 1647 and 1660 cm-1 both 
belonging to the protein Amide I region (Pretsch et al., 1989; Liu and Mantsch, 1999) (Figure 6.9 
and Table 6.5), thus suggesting an inverse relation with the protein content, which seems to be in 
agreement with the 1H NMR results which indicated an increase in glycoprotein signals (Table 6.1, 
page 165). In addition, the band at 1039 cm-1 correlated only positively with the band at           
1408 cm-1, (symmetric stretching of carboxylate group) and also positively with the 1134 cm-1     
(C-C/C-O stretching vibration) (Pretsch et al., 1989), thus indicating possible relations to organic 
acids found decreasing in pre-PTD.  
 
6.1.4.3. MIR/1H NMR SHY analysis 
 
Further analysis was pursued using MIR/1H NMR SHY analysis. A MIR/1H NMR SHY map was 
calculated by correlating the MIR 1200-900 cm-1 spectral region to the full range of standard 1H 
NMR spectra (0-10 ppm) for pre-PTD samples (Figure 6.10). All the significant correlations 
identified in SHY analysis are listed in Table 6.6.  
The 1039 cm-1 band correlated positively with amino acids resonances namely of alanine, 
isoleucine, leucine, histidine, lysine, phenylalanine, proline, threonine, tyrosine, valine, and also 
with -oxoisovalerate, citrate and glucose (Figure 6.10, Table 6.6). In addition, negative 
correlations with resonances in the regions of the 1H NMR spectrum corresponding to CH3 groups 
(Figure 6.10) were observed. On the other hand no significant correlation was registered for band 
1122 cm-1 (Figure 6.10), meaning that this band may be related to compounds present in 
concentrations below the NMR detection limit but which can be detected by MIR, or to 
compounds with no 1H NMR visible protons or absent of protons, such as an inorganic ion.  
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Figure 6.10 - Statistical heterospectroscopy (SHY) maps of MIR (1200-900 cm-1) / 1H-NMR (0-10 ppm) 
with correlation threshold of |r|>0.7 and p<0.001 for the pre-PTD group (n=14). Dashed horizontal 
lines indicate the bands of interest identified through loadings analysis and their correlations across 
the NMR 0-10 ppm region. 
 
Table 6.6 - List of MIR/1H NMR SHY correlations obtained between MIR 1200-900 cm-1 spectral region 
and the standard 1H-NMR (0-10 ppm) spectra of pre-PTD. 
MIR bands (cm⁻¹) 
change 
vs 
controls 
Positively correlated 
1
H-NMR 
signals 
Negatively correlated 
1
H-NMR 
signals 
1039 (C-C/C-O) 
-oxoisovalerate, citrate, glucose, 
Ala, Ile, Leu, His, Lys, Phe, Pro, Thr, 
Tyr, Val 
CH3 groups  
(in 0.08-0.79 ppm range) 
 
The positive correlation between the amino acids, citrate and -oxoisovalerate resonances 
and 1039 cm-1 band in pre-PTD (found decreasing when compared to controls) seems to be in 
agreement with the decreases of those metabolites in pre-PTD group when compared to controls, 
as observed previously by 1H NMR and UPLC-MS. Glucose, found positively correlated with      
1039 cm-1 band, seems to vary in a different direction in pre-PTD (a decrease) when compared 
with the its increase relative to controls detected by 1H NMR and UPLC-MS. This apparent 
contradiction may be justified by the fact that the most intense glucose bands occur in the region 
of 1065-1000 cm-1. Therefore, the positive correlation observed at 1039 cm-1 may simply result 
the positive correlation of glucose signals of both MIR and 1H NMR spectral domains. However, 
there is also the possibility that the 1039 cm-1 band results from a different compound, whose 
vibrations overlap with those of glucose, or that this compound contains no 1H NMR visible 
protons or is absent of protons, such as an inorganic ion. 
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6.1.5. Proposed interpretation of the metabolite variations in pre- PTD cases 
 
The multivariate analysis of 1H NMR, UPLC-MS and MIR data sets from control and pre-PTD 2nd 
trimester AF samples have led to PLS-DA models generally characterized by low predictive ability, 
which could be in principle improved by the use of a larger number of pre-PTD samples. 
Nevertheless, the careful analysis of such models provided a metabolite signature of possible 
early markers of PTD. This includes a small decrease in the amino acids alanine, isoleucine, 
leucine, glutamine, histidine, lysine, methionine, phenylalanine, proline, tyrosine and valine a well 
as a decrease in formate, -oxoisovalerate and citrate in pre-PTD cases. These variations were 
also accompanied by small increases in glucose, acetoacetate, -hydroxybutyrate, allantoin, 
choline, serine, threonine and proteins (including glycoproteins). Regarding the possible origin of 
the decreases of these amino acids, decreases in isoleucine have been reported in 2nd trimester 
AF of pre-PTD subjects (Ramón Y Cajal et al., 2007). In addition, significant fluxes of methionine 
and phenylalanine were observed after nutrient administration in PTD newborns when compared 
with term newborns (Thomas et al., 2008). Also glutamine, a non-essential amino acid, can 
become conditionally essential in preterm low-birth-weight newborns after administration of 
amino acids up to 90 hours after birth (Kadrofske et al., 2006). The decreases in the amino acids 
alanine, isoleucine, leucine, glutamine, histidine, lysine, methionine, phenylalanine, proline, 
tyrosine and valine could then indicate an early perturbation of the fetal-placental unit which 
plays a key role in amino acid transfer (Cetin, 2001). On the other hand, the increase noted in the 
essential amino acid threonine is not easily justifiable, especially in a context of decreases in most 
amino acids as observed previously. One possible explanation could be an increased need of 
threonine for protein synthesis as suggested by the increased incorporation of threonine in 
enteric tissues observed in preterm newborns after feeding (van der Schoor et al., 2007).  
Allantoin can be regarded as a non-enzymatic oxidation product of uric acid in humans 
(Shestopalov et al., 2006; Tolun et al., 2010). Therefore, the increase in allantoin noted in pre-PTD 
group suggests the possibility of occurrence of oxidative stress mediated by reactive oxidation 
species (ROS) (Wall et al., 2002). In fact, increased allantoin levels have been found in plasma and 
bronchoalveolar lavage fluid of preterm newborns who developed chronic lung disease when 
compared with healthy preterm newborns (Ogihara et al., 1998).  
The increase in glucose for the pre-PTD group may indicate hyperglycaemia, a condition that 
has been found in very low birth weight infants, which in turn is a condition associated with 
prematurity and other risk factors (Beardsall et al., 2010). Also the increases in ketone bodies -
hydroxybutyrate and acetoacetate noted in pre-PTD (by 1H NMR) can indicate deficient glucose 
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utilization and the need for alternative energetic substrates, also compatible with hyperglycaemic 
states such as does occurring in diabetes (Murray et al., 2003). However, no clinical indications of 
hyperglycaemia or diabetes have been found in the newborns corresponding to the pre-PTD cases 
studied, which complicates the interpretation of this finding.  
Choline, which was found increased in pre-PTD AF samples, was also found increased in 2nd 
trimester maternal urine samples (Diaz et al., 2011), thus suggesting accumulation of choline in 
both intra and extra-placental environments. Choline is metabolically connected to methionine 
(decreased in pre-PTD) and folate metabolism (Zeisel, 2006). Formate, decreased in pre-PTD, is in 
turn related to folate metabolism through formyltetrahydrofolate (Murray et al., 2003). 
Therefore, these variations in pre-PTD seem to suggest early perturbations of these metabolic 
pathways. There is also a metabolic connection between serine (increased in pre-PTD) and folate 
metabolism (Murray et al., 2003), thus establishing a possible link between the variation of serine 
and that of choline and formate. 
Finally, the increase in N-acetyl signals (seen by 1H NMR and by MIR intra-correlations) may 
possibly indicate high glycoprotein content in the pre-PTD group. In fact, the most abundant AF 
glycoprotein, transferrin, has been related to PTD in a previous report in relation to 
oligohydramnios and the occurrence of maternal anaemia, both conditions also associated with 
the occurrence of PTD (Gao et al., 2008). Another study regarding proteomic analysis of 3rd 
trimester AF found high levels of other proteins including another AF glycoprotein, -1-
microglobulin, in relation to PTD in the absence of intra-amniotic infection and also transferrin in 
relation to PTD with intra-amniotic infection (Bujold et al., 2008). However, identification of the 
glycoproteins underlying the variations observed in this study would require the use of 
proteomics methodologies, which was outside the scope of the present work. 
 
6.2. Analysis of 2nd trimester amniotic fluid composition for the prediction PE, IUGR and 
GDM (pre-PE, pre-IUGR groups, pre-diagnostic GDM) 
 
The following sections describe the results from the analysis of 2nd trimester AF metabolite 1H 
NMR and MIR profiles of preeclampsia (pre-PE), intrauterine growth restriction (pre-IUGR) and 
pre-diagnostic GDM cases when compared to a control group. UPLC-MS results were only 
obtained for pre-diagnostic GDM.  
In order to reduce the imbalance between pre-PE (n=9), pre-IUGR (n=8) and control groups in 
MVA of 1H NMR profiling data, a smaller group of control samples (n=40) was used (the same 
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group of control samples used for MIR analysis). Due to the reduced numbers of pre-PE and pre-
IUGR cases the respective profiling studies were still largely exploratory. 
 
6.2.1. 1H NMR and MIR profiling for comparison of control and pre- PE groups 
 
The 1H NMR spectra collected for comparison of control (n=40) and pre-PE (n=9) cases were 
analysed using PLS-DA, since no separations or trends were observed in PCA analysis. Separation 
tendencies were observed in the PLS-DA scores scatter plots for standard spectra (Figure 6.11a) 
and a complete separation was obtained for CPMG spectral data (Figure 6.11b). The diffusion-
edited spectra originated a PLS-DA model with Q2<0.2 (obtained from 7-fold CV), too low to be 
considered for further analysis (not shown).  
 
Figure 6.11 - Scores scatter plots from PLS-DA models of 1H NMR spectra 2nd trimester AF 
of control (■, n=40) and pre-PE (, n=9) groups: a) standard spectra, b) CPMG spectra. 
 
The MCCV results obtained for standard and CPMG models are shown in Figure 6.12. Both 
standard and CPMG data sets showed largely overlapped Q2 distributions of true and permuted 
class models, although with a small tendency for the separation of both distributions (Figure 
6.12a,b, left). However, the remaining MCCV parameters obtained for standard (85% classification 
rate, 0-40% sensitivity, average 95% specificity) (Figure 6.12a, right) and CPMG (89% classification 
rate, average 40% sensitivity and 100% specificity) (Figure 6.12b, right), demonstrate that the 
latter shows better performance, despite the still low predictive ability registered. In order to 
explore any possible variations occurring in pre-PE group, the PLS-DA loadings of the CPMG model 
were considered (Figure 6.13). 
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Figure 6.12 - MCCV results for PLS-DA models for a) standard and b) CPMG 1H NMR AF spectra of 
control (n=40) and pre-PE (n=9) groups. Q2 distributions (left) and ROC plots (right) of true classes 
and permuted classes models are shown. The average sensitivity, specificity and classification rate 
(CR) for the true class models are shown in the ROC plots. 
 
 
Figure 6.13 - Loadings from the PLS-DA models of CPMG spectra from control vs pre-PE colour-coded 
with VIP values. Amino acids in three-letter code; unassigned signals are indicated with their 
respective chemical shift values.  
 
 The resonances of lactate, glutamine, threonine, proline, unassigned spin-system 2.92 and 
3.15 ppm, and unassigned resonances 7.15 and 7.87 ppm were found increased in pre-PE cases 
(Figure 6.13). Conversely, the resonances of adipate and unassigned resonance 0.89 ppm were 
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found decreasing in pre-PE cases compared with controls (Figure 6.13). Peak integration and 
univariate analysis confirmed the statistical significance of such variations (p<0.05) (Table 6.8). 
The significant variations detected comprised those of adipate (decreasing in pre-PE), glutamine, 
proline and threonine, all increased in pre-PE (Table 6.8).  
 
Table 6.8 - List of significant metabolite variations (p<0.05) noted in 2nd trimester human 
AF samples of pre-PE relative to control group. a, signal within the metabolite spin-system 
chosen for integration; m, multiplet. 
metabolite 
1
H 
a
 
direction and 
magnitude of change 
p-value 
adipate 1.54 (m)  1.3 1.24×10
-4
 
glutamine 2.45 (m)  1.2 3.61×10
-2
 
proline 2.01 (m)  1.1 4.13×10
-3
 
threonine 4.26 (m)  1.2 2.23×10
-2
 
Unassigned 
    2.99 ppm 2.99 (m)  1.6 4.70×10
-2
 
3.78 ppm 3.78  1.2 5.97×10
-3
 
3.77 ppm 3.77  1.1 7.13×10
-3
 
3.97 ppm 3.97  1.2 2.04×10
-2
 
3.98 ppm 3.98  1.2 1.63×10
-2
 
7.37 ppm 7.37  1.2 1.00×10
-2
 
7.87 ppm 7.87  2.5 7.78×10
-3
 
 
The variations detected in 2nd trimester AF in the present study were not consistent with those 
obtained in a previous 1H NMR study, which compared 3rd trimester AF samples from PE affected 
cases (n=7) and controls (n=36) using univariate analysis of a few integrated resonances (Bock, 
1994). In the latter, significant decreases in the contents of acetate, choline, succinate and 
possibly citrate were found in the PE affected group (Bock, 1994). Bearing in mind that only a 
small number of PE cases were used (n=7), as in the present study (n=9), both studies must be 
considered as largely exploratory, thus requiring further improvement with the use of increased 
sample numbers. 
Metabolite variations were observed in connection to pre-PE found in 2nd trimester AF in other 
studies such as the decreases in palmitic acid (Witkin et al., 2012) and increases in oxidative stress 
marker F₂-isoprostane (Wang et al., 2011a). These metabolites are usually present in sub-M 
concentrations and, therefore, the absence of variation of such molecules 1H NMR spectra is not 
surprising. Protein changes have also been observed in 2nd trimester AF in connection with the 
later occurrence of PE, such as the elevated levels of matrix metalloproteinase-2 and respective 
inhibitors (Lavee et al., 2009), elevated levels of oxidized transthyretin (Vascotto et al., 2007) and 
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the over-expression of proteins albumin and apolipoprotein A-1 (Oh et al., 2012). However, 
protein identification using 1H NMR is very limited, as previously discussed in chapter 4 (section 
4.3.2, pages 108-110).   
No associations were found between the decrease noted in adipate and PE, which leads to no 
conclusions regarding its variation. Regarding the amino acids variations, increases in maternal 
serum and cord blood amino acid concentrations have been reported for PE cases, from which 
glutamine, proline and threonine were significantly increased in maternal blood, and also proline 
in cord blood when compared with controls (Evans et al., 2003). Other amino acids variations 
were found in maternal blood in PE cases, such as a reduced glutamine (Hsu et al., 2005), 
increased only in phenylalanine (Glew et al., 2004), or only increases in histidine (Turner et al., 
2008). The different results obtained in those studies seem to reflect the different sampling 
procedures used, which makes it difficult to correlate with variations observed here in AF.  
Despite the many alterations observed in AF, maternal and cord blood, a more complete 
understanding of the biochemical interrelationship between maternal and fetal side in PE would 
benefit from improved AF analysis. In order achieve this goal, improved 1H NMR based models 
with larger sample sizes should be considered as a further approach in the study of PE as a 
complement to other approaches using maternal plasma/serum and urine.    
  
Regarding the MIR data, no apparent differences were found by visual comparison between 
MIR spectra representative of pre-PE (n=9) and controls (n=40). Also a complete overlap between 
both groups was obtained in PCA scores plots of the 3000-2800 cm-1, 1800-1200 cm-1, 1200-900 
cm-1 spectral regions and 2nd derivative of 1200-900 cm-1 region (not shown). However, apparent 
separations were observed in the PLS-DA scores plot of 2nd derivative transformed 1200-900 cm-1 
region, although with a very low Q2 value (<0.2) (Figure 6.14). 
 
Figure 6.14 - Scores scatter plot of MIR PLS-DA model of the 2nd derivative 
of 1200-900 cm-1 region for control (, n=40) vs pre-PE (, n=9). 
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Despite the apparent tendency noted, MCCV results showed model with complete overlap of 
true and permuted class models in Q2 distributions and ROC plots (not shown), meaning no 
distinctions were found between true and permuted models. Therefore, the models were non-
predictive.  
The absence of predictive ability of MIR models is not surprising, given the poor predictive 
ability obtained in the respective 1H NMR models. Because the MIR spectrum is dominated by the 
most abundant AF components, namely glucose, lactate, proteins and some amino acids, these 
metabolites may mask the variation of less abundant metabolites, as noted in the previous 
chapter. Another important issue is the reduced number of samples composing the pre-PE group 
(n=9). Therefore, increasing sample size should, in principle, increase the models predictive ability 
of MIR analysis. 
 
6.2.2. 1H NMR and MIR profiling of pre- IUGR cases 
 
The PLS-DA scores of 1H NMR spectra of controls and pre-IUGR cases, representing the best 
results in terms of class separation are shown in Figure 6.15. 
 
Figure 6.15 - Scores scatter plots from PLS-DA of 1H NMR spectra 2nd trimester AF of 
pre-IUGR (○, n=8) and healthy controls (■, n=40): a) standard spectra, b) CPMG spectra. 
 
Indeed, a complete separation of pre-IUGR and control groups was obtained for PLS-DA model 
of CPMG spectra (Figure 6.15b), whereas only a separation tendency was obtained for the PLS-DA 
model of standard spectra (Figure 6.15a). The PLS-DA model obtained from diffusion-edited 
spectra was associated with a low Q2value (<0.2) and, therefore, not considered for further 
analysis. The MCCV analysis performed for the standard and CPMG PLS-DA models revealed also 
models associated with very low predictive ability. In fact, both standard and CPMG PLS-DA 
models showed completely overlapped Q2 distributions, as well as sensitivities below 20%, 
resulting in very low true positive rates. Figure 6.16 illustrates the MCCV results obtained for the 
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CPMG model. Due to the lack of predictive ability, the models loadings were not considered at 
this stage. 
 
Figure 6.16 - MCCV results for PLS-DA models for CPMG 1H NMR AF spectra of controls (n=40) 
and pre-IUGR (n=8). Q2 distributions (left) and ROC plots (right) of true classes and permuted 
classes models are shown. The average sensitivity, specificity and classification rate (CR) for the 
true class models are shown in the ROC plot. 
 
The PLS-DA analysis of MIR spectra from control (n=40) and pre-IUGR (n=8) groups showed an 
apparent separation, only observed in the 2nd derivative transformed 1200-900 cm-1 data set 
(Figure 6.17). However, the MCCV analysis of the PLS-DA model revealed a complete overlap of 
true and permuted class models in Q2 distributions and ROC plots (not shown) hence confirming 
the absence of predictive ability. 
 
Figure 6.17 - Scores scatter plot of MIR PLS-DA models of the 2nd derivative of 
1200-900 cm-1 region of control (, n=40) vs pre-IUGR (○, n=8). 
 
Once more it is important to recall the reduced number of pre-IUGR cases, which may be 
regarded as the main cause of low performance of the 1H NMR and MIR PLS-DA models obtained. 
Nevertheless, several metabolite variations noted in maternal and fetal blood plasma were found 
in connection with IUGR (Cetin et al., 1996; Marconi and Paolini, 2008; Favretto et al., 2012). Also, 
AF metabolite variations were found in pre-IUGR, namely increases in the levels of isoprostanes 
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(present in nanomolar concentrations) (Longini et al., 2005), as well as changes in catecholamines 
and respective metabolites (Divers et al., 1981); and also in 3rd trimester AF such increased levels 
of phosphatdylglycerol (Gross et al., 1982); and increases in nitric oxide (Di Iorio et al., 1997). All 
these metabolites are present in AF in low concentration (not being detected by 1H NMR and 
MIR), therefore further research using enlarged sample sizes and possibly more sensitive 
analytical methods, namely UPLC-MS, should be employed to improve the predictive ability of AF 
models in relation to IUGR. 
  
6.2.3. Analysis of 2nd trimester amniotic fluid composition for the prediction of GDM (pre-
diagnostic GDM group) 
 
Profiling studies were performed on 2nd trimester AF of pre-diagnostic GDM, compared with 
control group, by 1H NMR (pre-diagnostic GDM, n=35, control, n=90), UPLC-MS (pre-diagnostic 
GDM, n=23, control, n=26) and MIR (pre-diagnostic GDM, n=33, control, n=40). The PLS-DA 
analysis of the 1H NMR, UPLC-MS and MIR data sets resulted in models with separation 
tendencies between the pre-diagnostic GDM and control groups although characterized by low 
Q2<0.3 (not shown). However, the PLS-DA models were not validated by MCCV, showing in 
general large overlaps of true class and permuted class models in Q2 and ROC plots and hence 
were not further explored.  
These results are in general agreement with those obtained in an early stage of this work by 1H 
NMR profiling of 2nd trimester human AF (      et al., 2010), which used reduced sample sizes of 
both control (n=82) and pre-diagnostic GDM (n=27) groups with the corresponding PLS-DA model 
obtained (based on 1H NMR standard spectra) registering Q2=0.269 (based on 7-fold CV), which 
however was not evaluated by MCCV. Several significant metabolite variations were then 
reported including decreases in acetate, creatinine, formate, glycine, proline, serine, taurine, 
glycerophosphocholine and glutamate, together with a marked increase in glucose content in pre-
diagnostic GDM cases (      et al., 2010). In order to verify the occurrence of such variations in 
the present data sets, univariate analysis was performed on the assigned integrals of the 
corresponding 1H NMR signals and MS features (detected by UPLC-MS). The only variation thus 
confirmed was the one regarding glucose, which was expressed both as an increase in glucose 1H 
NMR signals, and also as an increase in the intensity of the hexose-related feature detected in 
UPLC-MS (HSS/ESI+ data set) as 203.05 m/z (sodium+hexose MS adduct) (Figure 6.18). 
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Figure 6.18 - Box-plots illustrating the statistical significant variation of glucose related signals in pre-
diagnostic GDM relative to control: a) integrals of glucose 1H NMR signal of pre-diagnostic GDM (n=35) 
and controls (n=90); b) hexose-related MS feature intensity of pre-diagnostic GDM group (n=23) and 
controls (n=26).  
 
The decrease of glutamate was also confirmed in UPLC-MS data (p=0.03) (MS feature 146.07 
m/z), but not in 1H NMR. The different results obtained for glutamate are certainly due to the 
differences in sample size used in both analytical platforms (1HNMR: pre-diagnostic GDM, n=35 
and control, n=90 vs UPLC-MS: pre-diagnostic GDM, n=23 and control, n=26).  
It seems clear that only glucose is increased consistently in 2nd trimester AF of pre-diagnostic 
GDM subjects, as shown by 1H NMR and UPLC-MS analysis. Glucose increase has been noted 
previously in 2nd trimester AF samples (at around 15 weeks gestation) using larger samples sets of 
both pre-diagnostic GDM (n=52) and control (n=356) (Tisi et al., 2011). Such an increase in glucose 
may result from increased glucose placental transport in GDM cases, which is then thought to 
trigger the fetal insulin production in insulin sensitive tissues (Star et al., 1997). This increase in 
insulin has also been measured in 2nd trimester AF GDM-diagnosed women (Star et al., 1997; Tisi 
et al., 2011). 
Given the pathophysiologic determinants of GDM which are primarily expressed in the 
maternal side, a more fruitful approach would be to focus on the search for early markers in 
maternal blood plasma or urine for instance. In fact, recent metabonomics work performed using 
2nd trimester blood plasma and urine has led to the detections of a possible set of early markers of 
the occurrence of GDM (Diaz et al., 2011), therefore opening a new avenue to explore new 
markers of GDM. 
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6.3. Analysis of 2nd trimester amniotic fluid composition for the prediction of PROM 
(pre-PROM group) 
 
The following sections describe the results from the analysis of 2nd trimester AF metabolite 1H 
NMR and MIR profiles of PROM (i.e., premature rupture of the membranes occurring after 37 g.w. 
prior to the initiation of uterine contractions) (pre-PROM group). Due to constraints in instrument 
availability at the time of analysis, UPLC-MS could not be acquired for pre-PROM samples.  
 
6.3.1. 1H NMR profiling for comparison of control and pre-PROM groups 
 
Standard, CPMG and diffusion-edited 1H NMR spectra obtained for 2nd trimester AF pre-PROM 
samples (n=45) were compared with spectra of matching control samples (n=90) using MVA. No 
separation tendencies were observed in the corresponding PCA scores scatter plots, hence the 
data sets were analysed by PLS-DA. A separation tendency was only obtained in PLS-DA of 
standard (Figure 6.19) whereas in the scores of PLS-DA of CPMG spectra the groups showed 
almost complete separation (not shown), however, the CPMG model registered Q2<0.1, too low 
to be considered. Diffusion-edited spectra originated a model with no separation between 
controls and pre-PROM in the corresponding scores plots, therefore it was also not considered for 
further analysis.  
 
Figure 6.19 - Scores scatter PLS-DA models of 1H NMR standard spectra 
of 2nd trimester AF of control (■, n=90) and pre-PROM (◊, n=45) groups.  
 
The MCCV analysis of standard spectra model from Figure 6.19, showed overlapped Q2 
distributions of true and permuted class models (Figure 6.20, left), and in the ROC plot, the 
sensitivity and specificity for true class models were in the ranges of 20-55% (average 36%) and 
80-90% (average 84%), respectively (Figure 6.20, right), as well as with a classification rate of 67%.  
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Figure 6.20 - MCCV results for PLS-DA models from standard 1H NMR AF spectra of control (n=90) and 
pre-PROM (n=45) groups. Q2 distributions (left) and ROC plots (right) of true classes and permuted 
classes models are shown. The average sensitivity, specificity and classification rate (CR) for the true 
class models are shown in the ROC plot. 
 
The MCCV indicate that the obtained model has no predictive value, and therefore no loadings 
analysis was performed. These results are in agreement with those obtained in an early stage of 
this work where similar groups were considered (pre-PROM (n=34) and control (n=82)) and a 
similar separation tendency was obtained in the PLS-DA scores plots of standard spectra 
(Q2=0.276, not validated by MCCV) (      et al., 2010). Moreover, significant metabolite 
variations were validated by univariate analysis in the previous study namely increases in 
methionine, glutamine and decreases in threonine and in 2 unassigned resonances (not shown). 
In order to verify the occurrence of such variations in the present data sets, univariate analysis 
was performed on the assigned integrals of the corresponding 1H NMR signals. The univariate 
analysis only confirmed the variation of one of the previously unassigned resonances centred at 
3.29 ppm (p=0.01), which means that the results obtained are very sensitive to the samples used. 
Therefore, it is not surprising to obtain 1H NMR models of pre-PROM with no predictive ability. 
 
6.3.2. MIR profiling for comparison of control and pre-PROM groups 
 
Amniotic fluid samples from pre-PROM (n=37) and controls (n=40) were also analysed using 
MIR spectroscopy. Initially, no apparent spectral differences were observed by visual inspection or 
by PCA. From the PLS-DA models obtained, only those from sub-spectral region 3000-2800 cm-1 
and from the 2nd derivative transformed 1200-900 cm-1 region, showed some separation tendency 
(Figure 6.21). Both 3000-2800 cm-1 and 2nd derivative transformed 1200-900 cm-1 spectral region 
PLS-DA models were subjected to MCCV, the results being shown in Figure 6.22. 
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Figure 6.21 - Scores scatter plot of control (, n=40) vs pre-PROM (, n=37) MIR PLS-DA models 
for the spectral regions with 3 technical replicates per sample: a) 3000-2800 cm-1, b) 2nd derivative 
of 1200-900 cm-1 regions. 
 
 
 
Figure 6.22 - MCCV results of MIR PLS-DA models of control (n=40) vs pre-PROM (n=37): a) 3000-2800 
cm-1 region; b) 2nd derivative of 1200-900 cm-1 region. Q2 distributions (left) and ROC plots (right) of 
true classes and permuted classes models are shown. The average sensitivity, specificity and 
classification rate (CR) for the true class models are shown in the ROC plots. 
 
The low predictive ability of the models is expressed by the MCCV results (Figure 6.22), which 
apart from tendencies of separation noted in Q2 distributions of true and permuted class models 
(Figure 6.22, left), register very modest MCCV parameters for both 3000-2800 cm-1 region model 
(69% classification rate, 70% sensitivity, 75% specificity) and for 2nd derivative of 1200-900 cm-1 
region model (62% classification rate, 60% sensitivity, 70% specificity) (Figure 6.22, right). 
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The MIR MCCV results show an improvement in predictive ability, expressed by tendencies of 
Q2 distributions and in sensitivity (true positive rates) when compared with the 1H NMR model 
from the previous section. Therefore, the loadings from PLS-DA models were considered for 
further analysis (Figure 6.23). 
Figure 6.23 - LV1 loadings from PLS-DA model of control (n=40) vs pre-PROM (n=37) for the 2nd 
derivative of 1200-900 cm-1 region. 
 
The whole 3000-2800 cm-1 region, corresponding to C-H stretching vibrations (Liu and 
Mantsch, 1999), containing the 3 maxima indicated in Figure 6.23a, seemed to be increased in 
pre-PROM cases, whereas for the 2nd derivative transformed 1200-900 cm-1 region model, two 
bands at 1122 cm-1 and at 1039 cm-1, were identified in the LV1 loadings as decreased in pre-
PROM cases relative to healthy controls (Figure 6.23b). These vibrations can be attributed to a 
wide range of compounds, namely lactate, proteins, lipids and amino acids, as shown previously 
in the spectral assignments in Figure 5.13 (chapter 5, section 5.1.5, page 139). Further assignment 
of such vibrations was attempted with aid of STOCSY analysis, as discussed in the following 
sections. 
 
6.3.3. Statistical spectroscopy correlation analysis of pre-PROM cases 
 
6.3.3.1. MIR STOCSY analysis 
 
STOCSY analysis was performed using all the pre-PROM samples (n=37). The resultant STOCSY 
intra-correlation map obtained is shown in Figure 6.24. The region 3000-2800 cm-1 did not add 
much more information since only a broad correlation was found along the 3000-2300 cm-1 range, 
and no significant correlations along the remaining spectrum were found (Figure 6.24a).  On the 
other hand, the bands at 1122 and 1039 cm-1 from the LV1 loadings of 2nd derivative PLS-DA 
model showed correlations only in the region of 1750-900 cm-1 (Figure 6.24a, dashed box) shown 
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in detail in Figure 6.24b. The significant correlations were searched along vertical dimension of 
the intra-correlation map 1750-900 cm-1 expansion (Figure 6.24b, Table 6.9).  
Figure 6.24 - MIR STOCSY map for the pre-PROM group (n=37): a) region 3000-900 cm-1; b) 1750-900 
cm-1 spectral expansion. Correlation threshold of |r|>0.8 and p<0.001 was used. Dashed vertical lines 
indicate the bands of interest identified through loadings analysis and their correlations across the 
1750-900 cm-1 spectral region. 
 
Table 6.9 - Correlations found in the MIR intra-correlations correlation maps obtained using pre-PROM 
spectra (Figure 6.24). The main MIR bands affected in pre-PROM by comparison with control group, 
with respective direction of change are also indicated. Assignments are given in brackets. 
MIR bands (cm⁻¹) 
change relative 
to control 
MIR / MIR positive correlations (cm
-1
) 
1122 (C-C/C-O)   
1414 (sCOO
-
) 
1039 (C-C/C-O)  1137 (C-C/C-O) 
 
No direct correlation between the two bands at 1122 cm-1 and at 1039 cm-1 was found, 
indicating the bands have originated from different molecules. Positive correlations only were 
found between 1122 cm-1 and 1414 cm-1; and for 1039 cm-1 and 1137 cm-1 (Figure 6.24b, Table 
6.9), which are also different from the correlations obtained for pre-PTD (considering that the 
bands 1122 cm-1 and 1039 cm-1 were found decreasing in both conditions). Therefore, the 
correlations indicate the involvement of different metabolites in pre-PROM.  
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The band at 1122 cm-1 which could be attributed to C-C/C-O stretching vibrations was found 
correlated with the 1414 cm-1 symmetric stretching carboxyl vibration, thus indicating the 
possible involvement of an organic or amino acid (Pretsch et al., 1989). On the other hand, the 
band at 1039 cm-1, attributed to C-C/C-O stretching vibrations was found correlated with a band 
at 1137 cm-1 also attributed to C-C/C-O stretching vibrations (Pretsch et al., 1989; Liu and 
Mantsch, 1999). This correlation could indicate the involvement of a carbohydrate molecule, 
sugar alcohol or alcohol in the variation of the band at 1039 cm-1 (Pretsch et al., 1989; Liu and 
Mantsch, 1999).  
 
6.3.3.2. MIR and 1H NMR SHY analysis 
 
In order to further investigate the origin of the MIR bands of interest in pre-PROM, correlation 
analysis was performed using MIR/1H NMR SHY using both MIR and 1H NMR spectra of pre-PROM, 
as shown in the corresponding SHY map obtained (Figure 6.25). 
From the 3000-2800 cm-1 region, only the band at 2955 cm-1 registered significant correlations 
(Figure 6.25a). Indeed the band at 2955 cm-1 was found positively correlated with several 
resonances in the region of CH3 groups and NH/aromatics regions (possibly related to proteins), 
whereas correlating negatively with the resonances of lysine, phenylalanine and myo-inositol 
(Figure 6.25a, Table 6.10). Interestingly, from SHY analysis the 1039 cm-1 band was found 
positively correlated with resonances of glucose, whereas the band at 1122 cm-1 was positively 
correlated with resonances of lactate (Figure 6.25b, Table 6.10). The SHY results seem to be in 
agreement with the intra-correlation results, which pointed to the relation of 1122 cm-1 with an 
organic acid molecule (lactate) and 1039 cm-1 with sugar or sugar alcohol type molecule (glucose). 
  
Table 6.10 - MIR/NMR SHY correlation obtained using pre-PROM spectra (Figure). The main MIR bands 
affected in pre-PROM by comparison to control group, with respective direction of change are also 
indicated. Assignments are given in brackets; amino acids are represented in 3 letter code. 
  MIR/NMR SHY correlations 
MIR bands (cm⁻¹) 
change relative 
to control
Positively correlated 
1
H-NMR signals 
Negatively correlated 
1
H-NMR signals 
2955 (C-H) 
(CH3 groups 0.24-0.72 ppm), 
(NH/aromatics 7.60-8.78 ppm) 
Lys, Phe, myo-inositol 
1122 (C-C/C-O)  Lactate - 
1039 (C-C/C-O)  Glucose - 
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Figure 6.25 - MIR/1H-NMR statistical heterospectroscopy (SHY) maps for pre-PROM group (n=37) of 1H-
NMR spectra (0-10 ppm region) and the MIR spectral regions: a) 3000-2800 cm-1, b) a) 1200-900 cm-1. 
A correlation threshold of |r|>0.7 was considered. Dashed horizontal lines indicate the bands of 
interest identified through loadings analysis and their correlations across the NMR spectrum. 
 
 
6.3.4. Proposed interpretation of the metabolite variations detected in pre-PROM cases 
 
Generally, the 1H NMR and MIR of 2nd trimester AF PLS-DA models obtained for the early 
prediction PROM showed poor predictive power, certainly resulting from the small number of 
variations detected by both methodologies. Although slight improvements were achieved in the 
predictive ability of MIR PLS-DA models, the interpretation of the results from the MIR PLS-DA 
loadings and STOCSY and SHY is very limited and must be interpreted with care. The MIR analysis 
did suggest the possible increase of proteins (C-H vibration and MIR/1H NMR correlations with 
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CH3 and NH groups) and concomitant decreases in lysine, phenylalanine and myo-inositol, 
together with decreases in glucose and lactate (suggested with basis on MIR/1H NMR). However, 
no association has been found in literature linking these variations with PROM. On the other 
hand, evidence gathered in other studies has suggested that PROM is related to biochemical 
processes involving degradation and dissociation of amnion membranes collagen with the 
involvement of proteolytic enzymes, matrix metalloproteinases (Stuart et al., 2005; Moore et al., 
2006) and due to the action of reactive oxygen species (ROS) (Caughey et al., 2008). Ascorbic acid, 
which plays an essential role in the synthesis of collagen and in the maintenance of the 
membrane integrity contributing to the antioxidant activity against free-radical damage, was 
found reduced in PROM membranes at 37 weeks of gestation (Stuart et al., 2005). In fact, one 
signal from ascorbate (multiplet at 4.01 ppm) was observed in 1H NMR CPMG spectra of 2nd 
trimester AF as mentioned in chapter 5 (section 5.1.2, Table 5.2, page 129). The comparison 
between control and pre-PROM based on the ascorbate signal revealed an average decrease of 
this signal in pre-PROM group. Although the difference was not statistically significant (p=0.059), 
it may indicate possible early deficiency in the AF ascorbate contents of PROM cases.  
It seems clear, however, that the use of more sensitive techniques, such as MS based methods 
could shed some more light in the small compositional changes occurring in 2nd trimester AF of 
pre-PROM cases (which escape the detection of both 1H NMR and MIR) in order to provide clues 
to the early membrane degradation process and possibly lead to the development of predictive 
methods of PROM.  
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7. Preliminary study of 2nd trimester maternal urine by ultra-performance 
liquid chromatography mass spectrometry (UPLC-MS) for the study and 
prediction of pregnancy disorders (FM and GDM) 
 
The work described in the present chapter constitutes an UPLC-MS profiling study of 2nd 
trimester maternal urine, whose principal objective was to explore any metabolic variations 
occurring in the maternal side as a result of prenatal disorders, and identify any possible 
relationships with those variations occurring in the fetal side (identified through AF analysis). The 
maternal urine samples were analysed separately from AF due of the reduced urine sample 
numbers available at the time of analysis compared to those of AF (as shown in Table 3.2, page 
60). Hence, the results presented here are only preliminary. For UPLC-MS profiling only two 
disorder groups were considered: FM (n=13) and pre-diagnostic GDM (n=20). To further 
complement UPLC-MS analysis, UPLC-MS / 1H NMR SHY analysis was performed using some of the 
previously published 1H NMR maternal urine spectra (Diaz et al., 2011), corresponding to the 
same samples analysed by UPLC-MS in the present study.  
The analysis of other disorders by UPLC-MS was not possible at this stage, due to the small 
number of samples gather up to the time of analysis, namely of pre-PTD (n=5), CD (n<5), pre-PE 
and pre-IUGR (n<4). However, the analysis of maternal urine of such groups is also worth pursuing 
by UPLC-MS, as it has been initiated by 1H NMR metabonomics for CD and pre-PTD (the subject of 
another PhD thesis) in an effort to develop less invasive diagnosis tools. Moreover, several studies 
using targeted analysis maternal urine, have suggested possible markers in connection with PE 
(Glew et al., 2004; Scioscia et al., 2007a) and early markers of oxidative stress in connection PE 
and PTD (Stein et al., 2008).  
 
7.1. Analysis of 2nd trimester maternal urine for the study of FM cases 
 
7.1.1. UPLC-MS profiling for comparison of control and FM groups 
 
The UPLC-MS data sets analysed originated clustered QCs sample distributions when 
compared to all maternal urine samples in their respective PCA scores scatter plots after Pareto 
and UV scaling (Annex III - Results from the UPLC-MS reproducibility evaluation). These 
observations indicated a good reproducibility of the data sets which were then considered suited 
for further MVA. 
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The PLS-DA scores scatter plots from controls vs FM models of the negative mode (ESI-) of both 
HSS and HILIC columns (Figure 7.1), showed that good separation between control and FM groups 
was achieved, with Q2 values of 0.528-0.736 (Table 7.1) indicating high predictive ability. On the 
other hand, the PLS-DA models corresponding to positive mode (ESI+) data sets (not shown) 
registered Q2 values of 0.242-0.363 (Table 7.1), which indicated lower predictive abilities. All 
models were the evaluated by MCCV. 
 
 
Figure 7.1 - PLS-DA scores scatter plots of UPLC-MS models of control (n=21) vs 
FM (n=13): a) HSS/ESI-, Pareto scaled; b) HSS/ESI-, UV scaled; c) HILIC/ESI-, 
Pareto scaled; d) HILIC/ESI-, UV scaled. 
 
 
Table 7.1 - Maternal urine UPLC-MS based PLS-DA parameters of control vs FM models. 
 
 
 
 
 
 
 
 
 
 
 
 
 
UPLC detection scaling or PLS-DA model parameters 
column mode transformation R²X R²Y Q² LV 
HSS ESI
+
 Pareto 0.772 0.242 0.242 2 
HSS ESI
+
 UV 0.337 0.834 0.363 2 
HSS ESI
-
 Pareto 0.372 0.958 0.558 4 
HSS ESI
-
 UV 0.340 0.996 0.736 4 
HILIC ESI
+
 Pareto 0.248 0.795 0.331 2 
HILIC ESI
+
 UV 0.251 0.822 0.313 2 
HILIC ESI
-
 Pareto 0.294 0.980 0.552 4 
HILIC ESI
-
 UV 0.248 0.998 0.673 4 
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Overlapping was observed between the true and permuted class models Q2 distributions, but 
with clear tendency for separation of true class models, with the majority of Q2 values located 
around Q2=0.4 (Figure 7.2, left). ROC plots indicated average specificities of 95% for the true class 
models of both data sets, sensitivity between 40-60% (average 47%) for HSS/ESI- (UV scaling) data 
set (Figure 7.2a, right) and a sensitivity between 50-60% (average 59%) for HILIC/ESI- (UV scaling) 
data set (Figure 7.2b, right). The good predictive ability of the presented models was also 
expressed in the classification rates obtained: 97% for HSS/ESI- (UV scaling) and 83% for HILIC/ESI- 
(UV scaling). Similar predictive abilities were obtained in MCCV of Pareto scaled HSS/ESI- and 
HILIC/ESI- data sets (not shown). 
 
Figure 7.2 - MCCV results of PLS-DA UPLC-MS models of control (n=21) vs FM (n=13): a) HSS/ESI- 
(UV scaling); b) HILIC/ESI- (UV scaling). 
 
Despite the moderate Q2 obtained for positive mode data sets, their respective PLS-DA models 
were not validated through MCCV, which were characterized by completely overlapped true and 
permuted classes in both Q2 distributions and ROC plots (not shown).The higher predictive ability 
of the PLS-DA models seem to indicate to a higher impact of metabolites ionizing preferentially in 
negative mode (ESI-) in the urinary profile of FM cases. 
Therefore, PLS-DA loadings analysis was performed for ESI- models in order to identify the MS 
features contributing to the separation observed in the controls vs FM PLS-DA models using the 
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same approach used for AF UPLC-MS data sets described in chapters 5 and 6. The resulting S-plot 
and covariance ratio plots obtained for LV1 of HILIC/ESI- UV model (Figure 7.3) illustrates the 
loadings analysis. The MS features were firstly selected from each S-plot of the separating 
component from PLS-DA scores scatter plots (Figure 7.3a), considering a correlation threshold of 
|p(corr)[1]|>0.5 (threshold lines, Figure 7.3a). The S-plot shown in Figure 7.3a, was derived from 
UV scaled data, therefore it different from the S-plots obtained from the Pareto scaled or log 
transformed data sets, such as the one shown in Figure 5.10a (chapter 5, page 135). The linear 
plot obtained in S-plots of UV scaled data results from the fact that the covariance (p[1]) which is 
scaled by standard deviation of each original variable (i.e. before scaling). In such an S-plot, only 
the correlation is needed to define the thresholds for feature selection. 
 
Figure 7.3 - PLS-DA control vs FM HILIC/ESI- UV model loadings selection: a) S-plot and b) 
covariance ratio plots of LV1 with correlation threshold limits indicated by dashed lines; dashed 
lines in the covariance ratio plot indicates the threshold for features selection. 
 
The features obtained from the S-plots were further evaluated according to their intrinsic 
variability over cross-validation by the use of covariance plots (Figure 7.3b). The features for 
which the standard error of the covariance was not greater than 25% than the covariance value 
(threshold of 4 indicated in the dashed line of Figure 7.3b) were the features with the most stable 
variation in the PLS-DA models, therefore being considered the MS features with highest impact 
in class separation.  
The significance of each of the MS features was also tested by univariate analysis. A list of 
significant assigned and partially assigned MS features together with the respective model of 
origin, variation in FM group and p-value is given in Table 7.2. 
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Table 7.2 - List of assigned significant UPLC-MS features obtained for 2nd trimester urine of the FM 
affected pregnancies compared to healthy controls. Feature intensities are indicated as: very high 
(>106), high (>105, <106), low (>104, <105) and very low (<104). a dimer and b adduct of hippurate. The 
names in brackets correspond to partially assigned features. 
metabolite 
UPLC 
Column 
detection 
mode 
m/z RT(min.) 
feature 
intensity 
model 
scaling 
direction and 
magnitude 
of variation 
p-value 
hippurate HSS ESI
-
 178.06 3.9 very high Pareto 1.5 6.5710
-03
 
 HSS ESI
-
 357.13 3.9 very high Pareto   
 HSS ESI
-
 442.19 3.9 high UV   
(glucuronidated) HSS ESI
-
 384.07 3.4 low UV 5.5 1.1610
-02
 
(sulfated) HSS ESI
-
 242.13 3.9 very low UV 1.5 1.8210-03 
(glucuronidated) HILIC ESI
-
 375.13 5.1 very low UV 3.1 4.0210
-03
 
(sulfated) HILIC ESI
-
 190.00 0.6 low UV 2.3 1.3010
-02
 
 
 
From the MS features presented in Table 7.2 only hippurate (decreasing in FM) and its 
respective MS adducts could be fully assigned (Table 7.2). Significant variations were also found 
for features corresponding to two glucuronidated metabolites (decreasing in FM), one sulfated 
metabolite (increased in FM) and another sulfated metabolite (decreased in FM). The assignment 
of these features were only partially achieved from their respective MS/MS fragmentation spectra 
shown in Figure 7.4, which lead to the identification of mass losses of negatively charged sulfate 
residue or the loss of a neutral glucuronic acid residue (neutral loss) (Figure 7.4, page 198).  
No further assignments were achieved for the remaining peaks detected in the MS/MS 
spectra. A list of 17 features found varying significantly (p<0.05) between control and FM group 
and for which no assignment was obtained at this stage is also presented in Annex VII - Lists of 
UPLC-MS unassigned features detected in maternal urine. It is worth mentioning that one of the 
unassigned relevant features which is found to be increased in urine of FM subjects (unassigned 
385.17 m/z) was also found to be increased in AF of FM subjects (Annex VII - Lists of UPLC-MS 
unassigned features detected in maternal urine) thus suggesting a possible connection between 
maternal and fetal environment. However, further assignment work is needed to identify the 
origin of such feature. 
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Figure 7.4 - Fragmentation mass spectra (MS/MS) of the partially assigned features:              
a) glucuronidated, 384.09 m/z, 3.4 min; b) sulfated, 242.13 m/z, 3.9 min; c) glucuronidated, 
375.13 m/z, 5.1 min; d) sulfated, 190.00 m/z, 0.6 min. The mass differences of 176 and 79.95 
correspond to the glucuronic acid neutral loss and the sulfate residues respectively. 
 
 
7.1.2. UPLC-MS/1H NMR SHY analysis of FM cases 
 
Similarly to what has been done in the previous chapters 5 and 6, UPLC-MS/1H NMR SHY 
analysis was performed using 1D STOCSY in order to find the correlations between the significant 
urine MS features obtained from the FM models from Table 7.2 and the full 1H NMR spectra of 
the maternal urine samples from FM affected cases. An 1D MS/NMR STOCSY plot obtained for 
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hippurate MS feature (178.06 m/z, 3.09 min) shown in Figure 7.5. The MS/NMR SHY 
representation highlights the signals from the 1H NMR spectrum that correlate with the MS 
feature (through correlation coefficient, r) as well as the direction of change (through covariance). 
In the example from Figure 7.5, the MS feature of hippurate correlated positively with the 1H 
NMR hippurate resonances, and negatively with several signals, which however registered non-
significant correlations (i.e., p>0.001). The complete list of lists the correlations found between 
maternal urine MS features and the full 1H NMR spectrum is shown in Table 7.3. 
  
Figure 7.5 - MS/NMR SHY analysis of hippurate MS feature (178.06 m/z, 3.09 min) and full 1H 
NMR spectra of urine. The indicated peaks registered significant correlations values: |r|0.70 
and (p<0.001). 
 
 
Table 7.3 – List of MS/NMR correlations obtained from SHY analysis of significant urine MS features 
and urine 1H NMR spectra of FM. Maximum or minimum correlations values |r|0.70 and (p<0.001) 
were considered. Assigned spin systems are indicated in bold. s, singlet, d, doublet, t, triplet, m, 
multiplet, bs, broad singlet; * variation relative to control group. 
 
 
metabolite 
 
m/z 
 
RT(min) 
direction 
of variation* 
1
H NMR resonances correlated: 
positively to the MS 
feature / ppm 
negatively to the MS 
feature / ppm 
      
hippurate 178.06 3.9  hippurate: 3.97(d), 7.56(t), 
7.64(t), 7.84(d), 8.52(bs) 
- 
glucuronidated 384.07 3.4  unknown: 1.83(m) - 
sulfated 242.13 3.9  unknown: 2.23, 2.25, 
3.19(s), 5.58 
unknown: 8.42(d) 
sulfated 239.07 3.3  unknown: 5.34(s) - 
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Besides the expected direct correlation between the hippurate MS feature and its own 1H 
NMR resonances (Figure 7.5), three of the remaining significant MS features (one glucuronidated 
compound and two sulfated metabolites) showed correlations with 1H NMR resonances that are 
unassigned at this stage (Table 7.3). Therefore, no further assignment or metabolic information 
could be retrieved through SHY analysis. 
 
 
7.1.3. Proposed interpretation of the urinary metabolite variations occurring in FM cases 
 
As viewed by UPLC-MS, FM cases have a considerably less impact on 2nd trimester maternal 
urine than in 2nd trimester AF, as shown previously in chapter 5. The main difference noted in 
maternal urine relates to decreased hippurate in FM-affected pregnancies, a change which was 
however not detected in previous 1H NMR work (Diaz et al., 2011), even though hippurate signals 
were clearly visible in 1H NMR spectra. This may reflect the different number of samples of both 
control (n=25 vs 21 here) and FM groups (n = 26 vs 13 here) in each study, and thus hippurate 
variations should be interpreted with care. Decreases in hippurate have been observed in the 
urine of lung cancer patients (Carrola et al., 2011), autistic children (Yap et al., 2010), and in cases 
of high blood pressure (Holmes et al., 2008), and have been associated with abnormalities in gut 
microflora. However, no link has been found, between hippurate and prenatal disorders. The 
other metabolite changes found in maternal urine from FM affected cases by UPLC-MS comprised 
two glucuronidated metabolites (375.13 and 384.07 m/z, decreased), one sulfated metabolite 
(190.00 m/z, decreased) and a second sulfated metabolite (242.13 m/z, increased), which have 
low/very low intensity in MS (Table 7.2) and may be present in small amounts not being detected 
by 1H NMR. Although only the partial assignment was only possible for the metabolites, several 
metabolites candidates can undergo conjugation reactions with glucuronic acid and sulfate prior 
to excretion into urine, including endogenous compounds (such as steroid hormones) and 
xenobiotics (Murray et al., 2003). None of the pregnant woman reported the use of any 
medication, nor did the m/z values fit the major drug conjugates (such as paracetamol, aspirin or 
ibuprofen). No match was also found between these metabolites and the major steroid hormones 
expected in urine during pregnancy (such as estriol, pregnenolone or progesterone). It seems 
possible, however, that conjugation reactions involving other endogenous or exogenous 
metabolites may be specifically affected in the FM cases. Also regarding steroid hormones, the 
feature at 463.20 m/z found at higher levels in 2nd trimester AF of FM affected subjects and 
tentatively assigned to estriol-3-glucuronide/estriol-16-glucuronide (as shown in chapter 5, Table 
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5.4, page 135) was also found higher in maternal urine of FM cases although with a lower 
significance (p = 0.033) when re-analysed by univariate methods, thus not meeting the loadings 
selection criteria used. This interesting observation provides a link between variations observed 
on both fetal and maternal sides. Once more, evidence was found on the connection between 
elevated estriol-3-glucuronide/estriol-16-glucuronide and the occurrence of FM. 
It is interesting to note that some variations observed previously by 1H NMR on maternal urine 
of FM affected pregnancies (e.g. increases in isoleucine, valine, choline, N-methyl-nicotinamide 
(NMND), threonine, cis-aconitate and hypoxanthine) (Diaz et al., 2011) were not observed in the 
present study. The specific UPLC-MS conditions chosen may play an important role in this 
apparent discrepancy since some of these compounds (namely threonine, cis-aconitate and 
hypoxanthine), known to be present in maternal urine in concentrations higher than a few mM 
could not be identified in the acquired urine datasets. On the other hand, isoleucine, valine, 
choline, N-methyl-nicotinamide (NMND), which could be identified in the maternal urine UPLC-
MS data sets, were not significantly altered in FM cases (p>0.05), as confirmed by univariate 
analysis. The above mentioned different composition of the control and FM groups may also have 
an influence in the different observed results. This demonstrates the need for an increase in 
sample size, re-analysis by UPLC-MS and possibly the search for these specific variations using 
targeted analysis. 
 
7.2. Analysis of 2nd trimester maternal urine for the study of pre-diagnostic GDM cases 
 
PLS-DA models were obtained for pre-diagnostic GDM and control groups. The PLS-DA models 
corresponding to HSS/ESI+ and HSS/ESI- UV scaled data sets models (Figure 7.6), where the most 
robust (Q2=0.478 and Q2=0.413, respectively) as shown in Table 7.4. Most of the separation 
between control and pre-diagnostic GDM cases was noted in LV2 (Figure 7.6), with similar 
separations being obtained for the remaining data sets as summarized in Table 7.4 (not shown).  
Despite their apparent good separation, none of the models could be validated through MCCV 
(results not shown), therefore the models showed no predictive power.  
These results contrast with those obtained previously for maternal urine by 1H NMR which 
resulted in predictive models for pre-diagnostic GDM (Diaz et al., 2011). In the 1H NMR study, 
several possible early markers of GDM were suggested such as 3-hydroxyisovalerate, 2-
hydroxyisobutyrate, choline, N-methyl-2-pyridone-5-carboxamide (2PY) and N-methyl-
nicotinamide (NMND) (Diaz et al., 2011). 
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Figure 7.6 - PLS-DA scores scatter plots of UPLC-MS models of control (n=21) vs pre-diagnostic 
GDM (n=20): a) HSS/ESI+, UV scaled; b) HSS/ESI-, UV scaled. 
 
Table 7.4 - Maternal urine UPLC-MS based PLS-DA parameters of control 
vs pre-diagnostic GDM models.  
 
 
 
 
 
 
 
 
 
Both choline (194.10 m/z in ESI-) and NMND (137.05 m/z, in ESI+), were however identified in 
UPLC-MS data sets, whereas the remaining metabolites were not detected, possibly due to early 
elution under the chromatographic conditions used. After re-analysis by univariate analysis, only 
choline was significantly increased (p = 0.020) in the pre-diagnostic GDM group, thus confirming 
the variation observed by 1H NMR which indicated a possible disturbance of choline metabolism 
(Diaz et al., 2011). Once more, the different results may simply reflect the different dimensions of 
both control (n=25 vs 21 here) and pre-diagnostic GDM (n=26 vs 20 here) groups used in both 
studies. Also the specific UPLC-MS conditions used may have hindered the detection of significant 
variation between controls and pre-diagnostic GDM cases, namely the variations of 3-
hydroxyisovalerate, 2-hydroxyisobutyrate and 2PY. The verification of such variations requires the 
re-analysis of control and pre-diagnostic GDM samples under UPLC-MS, using enlarged sample 
groups. 
UPLC detection scaling or PLS-DA model parameters 
column mode transformation R²X R²Y Q² LV 
HSS ESI+ Pareto 0.262 0.666 0.176 2 
HSS ESI+ UV 0.339 0.754 0.413 2 
HSS ESI- Pareto 0.255 0.676 0.217 2 
HSS ESI- UV 0.255 0.832 0.478 2 
HILIC ESI+ Pareto 0.262 0.670 0.164 2 
HILIC ESI+ UV 0.239 0.776 0.389 2 
HILIC ESI- Pareto 0.123 0.831 -0.038 2 
HILIC ESI- UV 0.150 0.883 0.322 2 
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8. Conclusions and future perspectives 
 
The work presented in this thesis represents a contribution to the study of 2nd trimester AF 
composition through metabonomics, in order to deepen the understanding of the biochemistry 
and pathophysiological alterations occurring in prenatal disorders namely, FM and CD, occurring 
during the 2nd trimester; PTD, PE, IUGR, GDM and PROM occurring during the 3rd trimester of 
pregnancy. This knowledge was used in order to explore new markers of FM and CD, and to 
devise predictive markers for the occurrence of PTD, PE, IUGR, GDM and PROM.  
The identification of the adequate AF storage and handling conditions necessary to ensure that 
minimal compositional changes occur during storage and analysis was of paramount importance 
for the proposed metabolic profiling studies. Therefore, a systematic study of AF compositional 
stability with time and temperature of storage using 1H NMR was performed for the first time to 
our knowledge. The study consisted of monitoring of the effects freeze-thaw cycles, storage at the 
temperatures of -20°C, -70°C and at room temperature (22°C) in AF composition. Compositional 
changes were noted in the contents of acetate, citrate, glutamate, glutamine and pyruvate during 
the first two months of storage at -20°C, suggesting storage at lower temperatures (-70°C or 
lower) for longer storage times. Variations were noted in the levels of acetate, glutamate and 
glutamine during the first 4 hours at room temperature, which remained nearly stable up to 8 
hours. Freeze-thaw cycles, introduced only minimal and sample dependent compositional 
changes, which should be minimized by avoiding freeze-thawing cycles. 
Further compositional characterization studies using 1H NMR spectroscopy were performed 
with the aim of increasing the knowledge of the composition of 2nd trimester AF from healthy 
pregnancies. Indeed, the work performed using high field 1H NMR and especially LC-NMR/MS 
methods, allowed the detection of metabolites present in concentrations of less than 10 M, and 
most notably enabled the identification of 6 metabolites from exogenous and endogenous origin 
not detected previously in AF by any other analytical technique. Moreover, the broad AF protein 
signals observed in 1H NMR were characterized for the first time using DOSY, uncovering three 
proteins spin-systems, and enabling also the estimation of their Mw. Although their assignment 
was not possible at this stage, at least one spin-system could be roughly attributed to the most 
abundant glycoprotein in AF transferrin. With these results it was possible to build a database of 
75 different compounds present in 2nd trimester AF of healthy pregnancies. 
Metabolic profiling studies performed on 2nd trimester AF using a combination of 1H NMR, 
UPLC-MS and MIR in connection with multivariate analysis, were used to explore the 
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compositional changes due to the occurrence of FM and CD. The most robust multivariate models 
were obtained for FM. In fact, irrespectively of the analytical platform considered, PLS-DA models 
of controls vs FM were associated with sensitivities of about 80% as well as specificities and 
classification rates above 80%. This resulted from the highest impact on 2nd trimester AF observed 
due to the occurrence of FM. The metabolic variations observed in all or the majority of analysed 
FM cases seemed to suggest impaired energy, amino acids and sugar metabolisms and also 
possibly abnormal kidney function. It was not possible, however to dwell on the effects of each 
particular type of FM on AF due the small sample size of each sub-group of FM obtained. In 
relation to diagnosed CD, PLS-DA models showing some discrimination between CD and control 
samples were only obtained with 1H NMR data, and were less robust when compared to FM 
models, being associated with sensitivities lower than 60%. The poorer predictive ability obtained 
could be attributed to the small number of metabolite changes expected to occur in such a 
heterogeneous group of CD (composed of several CD types). Once more, the small sample size of 
each sub-group of CD cases hindered the exploration of the effects of each CD type on the 2nd 
trimester AF composition. Nevertheless, the further analysis of AF composition using increased 
sample numbers of each CD type may be of great importance, for instance in relation to trisomy 
21, in order to devise diagnostic methods complementary to established diagnostic cytogenetics 
procedures. 
Regarding the groups of disorders occurring in 3rd trimester pregnancy, namely pre-PTD, pre-
PE, pre-IUGR, pre-diagnostic GDM and pre-PROM, 2nd trimester AF profiles were used primarily to 
devise multivariate models of early prediction of such disorders for which no established 
predictive methods are available. In general, the PLS-DA models obtained for these groups 
registered low predictive power (sensitivities lower than 70%). This is justifiable due to the 
smaller number of metabolite variations detected, or their absence, which may result from the 
temporal distance between AF collection and the occurrence of each disorder, but also, in the 
cases of pre-PTD, pre-PE and pre-IUGR, from the small number of samples analysed. Nevertheless, 
in spite of the poor models obtained, for which higher sample numbers should be considered in 
order to achieve predictive models, metabolites signals selected from the PLS-DA loadings were 
analysed by univariate analysis to explore possible biochemical variations, which may indicate the 
potential of markers for those disorders. Indeed a panel of significant metabolite changes were 
then detected in pre-PTD cases, thus indicating the potential of AF analysis for the development 
of prediction models of PTD. The variations were observed in the contents of amino acids, 
glucose, ketone bodies and allantoin suggesting earlier occurrence fetal-placental dysfunction, 
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hyperglycaemia and oxidative stress in pre-PTD subjects. Given the small number of metabolites 
variations detected for pre-PE (n=8) and their absence in pre-IUGR (n=9) cases and given the small 
sample sizes considered the analysis of these groups were largely exploratory at this stage. The 
increase in the sample numbers of the pre-PTD, pre-PE and pre-IUGR should then be used 
improve the sensitivity of the PLS-DA models. The results obtained for pre-diagnostic GDM, for 
which larger sample sizes were considered (n=23, 33 and 35, for UPLC-MS, MIR and 1H NMR 
respectively) seem to reflect the small number of metabolite changes found, mainly resulting 
from glucose. Similarly, the results obtained in the analysis of pre-PROM cases (n=45), seem 
suggest that few differences exited between 2nd trimester AF. Therefore, the analysis of maternal 
biofluids in the case of pre-diagnostic GDM, and the use of more sensitive analytical approaches 
such as UPLC-MS for AF analysis of pre-PROM, should be explored in order to improve the 
sensitivity of the respective models. 
UPLC-MS analysis of 2nd trimester maternal urine was also performed to explore the possible 
metabolic variations occurring in the maternal side as a result of prenatal disorders, and identify 
any possible relationships with those variations occurring in the fetal side (identified through AF 
analysis. The results were consistent with the higher impact of FM on metabolism, as seen 
through AF analysis. In comparison to AF, the maternal urine PLS-DA models showed however 
lower sensitivities (40-60%) despite the high classification rates (83-97%). The UPLC-MS study has 
also suggested possible markers, present in sub-M concentrations in connection with FM. 
However, not confirming previous variations detected in another study by 1H NMR (Diaz et al 
2011), which may have resulted from the reduced number of samples considered. The results 
obtained for pre-diagnostic GDM, showed once more non predictive models in connection with 
the results obtained for AF. Therefore, in the case of pre-diagnostic GDM, it can be suggested that 
the search for markers should be performed using maternal plasma for instance, which may be 
more sensitive to the biochemical and pathophysiological alterations resulting from the onset of 
the disease. 
Special mention is made to the limitation of the applicability of results presented, which were 
restricted to the small population of women who underwent amniocentesis procedure, i.e. to 
high risk and advanced maternal age pregnancies. More representative metabolic profiling studies 
should entail biofluids obtained less invasively (blood plasma and serum) or non-invasively (urine) 
and also consider pregnant women with a broader range of maternal ages and those at lower risk 
for prenatal disorders. 
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 Taking into account the results obtained in AF profiling, 1H NMR seemed to be the best suited 
for a first screening of AF composition. In fact, it presented an advantage over UPLC-MS and MIR 
in terms high throughput, reproducibility and ease of spectral interpretation, being inclusively 
used to aid interpretation of MIR and UPLC-MS data through SHY. MIR, which is the least 
expensive technique, has minimal AF preparation and possibility of high throughput. However, 
the MIR AF profiling procedure presented reproducibility issues which should be improved for 
future applications. UPLC-MS, which is the most sensitive technique, has a limited application to 
 m    b  c         mp    ( ≈120)              m        p    c b    y c                 mp   
preparation is more time consuming, which presents an important limitations for large scale AF 
profiling studies. The development of predictive methods may however, require the use of more 
sensitive techniques, such as UPLC-MS or other MS-based methods. 
The results presented demonstrate the potential of 2nd trimester AF and maternal urine 
metabolic profiling for the development of new prenatal diagnosis methods for high risk 
pregnancies, laying the ground for future studies which should involve enlarged sample numbers 
in order to improve prediction models and search for biomarkers.  
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Annex II - 1H NMR pulse programs. 
 
Pulse program noesy1d from Bruker library1: 
 
pl9 : power level for presaturation; d1: relaxation delay; d8: mixing time. 
 
Pulse program cpmgpr from Bruker library1: 
 
pl9 : power level for presaturation; d1: relaxation delay; d20: fixed echo time to allow elimination of 
diffusion and J-mod. effects; l4: loop for T2 filter. 
 
Pulse program ledbpgp2s1dpr from Bruker library1: 
 
d1: relaxation delay; d20: diffusion time; d21 eddy current delay; G6, G7, G8: z-gradients. A pulse for 
presaturation (with pl9 power) is also applied during d1 (not shown in the scheme). 
 
 
Pulse program stddiffesgp.3 from Bruker library1,2: 
                                                          
1
 Parella, T.; Pulse Program Catalogue: Volume I: 1D & 2D NMR Experiments. NMRGuide4.1 – Topspin 2.0. 
Germany, Bruker BioSpin GmbH, 2006. 
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p17: f1 channel - trim pulse [2.5msec]; pl10: f1 channel - power level for TOCSY-spinlock; p29: f1 
channel - trim pulse; pl29: f1 channel - power level for trim pulse; p12: f1 channel - 180 degree shaped 
pulse (Squa100.1000) [2msec]; sp1 : f1 channel - shaped pulse 180 degree; ;p13: f2 channel -  shaped 
pulse for saturation [50msec]; d20: saturation time; l5: loop for saturation (p13*l5: saturation time); 
G1, G2, G3: z-gradients. The on- and off-resonance irradiated frequencies are stored in a list file 
(fq2list).  
 
 
Pulse program lc1pncwps from Bruker library1: 
 
d1: relaxation delay; d8: mixing time; p121: f2 channel - power level for cw-decoupling; presaturation 
during relaxation delay and mixing time using shaped pulse for off-resonance presaturation. 
 
 
 
 
                                                                                                                                                                                
1
 Parella, T.; Pulse Program Catalogue: Volume I: 1D & 2D NMR Experiments. NMRGuide4.1 – Topspin 2.0. 
Germany, Bruker BioSpin GmbH, 2006. 
2
 The STD experiment is protected by international patents owned by: Alepharma, Raamfeld 67, 22397 
Hamburg, Germany. 
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Pulse program lc1pnf2 from Bruker library1: 
 
d1: relaxation delay; d8: mixing time; double presaturation during relaxation delay and mixing time 
using f1 and f2 chanels: pl9 (power level for f1 channel) and p121 (power level for f2 channel). 
 
 
1
 Parella, T.; Pulse Program Catalogue: Volume I: 1D & 2D NMR Experiments. NMRGuide4.1 – Topspin 2.0. 
Germany, Bruker BioSpin GmbH, 2006. 
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Annex III - UPLC-MS reproducibility evaluation 
 
The reproducibility of AF samples in UPLC-MS was evaluated. For this reason a quality control 
(QC) AF sample was injected between each 10 samples of each analytical batch. The 
reproducibility was evaluated by PCA of the QC samples (n=10) together with the remaining 
samples run in UPLC-MS profiling study (n=82). The QCs distribution in the scores scatter plots of 
PCA was inspected for each data set using after application of the scaling transformations Pareto 
scaling, unit variance (UV) scaling and logarithm transformation, which were used to minimize the 
dominance of higher intensity signals over less intense ones (Figure A1). 
Figure A1 - PCA scores scatter plots of AF UPLC-MS data sets using Pareto scaling (left), Unit variance 
scaling (centre) and Log transformation (right): a) HSS/ESI+, b) HSS/ESI-, c) HILIC/ESI+, d) HILIC/ESI-. QCs 
(,n=10) and study samples (○, n =82). 
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As shown in the PCA scores scatter plots of QCs and study samples, the QCs samples were 
clustered together for HSS/ESI+ data set in the 3 scaling transformations applied, with only a small 
drift noticed in PC1 of UV scaling (Figure A1a, centre). In the HSS/ESI- data set, the QCs show good 
clustering only when Log transformation was employed (Figure A1b, right). For HILIC data sets, 
HILIC/ESI+ showed good QC clustering in UV and Log transformed data (Figure A1c), whereas 
HILIC/ESI- only showed good clustering in the Log transformed data set (Figure A1d). 
The results demonstrate that better analytical stability seems to be achieved in HSS/ESI+ data 
sets, compared to data obtained using a HILIC column. This probably resulted from a poorer 
performance of the HILIC column. Therefore all Log transformed data sets and HSS/ESI+ (Pareto 
scaled) and HILIC/ESI+ (UV scaled) were used in further UPLC-MS multivariate analysis (MVA). 
 
To evaluate the reproducibility of the UPLC-MS maternal urine data sets, a PCA analysis of QC 
and study samples was also performed using the same approach used for UPLC-MS AF data sets 
(Figure A2, next page).  
Good clustering of QC samples was obtained in the PCA scores plots from all data sets of 
HSS/ESI+ (Figure A2a), Pareto and UV scaled data sets of HSS/ESI- (Figure A2b) as well as all 
HILIC/ESI- data sets (Figure A2d), which is indicative of reproducibility of those data sets.  
However, no clustering of the HILIC/ESI+ data sets was observed (Figure A2c), which may 
indicate an experimental drift resulting from the acquisition of this data set. Moreover, the 
logarithmic transformation also resulted in a small drift in the QCs of the HSS/ESI- data set (Figure 
A2c, right). The explanation for such drift is not clear since good clustering was observed for the 
Pareto and UV scaling of the same data set (Figure A2b).  
The maternal urine data sets which registered a good reproducibility using the different scaling 
procedures were considered for further control versus disease MVA. 
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Figure A2 - PCA scores scatter plots of maternal urine UPLC-MS data sets using Pareto scaling (left), 
Unit variance scaling (centre) and Log transformation (right): a) HSS/ESI+, b) HSS/ESI-, c) HILIC/ESI+, d) 
HILIC/ESI-. QCs (, n=10) and study samples (○, n =64). 
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Annex IV - MIR reproducibility evaluation 
 
A typical sequence of MIR spectra of AF recorded as a function of sample drying time is shown 
in Figure A3. Sample drying was necessary to remove the excess of water that contributed to the 
broad band absorbing around 3300 and 1700 cm-1 (Figure A3). 
 
Figure A3 - ATR - MIR spectra of human amniotic fluid recorded as a function of drying time. 
 
After 25 min, a spectrum with enhanced signal to noise ratio particularly in the fingerprint 
region (1800-600 cm-1) was obtained (Figure A3), for which proteins, lipids, organic acids (mainly 
lactate), amino acids, and glucose contribute importantly. 
 
In order to evaluate spectral reproducibility, the MIR spectra of a quality control (QC) sample 
were repeatedly acquired in the course of the study. PCA of the full spectra (Figure A4a) showed 
slightly less QC reproducibility, compared to that observed when narrower spectral ranges were 
considered (Figure A4b-e). The lower reproducibility of the full spectrum may be due to the 
relative variability of the O-H stretching () vibration at 3300 cm-1 which possibly reflected small 
deviations in bound water content. Some drift was also present in QCs of 3000-2800 cm-1 region 
along PC1 (Figure A4b), also possibly reflecting the contribution of the nearby water band at 3300 
cm-1. Smaller QC data point dispersion was obtained for the 1200-900 cm-1 (Figure A4d) and 1800-
1200 cm-1 regions (Figure A4c). Notably, second derivative transformation of the original spectra, 
which was used in the transformation of some spectral regions in order to correct baseline 
differences and increase resolution, resulted in slightly lesser QC dispersion when applied to 
1200-900 cm-1 spectral region (Figure A4e). 
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Figure A4 - PCA scores scatter plots of MIR spectra of AF of study samples (○, n=198) and QC sample 
aliquots (, n=20) of spectral regions: a) full spectra; b) 3000-2800 cm-1; c) 1800-1200cm-1; d) 1200-
900 cm-1; e) 1200-900 cm-1 region after 2nd derivative transformation. Three spectral replicates were 
used per sample.   
 
These results indicate that spectral stability and therefore a better reproducibility was 
obtained particularly when considering in the 1200-900 cm-1 and 1800-1200 cm-1 spectral regions, 
thus encouraging their use for MVA. However, second derivative transformation of data sets of 
3000-2800 and 1800-1200 cm-1 regions (not shown) gave results similar to that observed in Figure 
A4a, therefore these transformed data sets were not considered. Despite the drift noted in the 
PCA scores scatter plot of region 3000-2800 cm-1 (Figure A4b), this spectral region was also tested 
in MVA, due to the important contributions of several absorbing species in this particular spectral 
region. 
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Annex V – Full list of AF compounds identified by high resolution NMR and LC-NMR/MS 
 
Table A1 – Full list of AF compounds identified in this work by high resolution NMR and LC-NMR/MS. 
*newly assigned by NMR; ** detected for the first time in AF; ***partially assigned. 
amino acids and derivatives 
  Alanine Glutamate N,N-dimethylglycine 
Acetylcholine* Glutamine Ornithine* 
-aminobutyrate (ABA)* Glycine Pyroglutamate* 
Arginine* Histidine Taurine* 
Aspartate* Hydroxyproline* Threonine 
Betaine Isoleucine Proline 
Carnitine Indoxyl sulfate Phenylalanine 
Citrulline* Leucine Tyrosine 
Choline Lysine Tryptophan* 
Creatine Methionine Valine 
Creatinine N-acetylalanine** 
 Cystine* N-acetylglycine** 
 organic acids 
  Acetate -hydroxybutyrate Malate* 
Acetone* -hydroxyisobutyrate* 3-methyl-2-oxovalerate** 
Acetoacetate* -hydroxyisovalerate* -oxoisovalerate 
Citrate Hydroxypropionate* 2-oxoleucine** 
Formate Isovalerate** Oxaloacetate* 
Fumarate* -ketoglutarate* Pyruvate 
-hydroxybutyrate Lactate Succinate 
sugars 
  Glucose Fructose* Pentose* 
Mannose* Hexose disaccharide*** 
 Myo-inositol Methoxylated oligosaccharide*** 
 sugar alcohols 
  Sorbitol* Xylitol** 
 Proteins* 
  Protein system A (glycoprotein) Protein system B Protein system C 
other metabolites 
  Caffeine* Trimethylamine-N-oxide (TMAO)* Ethanolamine* 
Hippurate* Paraxanthine* Ethanol* 
Urea* 4-amino-hippurate* 
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Annex VI - Lists of UPLC-MS unassigned features detected in AF 
 
Table A2 - Unassigned significant features obtained from OPLS-DA controls vs FM models of 2nd 
trimester AF UPLC-MS analysis. 
    Amniotic Fluid - Fetal Malformations (FM)     
UPLC 
column 
Detection 
mode m/z RT(min.) 
Feature 
intensity 
Model scaling/ 
transformation 
direction 
of variation 
magnitude 
of variation p-value 
HSS ESI+ 125.97 0.4 low Pareto  2.8 1.0110
-05
 
HSS ESI+ 143.99 0.4 low Pareto  2.7 1.6110
-05
 
HSS ESI+ 185.02 0.4 low Pareto  2.3 5.6110
-07
 
HSS ESI+ 167.01 0.4 high Pareto  2.4 4.8510
-07
 
HSS ESI+ 122.53 0.4 low Log  2.7 5.6110
-07
 
HSS ESI+ 185.02 0.4 low Log  2.3 2.0210
-05
 
HSS ESI+ 239.96 0.4 low Log  2.7 2.5210
-05
 
HSS ESI+ 242.00 0.4 low Pareto  1.5 5.3610
-05
 
HSS ESI+ 507.23 0.5 low Log  3.7 8.9610
-05
 
HSS ESI+ 288.92 0.5 low Log  2.1 3.1010
-04
 
HSS ESI+ 248.08 0.8 very low Log  1.8 4.8510
-04
 
HSS ESI+ 209.05 1.0 low Pareto  2.0 2.2510
-05
 
HSS ESI+ 245.07 1.0 low Pareto  1.8 1.8010
-05
 
HSS ESI+ 267.06 1.0 low Pareto  1.7 5.4910
-06
 
HSS ESI+ 281.14 1.2 low Log  1.9 2.0210
-05
 
HSS ESI+ 137.03 1.4 low Pareto  2.4 4.8410
-06
 
HSS ESI+ 170.07 1.7 low Log  1.7 3.1010
-04
 
HSS ESI+ 153.03 1.7 low Pareto  1.7 3.4010
-04
 
HSS ESI+ 749.29 2.6 low Log  2.8 4.4410
-04
 
HSS ESI+ 387.17 2.6 low Log  2.1 8.9310
-06
 
HSS ESI+ 328.14 2.9 low Log  1.5 2.8310
-03
 
HSS ESI+ 310.13 2.9 low Log  1.6 1.1410
-06
 
HSS ESI+ 410.18 3.4 low Log  2.3 2.5910
-04
 
HSS ESI+ 819.35 3.4 low Log  3.5 2.9110
-06
 
HSS ESI+ 261.14 3.5 high Log  2.4 2.6710
-07
 
HSS ESI+ 363.22 5.7 low Log  1.7 7.4310
-04
 
HSS ESI+ 541.27 6.7 very low Log  2.0 1.4310
-05
 
HSS ESI+ 285.26 6.7 low Pareto  2.3 4.3410
-05
 
HSS ESI- 402.93 0.4 low Log  2.2 3.9010
-05
 
HSS ESI- 516.90 0.4 low Log  2.2 7.3110
-05
 
HSS ESI- 548.85 0.4 low Log  2.6 3.5010
-05
 
HSS ESI- 494.86 0.5 low Log  2.4 1.6710
-07
 
HSS ESI- 597.30 1.9 low Log  2.1 1.9610
-06
 
HSS ESI- 626.25 1.9 low Log  1.9 4.8410
-06
 
HSS ESI- 624.26 2.7 low Log  2.7 9.9010
-05
 
HSS ESI- 817.31 3.4 low Log  3.8 4.8410
-06
 
HSS ESI- 407.22 5.6 low Log  2.5 4.7910
-09
 
HSS ESI- 564.29 6.7 low Log  2.6 3.1410
-05
 
HILIC ESI+ 752.56 0.8 very low UV  1.6 2.5510
-04
 
HILIC ESI+ 123.06 0.9 very low UV  1.3 9.0210
-04
 
HILIC ESI+ 718.58 4.0 low UV  2.3 1.8010
-06
 
HILIC ESI+ 701.56 4.2 low UV  2.5 3.4910
-03
 
HILIC ESI+ 260.19 4.9 low UV  2.0 4.0110
-05
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Table A2 (cont.) 
Amniotic Fluid - Fetal Malformations (FM) 
UPLC 
column 
Detection 
mode m/z RT(min.) 
feature 
intensity 
Model  scaling/ 
transformation 
direction 
of variation 
magnitude 
of variation p-value 
HILIC ESI+ 177.07 4.9 low UV  1.8 8.8510
-07
 
HILIC ESI+ 397.13 4.9 low Log  2.7 3.0710
-07
 
HILIC ESI+ 367.09 5.2 low UV  1.4 1.1610
-07
 
HILIC ESI+ 299.10 5.2 very low UV  1.6 4.0610
-08
 
HILIC ESI+ 438.16 5.2 low UV  2.0 2.0710
-06
 
HILIC ESI+ 543.15 5.4 low Log  1.5 2.7910
-02
 
HILIC ESI+ 521.17 5.4 low Log  1.5 5.8710
-02
 
HILIC ESI+ 277.06 5.4 low Log  1.8 4.6610
-03
 
HILIC ESI+ 500.19 5.4 low Log  2.2 8.1210
-03
 
HILIC ESI+ 176.04 5.6 low UV  1.4 3.7210
-04
 
HILIC ESI+ 154.06 5.7 low UV  1.3 1.7310
-04
 
HILIC ESI+ 307.11 5.7 very low UV  1.5 1.5710
-04
 
HILIC ESI- 465.31 0.6 high Log  2.3 1.9610
-06
 
HILIC ESI- 413.20 0.7 low Log  2.1 1.6710
-07
 
HILIC ESI- 385.17 0.7 low Log  2.0 7.0210
-06
 
HILIC ESI- 401.16 0.7 low Log  2.7 8.1010
-05
 
HILIC ESI- 198.07 5.0 low Log  1.9 2.2910
-07
 
HILIC ESI- 497.17 5.4 low Log  1.7 1.8910
-02
 
HILIC ESI- 237.09 5.4 high Log  1.6 2.6610
-02
 
 
Table A3 - Unassigned significant features obtained from OPLS-DA controls vs pre-PTD models of 2nd 
trimester AF UPLC-MS analysis. 
Amniotic Fluid - pre-Premature Delivery (PTD) 
UPLC 
column 
Detection 
mode m/z RT(min.) 
feature 
intensity 
Model scaling/ 
transformation 
Direction of 
variation 
magnitude 
of variation p-value 
HSS ESI+ 331.12 0.6 low Log  1.8 6.1010
-03
 
HSS ESI+ 353.10 0.6 very low Log  1.9 1.5810
-02
 
HSS ESI+ 309.16 0.6 low Log  1.7 1.9310
-02
 
HSS ESI+ 226.12 0.7 low Log  1.7 4.6910
-02
 
HSS ESI- 597.09 0.7 low Log  1.8 3.3910
-03
 
HSS ESI+ 192.03 0.8 low Pareto  1.4 1.0410
-03
 
HSS ESI+ 222.04 1.0 low Log  2.0 6.8310
-03
 
HSS ESI+ 390.98 1.3 low Pareto  1.3 5.4510
-03
 
HSS ESI+ 247.14 1.4 high Log  2.2 1.3710
-03
 
HSS ESI+ 202.18 2.0 high Log  1.6 3.6410
-04
 
HSS ESI+ 749.29 2.6 very low Log  1.9 2.3310
-02
 
HSS ESI+ 247.16 2.9 low Pareto  1.3 6.1010
-03
 
HSS ESI- 371.06 3.1 low Log  1.9 2.6310
-04
 
HSS ESI- 248.06 3.4 low Log  2.9 6.7210
-04
 
HSS ESI+ 316.21 3.9 low Log  1.2 3.0610
-02
 
HSS ESI- 920.87 4.2 high Log  2.7 1.0510
-02
 
HSS ESI+ 361.20 5.7 very low Log  1.5 1.5910
-04
 
HILIC ESI+ 397.20 0.7 low UV  1.2 4.9210
-02
 
HILIC ESI+ 136.08 0.7 low UV  1.2 1.1810
-02
 
HILIC ESI+ 147.07 0.7 low UV  1.2 1.1810
-02
 
HILIC ESI+ 756.55 4.0 very low Log  1.4 4.7410
-03
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Table A3 (cont.) 
UPLC 
column 
Detection 
mode m/z RT(min.) 
feature 
intensity 
Model scaling/ 
transformation 
Direction of 
variation 
magnitude 
of variation p-value 
HILIC ESI+ 812.68 4.3 very low UV  1.7 9.4910
-03
 
HILIC ESI+ 785.66 4.4 very low Log  1.8 6.0110
-03
 
HILIC ESI+ 787.67 4.4 very low Log  1.4 1.4610
-02
 
HILIC ESI+ 260.19 4.9 low UV  1.8 4.1910
-03
 
HILIC ESI+ 169.99 4.9 low UV  1.4 4.1910
-03
 
HILIC ESI+ 246.17 5.3 low UV  1.6 1.2710
-03
 
HILIC ESI+ 527.25 7.2 low UV  1.7 6.0110
-03
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Table A4 - Unassigned significant features obtained from PLS-DA controls vs FM models of 2nd 
trimester maternal urine UPLC-MS profiling analysis. 
Maternal Urine - Fetal Malformations (FM) 
UPLC 
column 
Detection 
mode m/z RT(min.) 
feature 
intensity 
model 
scaling 
direction 
of variation 
magnitude 
of variation p-value 
HSS ESI- 203.07 0.63 very low UV  1.5 7.3910
-03
 
HSS ESI- 895.34 3.25 very low UV  1.5 3.1110
-03
 
HSS ESI- 239.07 3.3 very low UV  1.4 2.7310
-03
 
HSS ESI- 507.07 3.37 very low UV  2.7 1.3710
-03
 
HILIC ESI- 109.04 0.55 low UV  2.8 2.0210
-04
 
HILIC ESI- 879.36 0.69 very low UV  3.7 1.6910
-04
 
HILIC ESI- 769.35 0.70 very low UV  3.2 4.0010
-04
 
HILIC ESI- 799.39 0.70 very low UV  4.9 5.6910
-06
 
HILIC ESI- 813.38 0.71 low UV  4.0 1.0910
-06
 
HILIC ESI- 443.19 0.71 low UV  1.8 2.3910
-03
 
HILIC ESI- 829.38 0.71 low UV  3.7 1.9610
-06
 
HILIC ESI- 771.35 0.72 very low UV  2.6 6.4710
-04
 
HILIC ESI- 385.17 0.72 high UV  1.9 1.1610
-02
 
HILIC ESI- 857.42 0.72 very low UV  4.3 7.3010
-06
 
HILIC ESI- 859.42 0.74 very low UV  3.4 6.6010
-05
 
HILIC ESI- 281.08 1.35 very high Pareto  1.6 1.6010
-02
 
HILIC ESI- 617.21 5.16 low UV  1.8 4.0210
-03
 
 
 
 
 
